US20070078122A1 - Indolobenzazepine HCV NS5B inhibitors - Google Patents

Indolobenzazepine HCV NS5B inhibitors Download PDF

Info

Publication number
US20070078122A1
US20070078122A1 US11/516,435 US51643506A US2007078122A1 US 20070078122 A1 US20070078122 A1 US 20070078122A1 US 51643506 A US51643506 A US 51643506A US 2007078122 A1 US2007078122 A1 US 2007078122A1
Authority
US
United States
Prior art keywords
alkyl
cycloalkyl
amino
mmol
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/516,435
Other versions
US7473688B2 (en
Inventor
Carl Bergstrom
John Bender
Robert Gentles
Piyasena Hewawasam
Thomas Hudyma
John Kadow
Scott Martin
Alicia Regueiro-Ren
Kap-Sun Yeung
Yong Tu
Katharine Grant-Young
Xiaofan Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to US11/516,435 priority Critical patent/US7473688B2/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GENTLES, ROBERT G., HUDYMA, THOMAS W., BENDER, JOHN A., MARTIN, SCOTT W., TU, YONG, KADOW, JOHN F., YEUNG, KAP-SUN, GRANT-YOUNG, KATHARINE A., HEWAWASAM, PIYASENA, ZHENG, XIAOFAN, BERGSTROM, CARL P., REGUEIRO-REN, ALICIA
Publication of US20070078122A1 publication Critical patent/US20070078122A1/en
Application granted granted Critical
Publication of US7473688B2 publication Critical patent/US7473688B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • HCV Hepatitis C virus
  • HCV is a positive-stranded RNA virus. Based on a comparison of the deduced amino acid sequence and the extensive similarity in the 5′-untranslated region, HCV has been classified as a separate genus in the Flaviviridae family. All members of the Flaviviridae family have enveloped virions that contain a positive stranded RNA genome encoding all known virus-specific proteins via translation of a single, uninterrupted, open reading frame.
  • the single strand HCV RNA genome is approximately 9500 nucleotides in length and has a single open reading frame (ORF) encoding a single large polyprotein of about 3000 amino acids. In infected cells, this polyprotein is cleaved at multiple sites by cellular and viral proteases to produce the structural and non-structural (NS) proteins. In the case of HCV, the generation of mature non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) is effected by two viral proteases.
  • ORF open reading frame
  • the first one is believed to be a metalloprotease and cleaves at the NS2-NS3 junction; the second one is a serine protease contained within the N-terminal region of NS3 (also referred to as NS3 protease) and mediates all the subsequent cleavages downstream of NS3, both in cis, at the NS3-NS4A cleavage site, and in trans, for the remaining NS4A-NS4B, NS4B-NS5A, NS5A-NS5B sites.
  • the NS4A protein appears to serve multiple functions, acting as a cofactor for the NS3 protease and possibly assisting in the membrane localization of NS3 and other viral replicase components.
  • NS5B (also referred to as HCV polymerase) is a RNA-dependent RNA polymerase that is involved in the replication of HCV.
  • the HCV NS5B protein is described in “Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides (Bressanelli; S. et al., Journal of Virology 2002, 3482-3492; and Defrancesco and Rice, Clinics in Liver Disease 2003, 7, 211-242.
  • HCV NS5B inhibitors have been disclosed. See WO 2006/046039; WO 2006/046030; WO 2006/029912; WO 2005/080399; WO 2005014543; WO 200307945; WO 2003010140; WO 2003010141; WO 200204425; WO 200147883; Harper, S. A. et al. J. Med. Chem. 2005, 48, 4547; and Harper, S. A. et al. J. Med. Chem. 2005, 48, 1314, and references cited therein.
  • the invention encompasses compounds of formulas I, II, III, and IV, and pharmaceutically acceptable salts and solvates thereof, and compositions and methods of treatment using these compounds.
  • One aspect of the invention is a compound of formula I
  • Another aspect of the invention is a compound of formula I
  • Another aspect of the invention is a compound of formula I
  • Another aspect of the invention is a compound of formula I
  • Another aspect of the invention is compound of formula I where R 1 is CONR 7 R 8 ;
  • R 2 is CO 2 benzyl, CONR 9 R 10 , NHCO 2 (alkyl), NHCO 2 benzyl, NHCO(cycloalkyl), NHCOR 14 , NHCO((R 15 )alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R 6 )((CO 2 R 6 )alkyl), NHCON(R 6 )((CON(R 6 ) 2 )alkyl), or NHCON(R 6 )((COR 15 )alkyl);
  • Another aspect of the invention is a compound of formula I where the dashed line is a single bond and the carbon bearing the asterisk is of the R configuration.
  • Another aspect of the invention is a compound of formula I where the dashed line is a single bond and the carbon bearing the asterisk is of the S configuration.
  • Another aspect of the invention is a compound of formula I wherein the dashed line is a single bond.
  • Another aspect of the invention is a compound of formula I wherein the dashed line is a double bond.
  • Another aspect of the invention is a compound of formula II
  • Another aspect of the invention is a compound of formula III
  • Another aspect of the invention is a compound of formula IV.
  • Another aspect of the invention is compound of formula I where R 3 is hydrogen.
  • Another aspect of the invention is compound of formula I where R 3 is alkyl.
  • Another aspect of the invention is compound of formula I where R 4 is hydrogen.
  • Another aspect of the invention is compound of formula I where R 4 is chloro.
  • Another aspect of the invention is compound of formula I where R 4 is methoxy.
  • Another aspect of the invention is compound of formula I where R 5 is cyclohexyl.
  • Another aspect of the invention is compound of formula I where R 7 is SO 2 R 11 or SO 2 R 12 .
  • Another aspect of the invention is compound of formula I where R 7 is (R 13 )alkyl.
  • Another aspect of the invention is compound of formula I where R 9 is (R 12 )alkyl.
  • R 9 is (CON(R 6 ) 2 )alkyl or (COR 12 )alkyl.
  • Another aspect of the invention is compound of formula I where NR 9 R 10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1-2 substituents selected from methyl or fluoro.
  • Another aspect of the invention is compound of formula I where NR 9 R 10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 R 12 .
  • Another aspect of the invention is compound of formula I where NR 9 R 10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 substituent selected from pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, pyrimidinyl, pyrazinyl, and triazinyl.
  • NR 9 R 10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 substituent selected from the group consisting of CO 2 R 6 , (cycloalkyl)CO, (alkyl)CO, (hydroxyalkyl)CO, (acetoxyalkyl)CO, COPh, CON(R 6 ) 2 , and COR 12 .
  • Another aspect of the invention is compound of formula I where NR 9 R 10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 SO 2 R 11 or SO 2 R 12 .
  • Another aspect of the invention is compound of formula I where NR 9 R 10 taken together has one of the following substitution patterns where R denotes one of the substituents
  • Alkyl means a straight or branched alkyl group composed of 1 to 6 carbons.
  • Alkenyl means a straight or branched alkyl group composed of 2 to 6 carbons with at least one double bond.
  • Cycloalkyl means a monocyclic ring system composed of 3 to 7 carbons.
  • Haloalkyl and haloalkoxy include all halogenated isomers from monohalo substituted alkyl to perhalo substituted alkyl.
  • Aryl includes carbocyclic and heterocyclic aromatic substituents. Parenthetic and multiparenthetic terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R. Some compounds were drawn with implied hydrogens.
  • the following structure illustrates when the dashed line is a single bond.
  • the following structure illustrates when the dashed line is a double bond.
  • the invention includes all pharmaceutically acceptable salt forms of the compounds.
  • Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate.
  • Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.
  • the invention includes all stereoisomeric forms, including enantiomers and diastereomers as well as mixtures of stereoisomers such as racemates. Some stereoisomers can be made using methods known in the art. Stereoisomeric mixtures of the compounds and related intermediates can be separated into individual isomers according to methods commonly known in the art.
  • Formula I, II, III, or IV compounds may be made by methods known in the art including those described below. Some reagents and intermediates are known in the art. Other reagents and intermediates can be made by methods known in the art using readily available materials. The variables used to describe the synthesis of formula I, II, III, or IV compounds are intended only to illustrate how to make and are not to be confused with variables used in the claims or in other sections of the specification.
  • THF means tetrahydrofuran
  • DMF means N,N-dimethylformamide
  • RCM means ring-closing methasis
  • Boc means tert-butoxycarbonyl
  • TFA means trifluoracetic acid
  • DMA means N,N-dimethylacetamide
  • PPh 3 means triphenylphosphine
  • OAc means acetate
  • Me means methyl
  • COD (or cod) means 1,5-cyclooctadiene
  • dtbpy means 4,4′-di-tert-butyl-2,2′-bipyridine
  • dba means dibenzylideneacetone
  • Xantphos means 4,5-bis(diphenylphosphino)-9,9-dimethylxanthine
  • aq means aqueous
  • EtOH means ethanol
  • MeOH means methanol
  • TBTU means 2-(1H-benzotriazole-1
  • Indole 7 can be made from 6-carboxyindole by condensation with an appropriate ketone. After hydrogenation and esterification, the indole can be selectively brominated and coupled with a variety of aryl compounds, including aryl boronic compounds. Indole 7 can then be alkylated and compound 14 generated by metathesis.
  • ester 14 can selectively convert it to carboxylic acid 14a.
  • R benzyl
  • Reduction of 14a with hydrogen and palladium can give saturated acid 14b.
  • esters of formula I can be selectively hydrolyzed at the indolic ester followed by functionalization at this moiety. Subsequent transformations can then be attended to at the bridged ester moiety.
  • Carboxylic acids 14a and 14b can be transformed into their respective amides.
  • the acids can be activated for the coupling reaction by conversion to their acid chlorides with, for example, oxalyl chloride or thionyl chloride.
  • TBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluroborate) is used to effect the coupling of the acids with amines.
  • DMF, DMSO, and THF can be used as solvents.
  • Compounds 14c and 14d can be transformed to compounds 14f and 14g by methods known in the art.
  • Compounds 14f and 14g can be further elaborated at the carboxylic acid position.
  • HCV NS5B RdRp cloning, expression, and purification The cDNA encoding the NS5B protein of HCV, genotype 1b, was cloned into the pET21a expression vector. The protein was expressed with an 18 amino acid C-terminal truncation to enhance the solubility.
  • the E. coli competent cell line BL21 (DE3) was used for expression of the protein. Cultures were grown at 37° C. for ⁇ 4 hours until the cultures reached an optical density of 2.0 at 600 nm. The cultures were cooled to 20° C. and induced with 1 mM IPTG. Fresh ampicillin was added to a final concentration of 50 ⁇ g/ml and the cells were grown overnight at 20° C.
  • Cell pellets (3L) were lysed for purification to yield 15-24 mgs of purified NS5B.
  • the lysis buffer consisted of 20 mM Tris-HCl, pH 7.4, 500 mM NaCl, 0.5% triton X-100, 1 mM DTT, 1 mM EDTA, 20% glycerol, 0.5 mg/ml lysozyme, 10 mM MgCl2, 15 ug/ml deoxyribonuclease I, and Complete TM protease inhibitor tablets (Roche). After addition of the lysis buffer, frozen cell pellets were resuspended using a tissue homogenizer.
  • aliquots of the lysate were sonicated on ice using a microtip attached to a Branson sonicator.
  • the sonicated lysate was centrifuged at 100,000 ⁇ g for 1 hr at 4° C. and filtered through a 0.2 ⁇ m filter unit (Corning).
  • the protein was purified using three sequential chromatography steps: Heparin sepharose CL-6B, polyU sepharose 4B, and Hitrap SP sepharose (Pharmacia).
  • the chromatography buffers were identical to the lysis buffer but contained no lysozyme, deoxyribonuclease I, MgCl2 or protease inhibitor and the NaCl concentration of the buffer was adjusted according to the requirements for charging the protein onto the column.
  • Each column was eluted with a NaCl gradient which varied in length from 5-50 column volumes depending on the column type.
  • the resulting purity of the enzyme is >90% based on SDS-PAGE analysis.
  • the enzyme was aliquoted and stored at ⁇ 80° C.
  • HCV RdRp genotype 1b assays were run in a final volume of 60 ⁇ l in 96 well plates (Costar 3912).
  • the assay buffer is composed of 20 mM Hepes, pH 7.5, 2.5 mM KCl, 2.5 mM MgCl2, 1 mM DTT, 1.6 U RNAse inhibitor (Promega N2515), 0.1 mg/ml BSA (Promega R3961), and 2% glycerol. All compounds were serially diluted (3-fold) in DMSO and diluted further in water such that the final concentration of DMSO in the assay was 2%.
  • HCV RdRp genotype 1b enzyme was used at a final concentration of 28 nM.
  • a polyA template was used at 6 nM, and a biotinylated oligo-dT12 primer was used at 180 nM final concentration. Template was obtained commercially (Amersham 27-4110).
  • Biotinylated primer was prepared by Sigma Genosys. 3H-UTP was used at 0.6 ⁇ Ci (0.29 ⁇ M total UTP). Reactions were initiated by the addition of enzyme, incubated at 30° C. for 60 min, and stopped by adding 25 g of 50 mM EDTA containing SPA beads (4 ⁇ g/ ⁇ l, Amersham RPNQ 0007). Plates were read on a Packard Top Count NXT after >1 hr incubation at room temperature.
  • Modified HCV NS5B RdRp enzyme assay A modified enzyme assay was performed essentially as described for the standard enzyme assay except for the following: The biotinylated oligo dT12 primer was precaptured on streptavidin-coated SPA beads by mixing primer and beads in assay buffer and incubating at room temperature for one hour. Unbound primer was removed after centrifugation. The primer-bound beads were resuspended in 20 mM Hepes buffer, pH 7.5 and used in the assay at final concentrations of 20 mM primer and 0.67 ⁇ g/ ⁇ l beads.
  • Enzyme 14 nM was added to diluted compound followed by the addition of a mixture of template (0.2 nM), 3H-UTP (0.6 ⁇ Ci, 0.29 ⁇ M), and primer-bound beads, to initiate the reaction; concentrations given are final. Reactions were allowed to proceed for 4 hours at 30° C.
  • FRET Assay Preparation. To perform the HCV FRET screening assay, 96-well cell culture plates were used.
  • the FRET peptide (Anaspec, Inc.) (Taliani et al., Anal. Biochem. 1996, 240, 60-67) contains a fluorescence donor, EDANS, near one end of the peptide and an acceptor, DABCYL, near the other end.
  • the fluorescence of the peptide is quenched by intermolecular resonance energy transfer (RET) between the donor and the acceptor, but as the NS3 protease cleaves the peptide the products are released from RET quenching and the fluorescence of the donor becomes apparent.
  • RET intermolecular resonance energy transfer
  • the assay reagent was made as follows: 5 ⁇ cell Luciferase cell culture lysis reagent from Promega (#E153A) diluted to 1 ⁇ with dH 2 O, NaCl added to 150 mM final, the FRET peptide diluted to 20 uM final from a 2 mM stock.
  • HCV replicon cells with or without a Renilla luciferase reporter gene, were trypsinized and placed into each well of a 96-well plate with titrated test compounds added in columns 3 through 12; columns 1 and 2 contained a control compound (HCV protease inhibitor), and the bottom row contained cells without compound.
  • the plates were then placed in a CO 2 incubator at 37° C.
  • the signal to noise using an endpoint analysis after the reads was at least three-fold.
  • plates were rinsed with PBS, 50 ul of DMEM (high glucose) without phenol red was added and plates were then used for luciferase assay using the Promega Dual-Glo Luciferase Assay System.
  • Compound analysis was determined by quantification of the relative HCV replicon inhibition and the relative cytotoxicity values.
  • cytoxicity values the average Alamar Blue fluorescence signals from the control wells were set as 100% non-toxic. The individual signals in each of the compound test wells were then divided by the average control signal and multiplied by 100% to determine percent cytotoxicity.
  • HCV replicon inhibition values an average background value was obtained from the two wells containing the highest amount of HCV protease inhibitor at the end of the assay period. These numbers were similar to those obtained from na ⁇ ve Huh-7 cells.
  • the background numbers were then subtracted from the average signal obtained from the control wells and this number was used as 100% activity.
  • the individual signals in each of the compound test wells were then divided by the averaged control values after background subtraction and multiplied by 100% to determine percent activity.
  • EC 50 values for a protease inhibitor titration were calculated as the concentration which caused a 50% reduction in FRET or luciferase activity.
  • the two numbers generated for the compound plate, percent cytoxicity and percent activity were used to determine compounds of interest for further analysis.
  • Formula I, II, III, and IV compounds demonstrate activity against HCV NS5B and can be useful in treating HCV and HCV infection. Therefore, another aspect of the invention is a composition comprising a compound of formula I, II, III, or IV, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • compositions further comprising a compound having anti-HCV activity.
  • Another aspect of the invention is a composition where the compound having anti-HCV activity is an interferon.
  • the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.
  • compositions where the compound having anti-HCV activity is a cyclosporin.
  • cyclosporin is cyclosporin A.
  • compositions where the compound having anti-HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
  • Another aspect of the invention is a composition where the compound having anti-HCV activity is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH, and a nucleoside analog for the treatment of an HCV infection.
  • a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH, and a nucleoside analog for the treatment of an HCV infection.
  • compositions comprising a compound of formula I, II, III, or IV, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, an interferon and ribavirin.
  • Another aspect of the invention is a method of inhibiting the function of the HCV replicon comprising contacting the HCV replicon with a compound of formula I, II, III, or IV or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a method of inhibiting the function of the HCV NS5B protein comprising contacting the HCV NS5B protein with a compound of formula I, II, III, or IV or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a method of treating an HCV infection in a patient comprising administering to the patient a therapeutically effective amount of a compound of formula I, II, III, or IV or a pharmaceutically acceptable solvate or salt thereof.
  • the compound is effective to inhibit the function of the HCV replicon.
  • the compound is effective to inhibit the function of the HCV NS5B protein.
  • Another aspect of the invention is a method of treating an HCV infection in a patient comprising administering to the patient a therapeutically effective amount of a compound of formula I, II, III, or IV, or a pharmaceutically acceptable solvate or salt thereof, in conjunction with (prior to, after, or concurrently) another compound having anti-HCV activity.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is an interferon.
  • interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is a cyclosporin.
  • Another aspect of the invention is the method where the cyclosporin is cyclosporin A.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH, and a nucleoside analog for the treatment of an HCV infection.
  • a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH, and a nucleoside analog for the treatment of an HCV infection.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is effective to inhibit the function of target in the HCV life cycle other than the HCV NS5B protein.
  • “Therapeutically effective” means the amount of agent required to provide a meaningful patient benefit as understood by practitioners in the field of hepatitis and HCV infection.
  • Patient means a person infected with the HCV virus and suitable for therapy as understood by practitioners in the field of hepatitis and HCV infection.
  • Treatment Treatment
  • therapy Treatment
  • regimen Treatment
  • HCV infection HCV infection
  • compositions comprised of a therapeutically effective amount of a compound of Formula I, II, III, or IV or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients.
  • a therapeutically effective amount is that which is needed to provide a meaningful patient benefit.
  • Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles.
  • Compositions encompass all common solid and liquid forms including capsules, tablets, losenges, and powders as well as liquid suspensions, syrups, elixers, and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) are generally used for compositions.
  • compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg. Generally, other agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 0.25-1000 mg/unit.
  • Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 1-100 mg/mL.
  • the invention encompasses all conventional modes of administration; oral and parenteral methods are preferred.
  • the dosing regimen will be similar to other agents used clinically.
  • the daily dose will be 1-100 mg/kg body weight daily.
  • more compound is required orally and less parenterally.
  • the specific dosing regime will be determined by a physician using sound medical judgement.
  • the invention also encompasses methods where the compound is given in combination therapy. That is, the compound can be used in conjunction with, but separately from, other agents useful in treating hepatitis and HCV infection.
  • the compound of Formula I, II, III, or IV will generally be given in a daily dose of 1-100 mg/kg body weight daily in conjunction with other agents.
  • the other agents generally will be given in the amounts used therapeutically.
  • the specific dosing regime will be determined by a physician using sound medical judgement.
  • 3-Cyclohexyl-1H-indole-6-carboxylic acid 3-Cyclohexenyl-1H-indole-6-carboxylic acid (38 g) was added to a Parr bottle, followed by methanol (100 mL) and THF (100 mL). The bottle was flushed with argon and 10% palladium on carbon (1.2 g) was added. The flask was then evacuated and subsequently refilled with H 2 to a pressure of 55 psi, and the resultant mixture was shaken for 18 hours at RT. The catalyst was then removed by filtration through celite. Concentration of the filtrate provided the desired product as a pale purple solid (30.6 g, 79%). ESI-MS m/z 244 (MH+).
  • hexane mother liquor was concentrated and the residue was dissolved in hexane/ethyl acetate (5:1).
  • the solution was passed through a pad of silica gel with the same solvents. Concentration of the eluate followed by the addition of hexane (10 mL) resulted in the precipitation of additional product which was collected by filtration to provide 2.8 g (28%) of the desired product.
  • Methyl 11-cyclohexyl-6-hydroxy-6H-isoindolo[2,1-a]indole-3-carboxylate A stirred mixture of methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate (10.1 g, 30 mmol), 2-formylphenylboronic acid (5.4 g, 36 mmol), LiCl (3.8 g (90 mmol) and Pd (PPh 3 ) 4 (1.6 g, 1.38 mmol) in 1M Na 2 CO 3 (40 mL) and 1:1 EtOH-toluene (180 mL) was heated under nitrogen at 85° C. for 3 hours.
  • Methyl 13-cyclohexyl-6-(methoxycarbonyl)-7H-indolo[2, 1-a][2]benzazepine-10-carboxylate A stirred suspension of methyl 11-cyclohexyl-6-hydroxy-6H-isoindolo[2,1-a]indole-3-carboxylate (3.61 g, 10 mmol), Cs 2 CO 3 (3.91 g, 12 mmol) and trimethyl 2-phosphonoacetate (2.86g, 14 mmol) in an. DMF (40 mL) was heated at 60° C. under nitrogen for 3 h. The resultant yellow suspension was cooled to rt and water was added with vigorous stirring.
  • Methyl 13-cyclohexyl-6-(carboxy)-5H-indolo[2,1-a][2]benzazepine-10-carboxylate Methyl 13-cyclohexyl-6-(methoxycarbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate (308 mg, 0.72 mmol) was dissolved in N,N-dimethylformamide (5 mL) and treated with LiOH (173 mg, 7.2 mmol). The mixture was heated at 50° C. for 4 hr, after which the solvent was removed in vacuo.
  • Methyl 13-cyclohexyl-6-(morpholinylcarbonyl)-5H-indolo[2,1-a][2]benzazepine-10-carboxylate TBTU (145 mg, 0.45 mmol) was added to a stirred solution of Methyl 13-cyclohexyl-6-(carboxy)-5H-indolo[2,1-a][2]benzazepine-10-carboxylate (125 mg, 0.30 mmol), morpholine (26 ⁇ L, 0.30 mmol), and N,N-diisopropylethylamine 200 ⁇ L, 1.15 mmol) in DMF (2 mL). The mixture was stirred at 22° C.
  • tert-butyl 4-methylpiperazin-1-ylsulfonylcarbamate (89 mg, 0.32 mmol) was dissolved in TFA/DCM (1/1, 1 mL) and stirred for 2 h. removed the solvents in vacuo and added acid 2 (40 mg, 0.1 mmol), DMAP (129 mg, 1.06 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (61 mg, 0.3 mmol), DMF (1.5 mL). The mixture was stirred o/n and purified by prep HPLC to afford the product as a solid (6.3 mg, 9%).
  • Boc sulfamide (102 mg, 0.63 mmol) was dissolved in TFA/DCM (1/1, 1 mL) and stirred for 2 h. removed the solvents in vacuo and added acid 2 (40 mg, 0.1 mmol), DMAP (100 mg, 0.82 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (57 mg, 0.3 mmol), DMF (1.5 mL). The mixture was stirred o/n and purified by prep HPLC to afford the product as a solid (10.4 mg, 20%).
  • reaction mixture was stirred at rt for 15 min., diluted with H2O ( ⁇ 4 mL) and the solids were collected by filtration washed with H 2 O and dried under vacuum overnight to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-, methyl ester (168 mg, 0.30 mmol, 83%) as a yellow solid.
  • the reaction mixture was stirred at rt for 2 h, diluted with H2O ( ⁇ 6 mL) and the solids were collected by filtration, washed with H2O, dissolved into MeOH//THF (1:1, 4 mL) and treated with 1 M aqueous NaOH (0.60 mL).
  • the reaction mixture was stirred and heated at 80° C. with microwave irradiation for 20 min in a sealed tube, additional 1 M aqueous NaOH (0.10 mL.) was added and the reaction was reheated at 80° C. for 10 min.
  • the clear solution was diluted with H2O (1 mL), neutralized with 1M aqueous HCl (0.70 mL) and concentrated to remove organic solvents.
  • reaction mixture was stirred at rt for 15 min., diluted with H2O ( ⁇ 4 mL) and the solids were collected, by filtration washed with H2O and dried under vacuum overnight to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]carbonyl]-, methyl ester (170 mg, 0.30 mmol, 83%) as a yellow solid.
  • Trifluoroacetic acid (1.5 mL) was added dropwise to a stirred solution of 1-piperazinecarboxylic acid, 4-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-, 1,1-dimethylethyl ester (77 mg. 0.11 mmol) in CH2C12 (1.5 mL).
  • reaction solution was stirred 2 h, concentrated and the residue was purified by preparative HPLC (MeOH/H2O with TFA buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(1-piperazinylcarbonyl) (37 mg, 0.06 mmol, 56%) as a yellow solid.
  • the reaction mixture was stirred at rt for 1 h, diluted with H2O ( ⁇ 5 mL) stirred for 30 min, and the solids (288 mg) collected by filtration and flushed with H2O.
  • the crude solids were dissolved into MeOH/THF (1:1, 4 mL) and treated with 1M aqueous NaOH (0.75 mL).
  • the reaction mixture was stirred and heated at 80° C. with microwave irradiation for 15 min in a sealed tube.
  • the clear solution was diluted with H2O (5 mL), neutralized with 1M aqueous HCl (0.75 mL) and concentrated to remove organic solvents.
  • the resultant solids (247 mg) were collected by filtration and washed with H2O.
  • the crude solids were dissolved into MeOH/THF (1:1, 4 mL) and treated with 1M aqueous NaOH (0.75 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 15 min in a sealed tube. The clear solution was diluted with H2O (5 mL), neutralized with 1M aqueous HCl (0.75 mL) and concentrated to remove organic solvents. The resultant solids (257 mg) were collected by filtration and washed with H2O.
  • the crude solids were dissolved into MeOH/THF (1:1, 4 mL) and treated with 1M aqueous NaOH (0.75 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 15 min in a sealed tube. The clear solution was diluted with H2O (5 mL), neutralized with 1M aqueous HCl (0.75 mL) and concentrated to remove organic solvents.
  • the crude solids were dissolved into MeOH/THF (1:1, 4 mL) and treated with 1M aqueous NaOH (0.75 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 15 min in a sealed tube. The clear solution was diluted with H2O (5 mL), neutralized with 1M aqueous HCl (0.75 mL) and concentrated to remove organic solvents. The resultant solids (257 mg) were collected by filtration and washed with H2O.
  • reaction volume was then reduced to a total volume of 2.0 mL in a Savant Speedvac and the crude product was purified using a Dionex ELSD triggered preparative HPLC employing acetonitrile/water and 10 mM ammonium acetate buffer with a Sunfire, C18, 21.2 mm ⁇ 150 mm, 10 ⁇ m column at a focused gradient flow rate of 20 mL/min.
  • 1-piperazinecarboxylic acid 4-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-3-methyl-, 1,1-dimethylethyl ester.
  • the preparations in the following section uses the general protocols and procedures described below:
  • the diversity amines (0.108 mmol, 1.3 equiv) were weighed directly into successive reactor vessels of a multiposition reactor.
  • To each position in the reactor was then added the carboxylic acid template (500 uL of a 0.172 M stock solution in DMF, 0.086 mmol, 1.0 equiv) followed by 500 uL of a three-component stock solution in DMF containing EDC (0.108 mmol, 1.3 equiv), HOBt (0.108 mmol, 1.3 equiv), and N,N-diisopropylethylamine (0.430 mmol, 5.0 equiv).
  • EDC 0.108 mmol, 1.3 equiv
  • HOBt a three-component stock solution in DMF containing EDC
  • HOBt 0.108 mmol, 1.3 equiv
  • N,N-diisopropylethylamine
  • column 3 is defined as LCMS data:Gradient time: 2min; Flow rate: 4 mL/min; Stop time: Gradient time+1 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H2O with 0.1% TFA; Eluent B: 90% MeOH/10% H2O with 0.1% TFA; Column 3: Phenomenex-luna 10 ⁇ 4.6 ⁇ 50 mm S10.
  • TMSOK potassium trimethylsilanoate
  • TBTU (22 mg, 0.069 mmol) was added to a stirred solution of 6-carboxy-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-5H-indolo[2,1-a][2]benzazepine-10-carboxamide (25 mg, 0.049 mmol), homomorpholine hydrochloride (8.1 mg, 0.059 mmol), and N,N-diisopropylethylamine (0.3 mL, 1.74 mmol) in DMF (3 mL). The mixture was stirred at 22° C. for 20 min. The resulting solution was concentrated down to the volume of 2 mL on a Speed Vac® and filtered.
  • Methyl 2-(2-acetylphenyl)-3-cyclohexyl-1H-indole-6-carboxylate A 2M aqueous solution of Na 2 CO 3 (2.5 mL, 5.0 mmol) was added to a mixture of; methyl 3-cyclohexyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-6-carboxylate (766 mg, 2.0 mmol), 2′-bromoacetophenone (478 mg, 2.4 mmol) and LiCl (170 mg, 4.0 mmol), in ethanol (5 mL) and toluene (5 mL).
  • the solution was diluted with EtOAc (300 mL) and washed with H 2 O (150 mL), 1N aqueous HCl (2 ⁇ 100 mL) and brine (100 mL).
  • the combined aqueous layers were extracted with EtOAc (200 mL) and the organic layer was washed with 1N aqueous HCl (150 mL) and brine (50 mL).
  • the combined organic layers were dried (MgSO 4 ), filtered and concentrated to an oil.
  • Methyl isocyanate (94 mg, 1.6 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(1-piperazinylcarbonyl) (40 mg. 0.07 mmol) in CH 2 Cl 2 (1 mL) and stirred at rt for 2 h. The reaction was concentrated to dryness, slurried with Et 2 O and filtered.
  • reaction mixture was stirred at rt for 3 h, diluted with H 2 O ( ⁇ 10 mL) and the resulting solids were collected by filtration, washed with H 2 O and dried to yield methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl-3-methoxy-6-[[[2-(methylamino)-2-oxoethyl]amino]carbonyl]- (140 mg, 0.27 mmol, quant.) as a yellow solid, which was used without further purification.
  • the solids were dissolved into THF/MeOH (1:1, 6 mL) and 1M NaOH (aq.) (1.5 mL, 1.5 mmol).
  • the reaction mixture was heated in a sealed tube with microwave irradiation at 85° C. for 20 min.
  • the reaction was cooled, neutralized with 1M HCl (aq.) (1.5 mL, 1.5 mmol) and concentrated to remove organic solvents.
  • the reaction mixture was stirred at rt for 2 h, diluted with H 2 O ( ⁇ 12 mL) and the resulting solids were collected by filtration, washed with H 2 O and dried on the filter with aspirator vacuum for 1 h.
  • the solids were dissolved into THF/MeOH (1:1, 4 mL) and 1M NaOH (aq.) (1.0 mL, 1.0 mmol).
  • the reaction mixture was heated in a sealed tube with microwave irradiation at 85° C. for 20 min.
  • the reaction was cooled, neutralized with 1M HCl (aq.) (1.0 mL, 1.0 mmol) and concentrated.
  • reaction mixture was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N 10 -[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N 6 -[2-[(2-methoxyethyl)amino]-2-oxoethyl]-N 6 -methyl- (30 mg, 0.04 mmol, 75%) as a yellow solid.
  • Diastereomeric mixture of atrope isomers with amide rotamers Partial 1 HNMR (300 MHz, CDCl 3 ) ⁇ 11.30 (br s, 0.2H), 11.00 (br s, 0.5H), 8.35 (br s, 0.2H), 7.98 (br s, 0.6H), 7.89-7.66 (m, 2H), 7.37-7.28 (m, 1H), 6.95-6.85 (m, 2H), 6.10-6.00 (m, 0.5H), 5.08-4.98 (m, 0.4H), 3.86 (s, 3H), 3.01 (s, 6H).
  • LCMS m/e 666 (M ⁇ H) ⁇ , ret time 2.74 min, column A, 4 minute gradient.
  • reaction mixture was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N 6 -[2-(diethylamino)-2-oxoethyl]-N 10 -[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N 6 -methyl- (44 mg, 0.07 mmol, 86%) as an off-white solid.
  • reaction mixture was stirred at rt for 1 h, diluted with H 2 O ( ⁇ 5 mL), acidified with 1M HCl (aq.) ( ⁇ 0.75 mL) and the precipitate was collected by filtration.
  • the solids were rinsed with water and dried to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N 10 -[(dimethylamino)sulfonyl]-3-methoxy-N 6 -(2-methoxyethyl)-N 6 -methyl- (93 mg, 0.15 mmol, 91%) as a white solid.
  • reaction mixture was stirred at rt for 1 h, diluted with H 2 O ( ⁇ 5 mL), acidified with 1M HCl (aq.) ( ⁇ 0.75 mL) and the precipitate was collected by filtration.
  • the solids were rinsed with water and dried to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N 10 -[(dimethylamino)sulfonyl]-3-methoxy-N 6 -[(1-methyl-1H-imidazol-4-yl)methyl]- (102 mg, 0.16 mmol, 96%) as a bright yellow solid.
  • reaction mixture was stirred at rt for 1 h, diluted with H 2 O ( ⁇ 5 mL), acidified with 1M HCl (aq.) ( ⁇ 0.75 mL) and the precipitate was collected by filtration.
  • the solids were rinsed with water and dried to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N 10 -[(dimethylamino)sulfonyl]-N 6 -[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-3-methoxy- (104 mg, 0.16 mmol, 96%) as a bright yellow solid.
  • reaction mixture was stirred at rt for 1.5 h, diluted with H 2 O ( ⁇ 5 mL), acidified with 1M HCl (aq.) ( ⁇ 0.20 mL) and the precipitate was collected by filtration and flushed with H 2 O to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 3-methoxy, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[3-methoxyazetidinyl]carbonyl]- (57 mg, 0.09 mmol, 63%) as a yellow solid.
  • reaction mixture was stirred at rt for 1.5 h, diluted with H 2 O ( ⁇ 10 mL), acidified with 1M HCl (aq.) ( ⁇ 0.50 mL) and the precipitate was collected by filtration and flushed with H 2 O.
  • 1M NaOH aq.
  • the reaction solution was heated in a sealed tube with microwave irradiation at 85° C. for 30 min. The reaction was cooled, neutralized with 1M HCl (aq.) (0.75 mL, 0.75 mmol) and concentrated to remove organic solvents.
  • reaction mixture was stirred at rt for 1.5 h, diluted with H 2 O ( ⁇ 3 mL), acidified with 1N HCl(aq.) ( ⁇ 0.1 mL) and the precipitate was collected by filtration and flushed with H 2 O.
  • reaction mixture was stirred at rt for 1.5 h, diluted with H 2 O ( ⁇ 3 mL), acidified with IN HCl(aq.) ( ⁇ 0.1 mL) and the precipitate was collected by filtration and flushed with H 2 O.
  • reaction mixture was stirred at rt for 1.5 h, diluted with H 2 O ( ⁇ 3 mL), acidified with 1N HCl(aq.) ( ⁇ 0.1 mL) and the precipitate was collected by filtration and flushed with H 2 O.
  • reaction solution was stirred at rt for 30 min, quenched with MeOH and purified by preparative HPLC (MeOH/H 2 O with a TFA buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, N 6 -[2-(acetylmethylamino)ethyl]-13-cyclohexyl-N 10 -[(dimethylamino)sulfonyl]-3-methoxy-N 6 -methyl- (20 mg, 0.03 mmol, 18%) as a yellow solid.
  • reaction mixture was stirred at rt for 3 h, diluted with H 2 O ( ⁇ 5 mL), acidified with 1M HCl (aq.) ( ⁇ 0.20 mL) and the precipitate was collected by filtration and flushed with H 2 O.
  • 1M NaOH aq.
  • the reaction solution was heated in a sealed tube with microwave irradiation at 65° C. for 20 min. The reaction was cooled, neutralized with 1M HCl (aq.) (1 mL, 1.0 mmol) and concentrated to remove organic solvents.
  • reaction mixture was stirred at rt for 3 h, diluted with H 2 O ( ⁇ 5 mL), acidified with 1M HCl (aq.) ( ⁇ 0.20 mL) and the precipitate was collected by filtration and flushed with H 2 O.
  • 1M NaOH aq.
  • reaction solution was heated in a sealed tube with microwave irradiation at 65° C. for 20 min. The reaction was cooled, neutralized with 1M HCl (aq.) (0.6 mL, 0.6 mmol) and concentrated to remove organic solvents.
  • Method 1 Analysis Conditions: Column: XTERRA 4.6 ⁇ 50 mm S5; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range: 0-100% B; Gradient Time: 3 min; Flow Rate: 4 mL/min; Analysis Time: 4 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+); Fraction Collection: WV-triggered; Fraction Drying.
  • Method 2 Analysis Conditions: Column: PHENOMENEX-LUNA 4.6 ⁇ 50 mm S10; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range:0-100% B; Gradient Time: 2 min; Flow Rate: 4 mL/min; Analysis Time: 3 min; Detection: Detector 1: UV at 254 nm; Detector 2: MS (ESI+); Fraction Collection: UV-triggered; Fraction Drying.
  • Method 3 Analysis Conditions: Column: PHENOMENEX-LUNA 4.6 ⁇ 50 mm s10; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range:0-100%; Gradient Time: 3 min; Flow Rate: 4 mL/min; Analysis Time: 4 min; Detection: Detector 1: UV at 254 run; Detector 2: MS (ESI+); Fraction Collection: UV-triggered; Fraction Drying.
  • Method 4 Analysis Conditions: Column: PHENOMENEX-LUNA 4.6 ⁇ 50 mm s10; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range:0-100% B; Gradient Time: 2 min; Flow Rate: 4 mL/min; Analysis Time: 3 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+); Fraction Collection: UV-triggered; Fraction Drying.
  • Method 5 Analysis Conditions: Column: PHENOMENEX-LUNA 3.0 ⁇ 50 mm S10; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range:0-100% B; Gradient Time: 2 min; Flow Rate: 4 mL/min; Analysis Time: 3 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+); Fraction Collection: UV-triggered; Fraction Drying.
  • Step 1 Preparation of Compound 1A.
  • Step 1 Small amount of MeOH was added to a suspension of Compound 1 (0.46 g, 0.82) dispersed in THF (5 mL) and H 2 O (2 mL) till no solid in the mixture. LiOH.H 2 O (0.13 mmol 3.3 mmol)) was added. The mixture was stirred o/n, and removed the organic solvents in vacuo. The residue was acidified to pH 2, extracted with EtOAc/CH 2 Cl 2 .
  • Step 1 A mixture of compound 2 (0.075 g, 0.16 mmol), triethyl amine (0.057 mL, 0.4 mmol), 2,6-dimethylmorpholine (0.043 g, 0.38 mmol) and TBTU (0.066 g, 0.20 mmol) in DMF (1.5 mL) was stirred for 2 h and purified by prep HPLC to afford compound 3 as a yellow solid (0.0427 g, 42%).
  • LC-MS retention time: 3.47; MS m/z 647 M+H, Method 1).
  • Step 1 The trifluoroacetic acid salt of Compound 4 was obtained following the procedure described in preparation of compound 3 (44%).
  • Step 1 2-Chloro-2-oxoethyl acetate (1.5 mL, 14 mmol) was added to a solution of tert-butyl piperazine-1-carboxylate (2.0 g, 10.7 mmol), triethyl amine (2.2 mL, 16 mmoL) in dichloromethane (30 mL) at 0° C.
  • Step 2 A mixture of tert-butyl 4-(2-acetoxyacetyl)piperazine-1-carboxylate (0.073 g, 0.25 mmol) in trifluoroacetic acid/dichloromethane (1/1, 1.5 mL) was stirred for 0.5 h at r.t. The solvents were removed in vacuo to afford a brown residue. DMF (1.5 mL), Compound 2 (0.070 g, 0.13 mmol), Triethyl amine (0.089 mL 0.64 mmol), and TBTU (0.061 g, 0.19 mmol) were added to the residue.
  • Step 1 A mixture of Compound 5 (0.047 g, 0.07 mmol) LiOH.H2O (0.040 g, 1 mmol), THF (6 mL) MeOH (3 mL), and H 2 O (1 mL) was stirred for one day, acidified to pH 2 and extracted with Ethyl acetate/dicholoromethane (2 ⁇ ).
  • Step 1 Compound 7 was prepared from compound 2 by following the similar procedure of 3 in making compound 3 (47%). LC-MS (retention time: 2.09; MS m/z 702 M+H, Method 4).
  • Step 1 Compound 8 was prepared from compound 2 by following the similar procedure of Step 1 of Scheme 3 in making Compound 3 (20%).
  • Step 1 The trifluoroacetic acid salt of compound 11 was prepared from compound 11B and 11B by following the similar procedure of 10 in making compound 10 (18%).
  • LC-MS retention time: 3.00; MS m/z 662 M+H, Method 1).
  • Step 2 Preparation of compound 12.
  • a mixture of compound 12B (0.061 g, 0.09 mmol) and aqueous NaOH (1N 0.5 mL, 0.5 mmol)n and a few drops of MeOH was stirred at r.t. for 3 h. removed the organic solvent and the residue was partitioned between aqueous NaH2PO4 and EtOAc/THF. The organic solvent was washed with brine and dried (MgSO 4 ), removed the solvent and purified by prep HPLC to afford compound 12.
  • reaction mixture was cooled down, and added saturated NaH2PO4, extracted with EtOAc. the extraction was dried (Na 2 SO 4 ), removed the solvent in vacuo to provide a brown tar residue. The residue was dissolved in minimum amount of CH 2 Cl 2 and hexane was added till no solid coming out, filtered to provide a yellow solid.
  • Step 2 Preparation of compound 13B.
  • Compound 13B was prepared from Compound 13A by following the similar procedure of step 1 of Scheme 2 in making Compound 2 (100%) LC-MS (retention time: 3.50; MS m/z 580 M+H, Method 1).
  • Step 3 Preparation of compound 13.
  • Compound 13 was prepared from compound 13B by following the similar procedure of Step 1 of Scheme 3 in making compound 3 (100%).
  • Step 1 Compound 19 was prepared from compound 19A and compound 19B by following the similar procedure of Step 1 of scheme 10 in making compound 10 (45%).
  • LC retention times refer to a Phenomenex-Luna 3.0 ⁇ 50 mm S10 column w/gradient elution (A: 10% MeOH-90% H 2 O-0.1% TFA, B: 90% MeOH-10% H 2 O-0.1% TFA; 0% B to 100% B over 2 min), 5 uL injection, w/ flow rate of 4 mL/min.
  • the reaction was shaken on an Innova 2000 orbital shaker at 240 rpm overnight, at room temperature.
  • N-(morpholin-2-ylmethyl)acetamide N-(morpholin-2-ylmethyl)acetamide.
  • 4-benzylmorpholin-2-yl)methanamine 4 mL of dry dichloroethane in a 10 mL sealed tube.
  • the tube was sealed and the solution was stirred at 60° C. overnight.
  • reaction volume was then reduced to a total volume of 2.0 mL in a Savant Speedvac and the crude product was purified using a Shimadzu preparative HPLC employing acetonitrile/water and 10 mM trifluoroacetic acid buffer with a Waters Sunfire, C18, 19 mm ⁇ 100 mm, 5 ⁇ m column at a focused gradient of 50-100% B and a flow rate of 25 mL/min.
  • acyl azide was found to be stable at room temperature in a vacuum desiccator for up to one month.
  • the vial was capped and heated to 100° C. in a Biotage/Personal Chemistry Emrys Optomizer microwave for 25 minutes.
  • the crude reaction mixture was then evacuated to near dryness, taken up in a 1:1 ethyl acetate/hexane mixture and purified by flash chromatography to yield urea 3 (50-55% yield).
  • the mixture of enantiomers was taken up in methanol (10 mg/2 mL), injected onto the column and eluted with 85% CO 2 and 15% methanol with 0.1% trifluoroacetic acid buffer at a flow rate of 70 mL/minute.
  • the temperature was maintained at 35° C. and the pressure at 150 bar throughout the experiment and the elution of the products was monitored by a UV detector at a wave length of 210 nm.
  • Isomer A eluted 9.5-13.0 minutes.
  • Isomer B eluted 27.5-32.0 minutes.
  • the samples were concentrated en-vacuo to give enantiomerically pure ivory colored amorphous solids.
  • the chiral separation was accomplished using preparative chiral supercritical fluid chromatography (SFC) employing a Chiralpak OD-H, 30 ⁇ 250 mm, 5 ⁇ m column.
  • SFC preparative chiral supercritical fluid chromatography
  • the mixture of enantiomers was taken up in methanol (10 mg/2 mL), injected onto the column and eluted with 80% CO 2 and 20% methanol with 0.1% trifluoroacetic acid buffer at a flow rate of 70 mL/minute.
  • the temperature was maintained at 35° C. and the pressure at 150 bar throughout the experiment and the elution of the products was monitored by a UV detector at a wave length of 210 nm.
  • Isomer A eluted at 10.7-12.5 minutes.
  • Isomer B eluted at 15.8-19.5 minutes.
  • the samples were concentrated en-vacuo to give enantiomerically pure yellow amorphous solids.
  • LCMS data Gradient time: 2 min; Flow rate: 4 mL/min;, Stop time: Gradient time: +1 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H 2 O with 0.1% TFA; Eluent B: 90% MeOH /10% H 2 O with 0.1% TFA; Column 6: Phenomenex-luna 10 ⁇ C18 4.6 ⁇ 50 mm S10.
  • Step 1 A solution of tert-butyl piperazine-1-carboxylate (372.5 mg, 2.0 mmol) and N,N-diisopropylethylamine (517 mg, 4 mmol) in DMSO (2 mL) was rapidly added to a stirred solution of Fmoc-Gly OH (594.6 mg, 2 mmol) and TBTU (707 mg, 2.2 mmol) in DMSO (2 mL) at 10° C. The cooling bath was removed and stirred continued for 30 min at 22° C. The mixture was poured into water and the precipitated solid extracted into ethyl acetate.
  • the organic solution was washed (water(2 ⁇ ), dilute HCl, brine), dried (sodium sulfate) and concentrated to leave the product as a yellow froth.
  • a portion (140 mg) was purified on a silicic acid thick layer plate. The plate was eluted with methylene chloride:ethyl acetate (4:1). The band containing the product was extracted. The extract was concentrated and the residue crystallized form methanol to leave the titled compound.
  • Step 2 A solution of tert-butyl 4-(2-(((9H-fluren-9-yl)methoxy)carbonyl)acetyl)piperazine-1-carboxylate in TFA and methylene chloride (1:1) was stirred for 1 hr at 22° C. The solution was concentrated and the residue diluted with hexanes. Removal of the hexanes left the titled compound as a hygroscopic colorless foam. LCMS: m/z 366(MH + ), ret time 2.06 min.
  • LCMS data Gradient time: 2 min; Flow rate: 4 mL/min; Stop time: Gradient time +2 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H 2 O with 0.1% TFA; Eluent B: 90% MeOH/10% H 2 O with 0.1% TFA; Column 1: Phenomenex 10 ⁇ C18 4.6 ⁇ 50 mm.
  • LCMS m/z 575 (MH + ), ret time 2.73 min
  • LCMS data Gradient time: 2 min; Flow rate: 4 mL/min; Stop time: Gradient time +1 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H 2 O with 0.1% TFA; Eluent B: 90% MeOH/10% H 2 O with 0.1% TFA; Column 3: Phenomenex-luna 10 4.6 ⁇ 50 mm S10.
  • LCMS data Stop time: Gradient time +1 minute; Starting conc: 0% B unless otherwise noted; Eluent A: 5% CH 3 CN/95% H 2 O with 10 mM NH 4 OAc (for columns A, D and E); 10% MeOH/90% H 2 O with 0.1% TFA (for columns B and C); Eluent B: 95% CH 3 CN/5% H 2 O with 10 mM NH 4 OAc (for columns A, D and E); 90% MeOH/10% H 2 O with 0.1% TFA (for columns B and C); Column A: Phenomenex 10 ⁇ 4.6 ⁇ 50 mm C18; Column B: Phenomenex C18 10 ⁇ 3.0 ⁇ 50 mm; Column C: Phenomenex 4.6 ⁇ 50 mm C18 10; Column D: Phenomenex Lina C18 513.0 ⁇ 50 mm; Column E:Phenomenex 5 ⁇ 4.6 ⁇ 50 mm C18.
  • reaction mixture was stirred at rt for 2 h, and additional dimethylamine (2M in THF, 0.10 mL, 0.20 mmol) and HATU (70 mg, 0.18 mmol) were added.
  • the reaction was stirred at rt overnight, diluted with H2O ( ⁇ 10 mL), acidified with IN HCl(aq.) ( ⁇ 0.25 mL) and the precipitate was collected by filtration and flushed with H2O to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6,N6-bis[2-(dimethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy- (31 mg, 0.044 mmol, 67%) as a yellow solid.
  • D-alanine N-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-N-methyl-.
  • reaction mixture was stirred at rt for 2 h, diluted with H 2 O ( ⁇ 10mL), acidified with 1M HCl (aq.) ( ⁇ 0.50 mL), stirred 30 min. and the precipitate was collected by filtration and flushed with H 2 O.
  • reaction mixture was stirred at rt for 2 h, diluted with H 2 O ( ⁇ 10 mL), acidified with 1M HCl (aq.) ( ⁇ 0.50 mL), stirred 30 min. and the precipitate was collected by filtration and flushed with H 2 O.
  • reaction mixture was stirred at rt for 3 h, additional tert-butyl azetidin-3-ylcarbamate (100 mg, 0.58 mmol) and HATU (120 mg, 0.32 mmol) were added and the reaction mixture was stirred at rt for 2 h and then diluted with H 2 O and stirred.
  • reaction mixture was stiffed at rt for 2 h, concentrated and the residue was dissolved into MeOH and purified by preparative HPLC (CH 3 CN/H 2 O with 10 mM NH 4 OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[(3-amino-1-azetidinyl)carbonyl]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy- (31 mg, 0.05 mmol, 60%) as a fluffy yellow solid.
  • reaction mixture was stirred at rt for 2 h and then additional azetidin-3-ylmethanol (prepared by stirring tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (70 mg, 0.37 mmol) with trifluoroacetic acid (1 mL) for 10 min, and then concentrating to dryness) in DMF (0.5 mL) and HATU (70 mg, 0.18 mmol) were added.
  • azetidin-3-ylmethanol prepared by stirring tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (70 mg, 0.37 mmol) with trifluoroacetic acid (1 mL) for 10 min, and then concentrating to dryness
  • DMF 0.5 mL
  • HATU 70 mg, 0.18 mmol
  • reaction mixture was stirred 0.5 h, diluted with MeOH (0.5 mL) and purified by preparative HPLC (CH 3 CN/H 2 O with 10 mM NH 4 OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[3-(hydroxymethyl)-1-azetidinyl]carbonyl]-3-methoxy- (67 mg, 0.11 mmol, 85%) as a yellow solid.
  • reaction mixture was stirred at rt for 30 min., diluted with MeOH ( ⁇ 1 mL) and purified by preparative HPLC (CH 3 CN/H 2 O with 10 mM NH 4 OAc) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N 10 -[(dimethylamino)sulfonyl]-3-methoxy-N 6 -methyl-N 6 -(2-pyridinylmethyl)- (74 mg, 0.12 mmol, 77%) as a yellow solid.
  • reaction mixture was stirred at rt for 1 h diluted with MeOH ( ⁇ 1 mL) and purified by preparative HPLC (CH 3 CN/H 2 O with 10 mM NH 4 OAc) to yield 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]carbonyl]-3-methoxy- (90 mg, 0.13 mmol, 87%) as a yellow solid.
  • the reaction was stirred under a balloon of hydrogen overnight and again vacuum flushed with nitrogen (3 ⁇ ) and then with hydrogen (4 ⁇ ) and stirred under a balloon of hydrogen for 3 d.
  • the reaction was treated with additional 10% palladium on carbon (40 mg, 0.04 mmol), vacuum flushed with nitrogen (3 ⁇ ) and then with hydrogen (4 ⁇ ) and stirred under a balloon of hydrogen overnight.
  • the reaction was filtered through a pad of celite and concentrated.
  • reaction mixture was stirred at rt for 0.5 h, diluted with H 2 O (10 mL) and extracted with CH 2 Cl 2 (3 ⁇ 5 mL). The combine organics were concentrated, dissolved into ClCH 2 CH 2 Cl (6 mL) and treated with trifluoroacetic acid (4 mL). The reaction mixture was stirred at rt for 2 h and concentrated to dryness. The residue was dissolved into MeOH, loaded onto an SCX cartridge, flushed with MeOH, eluted with 2M NH 3 in MeOH and concentrated to dryness.
  • reaction mixture was diluted with MeOH and purified by preparative HPLC (CH 3 CN/H 2 O with 10 mM NH 4 OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[3-[(dimethylamino)carbonyl]-1-azetidinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-3-methoxy- (19 mg, 0.029 mmol, 27%) as a yellow solid.
  • reaction mixture was stirred at rt for 0.5 h, diluted with H 2 O (10 mL) and extracted with CH 2 Cl 2 (3 ⁇ 5 mL). The combine organics were concentrated, dissolved into ClCH 2 CH 2 Cl (6 mL) and treated with trifluoroacetic acid (4 mL). The reaction mixture was stirred at rt for 2 h and concentrated to dryness. The residue was dissolved into MeOH, loaded onto an SCX cartridge, flushed with MeOH, eluted with 2M NH 3 in MeOH and concentrated to dryness.
  • reaction mixture was diluted with MeOH and purified by preparative HPLC (CH 3 CN/H 2 O with 10 mM NH 4 OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-6-[[3-(4-morpholinylcarbonyl)-1-azetidinyl]carbonyl]- (19 mg, 0.028 mmol, 25%) as a yellow solid.
  • reaction mixture was stirred at rt for 2 h, then diluted with H 2 O, neutralized with 1N aqueous HCl (8 mL), concentrated, and the residue was partitioned between EtOAc and H 2 O. The organic phase was separated, washed with brine and concentrated to a white solid (1.1 g). The solid was dissolved into ClCH 2 CH 2 Cl (10 mL) and treated with trifluoroacetic acid (5 mL). The reaction mixture was stirred at rt for 2 h, and concentrated to yield crude 2-hydroxy-2-methyl-1-(piperazin-1-yl)propan-1-one (1.1 g) as yellow semi-solid.
  • reaction mixture was stirred at rt for 2 h, then diluted with MeOH and purified by prep HPLC (CH 3 CN/H 2 O with 10 mM NH 4 OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(2-hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]carbonyl]-3-methoxy- (78 mg, 0.11 mmol, 67%) as a yellow solid.
  • reaction mixture was stirred at rt for 2 h, and additional 1-hydroxycyclopropanecarboxylic acid (30 mg, 0.29 mmol), HATU (100 mg, 0.26 mmol) and triethylamine (0.10 mL) were added.
  • the reaction was stirred under a balloon of hydrogen overnight and again vacuum flushed with nitrogen (3 ⁇ ) and then with hydrogen (4 ⁇ ).
  • the reaction was stirred under a balloon of hydrogen for 1 d, treated with trifluoroacetic acid (2 drops), vacuum flushed with nitrogen (3 ⁇ ) and then with hydrogen (4 ⁇ ) and stirred 3 h.
  • the reaction mixture was filtered through a pad of celite and concentrated. The residue was dissolved MeOH (2 mL) treated with 10% palladium on carbon (70 mg, 0.07 mmol), vacuum flushed with nitrogen (3 ⁇ ) and then with hydrogen (4 ⁇ ) and stirred under a balloon of hydrogen for 2 d.
  • reaction mixture was stirred at rt for 16 h, then diluted with MeOH/DMSO and purified by prep HPLC (MeOH/H 2 O/0.1% TFA) to yield an orange solid, which was further purified by prep HPLC (CH 3 CN/H 2 O with 10 mM NH 4 OAc) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N 6 -[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-1-methyl-2-oxoethyl]-N 10 -[(dimethylamino)sulfonyl]-3-methoxy- (14 mg, 0.021 mmol, 12%) as a bright yellow solid.
  • acyl azide was found to be stable at room temperature in a vacuum desiccator for up to one month.
  • the crude reaction mixture was then evacuated to near dryness, taken up in 2 mL acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water and 10 mM trifluoroacetic acid buffer with a Waters Sunfire, C18, 19 mm ⁇ 100 mm, 5 ⁇ m column at a focused gradient of 50-100% B and a flow rate of 25 mL/min., to give dimethylamino sulfamide ureas 3 as yellow amorphous solids (35-50% yield).
  • 1,4-Piperazinedicarboxamide N-[13-cyclohexyl-10-[[[(dimethylamino) sulfonyl]amino]carbonyl]-6,7-dihydro-3-methoxy-5H-indolo[2,1-a][2]benzazepin-6-yl]-.
  • the chiral separation the R & S enantiomers was accomplished using preparative chiral supercritical fluid chromatography (SFC) employing a ChiralCel OD-H, 30 ⁇ 250 mm, 5 ⁇ m column.
  • the mixture of enantiomers was taken up in isopropanol (4 mg/1 mL), injected onto the column and eluted with 80% CO 2 and 20% methanol with 0.1% trifluoroacetic acid buffer at a flow rate of 70 mL/minute.
  • the temperature was maintained at 35° C. and the pressure at 150 bar throughout the experiment and the elution of the products was monitored by a UV detector at a wave length of 210 nm. Isomer A eluted at 13.92 minutes.
  • 1,3-Pyrrolidinedicarboxamide N ⁇ 1 ⁇ -[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-6,7-dihydro-3-methoxy-5H-indolo[2,1-a][2]benzazepin-6-yl]-.
  • LCMS data Gradient time: 2 min; Flow rate: 4 mL/min; Stop time: Gradient time +2 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H 2 O with 0.1% TFA; Eluent B: 90% MeOH/10% H 2 O with 0.1% TFA; Column 1: Phenomenex 10 ⁇ C18 4.6 ⁇ 50 mm.
  • the extract was washed (water (2 ⁇ ), brine), dried (sodium sulfate), and concentrated to leave a foam.
  • a solution of the foam in methylene chloride was applied to a silicic acid thick layer plate. The plate was developed with methylene chloride ⁇ 3% acetic acid. The band containing the product was removed and extracted with methylene chloride ⁇ 10% methanol. Removal of the solvents left the product (22.2 mg, 45 % yield) as a yellow solid.
  • the extract was washed (water (2 ⁇ ), brine), dried (magnesium sulfate), and concentrated to leave a froth.
  • a solution of the froth in methylene chloride was applied to a silicic acid thick layer plate. The plate was developed with methylene chloride ⁇ 2% acetic acid. The band containing the product was removed and extracted with methylene chloride ⁇ 10% methanol. Removal of the solvents left the product as a yellow solid.
  • the aqueous phase was extracted with ethyl acetate and the organic phases combined, washed with brine and dried over magnesium sulfate. Volatiles were removed in vacuuo to yield 1.47 g of crude product which was combined with 698 mg of a previous experiment.
  • the crude product was purified by silica gel chromatography eluting with a gradient of 10% ethyl acetate/dichloromethane to 25% ethyl acetate/dichloromethane to yield 1.64 g (84%) of product as a yellow solid.
  • the aqueous phase was extracted with ethyl acetate and the organic phases combined, washed with 0.1N hydrochloric acid then brine and dried over magnesium sulfate. Volatiles were removed in vacuuo to yield 1.98 g of crude product which was used in the next reaction without purification.
  • the crude acetal (1.4 g, 2.7 mMol) was dissolved in 30 mL of acetone and 2M hydrochloric acid (1.6 mL, 3.2 mMol) and briefly heated to reflux then allow to stir for 2.5 hrs before being briefly heated to reflux again and allowed to stir an additional 1.5 hrs.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
Figure US20070078122A1-20070405-C00001

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application Ser. No. 60/716,693 filed Sep. 13, 2005 and Ser. No. 60/771,501 filed Feb. 8, 2006.
    • BACKGROUND OF THE INVENTION
  • Hepatitis C virus (HCV) is a major human pathogen, infecting an estimated 170 million persons worldwide—roughly five times the number infected by human immunodeficiency virus type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma (Lauer, G. M.; Walker, B. D. N. Engl. J. Med. 2001, 345, 41-52).
  • HCV is a positive-stranded RNA virus. Based on a comparison of the deduced amino acid sequence and the extensive similarity in the 5′-untranslated region, HCV has been classified as a separate genus in the Flaviviridae family. All members of the Flaviviridae family have enveloped virions that contain a positive stranded RNA genome encoding all known virus-specific proteins via translation of a single, uninterrupted, open reading frame.
  • Considerable heterogeneity is found within the nucleotide and encoded amino acid sequence throughout the HCV genome. At least six major genotypes have been characterized, and more than 50 subtypes have been described. The major genotypes of HCV differ in their distribution worldwide, and the clinical significance of the genetic heterogeneity of HCV remains elusive despite numerous studies of the possible effect of genotypes on pathogenesis and therapy.
  • The single strand HCV RNA genome is approximately 9500 nucleotides in length and has a single open reading frame (ORF) encoding a single large polyprotein of about 3000 amino acids. In infected cells, this polyprotein is cleaved at multiple sites by cellular and viral proteases to produce the structural and non-structural (NS) proteins. In the case of HCV, the generation of mature non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) is effected by two viral proteases. The first one is believed to be a metalloprotease and cleaves at the NS2-NS3 junction; the second one is a serine protease contained within the N-terminal region of NS3 (also referred to as NS3 protease) and mediates all the subsequent cleavages downstream of NS3, both in cis, at the NS3-NS4A cleavage site, and in trans, for the remaining NS4A-NS4B, NS4B-NS5A, NS5A-NS5B sites. The NS4A protein appears to serve multiple functions, acting as a cofactor for the NS3 protease and possibly assisting in the membrane localization of NS3 and other viral replicase components. The complex formation of the NS3 protein with NS4A seems necessary to the processing events, enhancing the proteolytic efficiency at all of the sites. The NS3 protein also exhibits nucleoside triphosphatase and RNA helicase activities. NS5B (also referred to as HCV polymerase) is a RNA-dependent RNA polymerase that is involved in the replication of HCV. The HCV NS5B protein is described in “Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides (Bressanelli; S. et al., Journal of Virology 2002, 3482-3492; and Defrancesco and Rice, Clinics in Liver Disease 2003, 7, 211-242.
  • Currently, the most effective HCV therapy employs a combination of alpha-interferon and ribavirin, leading to sustained efficacy in 40% of patients (Poynard, T. et al. Lancet 1998, 352, 1426-1432). Recent clinical results demonstrate that pegylated alpha-interferon is superior to unmodified alpha-interferon as monotherapy (Zeuzem, S. et al. N. Engl. J. Med. 2000, 343, 1666-1672). However, even with experimental therapeutic regimens involving combinations of pegylated alpha-interferon and ribavirin, a substantial fraction of patients do not have a sustained reduction in viral load. Thus, there is a clear and important need to develop effective therapeutics for treatment of HCV infection.
  • HCV NS5B inhibitors have been disclosed. See WO 2006/046039; WO 2006/046030; WO 2006/029912; WO 2005/080399; WO 2005014543; WO 200307945; WO 2003010140; WO 2003010141; WO 200204425; WO 200147883; Harper, S. A. et al. J. Med. Chem. 2005, 48, 4547; and Harper, S. A. et al. J. Med. Chem. 2005, 48, 1314, and references cited therein.
    • DESCRIPTION OF THE INVENTION
  • The invention encompasses compounds of formulas I, II, III, and IV, and pharmaceutically acceptable salts and solvates thereof, and compositions and methods of treatment using these compounds.
  • One aspect of the invention is a compound of formula I
    Figure US20070078122A1-20070405-C00002
    • wherein:
    • R1 is CO2R6 or CONR7R8;
    • R2 is CO2R6, CO2benzyl, CONR9R10, NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO((R16)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((N(R6)2)alkyl), NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), NHCON(R6)((COR15)alkyl), NHCON(R6)((tetrahydropyranyl)alkyl),
      Figure US20070078122A1-20070405-C00003
    • R3 is hydrogen or alkyl;
    • R4 is hydrogen, halo, alkyl, alkoxy, or benzyloxy;
    • R5 is C5-7cycloalkyl;
    • R6 is hydrogen, alkyl, or cycloalkyl;
    • R7 is hydrogen, alkyl, cycloalkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
    • R8 is hydrogen, alkyl, or cycloalkyl;
    • or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
    • R9 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
    • R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
    • or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-4 substituents selected from the group consisting of halo, hydroxy, OPO(OR6)2, alkoxy, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (hydroxy)alkoxyalkyl, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)(R6)amino, (alkoxyCO)(R6)amino, (alkoxyalkylCO)(R6)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, ((hydroxy)cycloalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (alkylCO)(R6)aminoalkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
      Figure US20070078122A1-20070405-C00004
    • or NR9R10 taken together is
      Figure US20070078122A1-20070405-C00005
      Figure US20070078122A1-20070405-C00006
    • or NR9R10 taken together is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR6, NCO2R6, or O;
    • R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, ((R6)(R6)N)alkylamino, (((R6)(R6)N)alkyl)2amino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
    • R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy;
    • R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
    • R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, hydroxy, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, ((R6CO)(R6)amino)alkyl, (R15)alkyl, (R6CO)(R6)amino, R15, alkylCO, CF3CO, CO2R6, CON(R6)2, or SO2R6;
    • or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O;
    • R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents;
    • R16 is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, or pyridinyl, and is substituted with 0-2 alkyl substituents; and
    • the dashed line is either a single bond or a double bond, provided that if the dashed line is a single bond, the carbon bearing the asterisk is either of the R configuration, the S configuration, or a mixture of R and S;
    • or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a compound of formula I
    Figure US20070078122A1-20070405-C00007
    • wherein:
    • R1 is CONR7R5;
    • R2 is CO2R6, CO2benzyl, CONR9R10, NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO((R16)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((N(R6)2)alkyl), NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), NHCON(R6)((COR15)alkyl), NHCON(R6)((tetrahydropyranyl)alkyl),
      Figure US20070078122A1-20070405-C00008
    • R3 is hydrogen or alkyl;
    • R4 is hydrogen, halo, alkyl, alkoxy, or benzyloxy;
    • R5 is C5-7cycloalkyl;
    • R6 is hydrogen, alkyl, or cycloalkyl;
    • R7 is (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
    • R8 is hydrogen, alkyl, or cycloalkyl;
    • or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
    • R9 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
    • R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
    • or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-4 substituents selected from the group consisting of halo, hydroxy, OPO(OR6)2, alkoxy, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (hydroxy)alkoxyalkyl, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)(R6)amino, (alkoxyCO)(R6)amino, (alkoxyalkylCO)(R6)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, ((hydroxy)cycloalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (alkylCO)(R6)aminoalkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
      Figure US20070078122A1-20070405-C00009
    • or NR9R10 taken together is
      Figure US20070078122A1-20070405-C00010
      Figure US20070078122A1-20070405-C00011
    • or NR9R10 taken together is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR , NCO2R6, or O;
    • R11 is haloalkyl, alkoxy, ((R6)(R6)N)alkylamino, (((R6)(R6)N)alkyl)2amino, N,O-dimethylhydroxylamino;
    • R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy;
    • R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or tetrahydrofuranyl, and is substituted with 0-2 alkyl substituents;
    • R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, hydroxy, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, ((R6CO)(R6)amino)alkyl, (R15)alkyl, (R6CO)(R6)amino, R15, alkylCO, CF3CO, CO2R6, CON(R6)2, or SO2R6;
    • or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O;
    • R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents;
    • R16 is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, or pyridinyl, and is substituted with 0-2 alkyl substituents; and
    • the dashed line is either a single bond or a double bond, provided that if the dashed line is a single bond, the carbon bearing the asterisk is either of the R configuration, the S configuration, or a mixture of R and S;
    • or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a compound of formula I
    Figure US20070078122A1-20070405-C00012
    • wherein:
    • R1 is CO2R6 or CONR7R8;
    • R2 is CONR9R10, CO2benzyl, NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO((R16)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((N(R6)2)alkyl), NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), NHCON(R6)((COR15)alkyl), NHCON(R6)((tetrahydropyranyl)alkyl),
      Figure US20070078122A1-20070405-C00013
    • R3 is hydrogen or alkyl;
    • R4 is hydrogen, halo, alkyl, alkoxy, or benzyloxy;
    • R5 is C5-7cycloalkyl;
    • R6 is hydrogen, alkyl, or cycloalkyl;
    • R7 is hydrogen, alkyl, cycloalkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
    • R8 is hydrogen, alkyl, or cycloalkyl;
    • or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
    • R9 is cycloalkyl, dihydroxyalkyl, (alkoxy)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
    • R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
    • or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-4 substituents selected from the group consisting of halo, hydroxy, OPO(OR6)2, alkoxy, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (hydroxy)alkoxyalkyl, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)(R6)amino, (alkoxyCO)(R6)amino, (alkoxyalkylCO)(R6)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, ((hydroxy)cycloalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (alkylCO)(R6)aminoalkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
      Figure US20070078122A1-20070405-C00014
      provided that if NR9R10 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl it cannot be substituted with 0-2 substituents selected from alkyl, hydroxy, amino, alkylamino, dialkylamino, pyrrolidinyl, piperdinyl or pyridinyl;
    • or NR9R10 taken together is
      Figure US20070078122A1-20070405-C00015
      Figure US20070078122A1-20070405-C00016
    • or NR9R10 taken together is a [2.2.1 ] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR6, NCO2R6, or O;
    • R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, ((R6)(R6)N)alkylamino, (((R6)(R6)N)alkyl)2amino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
    • R12 is pyrrolidiyl, ylainyl, pierdineriyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy;
    • R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
    • R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, hydroxy, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, ((R6CO)(R6)amino)alkyl, (R15)alkyl, (R6CO)(R6)amino, R15, alkylCO, CF3CO, CO2R6, CON(R6)2, or SO2R6;
    • or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O;
    • R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents; and
    • the dashed line is either a single bond or a double bond, provided that if the dashed line is a single bond, the carbon bearing the asterisk is either of the R configuration, the S configuration, or a mixture of R and S;
    • or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a compound of formula I
    Figure US20070078122A1-20070405-C00017
    • wherein:
    • R1 is CO2R6 or CONR7R8;
    • R2 is CO2R6, CO2benzyl, CONR9R10, NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), or NHCON(R6)((COR15)alkyl);
    • R3 is hydrogen or alkyl;
    • R4 is hydrogen, halo, alkyl, alkoxy, or benzyloxy;
    • R5 is C5-7cycloalkyl;
    • R6 is hydrogen or alkyl;
    • R7 is hydrogen, alkyl, cycloalkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
    • R8 is hydrogen, alkyl, or cycloalkyl;
    • or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
    • R9 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
    • R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, or (dialkylamino)alkyl;
    • or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-4 substituents selected from the group consisting of halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)amino, (alkylCO)(alkyl)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
      Figure US20070078122A1-20070405-C00018
    • or NR9R10 taken together is
      Figure US20070078122A1-20070405-C00019
      Figure US20070078122A1-20070405-C00020
    • or NR9R10 taken together is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR6, NCO2R6, or O;
    • R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
    • R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy;
    • R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
    • R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (R15)alkyl, (R6CO)(alkyl)amino, R15, CF3CO, CO2R6, CON(R6)2, or SO2R6;
    • or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O;
    • R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents;
    • R16 is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, or tetrazolyl, and is substituted with 0-2 alkyl substituents; and the dashed line is either a single bond or a double bond, provided that if the dashed line is a single bond, the carbon bearing the asterisk is either of the R configuration, the S configuration, or a mixture of R and S;
    • or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is compound of formula I where R1 is CONR7R8;
    • R7 is alkoxy, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
    • R8 is hydrogen, alkyl, or cycloalkyl;
    • R11 is haloalkyl, alkoxy, or N,O-dimethylhydroxylamino;
    • R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy; and
    • R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or tetrahydrofuranyl, and is substituted with 0-2 alkyl substituents.
  • Another aspect of the invention is compound of formula I where R2 is CO2benzyl, CONR9R10, NHCO2(alkyl), NHCO2benzyl, NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), or NHCON(R6)((COR15)alkyl);
    • R6 is hydrogen or alkyl;
    • R9 is dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
    • R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, or (dialkylamino)alkyl;
    • or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and NR9R10 is substituted with 1 substituent selected from the group consisting of halo, haloalkyl, hydroxyalkyl, alkoxy, (alkoxy)alkyl, (alkylCO)amino, (alkylCO)(alkyl)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (PhCONH)alkyl, (R12)alkyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl (where piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy), phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
      Figure US20070078122A1-20070405-C00021
      and NR9R10 is further substituted with 0-3 substituents selected from the group consisting of halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)amino, (alkylCO)(alkyl)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
      Figure US20070078122A1-20070405-C00022
      or NR9R10 taken together is
      Figure US20070078122A1-20070405-C00023
      Figure US20070078122A1-20070405-C00024
      or NR9R10 taken together is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR6, NCO2R6, or O;
    • R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
    • R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
    • R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (R15)alkyl, (R6CO)(alkyl)amino, R15, CF3CO, CO2R6, CON(R6)2, or SO2R6;
    • or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O; and
    • R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents.
  • Another aspect of the invention is a compound of formula I where the dashed line is a single bond and the carbon bearing the asterisk is of the R configuration.
    Figure US20070078122A1-20070405-C00025
  • Another aspect of the invention is a compound of formula I where the dashed line is a single bond and the carbon bearing the asterisk is of the S configuration.
    Figure US20070078122A1-20070405-C00026
  • Another aspect of the invention is a compound of formula I wherein the dashed line is a single bond.
    Figure US20070078122A1-20070405-C00027
  • Another aspect of the invention is a compound of formula I wherein the dashed line is a double bond.
    Figure US20070078122A1-20070405-C00028
  • Another aspect of the invention is a compound of formula II
    Figure US20070078122A1-20070405-C00029
    • wherein:
    • R1 is CO2R6 or CONR7R8;
    • R4 is hydrogen, halo, alkyl, alkoxy, or benzyloxy;
    • R5 is C5-7cycloalkyl;
    • R6 is hydrogen or alkyl;
    • R7 is hydrogen, alkyl, cycloalkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
    • R8 is hydrogen, alkyl, or cycloalkyl;
    • or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
    • R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
    • R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy; and
    • R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
    • or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a compound of formula III
    Figure US20070078122A1-20070405-C00030
    • wherein:
    • R1 is CO2R6 or CONR7R8;
    • R2 is CO2R6, CO2benzyl, CONR9R10, NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), or NHCON(R6)((COR15)alkyl);
    • R3 is hydrogen or alkyl;
    • R5 is C5-7cycloalkyl;
    • R6 is hydrogen or alkyl;
    • R7 is hydrogen, alkyl, cycloalkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
    • R8 is hydrogen, alkyl, or cycloalkyl;
    • or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
    • R9 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
    • R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, or (dialkylamino)alkyl;
    • or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-4 substituents selected from the group consisting of halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)amino, (alkylCO)(alkyl)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
      Figure US20070078122A1-20070405-C00031
    • or NR9R10 taken together is
      Figure US20070078122A1-20070405-C00032
      Figure US20070078122A1-20070405-C00033
    • or NR9R10 taken together is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR6, NCO2R6, or O;
    • R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
    • R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy;
    • R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
    • R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (R15)alkyl, (R6CO)(alkyl)amino, R15, CF3CO, CO2R6, CON(R6)2, or SO2R6;
    • or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O;
    • R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents;
    • R16 is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, or tetrazolyl, and is substituted with 0-2 alkyl substituents; and
    • the dashed line is either a single bond or a double bond, provided that if the dashed line is a single bond, the carbon bearing the asterisk is either of the R configuration, the S configuration, or a mixture of R and S;
    • or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a compound of formula IV.
    Figure US20070078122A1-20070405-C00034
  • Some other aspects which apply to compounds of formula I, II, III, and IV where applicable.
  • Another aspect of the invention is compound of formula I where R3 is hydrogen.
  • Another aspect of the invention is compound of formula I where R3 is alkyl.
  • Another aspect of the invention is compound of formula I where R4 is hydrogen.
  • Another aspect of the invention is compound of formula I where R4 is chloro.
  • Another aspect of the invention is compound of formula I where R4 is methoxy.
  • Another aspect of the invention is compound of formula I where R5 is cyclohexyl.
  • Another aspect of the invention is compound of formula I where R7 is SO2R11 or SO2R12.
  • Another aspect of the invention is compound of formula I where R7 is (R13)alkyl.
  • Another aspect of the invention is compound of formula I where R9 is (R12)alkyl.
  • Another aspect of the invention is compound of formula I where R9 is (CON(R6)2)alkyl or (COR12)alkyl.
  • Another aspect of the invention is compound of formula I where NR9R10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1-2 substituents selected from methyl or fluoro.
  • Another aspect of the invention is compound of formula I where NR9R10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 R12.
  • Another aspect of the invention is compound of formula I where NR9R10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 substituent selected from pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, pyrimidinyl, pyrazinyl, and triazinyl.
  • Another aspect of the invention is compound of formula I where NR9R10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 substituent selected from the group consisting of CO2R6, (cycloalkyl)CO, (alkyl)CO, (hydroxyalkyl)CO, (acetoxyalkyl)CO, COPh, CON(R6)2, and COR12.
  • Another aspect of the invention is compound of formula I where NR9R10 taken together is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1 SO2R11 or SO2R12.
  • Another aspect of the invention is compound of formula I where NR9R10 taken together has one of the following substitution patterns where R denotes one of the substituents
    Figure US20070078122A1-20070405-C00035
  • Another aspect of the invention is that any scope of the variables R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, and the dashed line is meant to be used with any scope of the remaining variables.
  • Unless specified otherwise, these terms have the following meanings. “Alkyl” means a straight or branched alkyl group composed of 1 to 6 carbons. “Alkenyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one double bond. “Cycloalkyl” means a monocyclic ring system composed of 3 to 7 carbons. “Hydroxyalkyl,” “alkoxy” and other terms with a substituted alkyl moiety include straight and branched isomers composed of 1 to 6 carbon atoms for the alkyl moiety. “Haloalkyl” and “haloalkoxy” include all halogenated isomers from monohalo substituted alkyl to perhalo substituted alkyl. “Aryl” includes carbocyclic and heterocyclic aromatic substituents. Parenthetic and multiparenthetic terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R. Some compounds were drawn with implied hydrogens.
  • The following structure illustrates when the dashed line is a single bond.
    Figure US20070078122A1-20070405-C00036
  • The following structure illustrates when the dashed line is a double bond.
    Figure US20070078122A1-20070405-C00037
  • The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.
  • Some of the compounds of the invention possess asymmetric carbon atoms (for example, the compounds below). The invention includes all stereoisomeric forms, including enantiomers and diastereomers as well as mixtures of stereoisomers such as racemates. Some stereoisomers can be made using methods known in the art. Stereoisomeric mixtures of the compounds and related intermediates can be separated into individual isomers according to methods commonly known in the art.
    Figure US20070078122A1-20070405-C00038
    • Synthetic Methods
  • Formula I, II, III, or IV compounds may be made by methods known in the art including those described below. Some reagents and intermediates are known in the art. Other reagents and intermediates can be made by methods known in the art using readily available materials. The variables used to describe the synthesis of formula I, II, III, or IV compounds are intended only to illustrate how to make and are not to be confused with variables used in the claims or in other sections of the specification.
  • Abbreviations used within the schemes generally follow conventions used in the art. Some examples are as follows: THF means tetrahydrofuran; DMF means N,N-dimethylformamide; RCM means ring-closing methasis; Boc means tert-butoxycarbonyl; TFA means trifluoracetic acid; DMA means N,N-dimethylacetamide; PPh3 means triphenylphosphine; OAc means acetate; Me means methyl; COD (or cod) means 1,5-cyclooctadiene; dtbpy means 4,4′-di-tert-butyl-2,2′-bipyridine; dba means dibenzylideneacetone; Xantphos means 4,5-bis(diphenylphosphino)-9,9-dimethylxanthine; aq means aqueous; EtOH means ethanol; MeOH means methanol; TBTU means 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluroborate; DMSO means dimethylsulfoxide; HATU means O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; EEDQ means 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline; WSC means 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride; DMAP means 4-dimethylaminopyridine; n-Bu means n-butyl; BEMP means 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine, polymer-bound; DIPEA means diisopropylethylamine; and TEA means triethylamine.
  • Some compounds of formula I, II, III, or IV can be according to Schemes 1 and 2. Indole 7 can be made from 6-carboxyindole by condensation with an appropriate ketone. After hydrogenation and esterification, the indole can be selectively brominated and coupled with a variety of aryl compounds, including aryl boronic compounds. Indole 7 can then be alkylated and compound 14 generated by metathesis.
    Figure US20070078122A1-20070405-C00039
    Figure US20070078122A1-20070405-C00040
  • Further elaboration of ester 14 can selectively convert it to carboxylic acid 14a. For example, as shown in Scheme 3, partial hydrogenation of the benzyl ester 14 (R=benzyl), selective base-catalyzed hydrolysis of the dimethyl ester 14 (R=methyl), and cleavage of the tert-butyl ester 14 (R=tert-butyl) with trifluoroacetic acid can provide acid 14a. Reduction of 14a with hydrogen and palladium can give saturated acid 14b.
  • Alternatively, some esters of formula I can be selectively hydrolyzed at the indolic ester followed by functionalization at this moiety. Subsequent transformations can then be attended to at the bridged ester moiety.
    Figure US20070078122A1-20070405-C00041
  • Carboxylic acids 14a and 14b can be transformed into their respective amides. The acids can be activated for the coupling reaction by conversion to their acid chlorides with, for example, oxalyl chloride or thionyl chloride. Alternatively, TBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluroborate) is used to effect the coupling of the acids with amines. DMF, DMSO, and THF can be used as solvents. Compounds 14c and 14d can be transformed to compounds 14f and 14g by methods known in the art. Compounds 14f and 14g can be further elaborated at the carboxylic acid position.
    Figure US20070078122A1-20070405-C00042
  • General procedure for the preparation of some 13-cyclohexyl-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, diesters.
    Figure US20070078122A1-20070405-C00043
    (a) 1.2 equiv of 2, LiCl (3 equiv), Pd(PPh3)4 (0.04 equiv), 1M Na2CO3, EtOH-toluene, 85-90° C. (b) 1.2-1.5 equiv of 4, Cs2CO3 (1.2 equiv), DMF, 50-60° C.
  • An alternate route to some formula I compounds is shown in Scheme 5.
    Figure US20070078122A1-20070405-C00044
  • Some sulfamides can be made according to Scheme 6.
    Figure US20070078122A1-20070405-C00045
  • Other formula I compounds can be made according to Scheme 7.
    Figure US20070078122A1-20070405-C00046
    Figure US20070078122A1-20070405-C00047
  • Other compounds are described in the specific embodiments section.
    • Biological Methods
  • Some Formula I, II, III, or IV compounds demonstrated activity against HCV NS5B as determined in the following HCV RdRp assays.
  • HCV NS5B RdRp cloning, expression, and purification. The cDNA encoding the NS5B protein of HCV, genotype 1b, was cloned into the pET21a expression vector. The protein was expressed with an 18 amino acid C-terminal truncation to enhance the solubility. The E. coli competent cell line BL21 (DE3) was used for expression of the protein. Cultures were grown at 37° C. for ˜4 hours until the cultures reached an optical density of 2.0 at 600 nm. The cultures were cooled to 20° C. and induced with 1 mM IPTG. Fresh ampicillin was added to a final concentration of 50 μg/ml and the cells were grown overnight at 20° C.
  • Cell pellets (3L) were lysed for purification to yield 15-24 mgs of purified NS5B. The lysis buffer consisted of 20 mM Tris-HCl, pH 7.4, 500 mM NaCl, 0.5% triton X-100, 1 mM DTT, 1 mM EDTA, 20% glycerol, 0.5 mg/ml lysozyme, 10 mM MgCl2, 15 ug/ml deoxyribonuclease I, and Complete TM protease inhibitor tablets (Roche). After addition of the lysis buffer, frozen cell pellets were resuspended using a tissue homogenizer. To reduce the viscosity of the sample, aliquots of the lysate were sonicated on ice using a microtip attached to a Branson sonicator. The sonicated lysate was centrifuged at 100,000×g for 1 hr at 4° C. and filtered through a 0.2 μm filter unit (Corning).
  • The protein was purified using three sequential chromatography steps: Heparin sepharose CL-6B, polyU sepharose 4B, and Hitrap SP sepharose (Pharmacia). The chromatography buffers were identical to the lysis buffer but contained no lysozyme, deoxyribonuclease I, MgCl2 or protease inhibitor and the NaCl concentration of the buffer was adjusted according to the requirements for charging the protein onto the column. Each column was eluted with a NaCl gradient which varied in length from 5-50 column volumes depending on the column type. After the final chromatography step, the resulting purity of the enzyme is >90% based on SDS-PAGE analysis. The enzyme was aliquoted and stored at −80° C.
  • Standard HCV NS5B RdRp enzyme assay. HCV RdRp genotype 1b assays were run in a final volume of 60 μl in 96 well plates (Costar 3912). The assay buffer is composed of 20 mM Hepes, pH 7.5, 2.5 mM KCl, 2.5 mM MgCl2, 1 mM DTT, 1.6 U RNAse inhibitor (Promega N2515), 0.1 mg/ml BSA (Promega R3961), and 2% glycerol. All compounds were serially diluted (3-fold) in DMSO and diluted further in water such that the final concentration of DMSO in the assay was 2%. HCV RdRp genotype 1b enzyme was used at a final concentration of 28 nM. A polyA template was used at 6 nM, and a biotinylated oligo-dT12 primer was used at 180 nM final concentration. Template was obtained commercially (Amersham 27-4110). Biotinylated primer was prepared by Sigma Genosys. 3H-UTP was used at 0.6 μCi (0.29 μM total UTP). Reactions were initiated by the addition of enzyme, incubated at 30° C. for 60 min, and stopped by adding 25 g of 50 mM EDTA containing SPA beads (4 μg/μl, Amersham RPNQ 0007). Plates were read on a Packard Top Count NXT after >1 hr incubation at room temperature.
  • Modified HCV NS5B RdRp enzyme assay. A modified enzyme assay was performed essentially as described for the standard enzyme assay except for the following: The biotinylated oligo dT12 primer was precaptured on streptavidin-coated SPA beads by mixing primer and beads in assay buffer and incubating at room temperature for one hour. Unbound primer was removed after centrifugation. The primer-bound beads were resuspended in 20 mM Hepes buffer, pH 7.5 and used in the assay at final concentrations of 20 mM primer and 0.67 μg/μl beads. Order of addition in the assay: Enzyme (14 nM) was added to diluted compound followed by the addition of a mixture of template (0.2 nM), 3H-UTP (0.6 μCi, 0.29 μM), and primer-bound beads, to initiate the reaction; concentrations given are final. Reactions were allowed to proceed for 4 hours at 30° C.
  • IC50 values for compounds were determined using seven different [I]. IC50 values were calculated from the inhibition using the formula y=A+((B−A)/(1+((C/x)ˆD))).
  • FRET Assay Preparation. To perform the HCV FRET screening assay, 96-well cell culture plates were used. The FRET peptide (Anaspec, Inc.) (Taliani et al., Anal. Biochem. 1996, 240, 60-67) contains a fluorescence donor, EDANS, near one end of the peptide and an acceptor, DABCYL, near the other end. The fluorescence of the peptide is quenched by intermolecular resonance energy transfer (RET) between the donor and the acceptor, but as the NS3 protease cleaves the peptide the products are released from RET quenching and the fluorescence of the donor becomes apparent. The assay reagent was made as follows: 5× cell Luciferase cell culture lysis reagent from Promega (#E153A) diluted to 1× with dH2O, NaCl added to 150 mM final, the FRET peptide diluted to 20 uM final from a 2 mM stock.
  • To prepare plates, HCV replicon cells, with or without a Renilla luciferase reporter gene, were trypsinized and placed into each well of a 96-well plate with titrated test compounds added in columns 3 through 12; columns 1 and 2 contained a control compound (HCV protease inhibitor), and the bottom row contained cells without compound. The plates were then placed in a CO2 incubator at 37° C.
  • Assays. Subsequent to addition of the test compounds described above (FRET Assay Preparation), at various times the plate was removed and Alamar blue solution (Trek Diagnostics, #00-100) was added per well as a measure of cellular toxicity. After reading in a Cytoflour 4000 instrument (PE Biosystems), plates were rinsed with PBS and then used for FRET assay by the addition of 30 ul of the FRET peptide assay reagent described above (FRET Assay Preparation) per well. The plate was then placed into the Cytoflour 4000 instrument which had been set to 340 excite/490 emission, automatic mode for 20 cycles and the plate read in a kinetic mode. Typically, the signal to noise using an endpoint analysis after the reads was at least three-fold. Alternatively, after Alamar blue reading, plates were rinsed with PBS, 50 ul of DMEM (high glucose) without phenol red was added and plates were then used for luciferase assay using the Promega Dual-Glo Luciferase Assay System.
  • Compound analysis was determined by quantification of the relative HCV replicon inhibition and the relative cytotoxicity values. To calculate cytoxicity values, the average Alamar Blue fluorescence signals from the control wells were set as 100% non-toxic. The individual signals in each of the compound test wells were then divided by the average control signal and multiplied by 100% to determine percent cytotoxicity. To calculate the HCV replicon inhibition values, an average background value was obtained from the two wells containing the highest amount of HCV protease inhibitor at the end of the assay period. These numbers were similar to those obtained from naïve Huh-7 cells.
  • The background numbers were then subtracted from the average signal obtained from the control wells and this number was used as 100% activity. The individual signals in each of the compound test wells were then divided by the averaged control values after background subtraction and multiplied by 100% to determine percent activity. EC50 values for a protease inhibitor titration were calculated as the concentration which caused a 50% reduction in FRET or luciferase activity. The two numbers generated for the compound plate, percent cytoxicity and percent activity were used to determine compounds of interest for further analysis.
  • Representative data for some Formula I, II, III, and IV compounds are reported in Table 1.
    TABLE 1
    Structure IC50* EC50*
    Figure US20070078122A1-20070405-C00048
         		B E
    Figure US20070078122A1-20070405-C00049
         		B E
    Figure US20070078122A1-20070405-C00050
         		B E
    Figure US20070078122A1-20070405-C00051
    Figure US20070078122A1-20070405-C00052
    Figure US20070078122A1-20070405-C00053
         		B E
    Figure US20070078122A1-20070405-C00054
         		B E
    Figure US20070078122A1-20070405-C00055
         		B E
    Figure US20070078122A1-20070405-C00056
         		B E
    Figure US20070078122A1-20070405-C00057
         		B E
    Figure US20070078122A1-20070405-C00058
         		B E
    Figure US20070078122A1-20070405-C00059
         		B E
    Figure US20070078122A1-20070405-C00060
         		B E
    Figure US20070078122A1-20070405-C00061
         		B E
    Figure US20070078122A1-20070405-C00062
         		B E
    Figure US20070078122A1-20070405-C00063
         		B E
    Figure US20070078122A1-20070405-C00064
         		B E
    Figure US20070078122A1-20070405-C00065
         		B E
    Figure US20070078122A1-20070405-C00066
         		B E
    Figure US20070078122A1-20070405-C00067
         		B E
    Figure US20070078122A1-20070405-C00068
         		B E
    Figure US20070078122A1-20070405-C00069
         		B E
    Figure US20070078122A1-20070405-C00070
         		B E
    Figure US20070078122A1-20070405-C00071
         		B E
    Figure US20070078122A1-20070405-C00072
         		B E
    Figure US20070078122A1-20070405-C00073
         		B E
    Figure US20070078122A1-20070405-C00074
         		B E
    Figure US20070078122A1-20070405-C00075
         		B E
    Figure US20070078122A1-20070405-C00076
         		B E
    Figure US20070078122A1-20070405-C00077
         		B E
    Figure US20070078122A1-20070405-C00078
         		B E
    Figure US20070078122A1-20070405-C00079
         		B E
    Figure US20070078122A1-20070405-C00080
         		B E
    Figure US20070078122A1-20070405-C00081
         		B D
    Figure US20070078122A1-20070405-C00082
         		B E
    Figure US20070078122A1-20070405-C00083
         		B E
    Figure US20070078122A1-20070405-C00084
         		B E
    Figure US20070078122A1-20070405-C00085
         		B E
    Figure US20070078122A1-20070405-C00086
         		B D
    Figure US20070078122A1-20070405-C00087
         		B E
    Figure US20070078122A1-20070405-C00088
         		B E
    Figure US20070078122A1-20070405-C00089
         		B E
    Figure US20070078122A1-20070405-C00090
         		B E
    Figure US20070078122A1-20070405-C00091
         		B E
    Figure US20070078122A1-20070405-C00092
         		B E
    Figure US20070078122A1-20070405-C00093
         		B E
    Figure US20070078122A1-20070405-C00094
         		B E
    Figure US20070078122A1-20070405-C00095
         		B E
    Figure US20070078122A1-20070405-C00096
         		B C
    Figure US20070078122A1-20070405-C00097
         		B E
    Figure US20070078122A1-20070405-C00098
         		B E
    Figure US20070078122A1-20070405-C00099
    Figure US20070078122A1-20070405-C00100
         		B E
    Figure US20070078122A1-20070405-C00101
         		B E
    Figure US20070078122A1-20070405-C00102
         		B E
    Figure US20070078122A1-20070405-C00103
         		B E
    Figure US20070078122A1-20070405-C00104
         		B E
    Figure US20070078122A1-20070405-C00105
         		B D
    Figure US20070078122A1-20070405-C00106
         		B D
    Figure US20070078122A1-20070405-C00107
         		B D
    Figure US20070078122A1-20070405-C00108
         		B C
    Figure US20070078122A1-20070405-C00109
         		B E
    Figure US20070078122A1-20070405-C00110
         		B E
    Figure US20070078122A1-20070405-C00111
         		B F
    Figure US20070078122A1-20070405-C00112
         		B D
    Figure US20070078122A1-20070405-C00113
         		B D
    Figure US20070078122A1-20070405-C00114
         		B E
    Figure US20070078122A1-20070405-C00115
         		B E
    Figure US20070078122A1-20070405-C00116
         		K D
    Figure US20070078122A1-20070405-C00117
         		B D
    Figure US20070078122A1-20070405-C00118
         		B E
    Figure US20070078122A1-20070405-C00119
         		B E
    Figure US20070078122A1-20070405-C00120
         		A D
    Figure US20070078122A1-20070405-C00121
         		B E
    Figure US20070078122A1-20070405-C00122
         		B E
    Figure US20070078122A1-20070405-C00123
         		B E
    Figure US20070078122A1-20070405-C00124
         		B E
    Figure US20070078122A1-20070405-C00125
         		B E
    Figure US20070078122A1-20070405-C00126
         		B E
    Figure US20070078122A1-20070405-C00127
         		B E
    Figure US20070078122A1-20070405-C00128
         		B E
    Figure US20070078122A1-20070405-C00129
         		B E
    Figure US20070078122A1-20070405-C00130
         		B E
    Figure US20070078122A1-20070405-C00131
         		B E
    Figure US20070078122A1-20070405-C00132
         		B E
    Figure US20070078122A1-20070405-C00133
         		A G
    Figure US20070078122A1-20070405-C00134
         		B E
    Figure US20070078122A1-20070405-C00135
         		B E
    Figure US20070078122A1-20070405-C00136
         		A D
    Figure US20070078122A1-20070405-C00137
         		B D
    Figure US20070078122A1-20070405-C00138
         		B E
    Figure US20070078122A1-20070405-C00139
         		B E
    Figure US20070078122A1-20070405-C00140
         		B E
    Figure US20070078122A1-20070405-C00141
         		B E
    Figure US20070078122A1-20070405-C00142
         		A G
    Figure US20070078122A1-20070405-C00143
         		B E
    Figure US20070078122A1-20070405-C00144
         		B E
    Figure US20070078122A1-20070405-C00145
         		B E
    Figure US20070078122A1-20070405-C00146
         		B E
    Figure US20070078122A1-20070405-C00147
         		B D
    Figure US20070078122A1-20070405-C00148
         		B E
    Figure US20070078122A1-20070405-C00149
         		B E
    Figure US20070078122A1-20070405-C00150
         		B E
    Figure US20070078122A1-20070405-C00151
         		B E
    Figure US20070078122A1-20070405-C00152
         		A D
    Figure US20070078122A1-20070405-C00153
         		B E
    Figure US20070078122A1-20070405-C00154
         		B D
    Figure US20070078122A1-20070405-C00155
         		B E
    Figure US20070078122A1-20070405-C00156
         		B D
    Figure US20070078122A1-20070405-C00157
         		B E
    Figure US20070078122A1-20070405-C00158
    Figure US20070078122A1-20070405-C00159
         		B E
    Figure US20070078122A1-20070405-C00160
         		B E
    Figure US20070078122A1-20070405-C00161
         		B E
    Figure US20070078122A1-20070405-C00162
         		B E
    Figure US20070078122A1-20070405-C00163
    Figure US20070078122A1-20070405-C00164
         		B E
    Figure US20070078122A1-20070405-C00165
         		B E
    Figure US20070078122A1-20070405-C00166
         		B′
    Figure US20070078122A1-20070405-C00167
         		A D
    Figure US20070078122A1-20070405-C00168
         		B E
    Figure US20070078122A1-20070405-C00169
         		K D
    Figure US20070078122A1-20070405-C00170
         		B E
    Figure US20070078122A1-20070405-C00171
         		B E
    Figure US20070078122A1-20070405-C00172
    Figure US20070078122A1-20070405-C00173
         		B E
    Figure US20070078122A1-20070405-C00174
         		N D
    Figure US20070078122A1-20070405-C00175
         		B E
    Figure US20070078122A1-20070405-C00176
         		B E
    Figure US20070078122A1-20070405-C00177
         		B E
    Figure US20070078122A1-20070405-C00178
         		B E
    Figure US20070078122A1-20070405-C00179
         		A E
    Figure US20070078122A1-20070405-C00180
         		B E
    Figure US20070078122A1-20070405-C00181
         		B E
    Figure US20070078122A1-20070405-C00182
         		B D
    Figure US20070078122A1-20070405-C00183
         		B E
    Figure US20070078122A1-20070405-C00184
         		B E
    Figure US20070078122A1-20070405-C00185
         		B E
    Figure US20070078122A1-20070405-C00186
         		B E
    Figure US20070078122A1-20070405-C00187
         		B E
    Figure US20070078122A1-20070405-C00188
         		K D
    Figure US20070078122A1-20070405-C00189
         		A D
    Figure US20070078122A1-20070405-C00190
         		B E
    Figure US20070078122A1-20070405-C00191
         		A D
    Figure US20070078122A1-20070405-C00192
         		B E
    Figure US20070078122A1-20070405-C00193
         		B E
    Figure US20070078122A1-20070405-C00194
         		B E
    Figure US20070078122A1-20070405-C00195
         		B E
    Figure US20070078122A1-20070405-C00196
         		B E
    Figure US20070078122A1-20070405-C00197
         		B E
    Figure US20070078122A1-20070405-C00198
         		B E
    Figure US20070078122A1-20070405-C00199
         		B E
    Figure US20070078122A1-20070405-C00200
         		A D
    Figure US20070078122A1-20070405-C00201
         		B G
    Figure US20070078122A1-20070405-C00202
         		B E
    Figure US20070078122A1-20070405-C00203
         		B D
    Figure US20070078122A1-20070405-C00204
         		B D
    Figure US20070078122A1-20070405-C00205
         		B H
    Figure US20070078122A1-20070405-C00206
         		A H
    Figure US20070078122A1-20070405-C00207
         		A H
    Figure US20070078122A1-20070405-C00208
         		N H
    Figure US20070078122A1-20070405-C00209
         		A H
    Figure US20070078122A1-20070405-C00210
         		A H
    Figure US20070078122A1-20070405-C00211
         		A J
    Figure US20070078122A1-20070405-C00212
         		A H
    Figure US20070078122A1-20070405-C00213
         		A D
    Figure US20070078122A1-20070405-C00214
         		A D
    Figure US20070078122A1-20070405-C00215
         		B D
    Figure US20070078122A1-20070405-C00216
         		B E
    Figure US20070078122A1-20070405-C00217
         		B E
    Figure US20070078122A1-20070405-C00218
         		B E
    Figure US20070078122A1-20070405-C00219
         		B E
    Figure US20070078122A1-20070405-C00220
         		B E
    Figure US20070078122A1-20070405-C00221
         		B E
    Figure US20070078122A1-20070405-C00222
         		B E
    Figure US20070078122A1-20070405-C00223
         		B D
    Figure US20070078122A1-20070405-C00224
         		B D
    Figure US20070078122A1-20070405-C00225
         		B E
    Figure US20070078122A1-20070405-C00226
         		B E
    Figure US20070078122A1-20070405-C00227
         		B E
    Figure US20070078122A1-20070405-C00228
         		B E
    Figure US20070078122A1-20070405-C00229
         		B E
    Figure US20070078122A1-20070405-C00230
         		B E
    Figure US20070078122A1-20070405-C00231
         		B E
    Figure US20070078122A1-20070405-C00232
         		B E
    Figure US20070078122A1-20070405-C00233
         		B E
    Figure US20070078122A1-20070405-C00234
         		K  C**
    Figure US20070078122A1-20070405-C00235
         		B D

    A > 1 μM;

    B 0.01 μM-1 μM;

    C > 10 μM;

    D 1 μM-10 μM;

    E 1.0 μM-0.07 μM.

    IC50 values were determined using the preincubation protocol.

    EC50 values were determined using the FRET assay.
  • Data for some additional Formula I, II, III, and IV compounds are shown in Table 1a below.
    TABLE Ia
    Structure IC50* EC50*
    Figure US20070078122A1-20070405-C00236
         		B E
    Figure US20070078122A1-20070405-C00237
         		B E
    Figure US20070078122A1-20070405-C00238
         		B E
    Figure US20070078122A1-20070405-C00239
         		B
    Figure US20070078122A1-20070405-C00240
    Figure US20070078122A1-20070405-C00241
         		B
    Figure US20070078122A1-20070405-C00242
         		B
    Figure US20070078122A1-20070405-C00243
         		A
    Figure US20070078122A1-20070405-C00244
    Figure US20070078122A1-20070405-C00245
         		B
    Figure US20070078122A1-20070405-C00246
         		B
    Figure US20070078122A1-20070405-C00247
    Figure US20070078122A1-20070405-C00248
    Figure US20070078122A1-20070405-C00249
         		B
    Figure US20070078122A1-20070405-C00250
         		B
    Figure US20070078122A1-20070405-C00251
         		B
    Figure US20070078122A1-20070405-C00252
         		B
    Figure US20070078122A1-20070405-C00253
         		B
    Figure US20070078122A1-20070405-C00254
         		B
    Figure US20070078122A1-20070405-C00255
         		B
    Figure US20070078122A1-20070405-C00256
         		B
    Figure US20070078122A1-20070405-C00257
         		B
    Figure US20070078122A1-20070405-C00258
         		B
    Figure US20070078122A1-20070405-C00259
         		B
    Figure US20070078122A1-20070405-C00260
         		B
    Figure US20070078122A1-20070405-C00261
         		B
    Figure US20070078122A1-20070405-C00262
    Figure US20070078122A1-20070405-C00263
         		B
    Figure US20070078122A1-20070405-C00264
         		B
    Figure US20070078122A1-20070405-C00265
         		B
    Figure US20070078122A1-20070405-C00266
         		B
    Figure US20070078122A1-20070405-C00267
         		B
    Figure US20070078122A1-20070405-C00268
    Figure US20070078122A1-20070405-C00269
         		B
    Figure US20070078122A1-20070405-C00270
         		B
    Figure US20070078122A1-20070405-C00271
         		B
    Figure US20070078122A1-20070405-C00272
         		B
    Figure US20070078122A1-20070405-C00273
         		B
    Figure US20070078122A1-20070405-C00274
         		B
    Figure US20070078122A1-20070405-C00275
         		B
    Figure US20070078122A1-20070405-C00276
         		B
    Figure US20070078122A1-20070405-C00277
         		B
    Figure US20070078122A1-20070405-C00278
         		B
    Figure US20070078122A1-20070405-C00279
         		B
    Figure US20070078122A1-20070405-C00280
         		B
    Figure US20070078122A1-20070405-C00281
         		B
    Figure US20070078122A1-20070405-C00282
         		B
    Figure US20070078122A1-20070405-C00283
         		B
    Figure US20070078122A1-20070405-C00284
         		B
    Figure US20070078122A1-20070405-C00285
         		B
    Figure US20070078122A1-20070405-C00286
         		B
    Figure US20070078122A1-20070405-C00287
         		B
    Figure US20070078122A1-20070405-C00288
         		B E
    Figure US20070078122A1-20070405-C00289
         		B
    Figure US20070078122A1-20070405-C00290
         		B
    Figure US20070078122A1-20070405-C00291
         		A
    Figure US20070078122A1-20070405-C00292
         		B
    Figure US20070078122A1-20070405-C00293
         		B
    Figure US20070078122A1-20070405-C00294
         		B
    Figure US20070078122A1-20070405-C00295
         		B
    Figure US20070078122A1-20070405-C00296
         		B
    Figure US20070078122A1-20070405-C00297
         		B
    Figure US20070078122A1-20070405-C00298
         		B
    Figure US20070078122A1-20070405-C00299
         		B
    Figure US20070078122A1-20070405-C00300
         		B
    Figure US20070078122A1-20070405-C00301
         		B
    Figure US20070078122A1-20070405-C00302
         		B
    Figure US20070078122A1-20070405-C00303
         		B
    Figure US20070078122A1-20070405-C00304
         		A
    Figure US20070078122A1-20070405-C00305
         		B
    Figure US20070078122A1-20070405-C00306
         		B
    Figure US20070078122A1-20070405-C00307
         		A
    Figure US20070078122A1-20070405-C00308
         		B
    Figure US20070078122A1-20070405-C00309
         		B
    Figure US20070078122A1-20070405-C00310
         		B
    Figure US20070078122A1-20070405-C00311
         		B
    Figure US20070078122A1-20070405-C00312
         		B
    Figure US20070078122A1-20070405-C00313
         		B
    Figure US20070078122A1-20070405-C00314
         		B
    Figure US20070078122A1-20070405-C00315
         		B
    Figure US20070078122A1-20070405-C00316
         		B
    Figure US20070078122A1-20070405-C00317
         		F
    Figure US20070078122A1-20070405-C00318
         		B
    Figure US20070078122A1-20070405-C00319
         		B
    Figure US20070078122A1-20070405-C00320
         		B
    Figure US20070078122A1-20070405-C00321
         		B
    Figure US20070078122A1-20070405-C00322
         		F
    Figure US20070078122A1-20070405-C00323
         		B
    Figure US20070078122A1-20070405-C00324
         		B
    Figure US20070078122A1-20070405-C00325
         		B
    Figure US20070078122A1-20070405-C00326
         		B
    Figure US20070078122A1-20070405-C00327
         		B
    Figure US20070078122A1-20070405-C00328
         		B
    Figure US20070078122A1-20070405-C00329
    Figure US20070078122A1-20070405-C00330
         		B
    Figure US20070078122A1-20070405-C00331
         		B
    Figure US20070078122A1-20070405-C00332
         		B
    Figure US20070078122A1-20070405-C00333
    Figure US20070078122A1-20070405-C00334
    Figure US20070078122A1-20070405-C00335
    Figure US20070078122A1-20070405-C00336
    Figure US20070078122A1-20070405-C00337
    Figure US20070078122A1-20070405-C00338
    Figure US20070078122A1-20070405-C00339
    Figure US20070078122A1-20070405-C00340
    Figure US20070078122A1-20070405-C00341
    Figure US20070078122A1-20070405-C00342
    Figure US20070078122A1-20070405-C00343
    Figure US20070078122A1-20070405-C00344
    Figure US20070078122A1-20070405-C00345
    Figure US20070078122A1-20070405-C00346
    Figure US20070078122A1-20070405-C00347
         		B E
    Figure US20070078122A1-20070405-C00348
         		F E
    Figure US20070078122A1-20070405-C00349
         		B E
    Figure US20070078122A1-20070405-C00350
         		B E
    Figure US20070078122A1-20070405-C00351
         		B E
    Figure US20070078122A1-20070405-C00352
         		B E
    Figure US20070078122A1-20070405-C00353
         		B D
    Figure US20070078122A1-20070405-C00354
    Figure US20070078122A1-20070405-C00355
    Figure US20070078122A1-20070405-C00356
         		F E
    Figure US20070078122A1-20070405-C00357
         		B E
    Figure US20070078122A1-20070405-C00358
         		B E
    Figure US20070078122A1-20070405-C00359
         		F E
    Figure US20070078122A1-20070405-C00360
         		F E
    Figure US20070078122A1-20070405-C00361
         		B E
    Figure US20070078122A1-20070405-C00362
         		F E
    Figure US20070078122A1-20070405-C00363
         		B E
    Figure US20070078122A1-20070405-C00364
         		B E
    Figure US20070078122A1-20070405-C00365
         		F E
    Figure US20070078122A1-20070405-C00366
         		B E
    Figure US20070078122A1-20070405-C00367
         		B E
    Figure US20070078122A1-20070405-C00368
         		B E
    Figure US20070078122A1-20070405-C00369
         		B E
    Figure US20070078122A1-20070405-C00370
         		F E
    Figure US20070078122A1-20070405-C00371
         		B E
    Figure US20070078122A1-20070405-C00372
         		B E
    Figure US20070078122A1-20070405-C00373
         		B E
    Figure US20070078122A1-20070405-C00374
         		B E
    Figure US20070078122A1-20070405-C00375
         		B E
    Figure US20070078122A1-20070405-C00376
         		B E
    Figure US20070078122A1-20070405-C00377
         		B E
    Figure US20070078122A1-20070405-C00378
         		B E
    Figure US20070078122A1-20070405-C00379
         		B E
    Figure US20070078122A1-20070405-C00380
         		B E
    Figure US20070078122A1-20070405-C00381
         		B E
    Figure US20070078122A1-20070405-C00382
         		B E
    Figure US20070078122A1-20070405-C00383
         		B E
    Figure US20070078122A1-20070405-C00384
         		B E
    Figure US20070078122A1-20070405-C00385
         		B E
    Figure US20070078122A1-20070405-C00386
         		B E
    Figure US20070078122A1-20070405-C00387
         		B E
    Figure US20070078122A1-20070405-C00388
         		B E
    Figure US20070078122A1-20070405-C00389
         		B G
    Figure US20070078122A1-20070405-C00390
         		B E
    Figure US20070078122A1-20070405-C00391
         		B E
    Figure US20070078122A1-20070405-C00392
         		B E

    A > 1 μM;

    B 0.01 μM-1 μM;

    C > 10 μM;

    D > 1 μM-10 μM;

    E 1.0 μM-0.03 μM;

    F < 0.02 μM;

    G > 0.12 μM

    IC50 values were determined using the preincubation protocol.

    EC50 values were determined using the FRET assay.
  • Data for some additional Formula I, II, III, and IV compounds are shown in Table 1b below.
    TABLE 1b
    Structure IC50* EC50*
    Figure US20070078122A1-20070405-C00393
         		B E
    Figure US20070078122A1-20070405-C00394
         		B
    Figure US20070078122A1-20070405-C00395
         		B E
    Figure US20070078122A1-20070405-C00396
         		B C
    Figure US20070078122A1-20070405-C00397
         		F E
    Figure US20070078122A1-20070405-C00398
         		F E
    Figure US20070078122A1-20070405-C00399
         		B E
    Figure US20070078122A1-20070405-C00400
         		F E
    Figure US20070078122A1-20070405-C00401
         		F E
    Figure US20070078122A1-20070405-C00402
         		F E
    Figure US20070078122A1-20070405-C00403
         		B E
    Figure US20070078122A1-20070405-C00404
         		F
    Figure US20070078122A1-20070405-C00405
         		F
    Figure US20070078122A1-20070405-C00406
         		F
    Figure US20070078122A1-20070405-C00407
         		G C
    Figure US20070078122A1-20070405-C00408
         		B E
    Figure US20070078122A1-20070405-C00409
         		B H
    Figure US20070078122A1-20070405-C00410
         		B E
    Figure US20070078122A1-20070405-C00411
         		B D
    Figure US20070078122A1-20070405-C00412
         		B
    Figure US20070078122A1-20070405-C00413
         		B
    Figure US20070078122A1-20070405-C00414
         		B D
    Figure US20070078122A1-20070405-C00415
         		G
    Figure US20070078122A1-20070405-C00416
         		B E
    Figure US20070078122A1-20070405-C00417
         		B E
    Figure US20070078122A1-20070405-C00418
         		B E
    Figure US20070078122A1-20070405-C00419
         		B E
    Figure US20070078122A1-20070405-C00420
         		B D
    Figure US20070078122A1-20070405-C00421
         		B E
    Figure US20070078122A1-20070405-C00422
         		B E
    Figure US20070078122A1-20070405-C00423
         		B E
    Figure US20070078122A1-20070405-C00424
         		B E
    Figure US20070078122A1-20070405-C00425
         		B E
    Figure US20070078122A1-20070405-C00426
         		B E
    Figure US20070078122A1-20070405-C00427
         		B E
    Figure US20070078122A1-20070405-C00428
         		B E
    Figure US20070078122A1-20070405-C00429
         		B R
    Figure US20070078122A1-20070405-C00430
         		B E
    Figure US20070078122A1-20070405-C00431
         		B E
    Figure US20070078122A1-20070405-C00432
         		B E
    Figure US20070078122A1-20070405-C00433
         		B E
    Figure US20070078122A1-20070405-C00434
         		B E
    Figure US20070078122A1-20070405-C00435
         		B C
    Figure US20070078122A1-20070405-C00436
         		B E
    Figure US20070078122A1-20070405-C00437
         		B E
    Figure US20070078122A1-20070405-C00438
         		F E
    Figure US20070078122A1-20070405-C00439
         		B E
    Figure US20070078122A1-20070405-C00440
         		B E
    Figure US20070078122A1-20070405-C00441
         		B E
    Figure US20070078122A1-20070405-C00442
         		B E
    Figure US20070078122A1-20070405-C00443
         		B E
    Figure US20070078122A1-20070405-C00444
         		B E
    Figure US20070078122A1-20070405-C00445
         		B E
    Figure US20070078122A1-20070405-C00446
         		B E
    Figure US20070078122A1-20070405-C00447
         		B E
    Figure US20070078122A1-20070405-C00448
         		B E
    Figure US20070078122A1-20070405-C00449
         		B E
    Figure US20070078122A1-20070405-C00450
         		B E
    Figure US20070078122A1-20070405-C00451
         		B E
    Figure US20070078122A1-20070405-C00452
         		B E
    Figure US20070078122A1-20070405-C00453
         		B E
    Figure US20070078122A1-20070405-C00454
         		B E
    Figure US20070078122A1-20070405-C00455
         		B E
    Figure US20070078122A1-20070405-C00456
         		B E
    Figure US20070078122A1-20070405-C00457
         		B E
    Figure US20070078122A1-20070405-C00458
         		B E
    Figure US20070078122A1-20070405-C00459
         		B E
    Figure US20070078122A1-20070405-C00460
         		B E
    Figure US20070078122A1-20070405-C00461
         		B E
    Figure US20070078122A1-20070405-C00462
         		B E
    Figure US20070078122A1-20070405-C00463
         		B E
    Figure US20070078122A1-20070405-C00464
         		B E
    Figure US20070078122A1-20070405-C00465
         		B E
    Figure US20070078122A1-20070405-C00466
         		B E
    Figure US20070078122A1-20070405-C00467
         		B E
    Figure US20070078122A1-20070405-C00468
         		B E
    Figure US20070078122A1-20070405-C00469
         		B E
    Figure US20070078122A1-20070405-C00470
         		B E
    Figure US20070078122A1-20070405-C00471
         		B E

    A > 1 μM;

    B 0.02 μM-1 μM;

    C > 10 μM;

    D > 1 μM-10 μM;

    E 1.0 μM-0.03 μM;

    F < 0.02 μM;

    G > 12.5 μM;

    H > 0.37 μM;

    IC50 values were determined using the preincubation protocol.

    EC50 values were determined using the FRET assay.
  • Additionally, compounds disclosed in U.S. patent application Ser. No. 11/181,639, filed Jul. 14, 2005 were shown to have activity in these assays (see Table 2).
    TABLE 2
    Structure
    Figure US20070078122A1-20070405-C00472
    Figure US20070078122A1-20070405-C00473
    Figure US20070078122A1-20070405-C00474
    Figure US20070078122A1-20070405-C00475
    Figure US20070078122A1-20070405-C00476
    Figure US20070078122A1-20070405-C00477
    Figure US20070078122A1-20070405-C00478
    Figure US20070078122A1-20070405-C00479
    Figure US20070078122A1-20070405-C00480
    Figure US20070078122A1-20070405-C00481
    Figure US20070078122A1-20070405-C00482
    Figure US20070078122A1-20070405-C00483
    Figure US20070078122A1-20070405-C00484
    Figure US20070078122A1-20070405-C00485
    Figure US20070078122A1-20070405-C00486
    Figure US20070078122A1-20070405-C00487
    Figure US20070078122A1-20070405-C00488
    Figure US20070078122A1-20070405-C00489
    Figure US20070078122A1-20070405-C00490
    Figure US20070078122A1-20070405-C00491
    Figure US20070078122A1-20070405-C00492
    Figure US20070078122A1-20070405-C00493
    Figure US20070078122A1-20070405-C00494
    Figure US20070078122A1-20070405-C00495
    Figure US20070078122A1-20070405-C00496
    Figure US20070078122A1-20070405-C00497
    Figure US20070078122A1-20070405-C00498
    Figure US20070078122A1-20070405-C00499
    Figure US20070078122A1-20070405-C00500
    Figure US20070078122A1-20070405-C00501
    Figure US20070078122A1-20070405-C00502
    Figure US20070078122A1-20070405-C00503
    Figure US20070078122A1-20070405-C00504
    Figure US20070078122A1-20070405-C00505
    Figure US20070078122A1-20070405-C00506
    Figure US20070078122A1-20070405-C00507
    Figure US20070078122A1-20070405-C00508
    Figure US20070078122A1-20070405-C00509
    Figure US20070078122A1-20070405-C00510
    Figure US20070078122A1-20070405-C00511
    Figure US20070078122A1-20070405-C00512
    Figure US20070078122A1-20070405-C00513
    Figure US20070078122A1-20070405-C00514
    Figure US20070078122A1-20070405-C00515
    Figure US20070078122A1-20070405-C00516
    Figure US20070078122A1-20070405-C00517
    Figure US20070078122A1-20070405-C00518
    Figure US20070078122A1-20070405-C00519
    Figure US20070078122A1-20070405-C00520
    Figure US20070078122A1-20070405-C00521
    Figure US20070078122A1-20070405-C00522
    Figure US20070078122A1-20070405-C00523
    Figure US20070078122A1-20070405-C00524
    Figure US20070078122A1-20070405-C00525
    Figure US20070078122A1-20070405-C00526
    Figure US20070078122A1-20070405-C00527
    Figure US20070078122A1-20070405-C00528
    Figure US20070078122A1-20070405-C00529
    Figure US20070078122A1-20070405-C00530
    Figure US20070078122A1-20070405-C00531
    Figure US20070078122A1-20070405-C00532
    Figure US20070078122A1-20070405-C00533
    Figure US20070078122A1-20070405-C00534
    Figure US20070078122A1-20070405-C00535
    Figure US20070078122A1-20070405-C00536
    Figure US20070078122A1-20070405-C00537
    Figure US20070078122A1-20070405-C00538
    Figure US20070078122A1-20070405-C00539
    Figure US20070078122A1-20070405-C00540
    Figure US20070078122A1-20070405-C00541
    Figure US20070078122A1-20070405-C00542
    Figure US20070078122A1-20070405-C00543
    Figure US20070078122A1-20070405-C00544
    Figure US20070078122A1-20070405-C00545
    Figure US20070078122A1-20070405-C00546
    Figure US20070078122A1-20070405-C00547
    Figure US20070078122A1-20070405-C00548
    Figure US20070078122A1-20070405-C00549
    Figure US20070078122A1-20070405-C00550
    Figure US20070078122A1-20070405-C00551
    Figure US20070078122A1-20070405-C00552
    Figure US20070078122A1-20070405-C00553
    Figure US20070078122A1-20070405-C00554
    Figure US20070078122A1-20070405-C00555
    Figure US20070078122A1-20070405-C00556
    Figure US20070078122A1-20070405-C00557
    Figure US20070078122A1-20070405-C00558
    Figure US20070078122A1-20070405-C00559
    Figure US20070078122A1-20070405-C00560
    Figure US20070078122A1-20070405-C00561
    Figure US20070078122A1-20070405-C00562
    Figure US20070078122A1-20070405-C00563
    Figure US20070078122A1-20070405-C00564
    Figure US20070078122A1-20070405-C00565
    Figure US20070078122A1-20070405-C00566
    Figure US20070078122A1-20070405-C00567
    Figure US20070078122A1-20070405-C00568
    Figure US20070078122A1-20070405-C00569
    Figure US20070078122A1-20070405-C00570
    Figure US20070078122A1-20070405-C00571
    Figure US20070078122A1-20070405-C00572
    Figure US20070078122A1-20070405-C00573
    • Pharmaceutical Compositions and Methods of Treatment
  • Formula I, II, III, and IV compounds demonstrate activity against HCV NS5B and can be useful in treating HCV and HCV infection. Therefore, another aspect of the invention is a composition comprising a compound of formula I, II, III, or IV, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • Another aspect of the invention is a composition further comprising a compound having anti-HCV activity.
  • Another aspect of the invention is a composition where the compound having anti-HCV activity is an interferon. Another aspect of the invention is where the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.
  • Another aspect of the invention is a composition where the compound having anti-HCV activity is a cyclosporin. Another aspect of the invention is where the cyclosporin is cyclosporin A.
  • Another aspect of the invention is a composition where the compound having anti-HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
  • Another aspect of the invention is a composition where the compound having anti-HCV activity is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH, and a nucleoside analog for the treatment of an HCV infection.
  • Another aspect of the invention is a composition comprising a compound of formula I, II, III, or IV, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, an interferon and ribavirin.
  • Another aspect of the invention is a method of inhibiting the function of the HCV replicon comprising contacting the HCV replicon with a compound of formula I, II, III, or IV or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a method of inhibiting the function of the HCV NS5B protein comprising contacting the HCV NS5B protein with a compound of formula I, II, III, or IV or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention is a method of treating an HCV infection in a patient comprising administering to the patient a therapeutically effective amount of a compound of formula I, II, III, or IV or a pharmaceutically acceptable solvate or salt thereof. In another embodiment the compound is effective to inhibit the function of the HCV replicon. In another embodiment the compound is effective to inhibit the function of the HCV NS5B protein.
  • Another aspect of the invention is a method of treating an HCV infection in a patient comprising administering to the patient a therapeutically effective amount of a compound of formula I, II, III, or IV, or a pharmaceutically acceptable solvate or salt thereof, in conjunction with (prior to, after, or concurrently) another compound having anti-HCV activity.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is an interferon.
  • Another aspect of the invention is the method where the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is a cyclosporin.
  • Another aspect of the invention is the method where the cyclosporin is cyclosporin A.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5′-monophospate dehydrogenase inhibitor, amantadine, and rimantadine.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH, and a nucleoside analog for the treatment of an HCV infection.
  • Another aspect of the invention is the method where the other compound having anti-HCV activity is effective to inhibit the function of target in the HCV life cycle other than the HCV NS5B protein.
  • “Therapeutically effective” means the amount of agent required to provide a meaningful patient benefit as understood by practitioners in the field of hepatitis and HCV infection.
  • “Patient” means a person infected with the HCV virus and suitable for therapy as understood by practitioners in the field of hepatitis and HCV infection.
  • “Treatment,” “therapy,” “regimen,” “HCV infection,” and related terms are used as understood by practitioners in the field of hepatitis and HCV infection.
  • The compounds of this invention are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of a compound of Formula I, II, III, or IV or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients. A therapeutically effective amount is that which is needed to provide a meaningful patient benefit. Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles. Compositions encompass all common solid and liquid forms including capsules, tablets, losenges, and powders as well as liquid suspensions, syrups, elixers, and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) are generally used for compositions.
  • Solid compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg. Generally, other agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 0.25-1000 mg/unit.
  • Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 1-100 mg/mL.
  • The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other agents used clinically. Typically, the daily dose will be 1-100 mg/kg body weight daily. Generally, more compound is required orally and less parenterally. The specific dosing regime, however, will be determined by a physician using sound medical judgement.
  • The invention also encompasses methods where the compound is given in combination therapy. That is, the compound can be used in conjunction with, but separately from, other agents useful in treating hepatitis and HCV infection. In these combination methods, the compound of Formula I, II, III, or IV will generally be given in a daily dose of 1-100 mg/kg body weight daily in conjunction with other agents. The other agents generally will be given in the amounts used therapeutically. The specific dosing regime, however, will be determined by a physician using sound medical judgement.
  • Some examples of compounds suitable for compositions and methods are listed in Table 3.
    TABLE 3
    Type of Inhibitor or
    Brand Name Target Source Company
    Omega IFN IFN-ω BioMedicines Inc.,
    Emeryville, CA
    BILN-2061 serine protease inhibitor Boehringer Ingelheim
    Pharma KG, Ingelheim,
    Germany
    Summetrel antiviral Endo Pharmaceuticals
    Holdings Inc., Chadds
    Ford, PA
    Roferon A IFN-α2a F. Hoffmann-La Roche
    LTD, Basel, Switzerland
    Pegasys PEGylated IFN-α2a F. Hoffmann-La Roche
    LTD, Basel, Switzerland
    Pegasys and PEGylated IFN- F. Hoffmann-La Roche
    Ribavirin α2a/ribavirin LTD, Basel, Switzerland
    CellCept HCV IgG F. Hoffmann-La Roche
    immunosuppressant LTD, Basel, Switzerland
    Wellferon lymphoblastoid IFN- GlaxoSmithKline plc,
    αn1 Uxbridge, UK
    Albuferon —α albumin IFN-α2b Human Genome
    Sciences Inc., Rockville,
    MD
    Levovirin ribavirin ICN Pharmaceuticals,
    Costa Mesa, CA
    IDN-6556 caspase inhibitor Idun Pharmaceuticals
    Inc., San Diego, CA
    IP-501 antifibrotic Indevus Pharmaceuticals
    Inc., Lexington, MA
    Actimmune INF-γ InterMune Inc.,
    Brisbane, CA
    Infergen A IFN alfacon-1 InterMune
    Pharmaceuticals Inc.,
    Brisbane, CA
    ISIS 14803 antisense ISIS Pharmaceuticals
    Inc, Carlsbad, CA/Elan
    Phamaceuticals Inc.,
    New York, NY
    JTK-003 RdRp inhibitor Japan Tobacco Inc.,
    Tokyo, Japan
    Pegasys and PEGylated IFN-α2a/ Maxim Pharmaceuticals
    Ceplene immune modulator Inc., San Diego, CA
    Ceplene immune modulator Maxim Pharmaceuticals
    Inc., San Diego, CA
    Civacir HCV IgG Nabi
    immunosuppressant Biopharmaceuticals Inc.,
    Boca Raton, FL
    Intron A and IFN-α2b/α1-thymosin RegeneRx
    Zadaxin Biopharmiceuticals Inc.,
    Bethesda, MD/
    SciClone
    Pharmaceuticals Inc,
    San Mateo, CA
    Levovirin IMPDH inhibitor Ribapharm Inc., Costa
    Mesa, CA
    Viramidine IMPDH inhibitor Ribapharm Inc., Costa
    Mesa, CA
    Heptazyme ribozyme Ribozyme
    Pharmaceuticals Inc.,
    Boulder, CO
    Intron A IFN-α2b Schering-Plough
    Corporation,
    Kenilworth, NJ
    PEG-Intron PEGylated IFN-α2b Schering-Plough
    Corporation,
    Kenilworth, NJ
    Rebetron IFN-α2b/ribavirin Schering-Plough
    Corporation,
    Kenilworth, NJ
    Ribavirin ribavirin Schering-Plough
    Corporation,
    Kenilworth, NJ
    PEG-Intron/ PEGylated IFN- Schering-Plough
    Ribavirin α2b/ribavirin Corporation,
    Kenilworth, NJ
    Zadazim immune modulator SciClone
    Pharmaceuticals Inc.,
    San Mateo, CA
    Rebif IFN-β1a Serono, Geneva,
    Switzerland
    IFN-β and EMZ701 IFN-β and EMZ701 Transition Therapeutics
    Inc., Ontario, Canada
    T67 β-tubulin inhibitor Tularik Inc., South San
    Francisco, CA
    VX-497 IMPDH inhibitor Vertex Pharmaceuticals
    Inc., Cambridge, MA
    VX-950/LY-570310 serine protease inhibitor Vertex Pharmaceuticals
    Inc., Cambridge, MA/
    Eli Lilly and Co. Inc.,
    Indianapolis, IN
    Omniferon natural IFN-α Viragen Inc., Plantation,
    FL
    XTL-002 monoclonal antibody XTL
    Biopharmaceuticals
    Ltd., Rehovot, Isreal
    • DESCRIPTION OF SPECIFIC EMBODIMENTS
  • Figure US20070078122A1-20070405-C00574
  • 3-Cyclohexenyl-1H-indole-6-carboxylic acid. Cyclohexanone (96 mL, 0.926 mol) was added to a stirred solution of methyl indole-6-carboxylic acid (50.0 g, 0.335 mol) in methanol (920 mL) at 22° C. Methanolic sodium methoxide (416 mL of 25% w/w, 1.82 mol) was added in portions over 10 minutes. The mixture was stirred at reflux for 18 hours, cooled to room temperature, concentrated, diluted with cold water, and acidified with 36% HCl solution. The resulting precipitate was collected by filtration, washed with cold water, and dried over phosphorous pentoxide (0.1 mm) to provide the the title compound as a tan colored solid (80.9 g, 97.5% yield).
    Figure US20070078122A1-20070405-C00575
  • 3-Cyclohexyl-1H-indole-6-carboxylic acid. 3-Cyclohexenyl-1H-indole-6-carboxylic acid (38 g) was added to a Parr bottle, followed by methanol (100 mL) and THF (100 mL). The bottle was flushed with argon and 10% palladium on carbon (1.2 g) was added. The flask was then evacuated and subsequently refilled with H2 to a pressure of 55 psi, and the resultant mixture was shaken for 18 hours at RT. The catalyst was then removed by filtration through celite. Concentration of the filtrate provided the desired product as a pale purple solid (30.6 g, 79%). ESI-MS m/z 244 (MH+).
    Figure US20070078122A1-20070405-C00576
  • Methyl 3-cyclohexyl-1H-indole-6-carboxylate. Thionyl chloride (1 mL) was added to a stirred mixture of 3-cyclohexyl-1H-indole-6-carboxylic acid (30.4 g, 0.125 mol) in methanol (300 mL). The mixture was stirred at reflux for 18 hours, treated with decolorizing carbon, and filtered. The filtrate was concentrated to about 150 mL at which point crystallization occurred. The filtrate was cooled to room temperature and filtered. The solid was washed with cold methanol followed by diethyl ether to provide the desired product as a pale purple solid (22.2 g, 69% yield). ESI-MS m/z 258 (MH+); 1H NMR (300 MHz, CDCl3) δ 1.35 (m, 4H), 1.63 (s, 1H), 1.78 (m, 3H), 2.06 (d, J=8.05 Hz, 2H, 3.90 (m, 1H), 7.08 (d, J=1.83 Hz, 1H), 7.62 (s, 1H), 7.65 (s, 1H),7.74 (d, J=1.46 Hz, 1H), 7.77 (d, J=1.46 Hz, 1H), 8.08 (s, 1H).
    Figure US20070078122A1-20070405-C00577
  • Methyl 1H-indole-6-carboxylate. An ethereal solution of diazomethane (620 mL) was added slowly to a cooled, (−15° C.) stirred suspension of 6-indole carboxylic acid (45 g, 0.27 mol.) in diethyl ether (250 mL). Upon addition, the reaction mixture was stirred for a further 1 h at −15° C., after which the reaction was quenched by the slow addition of acetic acid (50 mL). The resultant mixture was then concentrated under reduced pressure, and the residue purified using flash chromatography on silica (60-120), using MDC as eluant.
    Figure US20070078122A1-20070405-C00578
  • Methyl 3-cyclohexyl-1H-indole-6-carboxylate. Cyclohexanone (42.46 mL, 0.40 mol) was added in a single portion to a stirred solution of methyl indole-6-carboxylate (47.8 g, 0.27 m) in dry dichloromethane (500 mL). The reaction mixture was then cooled to 10° C. and trifluoroacetic acid (63.13 mL, 0.8 m) was added dropwise followed by triethyl silane (174.5 mL, 1.09 m). Upon addition, the temperature was allowed to rise to rt, after which it was stirred for a further 12 h. Dichloromethane (200 mL) was then added and the reaction mixture was washed successively with with 10% sodium bicarbonate solution and brine. The organic layer dried over sodium sulfate, filtered and concentrated under vacuum. The resultant residuce was purified by flash chromatography on silica (60-120) using hexane-ethyl acetate (9.5:0.5) mixture as eluant. Homogeneous fractions were combined and evaporated to give 60 g of the desired product (85%). Analytical data on this material was consistant with that observed with a sample prepared by the alternative route described above.
    Figure US20070078122A1-20070405-C00579
  • Methyl 2-bromo-3-cyclohexyl-2-1H-indole-6-carboxylate. Dry pyridinium tribromide (12.0 g, 38 mmol) was added in one portion to a stirred and cooled (ice/water bath) solution of methyl 3-cyclohexyl-1H-indole-6-carboxylate (7.71 g, 30 mmol) in a mixture of THF (80 mL) and chloroform (80 mL). The flask was removed from the cooling bath and stirring was continued for 2 hours at room temperature. The mixture was sequentially washed with 1M NaHSO3 (2×50 mL) and 1N HCl (50 mL). It was then dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrate was treated with hexanes and the resulting precipitate was collected by filtration to provide the desired product as an off-white solid (5.8 g, 58%). 1H NMR (300 MHz, CDCl3) δ 1.38 (m, 3H), 1.85 (m, 7H), 2.81 (m, 1H), 7.71 (m, 2H), 8.03 (s, 1H), 8.47 (s, 1H).
  • The hexane mother liquor was concentrated and the residue was dissolved in hexane/ethyl acetate (5:1). The solution was passed through a pad of silica gel with the same solvents. Concentration of the eluate followed by the addition of hexane (10 mL) resulted in the precipitation of additional product which was collected by filtration to provide 2.8 g (28%) of the desired product.
    Figure US20070078122A1-20070405-C00580
  • Methyl 11-cyclohexyl-6-hydroxy-6H-isoindolo[2,1-a]indole-3-carboxylate. A stirred mixture of methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate (10.1 g, 30 mmol), 2-formylphenylboronic acid (5.4 g, 36 mmol), LiCl (3.8 g (90 mmol) and Pd (PPh3)4 (1.6 g, 1.38 mmol) in 1M Na2CO3 (40 mL) and 1:1 EtOH-toluene (180 mL) was heated under nitrogen at 85° C. for 3 hours. The reaction mixture was then cooled to RT, and extracted with EtOAc (2×100 mL). The extracts were washed sequentially with water and brine, then dried (MgSO4), filtered and conventrated in-vacuo to afforded 13.3 g of crude product. This material was triturated with DCM and hexanes to provide pure desired product (7.52 g, 70%). LC-MS: m/e 360 (M−H); 344 (M−17)+. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.33-1.60 (m, 4 H) 1.77-2.01 (m, 6H) 2.80 (d, J=11.83 Hz, 1 H) 3.02-3.18 (m, 1 H) 3.89 (s, 3 H) 6.49 (d, J=11.33 Hz, 1 H) 7.34 (t, J=7.55 Hz, 1 H) 7.46 (t, J=7.55 Hz, 1 H) 7.62 (d, J=7.30 Hz, 1 H) 7.66-7.74 (m, 2 H) 7.77 (d, J=7.81 Hz, 1 H) 8.21 (s, 1 H).
    Figure US20070078122A1-20070405-C00581
  • Methyl 13-cyclohexyl-6-(methoxycarbonyl)-7H-indolo[2, 1-a][2]benzazepine-10-carboxylate. A stirred suspension of methyl 11-cyclohexyl-6-hydroxy-6H-isoindolo[2,1-a]indole-3-carboxylate (3.61 g, 10 mmol), Cs2CO3 (3.91 g, 12 mmol) and trimethyl 2-phosphonoacetate (2.86g, 14 mmol) in an. DMF (40 mL) was heated at 60° C. under nitrogen for 3 h. The resultant yellow suspension was cooled to rt and water was added with vigorous stirring. A yellow precipitate formed which was collected by filtration. The solid was washed with water, and then air dried overnight to afford the title compound as a yellow powder (4.124 g, 96%). LC/MS: m/e 430 (MH+); 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.30-1.46 (m, J=14.86 Hz, 2 H) 1.55 (s, 2 H) 1.77 (s, 2 H) 1.85-2.18 (m, 4 H) 2.76-2.89 (m, 1 H) 3.84 (s, 3 H) 3.95 (s, 3 H) 4.19 (s, 1 H) 5.68 (s, 1 H) 7.38-7.63 (m, 4 H) 7.74 (dd, J=8.44, 1.39 Hz, 1 H) 7.81-7.98 (m, 2 H) 8.29 (d, J=1.0l Hz, 1 H).
    Figure US20070078122A1-20070405-C00582
  • Methyl 13-cyclohexyl-6-(carboxy)-5H-indolo[2,1-a][2]benzazepine-10-carboxylate. Methyl 13-cyclohexyl-6-(methoxycarbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate (308 mg, 0.72 mmol) was dissolved in N,N-dimethylformamide (5 mL) and treated with LiOH (173 mg, 7.2 mmol). The mixture was heated at 50° C. for 4 hr, after which the solvent was removed in vacuo. The residue was dissolved in H2O (5 mL) and the resultant mixture was acidified by the addition of a 10% aqueous HCL solution. A precipitate formed which was collected by filtration and air dried to afford the title compound as a bright yellow solid (290 mg, 97%). ESI-MS m/z [M+1]=415.
    Figure US20070078122A1-20070405-C00583
  • Methyl 13-cyclohexyl-6-(morpholinylcarbonyl)-5H-indolo[2,1-a][2]benzazepine-10-carboxylate. TBTU (145 mg, 0.45 mmol) was added to a stirred solution of Methyl 13-cyclohexyl-6-(carboxy)-5H-indolo[2,1-a][2]benzazepine-10-carboxylate (125 mg, 0.30 mmol), morpholine (26 μL, 0.30 mmol), and N,N-diisopropylethylamine 200 μL, 1.15 mmol) in DMF (2 mL). The mixture was stirred at 22° C. for 20 min. The resulting solution was then injected onto a Shimadzu reverse phase preparative HPLC. The product containing fraction was concentrated on a Speed Vac® to leave methyl 13-cyclohexyl-6-(morpholinylcarbonyl)-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid as a yellow solid (64 mg, 44%). ESI-MS m/z 487 (MH+); 1H NMR (500 MHz, CDCl3) δ 1.21 (m, 1 H), 1.34-1.55 (m, 3 H), 1.77 (m, 2 H), 1.91 (m, 1 H), 2.06 (m, 3 H), 2.83 (m, 1 H), 2.97-3.85 (m, 8 H), 3.97 (s, 3 H), 4.45 (m, 1 H), 5.07 (m, 1 H), 6.89 (s, 1 H), 7.41 (d, 1 H), 7.49 (m, 2 H), 7.57 (m, 1 H), 7.75 (m, 1 H), 7.89 (d, J=8.55 Hz, 1 H), 8.15 (s, 1 H).
    Figure US20070078122A1-20070405-C00584
  • A t-butanol (1.32 mL, 14 mmol) solution in CH2Cl2 (6 mL) was added dropwise to the solution of CSI (1.24 mL, 14 mmol) of CH2Cl2 (20 mL) at 0° C. The generated solution was stirred for 1.5 h at 0° C. A solution of morpholine (1.23 mL, 14 mmol) and triethylamine (5.9 mL, 42 mmol) in CH2Cl2 (10 mL) was added dropwise. The generated reaction mixture was stirred for 1 h at 0° C. and 1 h at r.t. The solvents were removed in vacuo and the residue was partitioned between EtOAc and cold 1N HCl. The organic layer was washed with cold 1N HCl, brine, dried (MgSO4), and removed the solvent to afford A-1 as a white solid (2.16 g, 92%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.48 (s, 9 H) 3.30-3.44 (m, 4 H) 3.66-3.80(m, 4 H) 7.19 (s, 1 H).
    Figure US20070078122A1-20070405-C00585
  • Dissolved A-1 (2.16 g, 13 mmol) in TFA (2 mL) and CH2Cl2 (2 mL) and stirred the mixture at r.t. for 5 h. Removed the solvents in vacuo to afford B-1 as a beige solid (1.35 g, 100%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.10-3.39 (m, 4 H) 3.63-3.96 (m, 4 H).
    Figure US20070078122A1-20070405-C00586
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.47 (s, 9 H) 1.85-1.98 (m, 4 H) 3.42-3.57 (m, 4 H) 7.00 (s, 1 H).
    Figure US20070078122A1-20070405-C00587
  • 1H NMR (400 MHz, MeOD) δ ppm 1.85-1.93 (m, 4 H) 3.17-3.28 (m, 4 H).
    Figure US20070078122A1-20070405-C00588
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.20 (t, J=7.18 Hz, 3 H) 1.47 (s, 9 H) 2.95 (s, 3 H) 3.35 (q, J=7.05 Hz, 2 H) 7.00 (s, 1 H).
    Figure US20070078122A1-20070405-C00589
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.20 (t, J=7.18 Hz, 6 H) 1.47 (s, 9 H) 3.41 (q, J=7.30 Hz, 3 H) 7.04 (s, 1 H).
    Figure US20070078122A1-20070405-C00590
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.50 (s, 9 H) 2.84 (s, 3 H) 3.80 (s, 3 H) 4.48 (s, 2 H) 6.43 (d, J=16.12 Hz, 1 H) 7.36 (d, J=8.06 Hz, 2 H) 7.48-7.54 (m, J=8.06 Hz, 2 H) 7.67 (d, J=15.86 Hz, 1 H).
    Figure US20070078122A1-20070405-C00591
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.21 (d, J=6.55 Hz, 6 H) 1.48 (s, 9 H) 3.47-3.66 (m, 1 H).
    Figure US20070078122A1-20070405-C00592
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.49 (s, 9 H) 2.83 (s, 3 H) 3.90 (s, 3 H) 4.52 (s, 2 H) 7.40 (d, J=8.06 Hz, 2 H) 8.01 (d, J=8.31 Hz, 2 H).
    Figure US20070078122A1-20070405-C00593
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 3.20-3.28 (m, 4 H) 3.51-3.57 (m, 4 H) 6.88-6.98 (m, J=8.31 Hz, 2 H) 7.21-7.31 (m, 2 H).
    Figure US20070078122A1-20070405-C00594
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.49 (s, 9 H) 2.83 (s, 3 H) 3.90 (s, 3 H) 4.52 (s, 2 H) 7.40 (d, J=8.06 Hz, 2 H) 8.01 (d, J=8.31 Hz, 2 H).
    Figure US20070078122A1-20070405-C00595
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.50 (s, 9 H) 2.83 (s, 3 H) 4.45 (s, 2 H) 7.29-7.44 (m, 5 H).
    Figure US20070078122A1-20070405-C00596
  • 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 1.42 (s, 9 H) 3.00 (t, J=5.80 Hz, 2 H) 3.68 (t, J=5.95 Hz, 2 H) 3.90 (s, 3 H) 4.65 (s, 2 H) 7.05 (s, 1 H) 7.16 (d, J=7.94 Hz, 1 H) 7.79-7.92 (m, 2 H).
    Figure US20070078122A1-20070405-C00597
  • 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.48 (s, 9 H) 3.08 (s, 3 H) 3.76 (s, 3 H) 4.95 (s, 1 H).
    Figure US20070078122A1-20070405-C00598
  • A t-butanol (1.32 mL, 14 mmol) solution in CH2Cl2 (5 mL) was added dropwise to the solution of CSI (1.24 mL, 14 mmol) of CH2Cl2 (20 mL) at 0° C. The generated solution was stirred for 1.5 h at 0° C. A solution of 1-methylpiperazine (1.52 mL, 14 mmol) and in CH2Cl2 (5 mL) was added dropwise at 0° C. After stirred for 5 min at 0° C., removed the bath and stirred at r.t. for 4 h. The reaction mixture was diluted with ether and filtered to afford a white solid (2.72 g, 69%). 1H NMR (400 MHz, MeOD) δ ppm 1.49 (s, 9 H) 2.92 (s, 3 H) 3.38 (s, 4 H) 3.65 (s, 4 H).
    Figure US20070078122A1-20070405-C00599
  • A mixture of trifluoromethanesulfonamide (89 mg, 0.6 mmol), added acid 2 (56 mg, 0.12 mmol), DMAP (89 mg, 0.73 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (57 mg, 0.27 mmol) in DMF (1.5 mL) was stirred o/n and purified by prep HPLC to afford the product as a solid (17.6 mg, 24 %). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.29-1.52 (m, 4 H) 1.66-1.79 (m, 2 H) 2.03 (s, 4 H) 2.79 (s, 1 H) 3.26-3.74 (m, 8 H) 4.21 (s, 1 H) 5.06 (s, 1 H) 6.89 (s, 1 H) 7.33-7.60 (m, 4 H) 7.68 (d, J=8.31 Hz, 1 H) 7.83-7.91 (m, 1 H) 8.33 (s, 1 H). LC-MS (retention time: 3.04; MS m/z 602 (M+H).
    Figure US20070078122A1-20070405-C00600
  • A mixture of morpholine-4-sulfonamide (46 mg, 0.28 mmol), added acid 1 (40 mg, 0.08 mmol), DMAP (82 mg, 0.67 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (57 mg, 0.30 mmol) in DMF (1.5 mL) was stirred o/n and purified by prep HPLC to afford the product as a solid (16 mg, 30%) 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.21-1.62 (m, 4 H) 1.90 (d, J=112.30 Hz, 6 H) 2.83 (s, 1 H) 3.28-3.88 (m, 16 H) 4.36 (s, 1 H) 5.12 (s, 1 H) 6.89 (s, 1 H) 7.35-7.63 (m, 5 H) 7.80-7.94 (m, 1 H) 8.14 (s, 1 H) LC-MS (retention time: 2.97; MS m/z 619 (M+H).
    Figure US20070078122A1-20070405-C00601
  • tert-butyl 4-methylpiperazin-1-ylsulfonylcarbamate (89 mg, 0.32 mmol) was dissolved in TFA/DCM (1/1, 1 mL) and stirred for 2 h. removed the solvents in vacuo and added acid 2 (40 mg, 0.1 mmol), DMAP (129 mg, 1.06 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (61 mg, 0.3 mmol), DMF (1.5 mL). The mixture was stirred o/n and purified by prep HPLC to afford the product as a solid (6.3 mg, 9%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.39 (d, J=7.30 Hz, 4 H) 1.76 (s, 2 H) 2.08 (d, J=12.84 Hz, 4 H) 2.75-2.91 (m, 4 H) 3.40-3.91 (m, 16 H) 4.22-4.42 (m,J=-18.13 Hz, 1 H) 5.15 (s, 1 H) 6.88 (s, 1 H) 7.41 (dd, J=7.30, 1.51 Hz, 1 H) 7.47-7.56 (m, 3 H) 7.55-7.62 (m, 1 H) 7.84-7.96 (m, J=8.81, 8.81 Hz, 1 H) 8.08 (s, 1 H): LC-MS (retention time: 2.71; MS m/z 632 (M+H).
    Figure US20070078122A1-20070405-C00602
  • The Boc sulfamide (102 mg, 0.63 mmol) was dissolved in TFA/DCM (1/1, 1 mL) and stirred for 2 h. removed the solvents in vacuo and added acid 2 (40 mg, 0.1 mmol), DMAP (100 mg, 0.82 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (57 mg, 0.3 mmol), DMF (1.5 mL). The mixture was stirred o/n and purified by prep HPLC to afford the product as a solid (10.4 mg, 20%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.13-2.18 (m, 10 H) 2.78-2.87 (m, 1 H) 3.26 (s, 3 H) 3.32-3.71 (m, 8 H) 3.82 (s, 3 H) 4.35 (s, 1 H) 5.12 (s, 1 H) 6.87(s, 1 H)7.34-7.63(m,4H) 7.82-7.87(m, 1 H) 7.91 (d, J=8.56 Hz, 1 H) 8.10 (s, 1 H), LC-MS (retention time: 3.00 ), MS m/z 593 (M++1).
    Figure US20070078122A1-20070405-C00603
  • A suspension of compound 18 (7.9 mg, 0.17 mmol) and small amount of Pd/C (10%) in THF/MeOH (1/2, 6 mL) was stirred under H2 balloon pressure for 4 h. Filtered off the solid and removed the solvents in vacuo to afford the product as a colorless solid (6.7 mg, 84%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.21-1.62 (m, 4 H) 1.75 (s, 2 H) 1.85-2.12 (m, 4 H) 2.86-2.96 (m, 3 H) 3.08-3.87 (m, 17 H) 4.08-4.42 (m, 1 H) 4.52-4.71 (m, J=14.86 Hz, 1 H) 7.31-7.65 (m, 5 H) 7.75-8.05 (m, 2 H) LC-MS (retention time: 3.08 ; MS m/z 621 (M+H).
    Figure US20070078122A1-20070405-C00604
  • A mixture of trifluoromethanesulfonamide (49 mg, 0.33 mmol), acid (31 mg, 0.07 mmol), DMAP (40 mg, 0.33 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (31 mg, 0.16 mmol) in DMF (1.5 mL) was stirred o/n and purified by prep HPLC to afford the product as a glass (4.2 mg, 10%). LC-MS (retention time: 3.09; MS m/z 604 (M+H).
    Figure US20070078122A1-20070405-C00605
  • A mixture of (1H-tetrazol-5-amine (45 mg, 0.53 mmol), acid (25 mg, 0.05 mmol), DMAP (100 mg, 0.82 mmol), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (80 mg, 0.16 mmol) in DMF (1.5 mL) was stirred o/n and purified by prep HPLC to afford the product as a glass (3.1 mg, 11%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.16-1.59 (m, 4 H) 1.59-1.82 (m, 2 H) 1.82-2.18 (m, 4 H) 2.84-3.00 (m, 4 H) 3.44-3.94 (m, 8 H) 4.18-4.37 (m, 2 H) 4.86 (d, J=15.36 Hz, 2 H) 7.30-7.54 (m, 5 H) 7.77-7.91 (m, J=7.30 Hz, 1 H) 8.45 (s, 1 H); LC-MS (retention time: 2.80 MS m/z 540 (M+H).
    Figure US20070078122A1-20070405-C00606
  • 13-Cyclohexyl-N-(methylsulfonyl)-6-[4-(2-oxopyrrolidin-1-yl)piperidine-1-carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. LS/MS: m/e 629 (MH+); 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.17-1.54 (m, 5 H) 1.64 (s, 2 H) 1.71-1.83 (m, 2 H) 2.01 (s, 6 H) 2.36-2.47 (m, 2 H) 2.83 (d, J=4.28 Hz, 2 H) 3.21-3.53 (m, 6 H) 3.47 (s, 3 H) 3.48 (s, 3 H) 3.92-4.10 (m, 1 H) 4.37 (s, 1 H) 5.02-5.23 (m, 1 H) 6.86 (s, 1 H) 7.36-7.63 (m, 5 H) 7.91 (d, J=8.56 Hz, 1 H) 8.18 (s, 1 H).
    Figure US20070078122A1-20070405-C00607
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (150 mg, 0.36 mmol), 2-(piperazin-1-yl)pyrimidine (63 mg, 0.38 mmol) and triethylamine (0.10 mL) in DMF (2 mL) was added HATU (160 mg, 0.42 mmol). The reaction mixture was stirred at rt for 15 min., diluted with H2O (˜4 mL) and the solids were collected by filtration washed with H2O and dried under vacuum overnight to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl]-, methyl ester (168 mg, 0.30 mmol, 83%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.28 (d, J=4.9 Hz, 2H), 8.16 (br s, 1H), 7.89 (d, J =8.6 Hz, 1H), 7.74 (dd, J=8.6 Hz, 1H), 7.59 (dd, J=7.6, 1.5 Hz, 1H), 7.52-7.45 (m, 2H), 7.40 (dd, J=7.3, 1.5 Hz, 1H), 7.25 (s, 1H), 6.51 (t, J=4.9 Hz, 1H), 5.15 (br s, 1H), 4.43(br s, 1H), 3.91 (s, 3H), 3.80-3.29 (m, 8H), 2.91-2.82 (m, 1H), 2.17-1.14 (m, 10H). LCMS: m/e 562 (M+H)+, ret time 2.07 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00608
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (200 mg, 0.48 mmol), 2-(piperazin-1-yl)pyrimidine (95 mg, 0.58 mmol) and triethylamine (0.20 mL, 1.45 mmol) in DMF (3 mL) was added HATU (220 mg, 0.58 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜6 mL) and the solids were collected by filtration, washed with H2O, dissolved into MeOH//THF (1:1, 4 mL) and treated with 1 M aqueous NaOH (0.60 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 20 min in a sealed tube, additional 1 M aqueous NaOH (0.10 mL.) was added and the reaction was reheated at 80° C. for 10 min. The clear solution was diluted with H2O (1 mL), neutralized with 1M aqueous HCl (0.70 mL) and concentrated to remove organic solvents. The resultant solids were collected by filtration, washed with H2O and dried under vacuum to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl] (125 mg, 0.23 mmol, 48%) as a light yellow solid. LCMS: m/e 548 (M+H)+, ret time 1.52 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00609
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl] (125 mg, 0.23 mmol), N,N-dimethylsulfamide (140 mg, 1.14 mmol) and DMAP (140 mg, 1.14 mmol) in dimethylacetamide (2 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (175 mg, 0.91 mmol). The reaction solution was stirred at 50° C. overnight, concentrated, purified by preparative HPLC (MeOH/2O with NH4OAc buffer) and repurified by preparative HPLC (MeOH/2O with TFA buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(2-pyrimidinyl)-1-piperazinyl]carbonyl] (44 mg, 0.067 mol, 29%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 9.23 (br s, 1H), 8.43 (d, J=4.9 Hz, 2H), 8.04 (s, 1H), 7.92 (d, J=8.5 Hz, 1H), 7.60 (br d, J=8.5 Hz, 1H), 7.54-7.45 (m, 3H), 7.42 (br d, J=7.6 Hz, 1H), 6.92 (s, 1H), 6.68 (t, J=4.9 Hz, 1H), 5.16 (br s, 1H), 4.41 (br s, 1H), 3.88-3.46 (m, 8H), 3.03 (s, 6H), 2.90-2.81 (m, 1H), 2.16-1.13 (m, 10H). LCMS: m/e 654 (M+H)+, ret time 2.87 min, column B, 2 minute gradient.
    Figure US20070078122A1-20070405-C00610
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (150 mg, 0.36 mmol), 2-(piperazin-1-yl)pyrimidine (76 mg, 0.38 mmol) and triethylamine (0.10 mL) in DMF (2 mL) was added HATU (160 mg, 0.42 mmol). The reaction mixture was stirred at rt for 15 min., diluted with H2O (˜4 mL) and the solids were collected, by filtration washed with H2O and dried under vacuum overnight to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]carbonyl]-, methyl ester (170 mg, 0.30 mmol, 83%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.15 (s, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.74 (br d, J=8.5 Hz, 1H), 7.58 (br d, J=7.6 Hz, 1H), 7.52-7.44 (m, 2H), 7.39 (br d, J=7.3 Hz, 1H), 6.85 (s, 1H), 5.12(br s, 1H), 4.40 (br s, 1H), 3.94 (s, 3H), 3.72-3.01 (m, 8H), 3.63 (dd, J=4.9, 4.3 Hz, 4H), 3.20 (dd, J=4.9, 4.3 Hz, 4H), 2.88-2.81 (m, 1H), 2.16-1.15 (m, 10H). LCMS: m/e 597 (M+H)+, ret time 1.82 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00611
  • To a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]carbonyl]-, methyl ester (142 mg, 0.24 mmol) in MeOH/THF (1:1, 2 mL) was added 1N aqueous NaOH (0.36 mL, 0.36 mmol). The reaction solution was stirred at rt for 1h, and then at 80° C. for 20 min. The reaction was cooled to rt, diluted with H2O (˜2 mL), neutralized with 1N aqueous HCl (0.36 mL, 0.36 mmol) and concentrated to removed organic solvents. The solids were collected by filtration, flushed with water, dissolved into MeOH and purified by preparative HPLC (MeOH/H2O with NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]carbonyl] (78 mg, 0.13 mmol, 56%) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ 8.19 (s, 1H), 7.89 (d, J=8.6 Hz, 1H), 7.63 (dd, J=8.6, 1.5 Hz, 1H), 7.61-7.53 (m, 4H), 7.02 (s, 1H), 5.18 (br s, 1H), 4.26 (br s, 1H), 3.56 (dd, J=4.9, 4.3 Hz, 4H), 3.53-3.47 (m, 4H), 3.19-3.13 (m, 4H), 3.14 (dd, J=4.9, 4.3 Hz, 4H), 2.84-2.76 (m, 1H), 2.12-1.99 (m, 3H), 1.75-1.10 (m, 7H). LCMS: m/e 583 (M+H)+, ret time 1.28 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00612
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]carbonyl] (70 mg, 0.12 mmol), N,N-dimethylsulfamide (75 mg, 0.60 mmol) and DMAP (75 mg, 0.61 mmol) in dimethylacetamide (1.5 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (92 mg, 0.48 mmol). The reaction solution was stirred at 50° C. overnight, concentrated, purified by preparative HPLC (MeOH/2O with NH4OAc buffer) and repurified by preparative HPLC (MeOH/2O with TFA buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(4-morpholinylcarbonyl)-1-piperazinyl]carbonyl] (28 mg, 0.041 mol, 34%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 9.09 (br s, 1H), 8.11 (s, 1H), 7.91 (d, J=8.5 Hz, 1H), 7.58 (br d, J=7.3 Hz, 1H), 7.54-7.45 (m, 3H), 7.41 (br d, J=7.3 Hz, 1H), 6.87 (s, 1H), 5.16 (br s, 1H), 4.37 (br s, 1H), 3.66 (dd, J=4.6, 4.6 Hz, 4H), 3.59-3.40 (m, 4H), 3.27(dd, J=4.6, 4.6 Hz, 4H), 3.19-3.07 (m, 4H), 3.06 (s, 6H), 2.89-2.80 (m, 1H), 2.13-1.17 (m, 10H). LCMS: m/e 674 (M−H)−, ret time 1.85 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00613
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (470 mg, 1.13 mmol), tert-butyl piperazine-1-carboxylate (250 mg, 1.36 mmol) and triethylamine (0.30 mL) in DMF (5 mL) was added HATU (520 mg, 1.36 mmol). The reaction mixture was stirred at rt for 1 h, diluted with H2O (˜6 mL) and extracted with EtOAc (2×10 mL). The combined organics were washed with brine (10 mL), dried (MgSO4), filtered and concentrated. The residue was dissolved into MeOH//THF (1:1, 10 mL) and treated with 1M aqueous NaOH (1.4 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 30 min in a sealed tube, additional 1M aqueous NaOH (0.50 mL.) was added and the reaction was reheated at 80° C. for 15 min. The clear solution was diluted with H2O (10 mL), neutralized with 1M aqueous HCl (1.9 mL) and concentrated to remove organic solvents. The resultant solids were collected by filtration, washed with H2O, dried under vacuum and purified by preparative HPLC (MeOH/H2O with NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]carbonyl] (335 mg, 0.59 mmol, 43%) as a yellow solid. 1H NMR (500 MHz, CD3OD) δ 8.23 (s, 1H), 7.92 (d, J=8.5 Hz, 1H), 7.75 (dd, J=8.5, 1.2 Hz, 1H), 7.65 (br d, J=6.4 Hz, 1H), 7.60-7.53 (m, 3H), 7.03 (s, 1H), 5.18 (br s, 1H), 4.43 (br s, 1H), 3.42-3.25 (m, 8H), 2.95-2.86 (m, 1H), 2.21-1.19 (m, 10H). LCMS: m/e 568 (M−H)−, ret time 1.36 min, column D, 2 minute gradient.
    Figure US20070078122A1-20070405-C00614
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]carbonyl] (100 mg, 0.18 mmol), N,N-dimethylsulfamide (110 mg, 0.89 mmol) and DMAP (110 mg, 0.90 mmol) in dimethylacetamide (2 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (135 mg, 0.71 mmol). The reaction solution was stirred at 50° C. overnight, concentrated, purified by preparative HPLC (MeOH/2O with NH4OAc buffer) to yield 1-piperazinecarboxylic acid, 4-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-, 1,1-dimethylethyl ester (49 mg, 0.073 mol, 40%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.10 (s, 1H), 7.91 (d, J=8.6 Hz, 1H), 7.58 (br d, J=7.6 Hz, 1H), 7.63-7.46 (m, 3H), 7.40 (br d, J=7.3 Hz, 1H), 6.87 (s, 1H), 5.15 (br s, 1H), 4.37 (br s, 1H), 3.56-3.22 (m, 8H), 3.06 (s, 6H), 2.89-2.81 (m, 1H), 2.15-1.15 (m, 10H), 1.44 (s, 9H). LCMS: m/e 676 (M+H)+, ret time 2.05 min, column B, 2 minute gradient.
    Figure US20070078122A1-20070405-C00615
  • Trifluoroacetic acid (1.5 mL) was added dropwise to a stirred solution of 1-piperazinecarboxylic acid, 4-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-, 1,1-dimethylethyl ester (77 mg. 0.11 mmol) in CH2C12 (1.5 mL). The reaction solution was stirred 2 h, concentrated and the residue was purified by preparative HPLC (MeOH/H2O with TFA buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(1-piperazinylcarbonyl) (37 mg, 0.06 mmol, 56%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 9.36 (br s, 1H), 8.25 (s, 1H), 7.87 (d, J=8.2 Hz, 1H), 7.61-7.39 (m, 5H), 6.91 (s, 1H), 5.16 (br s, 1H), 4.31 (br s, 1H), 3.88-3.39 (m, 8H), 2.98 (s, 6H), 2.89-2.75 (m, 1H), 2.11-1.13 (m, 10H). LCMS: m/e 576 (M+H)+, ret time 2.39 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00616
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (200 mg, 0.48 mmol), 1,2,3,4-tetrahydropyrazino[2,1-a]isoindol-6(10bH)-one hydrochloride (130 mg, 0.58 mmol) and triethylamine (0.20 mL) in DMF (3 mL) was added HATU (220 mg, 0.58 mmol). The reaction mixture was stirred at rt for 1 h, diluted with H2O (˜5 mL) stirred for 30 min, and the solids (288 mg) collected by filtration and flushed with H2O. The crude solids were dissolved into MeOH/THF (1:1, 4 mL) and treated with 1M aqueous NaOH (0.75 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 15 min in a sealed tube. The clear solution was diluted with H2O (5 mL), neutralized with 1M aqueous HCl (0.75 mL) and concentrated to remove organic solvents. The resultant solids (247 mg) were collected by filtration and washed with H2O. To a stirred solution of the crude solids (150 mg, 61% of total collected, ˜0.25 mmol), N,N-dimethylsulfamide (155 mg, 1.25 mmol) and DMAP (150 mg, 1.25 mmol) in dimethylacetamide (2 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (190 mg, 1.0 mmol). The reaction solution was stirred at 50° C. for 2h, diluted with water (5 mL) and the resulting solids were collected by filtration. The mother liquor was concentrated and the solids and the mother liquor were independently purified by preparative HPLC (MeOH/2O with NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[(3,4,6,10b-tetrahydro-6-oxopyrazino[2,1-a]isoindol-2(1H)-yl)carbonyl] (71 mg total, 27 mg from solids and 44 mg from mother liquor, 0.09 mol, 36% over 3 steps) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.96 (br s, 1H), 8.15 (s, 1H), 7.94 (d, J=8.6 Hz, 1H), 7.83 (s, 1H), 7.62 (d, J=7.6 Hz, 1H), 7.57-7.38 (m, 7H), 6.96 (s, 1H), 5.20 (br s, 1H), 4.44 (br s, 1H), 4.38-3.70 (m, 3H), 3.23-2.66 (m, 5H), 2.98 (s, 6H), 2.11-1.17 (m, 10H). LCMS: m/e 676 (M−H)−, ret time 1.61 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00617
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (200 mg, 0.48 mmol), 3(R)-methyl-1-benzoylpiperazine hydrochloride (130 mg, 0.58 mmol) and triethylamine (0.20 mL) in DMF (3 mL) was added HATU (220 mg, 0.58 mmol). The reaction mixture was stirred at rt for 1 h, diluted with H2O (˜5 mL) stirred for 30 min, and the solids (290 mg) collected by filtration and flushed with H2O. The crude solids were dissolved into MeOH/THF (1:1, 4 mL) and treated with 1M aqueous NaOH (0.75 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 15 min in a sealed tube. The clear solution was diluted with H2O (5 mL), neutralized with 1M aqueous HCl (0.75 mL) and concentrated to remove organic solvents. The resultant solids (257 mg) were collected by filtration and washed with H2O. To a stirred solution of the crude solids (145 mg, 56% of total collected, ˜0.25 mmol), N,N-dimethylsulfamide (155 mg, 1.25 mmol) and DMAP (150 mg, 1.25 mmol) in dimethylacetamide (2 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (190 mg, 1.0 mmol). The reaction solution was stirred at 50° C. for 2 h, diluted with water (5 mL) and the resulting solids were collected by filtration. The mother liquor was concentrated and the solids and the mother liquor were independently purified by preparative HPLC (MeOH/2O with NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[[(2R)-4-benzoyl-2-methyl-1-piperazinyl]carbonyl]-13-cyclohexyl-N-[(dimethylamino)sulfonyl] (79 mg total, 52 mg from solids and 27 mg from mother liquor, 0.11 mol, 42% over 3 steps) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H), 7.88 (d, J=8.6 Hz, 1H), 7.60-7.44 (m, 4H), 7.43-7.32 (m, 6H), 6.82 (br s, 1H), 5.21 (br s, 1H), 4.34 (br s, 1H), 4.58-3.34 (m, 7H), 3.06 (s, 6H), 2.87-2.78(m, 1H), 2.12-1.00 (m, 13H). LCMS: m/e 692 (M−H)−, ret time 1.69 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00618
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (200 mg, 0.48 mmol), 3(R)-methyl-1-benzoylpiperazine hydrochloride (130 mg, 0.58 mmol) and triethylamine (0.20 mL) in DMF (3 mL) was added HATU (220 mg, 0.58 mmol). The reaction mixture was stirred at rt for 1 h, diluted with H2O (˜5 mL) stirred for 30 min, and the solids (290 mg) collected by filtration and flushed with H2O. The crude solids were dissolved into MeOH/THF (1:1, 4 mL) and treated with 1M aqueous NaOH (0.75 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 15 min in a sealed tube. The clear solution was diluted with H2O (5 mL), neutralized with 1M aqueous HCl (0.75 mL) and concentrated to remove organic solvents. The resultant solids were collected by filtration, washed with H2O and dried under vacuum to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-[[(2R)-4-benzoyl-2-methyl-1-piperazinyl]carbonyl]-13-cyclohexyl (257 mg, 0.44 mol, 90%). LCMS: m/e 586 (M−H)−, ret time 1.48 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00619
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (200 mg, 0.48 mmol), 3(R)-methyl-1-benzoylpiperazine hydrochloride (130 mg, 0.58 mmol) and triethylamine (0.20 mL) in DMF (3 mL) was added HATU (220 mg, 0.58 mmol). The reaction mixture was stirred at rt for 1 h, diluted with H2O (˜5 mL) stirred for 30 min, and the solids (290 mg) collected by filtration and flushed with H2O. The crude solids were dissolved into MeOH/THF (1:1, 4 mL) and treated with 1M aqueous NaOH (0.75 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 15 min in a sealed tube. The clear solution was diluted with H2O (5 mL), neutralized with 1M aqueous HCl (0.75 mL) and concentrated to remove organic solvents. The resultant solids (257 mg) were collected by filtration and washed with H2O. To a stirred solution of the crude solids (145 mg, 56% of total collected, ˜0.25 mmol), N,N-dimethylsulfamide (155 mg, 1.25 mmol) and DMAP (150 mg, 1.25 mmol) in dimethylacetamide (2 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (190 mg, 1.0 mmol). The reaction solution was stirred at 50° C. for 2 h, diluted with water (5 mL) and the resulting solids were collected by filtration. The mother liquor was concentrated and the solids and the mother liquor were independently purified by preparative HPLC (MeOH/2O with NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[(4-benzoyl-1-piperazinyl)carbonyl]-13-cyclohexyl-N-[(dimethylamino)sulfonyl] (79 mg total, 52 mg from solids and 27 mg from mother liquor, 0.11 mol, 42% over 3 steps) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 9.07 (br s, 1H), 8.10 (s, 1H), 7.91 (d, J=8.2 Hz, 1H), 7.59 (d, J=8.6 Hz, 1H), 7.54-7.45 (m, 3H), 7.44-7.35 (m, 6H), 6.89 (s, 1H), 5.16 (br s, 1H), 4.36 (br s, 1H), 3.63-3.37 (m, 8H), 3.07 (s, 6H), 2.90-2.79 (m, 1H), 2.12-1.14 (m, 10H). LCMS: m/e 678 (M−H)−, ret time 1.66 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00620
  • To 0.05 mmol of 1 in 1.0 mL of anhydrous N,N-Dimethylformamide (DMF) in a 3 dram vial equipped with a teflon lined screw cap was added 0.15 mmol (3 eq.) of 2-(1H-Benzotriazole-1-yl)-1,1,3,3,-Tetramethyluronium Tetrafluoroborate (TBTU) in 1.0 mL of anhydrous DMF followed by the addition of 0.1 mmol (2 eq.) of amine 2 in 1.0 mL of anhydrous DMF. The reaction was shaken on an Innova 2000 orbital shaker at 240 rpm overnight at room temperature. The reaction volume was then reduced to a total volume of 2.0 mL in a Savant Speedvac and the crude product was purified using a Dionex ELSD triggered preparative HPLC employing acetonitrile/water and 10 mM ammonium acetate buffer with a Sunfire, C18, 21.2 mm×150 mm, 10 μm column at a focused gradient flow rate of 20 mL/min. Postpurification LC/MS data was obtained on a Waters analytical LC/Micromass Platform LC (ESI+) at 220 nm using the following set of conditions: Sunfire 5 μm C18, 4.6×100 mm column, with a focused gradient of 50-95% B (B=HPLC grade acetonitrile), (A=HPLC grade water with 0.1% ammonium acetate), in 7 minutes with a 1 minute hold. All NMR spectra were recorded at room temperature using a Bruker DRX500 spectrometer. The NMR solvent used was 1:1 (by volume) methyl alcohol-d4 (CD3OD)/chloroform-d (CDCl3). Chemical shifts were reported in ppm relative to CD3OD. Coupling constants were reported in hertz. Peak multiplicity was reported using the following abbreviations: s (singlet), d (doublet), t (triplet), m (multiplet), br (broad).
    Figure US20070078122A1-20070405-C00621
  • 1-piperazinecarboxylic acid, 4-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-3-methyl-, 1,1-dimethylethyl ester. 1H NMR: δ 0.75 (m, 4H), 1.26 (m, 1H), 1.00 (s, 9H), 1.06 (m, 3H), 1.32 (m, 2H), 1.50 (m, 1H), 1.63 (m, 3H), 2.44 (m, 2H), 2.59 (s, 6H), 2.74 (m, 1H), 2.89 (m, 3H), 3.42 (br s, 1H), 3.54 (br s, 1H), 3.96 (m, 1H), 4.67 (m, 1H), 6.47 (br s, 1H), 7.05 (m, 1H), 7.06-7.12 (m, 2H), 7.19 (m, 2H), 7.49 (d, 1H, J=8.71 Hz), 7.63 (br s, 1H). LC/MS: m/z 690.41, Rf 6.1 min., 100% purity.
    Figure US20070078122A1-20070405-C00622
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl]carbonyl]-. 1H NMR: δ 1.22 (m, 2H), 1.35-1.50 (br m, 3H), 1.73 (m, 2H), 1.73 (m, 2H), 1.92 (m, 1H), 2.03 (m, 3H), 2.86 (m, 1H), 2.92 (m, 2H), 2.99 (m, 1H), 3.00 (s, 6H), 3.63 (m, 2H), 3.73 (s, 2H), 3.87 (s, 3H), 4.30 (m, 1H), 5.02 (m, 1H), 6.89 (s, 1H), 7.04 (d, 1H, J=8.94 Hz), 7.42-7.51 (br m, 3H), 7.55 (m, 2H), 7.63 (d, 2H, J=8.71 Hz), 7.88 (d, 1H, J=8.47 Hz), 7.97 (s, 1H). LC/MS: m/z 746.27, Rf 4.5 min., 100% purity.
    Figure US20070078122A1-20070405-C00623
  • 1-piperazineacetic acid, 4-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-, ethyl ester. 1H NMR: δ 1.04 (m, 1H), 1.19 (m, 2H), 1.26 (t, 3H, J=7.10 Hz), 1.43 (m, 3H), 1.71 (m, 2H), 1.89 (m, 1H), 2.01 (m, 2H), 2.81 (m, 1H), 2.95 (m, 2H), 2.98 (s, 6H, ), 3.40 (m, 1H), 3.68 (br s, 1H), 4.03 (br s, 2H), 4.26 (m, 2H), 4.32 (m, 1H), 4.75 (m, 2H), 5.09 (m, 1H), 7.03 (s, 1H), 7.04-7.52 (br m, 5H), 7.87 (d, 1H, J=8.48 Hz), 8.02 (s, 1H). LC/MS: m/z 662.35, Rf3.0 min., 98.6% purity.
    Figure US20070078122A1-20070405-C00624
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[2-(4-morpholinyl)-2-oxoethyl]-1-piperazinyl]carbonyl]-. 1H NMR: δ 1.22 (m, 2H), 1.38 (m, 3H), 1.73 (m, 2H), 2.01 (m, 4H), 2.98 (m, 2H), 3.01 (m, 7H), 3.38 (m, 1H), 3.55 (m, 3H), 3.56 (m, 3H), 3.68 (m, 2H), 3.71 (s, 6H), 4.39 (m, 1H), 5.09 (m, 1H), 6.96 (br s, 1H), 7.52 (m, 5H), 7.89 (d, 1H, J=8.47 Hz), 8.06 (s, 1H). LC/MS: m/z 703.39, Rf 1.8 min., 100% purity.
    Figure US20070078122A1-20070405-C00625
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]-1-piperazinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-. 1H NMR: δ 0.88 (m, 1H), 1.26 (m, 2H), 1.41-1.55 (m, 3H), 1.77 (m, 2H), 2.05 (m, 1H), 2.09 (m, 2H), 2.90 (m, 1H), 3.04 (m, 6H), 3.47 (m, 1H), 3.63 (m, 2H), 3.75 (m, 3H), 3.86 (m, 1H), 4.29 (m, 1H), 4.42 (m, 2H), 4.95 (m, 1H), 5.15 (m, 1H), 6.84 (m, 3H), 7.00 (s, 1H), 7.52 (m, 2H), 7.59 (m, 4H), 7.92 (d, 2H, J=8.02 Hz), 8.07 (s, 1H). LC/MS: m/z 738.36, Rf 3.9 min., 99.4% purity.
    Figure US20070078122A1-20070405-C00626
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(2-methoxyethyl)-1-piperazinyl]carbonyl]-. 1H NMR: δ 0.91 (m, 1H), 1.29 (m, 3H), 1.45 (m, 4H), 1.81 (m, 2H), 2.05 (m, 6H), 1.36 (s, 1H), 2.92 (m, 1H), 3.07 (m, 3H), 3.22 (m, 2H), 3.41 (m, 3H), 3.72 (m, 3H), 3.78 (m, 3H), 4.46 (m, 1H), 5.21 (m, 1H), 7.08 (s, 1H), 7.61 (m, 5H), 7.97 (d, 1H, J=8.47 Hz), 8.13 (s, 1H). LC/MS: m/z 634.30, Rf 2.2 min., 99.5% purity.
    Figure US20070078122A1-20070405-C00627
  • 7H-indolo[2,1]-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[4-[cyclopropyl(phenylsulfonyl)amino]-1-piperidinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-. 1H NMR: δ 0.78 (m, 4H), 1.23 (m, 2H), 1.40 (m, 2H), 1.57 (m, 1H), 1.77 (m, 4H), 2.02 (m, 5H), 2.82 (m, 2H), 3.00 (s, 6H), 3.72 (m, 4H), 3.95 (m, 1H), 4.36 (m, 1H), 5.07 (m, 1H), 6.88 (br s, 1H), 7.56 (m, 8H), 7.80-7.89 (m, 3H), 8.03 (br s, 1H). LC/MS: m/z 770.36, Rf 5.0 min., 99.1% purity.
    Figure US20070078122A1-20070405-C00628
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(ethylsufonyl)-1-piperazinyl]carbonyl]-. 1H NMR: δ 0.90 (m, 1H), 1.29 (m, 2H), 1.36 (t, 3H, J=7.33 Hz), 1.45 (m, 3H), 1.80 (m, 2H), 2.08 (m, 4H), 2.91 (m, 3H), 3.07 (m, 3H), 3.37 (m, 6H), 3.42 (m, 2H), 3.78 (s, 1H), 4.46 (m, 1H), 5.14 (m, 1H), 6.98 (s, 1H), 7.59 (m, 3H), 7.66 (m, 2H), 7.98 (d, 1H, J=8.71 Hz), 8.13 (s, 1H). LC/MS: m/z 668.22, Rf 2.7 min., 100% purity.
    Figure US20070078122A1-20070405-C00629
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[(3,5-dimethyl-1-piperazinyl)carbonyl]-. 1H NMR: δ 0.84 (m, 1H), 1.23 (m, 6H), 1.38 (m, 2H), 1.47 (m, 2H), 1.74 (m, 2H), 1.98 (m, 5H), 2.73 (m, 2H), 2.84 (m, 2H), 3.00 (s, 6H), 3.10 (m, 1H), 3.73 (s, 1H), 4.44 m, 1H), 5.06 (m, 1H), 6.91 (br s, 1H), 7.46-7.61 (br m, 5H), 7.91 (d, 1H, J=8.48 Hz), 8.07 (br s, 1H). LC/MS: m/z 604.26, Rf 1.8 min., 99.4% purity.
    Figure US20070078122A1-20070405-C00630
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[[3-[(benzoylamino)methyl]-1-pyrrolidinyl]carbonyl]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-. H), 1.46 (m, 3H), 1.80 (m, 2H), 2.07 (m, 2H), 2.11 (m, 3H), 2.69 (m, 1H), 2.91 (m, 1H), 3.06 (s, 6H), 3.61 (m, 4), 3.91 (m, 1H), 4.32 (m, 1H), 5.28 (m, 1H), 7.18 (m, 1H), 7.42 (m, 3H), 7.48 (m, 5H), 7.76 (m, 1H), 7.79 (d, 1H, J=7.33 Hz), 7.94 (m, 1H), 8.07 (m, 1H). LC/MS: m/z 694.32, Rf 3.0 min., 100% purity.
    Figure US20070078122A1-20070405-C00631
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[(4,4-difluoro[1,4′-bipiperidin]-1′-yl)carbonyl]-N-[(dimethylamino)sulfonyl]-. 1H NMR: δ 0.91 (m, 1H), 1.29 (m, 2H), 1.46 (m, 3H), 1.64 (m, 1H), 1.81 (m, 2H), 1.98 (m, 2H), 2.12 (m, 4H), 2.38 (m, 4H), 2.70 (s, 1H), 2.92 (m, 3H), 3.04 (m, 2H), 3.07 (s, 6H), 3.15 (m, 2H), 3.78 (s, 1H), 4.48 (m, 1H), 5.15 (m, 1H), 6.99 (m, 1H), 7.59 (m, 5H), 7.99 (d, 1H, J=8.48 Hz), 8.13 (s, 1H). LC/MS: m/z 694.34, Rf 3.8 min., 100% purity.
    Figure US20070078122A1-20070405-C00632
  • 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-N6-(2-hydroxyethyl)-N6-methyl-. 1H NMR: δ 1.29 (m, 1H), 1.50 (m, 3H), 1.80 (m, 2H), 1.98 (m, 1H), 2.08 (m, 3H), 2.92 (m, 1H), 3.10 (m, 8H), 3.58 (m, 1H), 3.71 (m, 3H), 3.78 (s, 1H), 3.82 (m, 1H), 4.43 (m, 1H), 5.17 (m, 1H), 7.11 (s, 1H), 7.53 (m, 3H), 7.66 (m, 2H), 7.95 (d, 1H, J=8.47 Hz), 8.10 (m, 1H). LC/MS: m/z 565.18, Rf 1.9 min., 100% purity.
    Figure US20070078122A1-20070405-C00633
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[(1,3,4,6,11,11a-hexahydro-6-oxo-2H-pyrazino[1,2-b]isoquinolin-2-yl)carbonyl]-. 1H NMR: δ 1.26 (m, 1H), 1.45 (m, 2H), 1.60 (m, 1H), 1.80 (m, 2H), 1.96 (m, 1H), 2.10 (m, 3H), 2.88 (m, 1H), 2.98 (m, 6H), 3.03 (m, 3H), 3.19 (m, 1H), 3.75 (m, 2H), 4.40 (m, 2H), 4.83 (m, 2H), 5.16 (m, 1H), 7.05 (m, 1H), 7.35 (m, 1H), 7.57 (m, 4H), 7.62 (m, 3H), 7.95 (m, 2H), 8.09 (br s, 1H). LC/MS: m/z 692.31, Rf 3.3 min., 100% purity.
    Figure US20070078122A1-20070405-C00634
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl-6-[[4-(phenylsulfonyl)-1-piperazinyl]carbonyl]-. 1H NMR: δ 1.20 (m, 1H), 1.40 (m, 3H), 1.76 (m, 2H), 1.92 (m, 1H), 2.04 (m, 3H), 2.82 (m, 2H), 2.99 (m, 2H), 3.01 (s, 6H), 3.65 (m, 3H), 3.72 (m, 2H), 4.30 (m, 1H), 5.05 (m, 1H), 6.89 (s, 1H), 7.43-7.56 (br m, 4H), 7.60 (m, 3H), 7.69 (m, 3H), 7.89 (d, 1H, J=8.47 Hz), 7.97 (s, 1H). LC/MS: m/z 716.30, Rf 4.1 min., 100% purity.
    Figure US20070078122A1-20070405-C00635
  • 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-N6-(tetrahydro-2H-pyran-4-yl)-. 1H NMR: δ 1.24 (m, 2H), 1.51 (m, 3H), 1.63 (m, 1H), 1.77 (m, 2H), 1.94 (m, 2H), 2.06 (m, 2H), 2.65 (s, 1H), 2.87 (m, 1H), 3.04 (s, 6H), 3.51 (m, 3H), 4.01 (m, 3H), 4.14 (m, 1H), 5.61 (m, 1H), 7.53 (m, 4H), 7.60 (m, 2H), 7.89 (d, 1H, J=8.48 Hz), 8.10 (s, 1H). LC/MS: m/z 591.20, Rf 2.6 min., 100% purity.
    Figure US20070078122A1-20070405-C00636
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[(4-fluoro-1-piperidinyl)carbonyl]-. 1H NMR: δ 1.23 (m, 1H), 1.45 (m, 3H), 1.74 (m, 3H), 1.83 (m, 1H), 1.92 (m, 1H), 2.05 (m, 3H), 2.86 (m, 1H), 3.02 (s, 6H), 3.54 (m, 2H), 3.72 (m, 3H), 4.38 (m, 1H), 4.89 (m, 1H), 5.08 (m, 1H), 6.95 (s, 1H), 7.51 (m, 3H), 7.59 (m, 2H), 7.90 (d, 1H, J=8.48 Hz), 8.04 (s, 1H). LC/MS: m/z 593.24, Rf 3.5 min., 100% purity.
    Figure US20070078122A1-20070405-C00637
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[(4,4-difluoro-1-piperidinyl)carbonyl]-N-[(dimethylamino)sulfonyl]-. 1H NMR: δ 1.26 (m, 1H), 1.41 (m, 2H), 1.53 (m, 2H), 1.77 (m, 3H), 1.95 (m, 3H), 2.08 (m, 3H), 2.87 (m, 1H), 3.04 (s, 6H), 3.68 (m, 4H), 4.42 (m, 1H), 5.13 (m, 1H), 6.98 (s, 1H), 7.52 (m, 3H), 7.59 (m, 2H), 7.91 (d, 1H, J=8.47 Hz), 8.05 (s, 1H). LC/MS: m/z 611.24, Rf 4.0 min., 100% purity.
    Figure US20070078122A1-20070405-C00638
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[(3,3-difluoro-1-piperidinyl)carbonyl]-N-[(dimethylamino)sulfonyl]-. 1H NMR: δ 1.29 (m, 1H), 1.41 (m, 2H), 1.57 (m, 2H), 1.80 (m, 3H), 1.99 (m, 1H), 2.11 (m, 4H), 2.87 (m, 1H), 3.07 (s, 6H), 3.51 (m, 1H), 3.78 (m, 3H), 3.82 (m, 1H), 4.42 (m, 1H), 5.15 (m, 1H), 7.04 (s, 1H), 7.58 (m, 3H), 7.66 (m, 2H), 7.96 (d, 1H, J=8.71 Hz), 8.10 (s, 1H). LC/MS: m/z 611.25, Rf 4.0 min., 100% purity.
    Figure US20070078122A1-20070405-C00639
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-. 1H NMR: 6 0.85 (m, 2H), 0.94 (m, 2H), 1.26 (m, 1H), 1.48 (m, 3H), 1.80 (m, 3H), 1.98 (m, 1H), 2.09 (m, 3H), 2.89 (m, 1H), 3.04 (s, 6H), 3.58 (m, 3H), 3.75 (m, 5H), 4.42 (m, 1H), 5.15 (m, 1H), 7.02 (s, 1H), 7.56 (m, 3H), 7.63 (m, 2H), 7.94 (d, 1H, J=8.71 Hz), 8.09 (s, 1H). LC/MS: m/z 644.24, Rf 2.3 min., 99.3% purity.
    Figure US20070078122A1-20070405-C00640
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[(tetrahydro-3-oxo-1(2H)-pyridazinyl)carbonyl]-. 1H NMR: (Bruker DPX-300 in CD3OD) δ 1.43 (m, 4H), 1.76 (m, 2H), 1.92 (m, 3H), 2.08 (m, 3H), 2.25 (m, 1H), 2.38 (m, 1H), 2.86 (m, 1H), 3.01 (s, 6H), 3.59 (m, 1H), 3.72-3.88 (m, 1H), 4.36 (m, 1H), 5.26 (m, 1H), 7.18-7.26 (m, 1H), 7.52-7.62 (m, 5H), 7.92 (m, 1H), 8.12 (br s, 1H). LC/MS: m/z 590.34, Rf 1.97 min., 93% purity (Phenomenex 10 μm C18, 4.6×30 mm column; 2 min. gradient with a 1 minute hold employing 10-90% methanol/water/0.1% TFA).
  • The preparations in the following section uses the general protocols and procedures described below: The diversity amines (0.108 mmol, 1.3 equiv) were weighed directly into successive reactor vessels of a multiposition reactor. To each position in the reactor was then added the carboxylic acid template (500 uL of a 0.172 M stock solution in DMF, 0.086 mmol, 1.0 equiv) followed by 500 uL of a three-component stock solution in DMF containing EDC (0.108 mmol, 1.3 equiv), HOBt (0.108 mmol, 1.3 equiv), and N,N-diisopropylethylamine (0.430 mmol, 5.0 equiv). The reactions were capped with a septum and agitated overnight via orbital shaker at room temperature.
  • Purification was effected by injecting the reaction mixture directly onto a preparative LCMS system using one of the following conditions:
  • Analysis Conditions: Column: Waters SunFire Prep C18 OBD, 19×100 mm×5 um; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range: 40-100% B; Gradient Time: 10 min; Flow Rate: 20 mL/min; Analysis Time: 15 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+); Fraction Collection: WV-triggered; Fraction Drying: Savant Speedvac.
  • Analysis Conditions: Column: Phenomenex Luna C18(2), 4.6×50 mm×5 um; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range: 0-100% B; Gradient Time: 4 min; Flow Rate: 4 mL/min; Analysis Time: 5 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+); Detector 3: ELSD.
    Figure US20070078122A1-20070405-C00641
    Figure US20070078122A1-20070405-C00642
  • For the next set of procedures column 3 is defined as LCMS data:Gradient time: 2min; Flow rate: 4 mL/min; Stop time: Gradient time+1 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H2O with 0.1% TFA; Eluent B: 90% MeOH/10% H2O with 0.1% TFA; Column 3: Phenomenex-luna 10μ 4.6×50 mm S10.
    Figure US20070078122A1-20070405-C00643
  • 7H-indolo[2,1-a][2}benzazepine-10-carboxylic acid, 1 3-cyclohexyl-6-[[4-(1H-1,2,3-triazol-1-yl)piperidinyl]carbonyl], methyl ester. o a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (50 mg, 0.12 mmol), 4-(1H-1,2,3-triazol-1-yl)piperidine (74 mg, 0.48 mmol) and DMAP (58 mg, 0.48 mmol) in DMF (2 mL) was added HATU (182 mg, 0.48 mmol). The reaction mixture was stirred at rt for 22 h, diluted with EtOAc (4 mL) and H2O (˜4 mL). The organic phase was separated, dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in methanol and purified using reverse phase prep-HPLC to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(1H-1,2,3-triazol-1-yl)piperidinyl]carbonyl], methyl ester. 1H NMR (500 MHz, CDCl3) δ 8.28 (d, J=4.9 Hz, 2H), 8.16 (br s, 1H), 7.89 (d, J=8.6 Hz, 1H), 7.74 (dd, J=8.6 Hz, 1H), 7.59 (dd, J=7.6, 1.5 Hz, 1H), 7.52-7.45 (m, 2H), 7.40 (dd, J=7.3, 1.5 Hz, 1H), 7.25 (s, 1H), 6.51 (t, J=4.9 Hz, 1H), 5.15 (br s, 1 H), 4.43(br s, 1H), 3.91 (s, 3H), 3.80-3.29 (m, 8H), 2.91-2.82 (m, 1H), 2.17-1.14 (m, 10H). LCMS: m/e 550 (M+H)+, ret time 2.55 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00644
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(1H-1,2,3-triazol-1-yl)piperidinyl]carbonyl]. To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(1H-1,2,3-triazol-1-yl)piperidinyl]carbonyl], methyl ester (10 mg, 0.018 mmol), in THF (1 mL) was added TMSSiOK (5 mg, 0.036 mmol). The reaction mixture was stirred at rt for 3.5 h, and purified using reverse phase prep-HPLC to afford 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(1H-1,2,3-triazol-1-yl)piperidinyl]carbonyl] as a pale yellow solid. LCMS: m/e 536 (M+H)+, ret time 2.45 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00645
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(1H-1,2,3-triazol-1-yl)piperidinyll]carbonyl]. To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(1H-1,2,3-triazol-1-yl)piperidinyl]carbonyl] (30 mg, 0.056 mmol), N,N-dimethylsulfamide (35 mg, 0.28 mmol) and DMAP (34 mg, 0.28 mmol) in dimethylacetamide (1 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (43 mg, 0.22 mmol). The reaction solution was stirred in a sealed tube under nitrogen at 50° C. overnight and purified by reverse phase prep-HPLC to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(1H-1,2,3-triazol-1-yl)piperidinyll]carbonyl] as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.84 (br s, 1H), 7.92 (s, 1H), 7.87 (d, J=8.5 Hz, 1H), 7.60-7.42 (m, 6H), 6.87 (s, 1H), 5.39 (br s, 1H), 4.75 (br s, 1H), 4.35 (s, 1H), 4.20 (m, 4H), 3.08 (s, 6 H), 2.83 (m, 1H), 2.05-1.35 (m, 14H). LCMS: m/e 642 (M+H)+, ret time 2.18 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00646
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl), methyl ester. To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (100 mg, 0.24 mmol), 1,4-dioxa-8-azaspiro[4,5]decane (67 mg, 0.48 mmol) and DMAP (58 mg, 0.48 mmol) in DMF (3 mL) was added HATU (182 mg, 0.48 mmol). The reaction mixture was stirred at rt overnight and purified using reverse phase prep-HPLC to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl), methyl ester. LCMS: m/e 541 (M+H)+, ret time 2.47 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00647
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)-. To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl), methyl ester (40 mg, 0.018 mmol), in THF (1 mL) and MeOH (1 mL) was added 1 M NaOH (0.12 mL, 0.12 mmol). The reaction mixture was heated in a sealed tube at 70° C. for 7 h; cooled to rt overnight and heated again at 70° C. for 5 h after. The mixture was purified using reverse phase prep-HPLC to afford 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)- as a pale yellow solid. LCMS: m/e 527 (M+H)+, ret time 2.55 min, column 3,2 minute gradient.
    Figure US20070078122A1-20070405-C00648
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(1, 4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)-. To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)- (30 mg, 0.056 mmol), N,N-dimethylsulfamide (35 mg, 0.28 mmol) and DMAP (34 mg, 0.28 mmol) in dimethylacetamide (1 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (43 mg, 0.22 mmol). The reaction solution was stirred in a sealed tube under nitrogen at 50° C. overnight and purified by reverse phase prep-HPLC to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)- as a pale yellow solid. 1H NMR (500 MHz, CDCl3) δ. 9.1 (s, 1H), 8.04 (s, 1H), 7.90 (d, J=8.5 Hz, 1H), 7.58-7.40 (m, 4H), 6.88 (s, 1H), 5.12 (br s, 1H), 4.39 (br s, 1H), 3.93 (s, 4H), 3.70-3.30 (m, 4H), 3.01 (s, 6H), 2.8 (m, 1H), 2.10-1.25 (m, 14H). LCMS: m/e 633 (M+H)+, ret time 2.28 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00649
  • 1-cyclohexyl-3-(3-oxo-3-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)propyl)-2-phenyl-3H-indene-5-carboxylic acid, methyl ester. To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (100 mg, 0.24 mmol), 4-(N-2-pyrrolidinone)-piperidine hydrochloride (98 mg, 0.48 mmol) and DMAP (58 mg, 0.48 mmol) in DMF (2 mL) was added HATU (182 mg, 0.48 mmol). The reaction mixture was stirred at rt for 22 h and purified using reverse phase prep-HPLC to yield 1-cyclohexyl-3-(3-oxo-3-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)propyl)-2-phenyl-3H-indene-5-carboxylic acid, methyl ester. LCMS: m/e 566 (M+H)+, ret time 2.36 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00650
  • 1-cyclohexyl-3-(3-oxo-3-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)propyl)-2-phenyl-3H-indene-5-carboxylic acid. To a stirred solution of 1-cyclohexyl-3-(3-oxo-3-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)propyl)-2-phenyl-3H-indene-5-carboxylic acid, methyl ester (460 mg, 0.1 mmol), in THF (1 mL) and MeOH (1 mL) was added 1M NaOH (0.16 mL, 0.16 mmol). The reaction mixture was heated in a sealed tube at 70° C. for 4 h. 1M NaOH (0.2 mL, 0.2 mmol) was added and heated for 5 h more. 1N HCl (0.5 mL) was added and the volatiles were removed in vacuo. A precipitate formed and it was collected by filtration and dried at open air to afford 1-cyclohexyl-3-(3-oxo-3-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)propyl)-2-phenyl-3H-indene-5-carboxylic acid as a pale yellow solid. LCMS: m/e 552 (M+H)+, ret time 2.10 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00651
  • 1-cyclohexyl-N-[(dimethylamino)sulfonyl]3-(3-oxo-3-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)propyl)-2-phenyl-3H-indene-5-carboxamide. To a stirred solution of 1-cyclohexyl-3-(3-oxo-3-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)propyl)-2-phenyl-3H-indene-5-carboxylic acid, (46 mg, 0.083 mmol), N,N-dimethylsulfamide (51 mg, 0.42 mmol) and DMAP (51 mg, 0.42 mmol) in dimethylacetamide (1 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (64 mg, 0.33 mmol). The reaction solution was stirred in a sealed tube under nitrogen at 50° C. overnight and purified by reverse phase prep-HPLC to yield 1-cyclohexyl-N-[(dimethylamino)sulfonyl]3-(3-oxo-3-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)propyl)-2-phenyl-3H-indene-5-carboxamide as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 8.91 (br s, 1H), 8.09 (s, 1H), 7.92 (d, J=8.5 Hz, 1H), 7.57-7.41 (m, 5H), 6.86 (s, 1H), 5.10 (br s, 1H), 4.41 (br s, 1H), 4.05-3.50 (m, 7H), 3.07 (s, 6H), 2.81 (m, 1H), 2.44 (m, 2H), 2.05-1.38 (m, 16H). LCMS: m/e 658 (M+H)+, ret time 2.43 min, column 3, 2 minute gradient. The next set of experimental procedures constitute a the start of a new section which stand alone:
    Figure US20070078122A1-20070405-C00652
  • 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[(4-morpholinylcarbonyl)amino]-, methyl ester. To the acid (5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-6,7-dihydro-, 10-methyl ester) (30 mg, 71.9 μmol) in a round-bottomed flask at r.t. under N2 was added a solution of triethylamine (9 mg, 88.9 μmol) in MeCN (0.6 ml), followed by a solution of diphenylphosphoryl azide (DPPA) (24 mg, 87.2 μmol) in MeCN (0.4 ml). The mixture was stirred at r.t. for 75 min., and then at 50° C. for 1 hr. After cooling to r.t., the mixture was added a solution of morpholine (19 mg, 218 μmol) in MeCN (0.3 ml) and then stirred at 50° C. for 1 hr. The mixture was cooled to r.t. and the volatiles evaporated. The residue obtained was purified by preparative thin layer chromatography (500 μm×20 cm×20 cm plate) using 5% MeOH/CH2Cl2 as eluent to give the urea, 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[(4-morpholinylcarbonyl)amino]-, methyl ester (14.4 mg, 40%). 1H NMR (500 MHz): (CD3OD) δ 8.02 (s, 1H), 7.90 (d, J=8.5, 1H), 7.72 (d, J=8.5, 1H), 7.52-7.44 (m, 4H), 4.61 (d, J=15.5, 1H), 4.45-4.42 (m, 1H), 3.96 (s, 3H), 3.66-3.59 (overlapping m, 5H), 3.48-3.43 (overlapping m, 3H), 3.33-3.30 (m, 1H), 3.05-2.99 (m, 1H), 2.92 (dd, J=13, 6.5, 1H), 2.50 (t, J=12.5, 1H), 2.16-2.05 (overlapping m, 3H), 1.98-1.96 (b m, 1H), 1.82 (b m, 2H), 1.67-1.64 (b m, 1H), 1.55-1.40 (overlapping m, 2H), 1.36-1.25 (b m, 1H); Analytical HPLC method: Solvent A=10% MeOH—90% H2O—0.1% TFA, Solvent B=90% MeOH—10% H2O—0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=502.31, HPLC Rt=2.022 min.
    Figure US20070078122A1-20070405-C00653
  • 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[(4-morpholinylcarbonyl)amino]-. To the methyl ester (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[(4-morpholinylcarbonyl)amino]-, methyl ester) (14.4 mg, 28.7 μmol) in a round-bottomed flask at r.t. under N2 was added a solution of potassium trimethylsilanoate (TMSOK) (82 mg, about 575 μmol, 90% tech) in THF (2 ml), and the mixture stirred at r.t. for 94 hr. The mixture was evaporated to dryness, and the residue added hydrochloric acid (3 ml, 1 N). The white precipitates were filtered, and washed with hexane (3×1 ml) and then dried to give the acid, 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[(4-morpholinylcarbonyl)amino]- (11.6 mg, 83%). 1H NMR (500 MHz): (CD3OD) δ 8.05 (s, 1H), 7.90 (d, J=8.5, 1H), 7.73 (d, J=8.5, 1H), 7.52-7.42 (m, 4H), 4.61 (d, J=15, 1H), 4.45-4.41 (m, 1H), 3.71-3.60 (overlapping m, 5H), 3.47-3.43 (overlapping m, 3H), 3.31-3.29 (m, 1H), 3.04-2.99 (m, 1H), 2.92 (dd, J=13, 7, 1H), 2.50 (t, J=12, 1H), 2.17-2.05 (overlapping m, 3H), 1.99-1.96 (b m, 1H), 1.82 (b m, 2H), 1.68-1.65 (b m, 1H), 1.55-1.41 (overlapping m, 2H), 1.34-1.26 (b m, 1H); Analytical HPLC method: Solvent A=10% MeOH—90% H2O—0.1% TFA, Solvent B=90% MeOH—10%H2O—0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=488.28, HPLC Rt=1.938 min.
    Figure US20070078122A1-20070405-C00654
  • 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[(4-morpholinylcarbonyl)amino]-. To the acid (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[(4-morpholinylcarbonyl)amino]-) (13.6 mg, 27.9 μmol) in a round-bottomed flask at r.t. under N2 was added a solution of 1,1′-carbonyldiimidazole (CDI) (5.9 mg, 36.4 μmol) in THF (1 ml), and the mixture was stirred at 50° C. for 2 hr. After cooling to r.t., the reaction mixture was added a mixture of N,N-dimethylsulfamide (4.5 mg, 36.2 μmol) and DBU (6.2 mg, 40.7 μmol) in THF (0.3 ml), and then stirred at r.t. for 17.5 hr. The reaction was then added another mixture of N,N-dimethylsulfamide (9 mg, 72.5 μmol) and DBU (12 mg, 78.7 μmol) in THF (0.3 ml), and stirred at 50° C. for 8 hr. After cooling to r.t., the volatiles were evaporated and the residue added hydrochloric acid (1.5 ml, 1N). The aqueous mixture was removed by pipet, and the white solid residue purified by preparative thin layer chromatography (500 μm×20 cm×20 cm plate) using 5% MeOH/CH2Cl2 as eluent to give the amide 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-morpholinylcarbonyl)amino]-. 1H NMR (500 MHz) : (CD3OD) δ 7.98 (d, J=1.5, 1H), 7.93 (d, J=8.5, 1H), 7.62 (dd, J=1.5, 8.5, 1H), 7.51-7.45 (overlapping m, 4H), 4.64 (d, J=15, 1H), 4.45 (m, 1H), 3.73-3.58 (overlapping m, 6H), 3.50-3.40 (overlapping m, 2H), 3.29 (m, 1H), 3.03 (s overlapping with m, 7H), 2.93 (dd, 1H), 2.50 (t, J=12, 1H), 2.17-2.03 (overlapping m, 3H), 2.00-1.94 (b m, 1H), 1.87-1.77 (b m, 2H), 1.69-1.63 (b m, 1H), 1.57-1.40 (overlapping m, 2H), 1.361.25 (b m, 1H); Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=594.34, HPLC Rt=1.895 min.
    Figure US20070078122A1-20070405-C00655
  • 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(homomorpholinylcarbonyl)-5H-indolo[2,1-a][2]benzazepine-10-carboxamide. TBTU (22 mg, 0.069 mmol) was added to a stirred solution of 6-carboxy-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-5H-indolo[2,1-a][2]benzazepine-10-carboxamide (25 mg, 0.049 mmol), homomorpholine hydrochloride (8.1 mg, 0.059 mmol), and N,N-diisopropylethylamine (0.3 mL, 1.74 mmol) in DMF (3 mL). The mixture was stirred at 22° C. for 20 min. The resulting solution was concentrated down to the volume of 2 mL on a Speed Vac® and filtered. The filtrate was injected on the Shimadzu preparative liquid chromatograph. The product containing fraction was concentrated on a Speed Vac® to leave the titled compound as a white solid (28 mg, 97 %). ESI-MS m/z 591 (MH+); 1H NMR (500 MHz, Solvent) δ 1.16-1.32 (m, 1 H) 1.38-1.55 (m, 4 H) 1.75-1.86 (m, 2 H) 1.90-2.21 (m, 5 H) 2.90 (m, 1 H) 3.04 (s, 6 H) 3.39-3.93 (m, 8 H) 4.42 (m, 1 H) 5.20 (m, 1 H) 7.05 (s, 1 H) 7.57 (m, 3 H) 7.63 (m, 2 H) 7.96 (d, J=8.55 Hz, 1 H) 8.15 (s, 1 H).
  • The following library of 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(substituted-aminocarbonyl)-5H-indolo[2,1-a][2]benzazepine-10-carboxamides was synthesized using the protocols described in the preceding section.
    Structure Physiochemical Data
    Figure US20070078122A1-20070405-C00656
         		ESI-MS m/z 631 (MH+); Rt 1.71 min
    Figure US20070078122A1-20070405-C00657
         		ESI-MS m/z 590 (MH+); Rt 1.85 min
    Figure US20070078122A1-20070405-C00658
         		ESI-MS m/z 590 (MH+); Rt 2.03 min
    Figure US20070078122A1-20070405-C00659
         		ESI-MS m/z 654 (MH+); Rt 2.53 min
    Figure US20070078122A1-20070405-C00660
         		ESI-MS m/z 618 (MH+); Rt 2.52 min
    Figure US20070078122A1-20070405-C00661
         		ESI-MS m/z 688 (MH+); Rt 2.68 min
    Figure US20070078122A1-20070405-C00662
         		ESI-MS m/z 589 (MH+); Rt 2.56 min
    Figure US20070078122A1-20070405-C00663
         		ESI-MS m/z 674 (MH+); Rt 2.64 min
    Figure US20070078122A1-20070405-C00664
         		ESI-MS m/z 652 (MH+); Rt 2.71 min
    Figure US20070078122A1-20070405-C00665
         		ESI-MS m/z 646 (MH+); Rt 2.59 min
    Figure US20070078122A1-20070405-C00666
         		ESI-MS m/z 621 (MH+); Rt 2.62 min
    Figure US20070078122A1-20070405-C00667
         		ESI-MS m/z 595 (MH+); Rt 2.52 min
    Figure US20070078122A1-20070405-C00668
         		ESI-MS m/z 605 (MH+); Rt 2.65 min
    Figure US20070078122A1-20070405-C00669
         		ESI-MS m/z 623 (MH+); Rt 2.64 min
    Figure US20070078122A1-20070405-C00670
         		ESI-MS m/z 579 (MH+); Rt 2.61 min
    Figure US20070078122A1-20070405-C00671
         		ESI-MS m/z 730 (MH+); Rt 2.68 min
    Figure US20070078122A1-20070405-C00672
         		ESI-MS m/z 648 (MH+); Rt 2.46 min
    Figure US20070078122A1-20070405-C00673
         		MS m/z 540 (MH+); 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 1.07-2.18 (m, 18 H) 2.66-2.91 (m, 4 H) 3.93-3.96 (m, 3 H) 4.41 (s, 1 H) 4.97-5.12 (m, 1 H) 5.22-5.34 (m, 1 H) 6.78 (s, 1 H) 7.32-7.39 (m, 1 H) 7.41-7.50 (m, 3 H) 7.52-7.59 (m, 1 H) 7.68 (d, J = 8.42 Hz, 1 H) 7.85 (d, J =8.42 Hz, 1 H) 8.09 (s, 1 H).
    Figure US20070078122A1-20070405-C00674
         		1H NMR (500 Mhz, DMSO-D6) δ ppm 1.12-1.33 (m, 3 H) 1.37-1.48 (m, 4 H) 1.67-1.76 (m, 4 H) 1.79 (s, 3 H) 1.99-2.12 (m, 4 H) 2.74-2.84 (m, 1 H) 3.78 (s, 1 H) 4.23-4.35 (m, 1 H) 5.07-5.17 (m, 1 H) 6.96 (s, 1 H) 7.57-7.61 (m, 3 H) 7.63 (d, J = 8.24 Hz, 1 H) 7.82 (d, J = 7.32 Hz, 1 H) 7.91 (d, J = 8.55 Hz, 1 H) 8.17 (s, 1 H).
  • Figure US20070078122A1-20070405-C00675
  • Methyl 2-(2-acetylphenyl)-3-cyclohexyl-1H-indole-6-carboxylate. A 2M aqueous solution of Na2CO3 (2.5 mL, 5.0 mmol) was added to a mixture of; methyl 3-cyclohexyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-6-carboxylate (766 mg, 2.0 mmol), 2′-bromoacetophenone (478 mg, 2.4 mmol) and LiCl (170 mg, 4.0 mmol), in ethanol (5 mL) and toluene (5 mL). The mixture was then degassed by sequentially applying vacuum followed by flushing with N2. Pd(PPh3)4 (115 mg, 0.1 mmol) was then added and the reaction heated at 80° C. for 4 hr. The reaction mixture was then filtered and concentrated under reduced pressure. The resultant residue was purified by silica gel flash chromatography using hexanes to 20% ethyl acetate in hexanes as eluent to give the title compound as a white foam which could be crushed to a powder, (686 mg, 91% yield). MS m/z 374(M−H−); 1H NMR (500 MHz, CD3OD) δ ppm 1.30 (m, 1 H) 1.41-1.64 (m, 3 H) 1.82-2.21 (m, 9 H) 3.26 (m, 1 H) 3.95 (s, 3 H) 7.40 (m, 1 H) 7.49 (m, 1 H) 7.61 (m, 1 H) 7.69 (m, 1 H) 7.79 (m, 1 H) 7.84 (m, 1 H) 8.29 (s, 1 H).
    Figure US20070078122A1-20070405-C00676
  • 7H-indolo[2,1-a][2]benzazepine-6,10-carboxylic acid, 13-cyclohexyl-5-methyl-, dimethyl ester. To a solution of methyl 2-(2-acetylphenyl)-3-cyclohexyl-1H-indole-6-carboxylate (400 mg, 1.065 mmol) in DMF (10 mL), Cs2CO3 (521 mg, 1.6 mmol) and trimethyl2-phosphonoacrylate (310 mg, 1.6 mmol) were added. The reaction mixture was heated at 60° C. overnight. It was then quenched by the addition of water after which a precipitate formed. This was collected by filtration, and dried under vacuum to give the crude product as a light yellow solid (380 mg, 80% yield). 10 mg of this material was purified by Prep. reverse phase HPLC to provide pure, 7H-indolo[2,1-a][2]benzazepine-6,10-carboxylic acid, 13-cyclohexyl-5-methyl-, dimethyl ester. MS m/z 444(MH+); 1H NMR (500 MHz, CD3OD) δ ppm 1.15-1.66 (m, 4 H) 1.76-1.87 (m, 2 H) 1.97 (m, 1 H) 2.02-2.22 (m, 3 H) 2.49 (s, 3H) 2.95 (m, 1 H) 3.83 (s, 3 H) 3.97 (s, 3 H) 4.09 (d, J=14.65 Hz, 1 H) 5.49 (d, J=14.65 Hz, 1 H) 7.55-7.61 (m, 3 H) 7.70 (dd, J=8.39, 1.37 Hz, 1 H) 7.76 (m, 1 H) 7.88 (d, J=8.55 Hz, 1 H) 8.33 (s, 1 H).
    Figure US20070078122A1-20070405-C00677
  • 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-5-methyl-, 10-methyl ester. To a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-carboxylic acid, 13-cyclohexyl-5-methyl-, dimethyl ester (179, 0.4 mmol) in THF (10 mL), 1M solution of Bu4NOH (0.6 mL, 0.6 mmol) in methanol was added. The reaction mixture was stirred at rt. for two days. It was then concentrated, acidified with 1N HCl solution and extracted with ethyl acetate (2×30 mL). The organic layers were combined, dried (MgSO4), filtered and concentrated in vacuo. The resultant residue was purified by Prep. reverse phase HPLC column to give the title compound as a yellow solid, (90 mg, 52% yield). MS m/z 430(MH+); 1H NMR (300 MHz, DMSO-D6) δ ppm 1.10-1.27 (m, 1H) 1.32-1.59 (m, 3 H) 1.64-1.79 (m, 2 H) 1.81-1.94 (m, 1 H) 1.94-2.13 (m, 3 H) 2.41 (s, 3 H) 2.86 (m, 1 H) 3.87 (s, 3 H) 3.98 (d, J=14.64 Hz, 1 H) 5.43 (d, J=14.64 Hz, 1 H) 7.49-7.67 (m, 4 H) 7.74-7.83 (m, 1 H) 7.91 (d, J=8.42 Hz, 1 H) 8.22 (s, 1 H) 13.00 (s, 1 H).
    Figure US20070078122A1-20070405-C00678
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-5-methyl-6-(4-morpholinylcarbonyl)-, methyl ester. To a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-5-methyl-, 10-methyl ester (120 mg, 0.28 mmol) in DMSO (3.0 mL), TBTU (135 mg, 0.42 mmol) and DIPEA (0.244 mL, 1.4 mmol) were added. The reaction mixture was stirred at rt for 15 min. Then morpholine (0.037 mL, 0. 42 mmol) was added and the reaction mixture was stirred at rt for overnight. It was then concentrated under reduced pressure and the residue was purified by Prep. reverse phase HPLC to give the title compound as a white solid, (115 mg, 82% yield). MS m/z 499(MH+); 1H NMR (500 MHz, CD3OD) δ ppm Compound exists as a complex mixture of rotamers.
    Figure US20070078122A1-20070405-C00679
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-5-methyl-6-(4-morpholinylcarbonyl)-. 2N NaOH solution (1.0 mL) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-5-methyl-6-(4-morpholinylcarbonyl)-, methyl ester (100 mg, 0.2 mmol)in a THF/Methanol mixture (2.0 mL/2.0 mL) in a sealed tube. The reaction mixture was heated at 90° C. under microwave conditions for 10 min. It was then concentrated and acidified with 1N HCl solution after which a precipitate formed. This was collected by filtration and dried under vacuum to provide the title compound as an off-white solid, (75 mg, 77% yield). MS m/z 485(MH+); 1H NMR (300 MHz, CD3OD) δ ppm exists as rotamers.
  • The general methods below were used with the following experimental procedures until indicated otherwise: LCMS data: Stop time: Gradient time +1 minute; Starting conc: 0% B unless otherwise noted; Eluent A: 5% CH3CN/95% H2O with 10 mM NH4OAc (for columns A and D); 10% MeOH/90% H2O with 0.1% TFA (for columns B and C); Eluent B: 95% CH3CN/5% H2O with 10 mM NH4OAc (for columns A and D); 90% MeOH/10% H2O with 0.1% TFA (for columns B and C); Column A: Phenomenex 10μ 4.6×50 mm C18; Column B: Phenomenex C18 10μ 3.0×50 mm; Column C: Phenomenex 4.6×50 mm C18 10μ; Column D: Phenomenex Lina C18 5μ 3.0×50 mm; Column E: Phenomenex 5μ 4.6×5.0 mm C18.
  • To a slurried solution of methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate (4.3 g, 13 mmol), 4-methoxy-2-formylphenylboronic acid (3.0 g, 17 mmol) and LiCl (2.2 g, 51 mmol) in EtOH/toluene (1:1, 100 mL) was added Pd(PPh3)4 (1.4 g, 1.3 mmol) and then 1M Na2CO3 (aq.) (32 mL, 32 mmol). The reaction solution was flushed with nitrogen and heated at 100° C. for 3 h and cooled to rt. The reaction was concentrated to remove EtOH, diluted with H2O (200 mL) and extracted with EtOAc (2×150 mL). The combined organics were washed with brine (100 mL), dried (MgSO4), filtered and concentrated to dryness. The residue was triturated with CH2Cl2 and the solids were collected by filtrated and washed with Et2O and CH2Cl2 to yield methyl 11-cyclohexyl-6-hydroxy-8-methoxy-6H-isoindolo[2,1-a]indole-3-carboxylate (3.0 g, 8.0 mmol, 63%) as a yellow solid which was used without further purification. LCMS: m/e 374 (M+H)+, ret time 3.09 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00680
  • A solution of methyl 11-cyclohexyl-6-hydroxy-8-methoxy-6H-isoindolo[2,1-a]indole-3-carboxylate (2.9 g, 7.4 mmol), methyl 2-(dimethoxyphosphoryl)acrylate (2.6 g, 11 mmol), cesium carbonate (3.6 g, 11 mmol) in DMF (20 mL) was heated at 60° C. for 2 h and cooled to rt. The stirring reaction mixture was diluted with H2O (50 mL) and the precipitates were collected by filtration to yield dimethyl 13-cyclohexyl-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylate (3.3 g, 7.1 mmol, 97%) as a yellow solid which was used without further purification. LCMS: m/e 460 (M+H)+, ret time 3.35 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00681
  • A solution of tetrabutylammonium hydroxide (1M in MeOH, 2.2 mL, 2.2 mmol) was added to a stirring solution of dimethyl 13-cyclohexyl-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylate (1.0 g, 2.2 mmol) in THF (75 mL) and stirred at rt overnight. The reaction mixture was concentrated to ˜30 mL, diluted with EtOAc (120 mL), washed with 0.5 M HCl (aq.) (2×50 mL) and brine (40 mL), dried (MgSO4), filtered and concentrated to dryness to yield methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 3-methoxy, 6-carboxylic acid (1.0 g, 2.2 mmol, quant.) as a yellow solid which was used without further purification. LCMS: m/e 446 (M+H)+, ret time 1.54 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00682
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-I0-carboxylate, 13-cyclohexyl, 3-methoxy, 6-carboxylic acid (120 mg, 0.27 mmol), 2-N,N-dimethyl-2-(methylamino)acetamide (40 mg, 0.32 mmol) and triethylamine (0.11 mL) in DMF (2 mL) was added HATU (125 mg, 0.32 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜10 mL) and the resulting solids were collected by filtration, washed with H2O and dried to yield methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl-3-methoxy-6-[[[2-(dimethylamino)-2-oxoethyl]methylamino]carbonyl]- (127 mg, 0.23 mmol, 87%) as a yellow solid, which was used without further purification. LCMS: m/e 544 (M+H)+, ret time 1.88 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00683
  • Methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl-3-methoxy-6-[[[2-(dimethylamino)-2-oxoethyl]methylamino]carbonyl]- (117 mg, 0.21 mmol) was dissolved into THF/MeOH (1:1, 2 mL) and 1M NaOH (aq.) (0.5 mL, 0.5 mmol). The reaction mixture was heated in a sealed tube with microwave irradiation at 85° C. for 20 min. The reaction was cooled, neutralized with 1M HCl (aq.) (0.5 mL, 0.5 mmol) and concentrated to remove organic solvents. The residue was slurried with H2O and the solids were collected by filtration, flushed with H2O, and purified by preparative HPLC to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[[[2-(dimethylamino)-2-oxoethyl]methylamino]carbonyl]- (71 mg, 0.13 mmol, 63%) as a yellow solid. Mixture of amide rotamers: 1HNMR (500 MHz, CD3OD) δ 8.24 (br s, 1H), 7.88 (d, J=8.4 Hz, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.18-6.88 (m, 2H), 7.14 (dd, J=8.4, 2.2 Hz, 1H), 5.14 (br s, 1H), 4.49-4.12 (m, 2H), 3.97-3.88 (m, 1H), 3.93 (s, 3H), 3.15-2.83 (m, 7H), 2.56 (s, 1.5H), 2.42 (s, 1.5H), 2.23-1.73 (m, 6H), 1.59-1.17 (m, 4H). LCMS: m/e 530 (M+H)+, ret time 1.40 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00684
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[[[2-(dimethylamino)-2-oxoethyl]methylamino]carbonyl]- (53 mg, 0.10 mmol), N,N-dimethylsulfamide (62 mg, 0.50 mmol) and DMAP (61 mg, 0.50 mmol) in dimethylacetamide (1.5 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (76 mg, 0.40 mmol). The reaction solution was stirred at 50° C. for 5 h, concentrated under a steam of nitrogen, diluted with MeOH (1 mL) and purified by preparative HPLC (CH3CN/H2O with TFA buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[2-(dimethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl- (13 mg, 0.02 mmol, 20%) as a yellow solid. 1HNMR (500 MHz, CD3OD) δ 8.19 (s, 0.5H), 8.12 (s, 0.5H), 7.91 (d, J=8.1 Hz, 1H), 7.63 (d, J=8.1 Hz, 1H), 7.60-7.50 (m, 1H), 7.20-6.93 (m, 3H), 5.14 (br s, 1H), 4.46-4.11 (m, 2H), 3.96-3.87 (m, 1H), 3.93 (s, 3H), 3.12-2.86 (m, 13H), 2.45 (br s, 3H), 2.20-1.74 (m, 6H), 1.57-1.19 (m, 4H). LCMS: m/e 636 (M+H)+, ret time 2.82 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00685
  • A solution of methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate (20 g, 60 mmol) and LiOH (3.8 g, 160 mmol) in MeOH/THF/H2O (1:1:1, 300 mL) was heated at 90° C. for 2 h. The reaction mixture was cooled in an ice/H2O bath, neutralized with 1M HCl (˜160 mL) diluted with H2O (250 mL) and stirred for 1 h at rt. The precipitates were collected by filtration rinse with H2O and dried to yield 2-bromo-3-cyclohexyl-1H-indole-6-carboxylic acid (quant.) which was used without further purification.
  • Carbonyl diimidazole (6.0 g, 37 mmol) was added to a solution of 2-bromo-3-cyclohexyl-1H-indole-6-carboxylic acid (10 g, 31 mmol) in THF (30 mL) and the reaction was stirred at 50° C. for 2 h (a white precipitate had formed). The reaction was cooled to rt and treated with N,N-dimethylsulfamide (4.6 g, 37 mmol). Then DBU (6.7 mL) in THF (20 mL) was added dropwise and the reaction was stirred at rt overnight. The solution was diluted with EtOAc (300 mL) and washed with H2O (150 mL), 1N aqueous HCl (2×100 mL) and brine (100 mL). The combined aqueous layers were extracted with EtOAc (200 mL) and the organic layer was washed with 1N aqueous HCl (150 mL) and brine (50 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to an oil. The oil was diluted with Et2O and concentrated to a semi-solid which was triturated with Et2O to yield 2-bromo-3-cyclohexyl-N-[(dimethylamino)sulfonyl]-indole-6-carboxamide (6.1 g, 14 mmol, 46%) as a light yellow solid. The organic washes where concentrated and purified by silica gel chromatography (20-35% EtOAc/hexanes) to yield additional 2-bromo-3-cyclohexyl-N-[(dimethylamino)sulfonyl]-indole-6-carboxamide (2.5 g, 6 mmol, 19%). 1HNMR (500 MHz, CD3OD) δ 7.90 (d, J=1.8 Hz, 1H), 7.77 (d, J=8.5 Hz, 1H), 7.56 (dd, J=1.8, 8.5 Hz, 1H), 3.01 (s, 6H), 2.93-2.86 (m, 1H), 2.04-1.76 (m, 7H), 1.54-1.37 (m, 3H). LCMS: m/e 426 (M−H)−, ret time 1.55 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00686
  • To a slurried solution of 2-bromo-3-cyclohexyl-N-[(dimethylamino)sulfonyl]-indole-6-carboxamide (4.3 g, 10 mmol), 4-methoxy-2-formylphenylboronic acid (2.5 g, 14 mmol) and LiCl (1.05 g, 25 mmol) in EtOH/toluene (1:1, 80 mL) was added Pd(PPh3)4 (1.12 g, 1.0 mmol) and then 1M Na2CO3 (aq.) (30 mL, 30 mmol). The reaction solution was flushed with nitrogen and heated at 85° C. for 18 h and cooled to rt. The reaction was diluted with EtOAc (200 mL), washed with 0.5N aqueous HCl (100 mL) and brine (50 mL), dried (MgSO4), filtered and concentrated to yield 11-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-hydroxy-8-methoxy-6H-isoindolo[2,1-a]indole-3-carboxamide which was used without further purification. LCMS: m/e 482 (M−H)−, ret time 1.63 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00687
  • A solution of 11-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-hydroxy-8-methoxy-6H-isoindolo[2,1-a]indole-3-carboxamide (10 mmol, crude from previous experiment), methyl 2-(dimethoxyphosphoryl)acrylate (2.9 g, 15 mmol), cesium carbonate (3.9 g, 12 mmol) in DMF (30 mL) was heated at 60° C. for 3h. Additional methyl 2-(dimethoxyphosphoryl)acrylate (1.2 g, 6 mmol) was added and the reaction was heated at 70° C. for 2 h. Additional methyl 2-(dimethoxyphosphoryl)acrylate (0.8 g, 4 mmol), cesium carbonate (1.6 g, 5 mmol) and DMF (6 mL) were added and the react was heated at 60° C. for 10 h and cooled to rt. The stirring reaction mixture was diluted with H2O (150 mL), neutralized with 1N aqueous HCl and the precipitates were collected by filtration. The solids were purified by silica gel chromatography (Biotage Horizon, 65M, 25-50% EtOAc/hexanes) to yield methyl 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6-carboxylate-10-carboxamide (4.0 g, 7.2 mmol, 72% over two steps) as a yellow solid. 1HNMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 8.09 (s, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.80 (s, 1H), 7.50 (d, J=8.4 Hz, 1H), 7.42 (d, J=8.8 Hz, 1H), 7.08 (dd, J=2.6, 8.8 Hz, 1H), 6.98 (d, J=2.6 Hz, 1H), 5.75-5.51 (m, 1H), 4.29-4.01 (m, 1H), 3.89 (s, 3H), 3.82 (s, 3H), 3.05 (s, 6H), 2.87-2.73 (m, 1H), 2.11-1.12 (m, 10H). LCMS: m/e 550 (M−H)−, ret time 3.21 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00688
  • Added 1M NaOH (aq.) (5 mL, 5 mmol) to a solution of methyl 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6-carboxylate-10-carboxamide (900 mg, 1.6 mmol) in THF/MeOH (1:1, 14 mL) and heated the reaction mixture in a sealed tube with microwave irradiation at 85° C. for 30 min. The reaction was cooled, neutralized with 1M HCl (aq.) (5 mL, 5.0 mmol) and concentrated to remove organic solvents. The residue was slurried with H2O and the solids were collected by filtration, flushed with H2O and dried to yield 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (807 mg, 1.5 mmol, 92%) as a yellow solid. LCMS: m/e 536 (M−H)−, ret time 2.18 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00689
  • 10% Palladium on carbon (200 mg, 0.19 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[(4-acetyl-1-piperazinyl)carbonyl]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]- (79 mg, 0.13 mmol) in MeOH (10 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction mixture was stirred under a balloon of hydrogen for 3 d, filtered through a pad of celite and concentrated. The residue was purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[(4-acetyl-1-piperazinyl)carbonyl]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro- (16 mg, 0.03 mmol, 20%) as a white powder. Mixture of atrope diastereomers: 1HNMR (500 MHz, CD3OD) δ 8.09 (s. 0.3H), 7.99 (s. 0.7H), 7.91 (d, J=8.6 Hz, 0.3H), 7.89 (d, J=8.6 Hz, 0.7H), 7.63 (d, J=7.9 Hz, 0.3H), 7.59 (d, J=7.9 Hz, 0.7H), 7.52-7.28 (m, 4H), 4.64-4.56 (m, 0.7H), 4.50 (dd, J=6.1, 14.0 Hz, 0.3H), 4.14-4.05 (m, 0.3H), 3.94-3.57 (m, 9H), 3.02 (s, 4H), 3.01 (s, 2H), 2.98-2.91 (m, 1H), 2.88-2.68 (m, 2H), 2.19 (s, 2H), 2.11 (s, 1H), 2.16-1.91 (m, 4H), 1.87-1.76 (m, 2H) 1.67-1.22 (m, 4H). LCMS: m/e 618 (M−H)−, ret time 1.59 min, column A, 3 minute gradient.
    Figure US20070078122A1-20070405-C00690
  • 10% Palladium on carbon (84 mg, 0.08 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]- (84 mg, 0.14 mmol) in MeOH (6 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction mixture was stirred under a balloon of hydrogen for 1 d. Additional 10% palladium on carbon (100 mg, 0.9 mmol) was added and the reaction mixture was vacuum flushed with nitrogen (3×), with hydrogen (3×) and then stirred under a balloon of hydrogen for 3 d. The reaction mixture was filtered through a pad of celite and concentrated. The residue was purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]- (39 mg, 0.06 mmol, 44%) as a yellow solid. Mixture of atrope diastereomers: 1HNMR (500 MHz, CD3OD) δ 8.10 (s. 0.3H), 8.02 (s. 0.7H), 7.92 (d, J=8.6 Hz, 0.3H), 7.90 (d, J=8.6 Hz, 0.7H), 7.63 (d, J=8.5 Hz, 0.3H), 7.58 (d, J=8.5 Hz, 0.7H), 7.53-7.31 (m, 4H), 4.64-4.47 (m, 1H), 4.15-3.64 (m, 5H), 3.55-3.27 (m, 5H), 3.04-2.96 (m, 9H), 2.94-2.76 (m, 3H), 2.19-1.23 (m, 10H). LCMS: m/e 654 (M−H)−, ret time 1.73 min, column A, 3 minute gradient.
    Figure US20070078122A1-20070405-C00691
  • Allyl isocyanate (94 mg, 1.1 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(1-piperazinylcarbonyl) (40 mg. 0.07 mmol) in CH2Cl2 (1 mL) and stirred at rt for 2 h. The reaction was concentrated to dryness, slurried with Et2O, filtered, and the solids were purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[(2-propenylamino)carbonyl]-1-piperazinyl]carbonyl]- (15 mg, 0.02 mmol, 32%) as a yellow powder. 1HNMR (500 MHz, CD3OD) δ 8.17 (s. 1H), 7.95 (d, J=8.6 Hz, 1H), 7.68-7.53 (m, 5H) 7.06 (s, 1H), 5.90-5.81 (m, 1H), 5.25-5.15 (m, 1H), 5.15 (dd, J=1.6, 17.3 Hz, 1H), 5.07 (dd, J=1.6, 10.4 Hz, 1H), 4.47-4.35 (m, 1H), 3.80-3.74 (m, 2H), 3.67-3.27 (m, 8H), 3.01 (s, 6H), 2.95-2.85 (m, 1H), 2.20-1.18 (m, 10H). LCMS: m/e 659 (M+H)+, ret time 2.79 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00692
  • Methyl isocyanate (94 mg, 1.6 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(1-piperazinylcarbonyl) (40 mg. 0.07 mmol) in CH2Cl2 (1 mL) and stirred at rt for 2 h. The reaction was concentrated to dryness, slurried with Et2O and filtered. The solids were dissolved into DMF and purified by preparative HPLC (MeOH/H2O with a TFA buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[(methylamino)carbonyl]-1-piperazinyl]carbonyl]- (13 mg, 0.02 mmol, 30%) as a yellow solid. 1HNMR (500 MHz, CD3OD) δ 8.16 (s. 1H), 7.97 (d, J=8.6 Hz, 1H), 7.69-7.53 (m, 5H) 7.06 (s, 1H), 5.25-5.14 (m, 1H), 4.46-4.34 (m, 1H), 3.68-3.23 (m, 8H), 3.03 (s, 6H), 2.95-2.85 (m, 1H), 2.72 (s, 3H), 2.20-1.74 (m, 6H), 1.57-1.17 (m, 4H). LCMS: m/e 631 (M−H)−, ret time 1.54 min, column A, 3 minute gradient.
    Figure US20070078122A1-20070405-C00693
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 3-methoxy, 6-carboxylic acid (120 mg, 0.27 mmol), N-(2-aminoethyl)acetamide (45 mg, 0.44 mmol) and triethylamine (0.11 mL) in DMF (2 mL) was added HATU (125 mg, 0.32 mmol). The reaction mixture was stirred at rt for 2 h, concentrated and purified by preparative HPLC (CH3CN/H2O with a TFA buffer) to yield methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylate, N6-[2-(acetylamino)ethyl]-13-cyclohexyl-3-methoxy (54 mg, 0.10 mmol, 38%) as a yellow solid. LCMS: m/e 528 (M−H)−, ret time 1.83 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00694
  • Added 1M NaOH (aq.) (0.4 mL, 0.4 mmol) to a solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylate, N6-[2-(acetylamino)ethyl]-13-cyclohexyl-3-methoxy (54 mg, 0.10 mmol) in THF/MeOH (1:1, 2 mL) and heated the reaction mixture in a sealed tube with microwave irradiation at 85° C. for 20 min. The reaction was cooled, neutralized with 1M HCl (aq.) (0.4 mL, 0.4 mmol) and concentrated to remove organic solvents. The residue was slurried with H2O and the solids were collected by filtration, flushed with H2O and dried to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid, N6-[2-(acetylamino)ethyl]-13-cyclohexyl-3-methoxy (44 mg, 0.09 mmol, 90%) as a yellow powder. 1HNMR (500 MHz, CD3OD) δ 8.29 (s. 1H), 7.86 (d, J=8.2 Hz, 1H), 7.71 (d, J=8.2 Hz, 1H), 7.59 (d, J=8.5 Hz, 1H), 7.50 (s, 1H), 7.18 (d, J=8.5 Hz, 1H), 7.14 (s, 1H), 5.72-5.59 (m, 1H), 4.23-4.10 (m, 1H), 3.95 (s, 3H), 3.49-3.27 (m, 4H), 2.93-2.85 (m, 1H), 2.20-1.75 (m, 6H), 1.89 (s, 3H), 1.58-1.18 (m, 4H). LCMS: m/e 514 (M−H)−, ret time 1.35 min, column A, 3 minute gradient.
    Figure US20070078122A1-20070405-C00695
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid, N6-[2-(acetylamino)ethyl]-13-cyclohexyl-3-methoxy (33 mg, 0.06 mmol), N,N-dimethylsulfamide (64 mg, 0.51 mmol) and DMAP (40 mg, 0.32 mmol) in dimethylacetamide (0.5 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (50 mg, 0.26 mmol). The reaction solution was stirred at rt 1 h and then at 45° C. for 2 h, diluted with MeOH (1 mL) and purified by preparative HPLC (CH3CN/H2O with TFA buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, N6-[2-(acetylamino)ethyl]-13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy- (12 mg, 0.02 mmol, 30%) as a yellow solid. 1HNMR (500 MHz, CDCl3) δ 10.12 (s, 1H), 8.71 (s. 1H), 7.92 (d, J=8.5 Hz, 1H), 7.84 (s, 1H), 7.81 (dd, J=1.2, 8.5 Hz, 1H), 7.77 (br s, 1H), 7.50 (d, J=8.5 Hz, 1H), 7.08 (dd, J=2.8, 8.6 Hz, 1H), 7.03 (d, J=2.8 Hz, 1H), 6.35 (br t, J=6.1 Hz, 1H), 5.24-5.11 (m, 1H), 4.39-4.25 (m, 1H), 3.95 (s, 3H), 3.62-3.23 (m, 4H), 3.03 (s, 6H), 2.87-2.79 (m, 1H), 2.21-1.70 (m, 6H), 2.19 (s, 3H), 1.61-1.14 (m, 4H). LCMS: m/e 620 (M−H)−, ret time 2.43 min, column E, 4 minute gradient.
    Figure US20070078122A1-20070405-C00696
  • 10% Palladium on carbon (80 mg, 0.08 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[2-(dimethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl- (35 mg, 0.06 mmol) in MeOH (2 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction mixture was stirred under a balloon of hydrogen for 2.5 d, filtered through a pad of celite and concentrated. The residue was purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[2-(dimethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N6-methyl- (6 mg, 0.01 mmol, 20%) as an off-white solid. 1HNMR (500 MHz, CDCl3) δ 11.11 (s, 1H), 8.09 (s. 1H), 7.74 (d, J=8.6 Hz, 1H), 7.71 (dd, J=1.2, 8.6 Hz, 1H), 7.34 (d, J=8.2 Hz, 1H), 6.96-6.90 (m, 2H), 4.85 (d, J=15.9 Hz, 1H), 4.58 (d, J=14.7 Hz, 1H), 4.04-3.84 (m, 3H), 3.89 (s, 3H), 3.51-3.45 (m, 1H), 3.35 (s, 3H), 3.40-3.20 (m, 3H), 3.09-3.01 (m, 1H), 3.04 (s, 3H), 3.03 (s, 6H), 3.00 (s, 3H), 2.64-2.58 (m, 1H), 2.10-1.19 (m, 10H). LCMS: m/e 636 (M−H)−, ret time 2.69 min, column E, 4 minute gradient.
    Figure US20070078122A1-20070405-C00697
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 3-methoxy, 6-carboxylic acid (120 mg, 0.27 mmol), 2-amino-N-methylacetamide hydrochloride (52 mg, 0.432 mmol) and triethylamine (0.15 mL) in DMF (2 mL) was added HATU (125 mg, 0.32 mmol). The reaction mixture was stirred at rt for 3 h, diluted with H2O (˜10 mL) and the resulting solids were collected by filtration, washed with H2O and dried to yield methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl-3-methoxy-6-[[[2-(methylamino)-2-oxoethyl]amino]carbonyl]- (140 mg, 0.27 mmol, quant.) as a yellow solid, which was used without further purification.
    Figure US20070078122A1-20070405-C00698
  • Added 1M NaOH (aq.) (0.5 mL, 0.5 mmol) to a solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl-3-methoxy-6-[[[2-(methylamino)-2-oxoethyl]amino]carbonyl]- (140 mg, 0.27 mmol) in THF/MeOH (1:1, 3 mL) and heated the reaction mixture in a sealed tube with microwave irradiation at 80° C. for 20 min., then at 85° C. for 10 min. The reaction was cooled, neutralized with 1M HCl (aq.) (0.5 mL, 0.5 mmol) and concentrated to remove organic solvents. The residue was slurried with H2O and the solids were collected by filtration, flushed with H2O and dried to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[[[2-(methylamino)-2-oxoethyl]amino]carbonyl]- (123 mg, 0.25 mmol, 90%) as a yellow solid. 1HNMR (500 MHz, CD3OD) δ 8.30 (s. 1H), 7.87 (d, J=8.5 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.62 (s, 1H), 7.60 (d, J=8.5 Hz, 1H), 7.20 (d, J=8.5 Hz, 1H), 7.15 (s, 1H), 5.74-5.60 (m, 1H), 4.24-4.11 (m, 1H), 4.02-3.88 (m, 2H), 3.95 (s, 3H), 2.95-2.84 (m, 1H), 2.75 (s, 3H), 2.22-1.17 (m, 10H). LCMS: m/e 500 (M−H)−, ret time 1.38 min, column A, 3 minute gradient.
    Figure US20070078122A1-20070405-C00699
  • To a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[[[2-(methylamino)-2-oxoethyl]amino]carbonyl]- (110 mg, 0.22 mmol), N,N-dimethylsulfamide (136 mg, 1.10 mmol) and DMAP (134 mg, 1.10 mmol) in dimethylformamide (2 mL) was added PS-carbodiimide (576 mg, 1.3 mmol/g, 0.88 mmol). The reaction solution was shaken at rt overnight, filtered, concentrated and purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-[2-(methylamino)-2-oxoethyl]- (40 mg, 0.07 mmol, 30%) as a yellow solid. 1HNMR (500 MHz, CD3OD) δ 8.13 (s. 1H), 7.85 (d, J=8.6 Hz, 1H), 7.60-7.52 (m, 3H), 7.15 (dd, J=2.8, 8.8 Hz, 1H), 7.10 (d, J=2.8 Hz, 1H), 5.64-5.53 (m, 1H), 4.19-4.07 (m, 1H), 3.96-3.86 (m, 2H), 3.91 (s, 3H), 2.99 (s, 6H), 2.89-2.80 (m, 1H), 2.71 (s, 3H), 2.16-1.70 (m, 6H), 1.54-1.16 (m, 4H). LCMS: m/e 606 (M−H)−, ret time 1.57 min, column A, 3 minute gradient.
    Figure US20070078122A1-20070405-C00700
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (366 mg, 0.88 mmol), 2-N,N-dimethyl-2-(methylamino)acetamide (120 mg, 1.03 mmol) and triethylamine (0.37 mL) in DMF (6 mL) was added HATU (400 mg, 1.05 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜20 mL) and the resulting solids were collected by filtration, washed with H2O and dried on the filter with aspirator vacuum for 1 h. The solids were dissolved into THF/MeOH (1:1, 6 mL) and 1M NaOH (aq.) (1.5 mL, 1.5 mmol). The reaction mixture was heated in a sealed tube with microwave irradiation at 85° C. for 20 min. The reaction was cooled, neutralized with 1M HCl (aq.) (1.5 mL, 1.5 mmol) and concentrated to remove organic solvents. The residue was slurried with H2O and the solids were collected by filtration, flushed with H2O and dried to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[[2-(dimethylamino)-2-oxoethyl]methylamino]carbonyl]- (406 mg, 0.81 mmol, 92%) as a yellow solid. Mixture of amide rotamers: 1HNMR (300 MHz, DMSO-d6) δ 12.58 (br s, 1H), 8.17 (br s, 0.5H), 8.13 (br s, 0.5H), 7.89 (d, J=8.8 Hz, 1H), 7.66-7.45 (m, 5H), 7.07 (br s, 0.5H), 6.90 (br s, 0.5H), 5.24-4.96 (m, 1H), 4.39-4.03 (m, 3H), 3.08-2.75 (m, 7H), 2.63 (s, 1.5H), 2.54 (s, 1.5H), 2.14-1.63 (m, 6H), 1.52-1.04 (m, 4H). LCMS: m/e 498 (M−H)−, ret time 1.36 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00701
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid, 3-methoxy (200 mg, 0.45 mmol), 2-(methylamino)-1-morpholinoethanone (86 mg, 0.54 mmol) and triethylamine (0.19 mL) in DMF (3 mL) was added HATU (205 mg, 0.54 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜12 mL) and the resulting solids were collected by filtration, washed with H2O and dried on the filter with aspirator vacuum for 1 h. The solids were dissolved into THF/MeOH (1:1, 4 mL) and 1M NaOH (aq.) (1.0 mL, 1.0 mmol). The reaction mixture was heated in a sealed tube with microwave irradiation at 85° C. for 20 min. The reaction was cooled, neutralized with 1M HCl (aq.) (1.0 mL, 1.0 mmol) and concentrated. The residue was slurried with H2O and the solids were collected by filtration, flushed with H2O, dried and purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]carbonyl]- (163 mg, 0.29 mmol, 63%) as a yellow solid and 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-[[(carboxymethyl)methylamino]carbonyl]-13-cyclohexyl-3-methoxy- (13 mg, 0.03 mmol, 6%) as a yellow solid. Data for 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]carbonyl]-: 1HNMR (300 MHz, CDCl3) δ 8.26 (br s. 1H), 7.85 (d, J=8.4 Hz, 1H), 7.74 (dd, J=1.1, 8.4 Hz, 1H), 7.48 (d, J=8.8 Hz, 1H), 7.03 (dd, J=2.7, 8.8 Hz, 1H), 7.00-6.92 (m, 1H), 6.89 (br s, 1H), 5.23-5.06 (m, 1H), 4.47-4.31 (m, 1H), 3.87 (s, 3H), 3.78-3.37 (m, 6H), 3.05-2.73 (m, 5H), 2.13-1.69 (m, 6H), 2.08 (s, 3H), 1.46-1.13 (m, 4H). LCMS: m/e 570 (M−H)−, ret time 1.38 min, column A, 2 minute gradient. Data for 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-[[(carboxymethyl)methylamino]carbonyl]-13-cyclohexyl-3-methoxy-. 1HNMR (300 MHz, DMSO-d6) δ 8.09 (s. 1H), 7.82 (d, J=9.5 Hz, 1H), 7.57 (d, J=8.4 Hz, 1H), 7.47 (d, J=9.5 Hz, 1H), 7.24-6.95 (m, 3H), 5.20-5.02 (m, 1H), 4.23-4.04 (m, 1H), 3.86 (s, 3H), 3.86-3.74 (m, 2H), 2.85 (s, 3H), 2.82-2.71 (m, 1H), 2.12-1.12 (m, 10H). LCMS: m/e 503 (M+H)+, ret time 2.83 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00702
  • To a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[[2-(dimethylamino)-2-oxoethyl]methylamino]carbonyl]- (180 mg, 0.36 mmol), N,N-dimethylsulfamide (134 mg, 1.08 mmol) and DMAP (122 mg, 1.08 mmol) in dimethylformamide (2 mL) was added PS-carbodiimide (830 mg, 1.3 mmol/g, 1.08 mmol). The reaction solution was shaken at 45° C. overnight, filtered, concentrated and purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[2-(dimethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-N6-methyl- (90 mg, 0.15 mmol, 41%) as a yellow solid. 1HNMR (300 MHz, CDCl3) δ 8.12 (br s. 1H), 7.88 (d, J=8.8 Hz, 1H), 7.71-7.52 (m, 2H), 7.50-7.35 (m, 3H), 6.86 (s, 1H), 5.15-5.01 (m, 1H), 4.67-4.51 (m, 1H), 3.79-3.62 (m, 1H), 3.14-2.92 (m, 12H), 2.88-2.75 (m, 1H), 2.48 (br s, 3H), 2.10-1.65 (m, 6H), 1.55-1.08 (m, 4H). LCMS: m/e 604 (M−H)−, ret time 2.57 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00703
  • To a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]carbonyl]- (106 mg, 0.19 mmol), N,N-dimethylsulfamide (70 mg, 0.56 mmol) and DMAP (70 mg, 0.56 mmol) in dimethylformamide (1.2 mL) was added PS-carbodiimide (428 mg, 1.3 mmol/g, 0.56 mmol). The reaction solution was shaken at 45° C. for 6 h, filtered, concentrated and purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-[2-(4-morpholinyl)-2-oxoethyl]- (26 mg, 0.04 mmol, 21%) as a yellow solid. Mixture of amide rotamers: 1HNMR (300 MHz, CD3OD) δ 8.25-8.08 (m, 1H), 7.92 (d, J=8.4 Hz, 1H), 7.64-7.52 (m, 2H), 7.20-6.95 (m, 3H), 5.30-5.04 (m, 1H), 4.59-4.27 (m, 3H), 3.93 (s, 3H), 3.78-3.48 (m, 4H), 3.33 (s, 3H), 3.03 (s, 6H), 3.10-2.82 (m, 5H), 2.21-1.72 (m, 6H), 1.58-1.21 (m, 4H). LCMS: m/e 678 (M+H)+, ret time 3.52 min, column B, 4 minute gradient.
    Figure US20070078122A1-20070405-C00704
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (100 mg, 0.19 mmol), N,N-diethyl-2-(methylamino)acetamide hydrochloride (41 mg, 0.23 mmol) and triethylamine (0.11 mL) in DMF (2 mL) was added HATU (85 mg, 0.22 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜8 mL) and extracted with EtOAc (3×5 mL), the combined organics were concentrated and purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[2-(diethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl- (68 mg, 0.10 mmol, 55%) as a yellow solid. 1HNMR (300 MHz, CDCl3) δ 9.91 (br s, 1H), 8.06 (br s, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.67-7.58 (m, 1H), 7.48 (d, J=8.4 Hz, 1H), 7.02 (dd, J=2.6, 8.4 Hz, 1H), 6.89 (br s, 1H), 6.83 (br s, 1H), 5.11-5.01 (m, 1H), 4.62-4.83 (m, 2H), 3.87 (s, 3H), 3.83-3.23 (m, 5H), 3.04 (s, 6H), 2.87-2.73 (m, 1H), 2.46 (s, 3H), 2.09-1.03 (m, 16H). LCMS: m/e 662 (M−H)−, ret time 2.98 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00705
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (100 mg, 0.19 mmol), N,N-diethyl-2-(methylamino)acetamide hydrochloride (41 mg, 0.22 mmol) and triethylamine (0.11 mL) in DMF (2 mL) was added HATU (85 mg, 0.23 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜8 mL) and extracted with EtOAc (3×5 mL), the combined organics were concentrated and purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-N6-methyl- (58 mg, 0.09 mmol, 47%) as a yellow solid. Mixture of amide rotamers: 1H-NMR (300 MHz, CDCl3) δ 8.21 (s, 0.25H), 8.02 (s, 0.75H), 7.86 (d, J=8.8 Hz, 0.75H), 7.83 (d, J=8.8 Hz, 0.25H), 7.68-7.58 (m, 1H), 7.51 (d, J=7.8 Hz, 0.25H), 7.49 (d, J=7.8 Hz, 0.75H), 7.03 (dd, J=2.6, 8.8 Hz, 1H), 6.88 (d, J=2.6 Hz, 1H), 6.81 (s, 1H), 5.14-5.03 (m, 1H), 4.48-4.34 (m, 1H), 3.88 (s, 3H), 3.67-3.42 (m, 4H), 3.34 (s, 0.75H), 3.31 (s, 2.25H), 3.09-2.99 (m, 1H), 3.04 (s, 6H), 2.87-2.72 (m, 1H), 2.57-2.44 (m, 1H), 2.49 (s, 0.75H), 2.07 (s, 2.25H), 2.11-1.23 (m, 10H). LCMS: m/e 664 (M−H)−, ret time 2.69 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00706
  • 10% Palladium on carbon (38 mg, 0.04 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-N6-methyl- (40 mg, 0.06 mmol) in MeOH (2 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction mixture was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N6-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-N6-methyl- (30 mg, 0.04 mmol, 75%) as a yellow solid. Diastereomeric mixture of atrope isomers with amide rotamers: Partial 1HNMR (300 MHz, CDCl3) δ 11.30 (br s, 0.2H), 11.00 (br s, 0.5H), 8.35 (br s, 0.2H), 7.98 (br s, 0.6H), 7.89-7.66 (m, 2H), 7.37-7.28 (m, 1H), 6.95-6.85 (m, 2H), 6.10-6.00 (m, 0.5H), 5.08-4.98 (m, 0.4H), 3.86 (s, 3H), 3.01 (s, 6H). LCMS: m/e 666 (M−H)−, ret time 2.74 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00707
  • 10% Palladium on carbon (50 mg, 0.05 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[2-(diethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl- (51 mg, 0.08 mmol) in MeOH (2 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction mixture was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[2-(diethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N6-methyl- (44 mg, 0.07 mmol, 86%) as an off-white solid. Partial 1HNMR (300 MHz, CDCl3) δ 11.3 (s, 1H), 8.04 (s, 1H), 7.81 (d, J=8.4 Hz, 1H), 7.69 (d, J=8.4 Hz, 1H), 7.31 (d, J=8.0 Hz, 1H), 6.94-6.86 (m, 2H), 4.80-4.71 (m, 1H), 4.60-4.52 (m, 1), 3.86 (s, 3H), 3.33 (s, 3H), 3.01 (s, 6H). LCMS: m/e 664 (M−H)−, ret time 3.12 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00708
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (90 mg, 0.17 mmol), 2-methoxy-N-methylethanamine (22 mg, 0.25 mmol) and triethylamine (0.10 mL) in DMF (2 mL) was added HATU (82 mg, 0.22 mmol). The reaction mixture was stirred at rt for 1 h, diluted with H2O (˜5 mL), acidified with 1M HCl (aq.) (˜0.75 mL) and the precipitate was collected by filtration. The solids were rinsed with water and dried to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-(2-methoxyethyl)-N6-methyl- (93 mg, 0.15 mmol, 91%) as a white solid. 1HNMR (300 MHz, DMSO-d6) δ 11.59 (s, 1H), 8.34 (s, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.63 (br d, J=8.4 Hz, 1H), 7.50 (d, J=9.2 Hz, 1H), 7.21-7.13 (m, 1H), 7.16 (s, 1H), 6.98 (s, 1H), 5.21-4.98 (m, 1H), 4.40-4.18 (m, 1H), 3.88 (s, 3H), 3.57-3.41 (m, 2H), 3.29 (s, 3H), 3.17-3.04 (m, 2H), 2.92 (s, 3H), 2.91 (s, 6H), 2.82-2.73 (m, 1H), 2.12-1.14 (m, 10H). LCMS: m/e 609 (M+H)+, ret time 2.11 min, column C, 2 minute gradient.
    Figure US20070078122A1-20070405-C00709
  • 10% Palladium on carbon (77 mg, 0.07 mnol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-(2-methoxyethyl)-N6-methyl- (65 mg, 0.11 mmol) in MeOH/CH2Cl2 (1:1, 4 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N6-(2-methoxyethyl)-N6-methyl- (60 mg, 0.10 mmol, 92%) as a light yellow solid. Mixture of atrope diastereomers. 1HNMR (300 MHz, CD3OD) δ 8.10-7.92 (m, 1H), 7.91-7.83 (m, 1H), 7.62-7.51 (m, 1H), 7.42-7.33 (m, 1H), 7.10-6.84 (m, 2H), 4.67-4.44 (m, 1H), 3.93-3.86 (m, 3H), 3.84-3.21 (m, 1H), 3.06-2.86 (m, 8H), 2.83-2.64 (m, 2H), 2.18-1.19 (m, 10H). LCMS: m/e 611 (M+H)+, ret time 2.12 min, column C, 2 minute gradient.
    Figure US20070078122A1-20070405-C00710
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (90 mg, 0.17 mmol), (1-methyl-1H-imidazol-4-yl)methanamine (28 mg, 0.25 mmol) and triethylamine (0.10 mL) in DMF (2 mL) was added HATU (82 mg, 0.22 mmol). The reaction mixture was stirred at rt for 1 h, diluted with H2O (˜5 mL), acidified with 1M HCl (aq.) (˜0.75 mL) and the precipitate was collected by filtration. The solids were rinsed with water and dried to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-[(1-methyl-1H-imidazol-4-yl)methyl]- (102 mg, 0.16 mmol, 96%) as a bright yellow solid. 1HNMR (300 MHz, CD3OD) δ 8.46 (s, 1H), 8.14 (d, J=1.5 Hz, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.62-7.54 (m, 3H), 7.33 (s, 1H), 7.20 (dd, J=2.9, 8.8 Hz, 1H), 7.13 (d, J=2.9 Hz, 1H), 5.70-5.55 (m, 1H), 4.50 (s, 2H), 4.29-4.11 (m, 1H), 3.94 (s, 3H), 3.83 (s, 3H), 3.04 (s, 6H), 2.89-2.80 (m, 1H), 2.23-1.16 (m, 10H). LCMS: m/e 632 (M+H)+, ret time 1.81 min, column C, 2 minute gradient.
    Figure US20070078122A1-20070405-C00711
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (90 mg, 0.17 mmol), (1,3-dimethyl-1H-pyrazol-5-yl)methanamine (31 mg, 0.25 mmol) and triethylamine (0.10 mL) in DMF (2 mL) was added HATU (82 mg, 0.22 mmol). The reaction mixture was stirred at rt for 1 h, diluted with H2O (˜5 mL), acidified with 1M HCl (aq.) (˜0.75 mL) and the precipitate was collected by filtration. The solids were rinsed with water and dried to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-N6-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-3-methoxy- (104 mg, 0.16 mmol, 96%) as a bright yellow solid. 1HNMR (300 MHz, CD3OD) δ 8.15 (s, 1H), 7.91 (d, J=8.4 Hz, 1H), 7.62-7.54 (m, 2H), 7.52 (s, 1H), 7.18 (dd, J=8.8 Hz, 1H), 7.13 (br s, 1H), 6.06 (s, 1H), 5.72-5.52 (m, 1H), 4.50 (s, 2H), 4.27-4.10 (m, 1H), 3.93 (s, 3H), 3.80 (s, 3H), 3.03 (s, 6H), 2.95-2.80 (m, 1H), 2.23-1.15 (m, 10H), 2.18 (s, 3H). LCMS: m/e 645 (M+H)+, ret time 2.09 min, column C, 2 minute gradient.
    Figure US20070078122A1-20070405-C00712
  • 10% Palladium on carbon (75 mg, 0.07 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-[(1-methyl-1H-imidazol-4-yl)methyl]- (60 mg, 0.10 mmol) in MeOH/CH2Cl2 (1:1, 4 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N6-[(1-methyl-1H-imidazol-4-yl)methyl]- (60 mg, 0.09 mmol, 90%) as a bright yellow solid. Mixture of atrope diastereomers. LCMS: m/e 633 (M+H)+, ret time 1.73 min, column C, 2 minute gradient.
    Figure US20070078122A1-20070405-C00713
  • 10% Palladium on carbon (75 mg, 0.07 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-N6-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-3-methoxy- (60 mg, 0.09 mmol) in MeOH/CH2Cl2 (2:1, 3 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N6-(1,3-dimethyl-1H-pyrazol-5-yl)methyl (51 mg, 0.08 mmol, 86%) as a bright yellow solid. Mixture of atrope diasteromers: 1HNMR (300 MHz, CD3OD) δ 8.09 (s, 0.3H), 7.98 (s, 0.7H), 7.90 (d, J=8.4 Hz, 0.3H), 7.88 (d, J=8.4 Hz, 0.7H), 7.61-7.53 (m, 1H), 7.42-7.34 (m, 1H), 7.07-6.98 (m, 1.7H), 6.86 (d, J=2.6 Hz, 0.3H), 6.23 (s, 0.3H), 6.15 (s, 0.7H), 4.87-4.57 (m, 2H), 4.54-4.34 (m, 2H), 3.90 (s, 2.1H), 3.89 (s, 0.9H), 3.87 (s, 0.9H), 3.84 (s, 2.1H), 3.26-3.07 (m, 1H) 3.03 (s, 6H), 2.99-2.67 (m, 3H), 2.29 (s, 0.9H), 2.26 (s, 2.1H), 2.21-1.20 (m, 10H). LCMS: m/e 647 (M+H)+, ret time 2.01 min, column C, 2 minute gradient.
    Figure US20070078122A1-20070405-C00714
  • 10% Palladium on carbon (75 mg, 0.07 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-[(1-methyl-1H-imidazol-4-yl)methyl]- (60 mg, 0.10 mmol) in MeOH/CH2Cl2 (1:1, 4 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N6-[(1-methyl-1H-imidazol-4-yl)methyl]- (60 mg, 0.09 mmol, 90%) as a bright yellow solid. Mixture of atrope diastereomers. LCMS: m/e 633 (M+H)+, ret time 1.73 min, column C, 2 minute gradient.
    Figure US20070078122A1-20070405-C00715
  • 10% Palladium on carbon (75 mg, 0.07 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-N6-[(1,3-dimethyl-1H-pyrazol-5-yl)methyl]-3-methoxy- (60 mg, 0.09 mmol) in MeOH/CH2Cl2 (2:1, 3 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N6-(1,3-dimethyl-1H-pyrazol-5-yl)methyl (51 mg, 0.08 mmol, 86%) as a bright yellow solid. Mixture of atrope diastereomers: 1HNMR (300 MHz, CD3OD) δ 8.09 (s, 0.3H), 7.98 (s, 0.7H), 7.90 (d, J=8.4 Hz, 0.3H), 7.88 (d, J=8.4 Hz, 0.7H), 7.61-7.53 (m, 1H), 7.42-7.34 (m, 1H), 7.07-6.98 (m, 1.7H), 6.86 (d, J=2.6 Hz, 0.3H), 6.23 (s, 0.3H), 6.15 (s, 0.7H), 4.87-4.57 (m, 2H), 4.54-4.34 (m, 2H), 3.90 (s, 2.1H), 3.89 (s, 0.9H), 3.87 (s, 0.9H), 3.84 (s, 2.1H), 3.26-3.07 (m, 1H) 3.03 (s, 6H), 2.99-2.67 (m, 3H), 2.29 (s, 0.9H), 2.26 (s, 2.1 H), 2.21-1.20 (m, 10H). LCMS: m/e 647 (M+H)+, ret time 2.01 min, column C, 2 minute gradient.
    Figure US20070078122A1-20070405-C00716
  • 10% Palladium on carbon (60 mg, 0.06 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-[2-(4-morpholinyl)-2-oxoethyl]- (59 mg, 0.09 mmol) in MeOH (3 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (3×). The reaction mixture was stirred under a balloon of hydrogen overnight. The reaction mixture was once again vacuum flushed with nitrogen (3×) and then with hydrogen (3×) and stirred under a balloon of hydrogen overnight. The solution was filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N6-methyl-N6-[2-(4-morpholinyl)-2-oxoethyl]- (31 mg, 0.05 mmol, 53%) as a yellow solid. Mixture of atrope diastereomers: 1HNMR (500 MHz, CDCl3) δ 10.85 (br s, 1H), 8.07 (s, 1H), 7.85 (d, J=8.5 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.34 (d, J=8.2 Hz, 1H), 6.93 (d, J=8.2 Hz, 1H), 6.91 (s, 1H), 4.75-4.33 (m, 2H), 3.88 (s, 3H), 3.94-2.44 (m, 13H), 3.31 (s, 3H), 3.02 (s, 6H), 2.95-2.84 (m, 1H), 2.19-1.17 (m, 10H). LCMS: m/e 678 (M−H)−, ret time 2.77 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00717
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (80 mg, 0.15 mmol), 3-methoxyazetidine hydrochloride (28 mg, 0.22 mmol) and triethylamine (0.09 mL) in DMF (1.5 mL) was added HATU (85 mg, 0.22 mmol). The reaction mixture was stirred at rt for 1.5 h, diluted with H2O (˜5 mL), acidified with 1M HCl (aq.) (˜0.20 mL) and the precipitate was collected by filtration and flushed with H2O to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 3-methoxy, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[3-methoxyazetidinyl]carbonyl]- (57 mg, 0.09 mmol, 63%) as a yellow solid. 1HNMR (500 MHz, CDCl3) δ 9.68 (s, 1H), 8.10 (s, 1H), 15 7.88 (d, J=8.5 Hz, 1H), 7.57 (d, J=8.5 Hz, 1H), 7.52 (d, J=8.5 Hz, 1H), 7.11-7.05 (m, 2H), 6.09 (s, 1H), 5.59-5.47 (m, 1H), 4.39-3.95 (m, 6H), 3.91 (s, 3H), 3.28 (s, 3H), 3.06 (s, 6H), 2.86-2.77 (m, 1H), 2.14-1.14 (m 10H). LCMS: m/e 605 (M−H)−, ret time 3.07 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00718
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (180 mg, 0.34 mmol), methyl 2-(methylamino)acetate hydrochloride (70 mg, 0.50 mmol) and triethylamine (0.19 mL) in DMF (2.5 mL) was added HATU (190 mg, 0.50 mmol). The reaction mixture was stirred at rt for 1.5 h, diluted with H2O (˜10 mL), acidified with 1M HCl (aq.) (˜0.50 mL) and the precipitate was collected by filtration and flushed with H2O. To a solution of the yellow solids in THF/MeOH (1:1, 3 mL) was added 1M NaOH (aq.) (0.75 mL, 0.75 mmol). The reaction solution was heated in a sealed tube with microwave irradiation at 85° C. for 30 min. The reaction was cooled, neutralized with 1M HCl (aq.) (0.75 mL, 0.75 mmol) and concentrated to remove organic solvents. The residue was slurried with H2O and the solids were collected by filtration, flushed with H2O and dried to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-acetic acid (148 mg, 0.24 mmol, 72%) as a yellow solid. LCMS: m/e 607 (M−H)−, ret time 2.05 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00719
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-acetic acid (45 mg, 0.074 mmol), azetidine hydrochloride (11 mg, 0.11 mmol) and triethylamine (0.05 mL) in DMF (1 mL) was added HATU (37 mg, 0.10 mmol). The reaction mixture was stirred at rt for 1.5 h, diluted with H2O (˜3 mL), acidified with 1N HCl(aq.) (˜0.1 mL) and the precipitate was collected by filtration and flushed with H2O. The solids were dissolved into MeOH and purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-[2-(azetidinyl)-2-oxoethyl]- (27 mg, 0.04 mmol, 56%) as a yellow solid. 1HNMR (500 MHz, CDCl3) δ 10.65 (s, 1H), 8.13 (s, 1H), 7.87 (d, J=8.0 Hz, 1H), 7.68 (d, J=8.0 Hz, 1H), 7.51 (d, J=8.6 Hz, 1H), 7.05 (br d, J=8.6 Hz, 1H), 6.91 (br s, 1H), 6.81 (s, 1H), 5.04 (br d, J=13.7 Hz, 1H), 4.44 (br d, J=13.7 Hz, 1H), 4.40-4.11 (m, 4H), 3.89 (s, 3H), 3.48-3.40 (m, 1H), 3.10-3.02 (m, 1H), 3.06 (s, 6H), 2.86-2.76 (m, 1H), 2.48-1.14 (m, l5H). LCMS: m/e 648 (M+H)+, ret time 3.55 min, column B, 4 minute gradient.
    Figure US20070078122A1-20070405-C00720
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-acetic acid (45 mg, 0.074 mmol), ethylmethylamine (7 mg, 0.11 mmol) and triethylamine (0.05 mL) in DMF (1 mL) was added HATU (37 mg, 0.10 mmol). The reaction mixture was stirred at rt for 1.5 h, diluted with H2O (˜3 mL), acidified with IN HCl(aq.) (˜0.1 mL) and the precipitate was collected by filtration and flushed with H2O. The solids were dissolved into MeOH and purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-[2-(methylethylamino)-2-oxoethyl]- (29 mg, 0.04 mmol, 60%) as a yellow solid. Mixture of rotamers. 1HNMR (500 MHz, CDCl3) δ 10.06-9.89 (m, 1H), 8.14-8.06 (m, 1H), 7.87 (d, J=8.5 Hz, 1H), 7.69-7.62 (m, 1H), 7.51 (d, J=8.5 Hz, 1H), 7.05 (dd, J=2.4, 8.5 Hz, 1H), 6.94-6.88 (m, 1H), 6.85-6.81 (m, 1H), 5.12-5.01 (m, 1H), 4.69-4.54 (m, 1H), 4.47-4.38 (m, 1H), 3.90 (s, 3H), 3.87-3.50 (m, 2H), 3.38-3.27 (m, 1H), 3.09-2.95 (m, 3H), 3.06 (s, 6H), 2.87-2.77 (m, 1H), 2.52-1.07 (m, 16H). LCMS: m/e 650 (M+H)+, ret time 3.60 min, column B, 4 minute gradient.
    Figure US20070078122A1-20070405-C00721
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-acetic acid (45 mg, 0.074 mmol), 3-methoxyazetidine hydrochloride (14 mg, 0.11 mmol) and triethylamine (0.05 mL) in DMF (1 mL) was added HATU (37 mg, 0.10 mmol). The reaction mixture was stirred at rt for 1.5 h, diluted with H2O (˜3 mL), acidified with 1N HCl(aq.) (˜0.1 mL) and the precipitate was collected by filtration and flushed with H2O. The solids were dissolved into MeOH and purified by preparative HPLC (MeOH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-[2-(3-methoxyazetidinyl)-2-oxoethyl]- (41 mg, 0.06 mmol, 82%) as a yellow solid. Mixture of rotamers. 1HNMR (500 MHz, CDCl3) δ 10.58-10.42 (m, 1H), 8.13-8.02 (m, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.69-7.59 (m, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.03 (dd, J=2.6, 8.4 Hz, 1H), 6.88 (d, J=2.6 Hz, 1H), 6.83-6.72 (m, 1H), 5.07-4.93 (m, 1H), 4.52-3.92 (m, 6H), 3.87 (s, 3H), 3.60-2.92 (m, 2H), 3.26 (s, 3H), 3.04 (s, 6H), 2.84-2.73 (m, 1H), 2.55-1.11 (m, 13H). LCMS: m/e 673 (M+H)+, ret time 3.57 min, column B, 4 minute gradient.
    Figure US20070078122A1-20070405-C00722
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (90 mg, 0.17 mmol), N1,N2-dimethylethane-1,2-diamine (150 mg, 1.7 mmol) and triethylamine (0.95 mL) in DMF (2 mL) was added HATU (82 mg, 0.22 mmol). The reaction mixture was stirred at rt overnight, diluted with H2O (˜3 mL), acidified with 1M HCl (aq.) and the precipitate was collected by filtration and flushed with H2O. To a solution of the yellow solids in triethylamine (0.95 mL) and THF (1.5 mL) was added acetyl chloride (0.03 mL, 40 mmol). The reaction solution was stirred at rt for 30 min, quenched with MeOH and purified by preparative HPLC (MeOH/H2O with a TFA buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, N6-[2-(acetylmethylamino)ethyl]-13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl- (20 mg, 0.03 mmol, 18%) as a yellow solid. 1HNMR (500 MHz, CDCl3) δ 11.55 (s, 1H), 8.42 (s, 1H), 7.87 (d, J=8.6 Hz, 1H), 7.75 (d, J=8.6 Hz, 1H), 7.46 (d, J=8.8 Hz, 1H), 7.01 (dd, J=2.6, 8.8 Hz, 1H), 6.86 (d, J=2.6 Hz, 1H), 6.77 (s, 1H), 4.76-4.29 (m, 2H), 3.86 (s, 3H), 3.16-2.69 (m, 5H), 3.11 (s, 3H), 3.01 (s, 6H), 2.52 (s, 3H), 2.24 (s, 3H), 2.84-2.73 (m, 1H), 2.16-1.14 (m, 10H). LCMS: m/e 673 (M+H)+, ret time 2.18 min, column C, 2 minute gradient.
    Figure US20070078122A1-20070405-C00723
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (150 mg, 0.28 mmol), dimethyl 2,2′-azanediyldiacetate hydrochloride (83 mg, 0.42 mmol) and triethylamine (0.16 mL) in DMF (2 mL) was added HATU (140 mg, 0.36 mmol). The reaction mixture was stirred at rt for 3 h, diluted with H2O (˜5 mL), acidified with 1M HCl (aq.) (˜0.20 mL) and the precipitate was collected by filtration and flushed with H2O. To a solution of the bright yellow solids in THF/MeOH (1:1, 3 mL) was added 1M NaOH (aq.) (1 mL, 1.0 mmol). The reaction solution was heated in a sealed tube with microwave irradiation at 65° C. for 20 min. The reaction was cooled, neutralized with 1M HCl (aq.) (1 mL, 1.0 mmol) and concentrated to remove organic solvents. The residue was slurried with H2O and the solids were collected by filtration dissolved into MeOH and purified by preparative HPLC (CH3CH/H2O with an NH4OAc buffer) to yield glycine, N-(carboxymethyl)-N-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]- (88 mg, 0.13 mmol, 48%) as a yellow powder. Partial 1HNMR (300 MHz, DMSO-d6) δ 8.04 (s, 1H), 7.71-7.65 (m, 2H), 7.46 (d, J=8.4 Hz, 1H), 7.14 (dd, J=2.6, 8.4 Hz, 1H), 6.98 (d, J=2.6 Hz, 1H), 6.89 (s, 1H), 3.86 (s, 3H), 2.67 (s, 6H). LCMS: m/e 651 (M−H)−, ret time 1.67 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00724
  • To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (150 mg, 0.28 mmol), (S)-3-methyl-2-(methylamino)butanoic acid hydrochloride (77 mg, 0.42 mmol) and triethylamine (0.16 mL) in DMF (2 mL) was added HATU (140 mg, 0.36 mmol). The reaction mixture was stirred at rt for 3 h, diluted with H2O (˜5 mL), acidified with 1M HCl (aq.) (˜0.20 mL) and the precipitate was collected by filtration and flushed with H2O. To a solution of the bright yellow solids in THF/MeOH (1:1, 3 mL) was added 1M NaOH (aq.) (0.6 mL, 0.6 mmol). The reaction solution was heated in a sealed tube with microwave irradiation at 65° C. for 20 min. The reaction was cooled, neutralized with 1M HCl (aq.) (0.6 mL, 0.6 mmol) and concentrated to remove organic solvents. The residue was slurried with H2O and the solids were collected by filtration dissolved into MeOH and purified by preparative HPLC (CH3CH/H2O with an NH4OAc buffer) to yield L-valine, N-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-N-methyl- (155 mg, 0.24 mmol, 85%) as a yellow powder. LCMS: m/e 649 (M−H)−, ret time 2.25 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00725
  • To a stirred solution of acid (50 mg, 0.077 mmol), dimethylamine (2M in THF, 0.80 mL, 0.16 mmol) and triethylamine (0.05 mL) in DMF (1.5 mL) was added HATU (40 mg, 0.10 mmol). The reaction mixture was stirred at rt for I h, diluted with H2O (˜5 mL), acidified with 1M HCl (aq.) (˜0.20 mL) and the precipitate was collected by filtration and flushed with H2O. The solids were dissolved into MeOH and purified by preparative HPLC (CH3CH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[(1S)-1-[(dimethylamino)carbonyl]-2-methylpropyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl- (21 mg, 0.03 mmol, 40%) as a yellow powder. 1HNMR (300 MHz, CDCl3) δ 7.92 (s, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.48 (d, J=8.4 Hz, 1H), 7.51-7.39 (m, 1H), 7.04 (dd, J=2.6, 8.8 Hz, 1H), 6.88 (d, J=2.6 Hz, 1H), 6.78 (s, 1H), 5.14-4.84 (m, 2H), 4.48-4.29 (m, 1H), 3.88 (s, 3H), 3.19 (s, 3H), 3.03 (s, 6H), 2.98 (s, 3H), 2.87-2.57 (m, 4H), 2.38-1.11 (m, 11H), 0.93 (br s, 6H). LCMS: m/e 676 (M−H)−, ret time 3.05 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00726
  • To a stirred solution of acid (50 mg, 0.077 mmol), morpholine (15 mg, 0.15 mmol) and triethylamine (0.05 mL) in DMF (1.5 mL) was added HATU (40 mg, 0.10 mmol). The reaction mixture was stirred at rt for 1 h, diluted with H2O (˜5 mL), acidified with 1M HCl (aq.) (˜0.20 mL) and the precipitate was collected by filtration and flushed with H2O. The solids were dissolved into MeOH and purified by preparative HPLC (CH3CH/H2O with an NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-[(1S)-2-methyl-1-(4-morpholinylcarbonyl)propyl]- (28 mg, 0.04 mmol, 51%) as a yellow powder. 1HNMR (300 MHz, CDCl3) δ 7.91 (s, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.49 (d, J=8.8 Hz, 1H), 7.51-7.38 (m, 1H), 7.04 (dd, J=2.6, 8.8 Hz, 1H), 6.88 (d, J=2.6 Hz, 1H), 6.76 (s, 1H), 5.10-4.83 (m, 2H), 4.46-4.28 (m, 1H), 3.88 (s, 3H), 3.79-3.58 (m, 8H), 3.03 (s, 6H), 2.85-2.62 (m, 4H), 2.40-2.25 (m, 1H), 2.11-1.12 (m, 10H), 1.01-0.80 (m, 6H). LCMS: m/e 718 (M−H)−, ret time 3.05 min, column A, 4 minute gradient.
  • The following HPLC methods and conditions apply to the experimental procedures below until otherwise noted:
  • Method 1: Analysis Conditions: Column: XTERRA 4.6×50 mm S5; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range: 0-100% B; Gradient Time: 3 min; Flow Rate: 4 mL/min; Analysis Time: 4 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+); Fraction Collection: WV-triggered; Fraction Drying.
  • Method 2: Analysis Conditions: Column: PHENOMENEX-LUNA 4.6×50 mm S10; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range:0-100% B; Gradient Time: 2 min; Flow Rate: 4 mL/min; Analysis Time: 3 min; Detection: Detector 1: UV at 254 nm; Detector 2: MS (ESI+); Fraction Collection: UV-triggered; Fraction Drying.
  • Method 3: Analysis Conditions: Column: PHENOMENEX-LUNA 4.6×50 mm s10; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range:0-100%; Gradient Time: 3 min; Flow Rate: 4 mL/min; Analysis Time: 4 min; Detection: Detector 1: UV at 254 run; Detector 2: MS (ESI+); Fraction Collection: UV-triggered; Fraction Drying.
  • Method 4: Analysis Conditions: Column: PHENOMENEX-LUNA 4.6×50 mm s10; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range:0-100% B; Gradient Time: 2 min; Flow Rate: 4 mL/min; Analysis Time: 3 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+); Fraction Collection: UV-triggered; Fraction Drying.
  • Method 5: Analysis Conditions: Column: PHENOMENEX-LUNA 3.0×50 mm S10; Mobile Phase: (A) 10:90 methanol:water; (B) 90:10 methanol:water; Buffer: 0.1% TFA; Gradient Range:0-100% B; Gradient Time: 2 min; Flow Rate: 4 mL/min; Analysis Time: 3 min; Detection: Detector 1: UV at 220 nm; Detector 2: MS (ESI+); Fraction Collection: UV-triggered; Fraction Drying.
    Figure US20070078122A1-20070405-C00727
  • 13-Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-methoxycarbonyl-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: Preparation of Compound 1A. A mixture of 2-bromo-3-cyclohexyl-1H-indole-6-carboxylic acid (1.0 g, 2.34 mmol) and CDI (0.492 g, 3.04 mmol) in THF (10 mL) was heated at 50° C. for 0.5 h, cooled down, added morpholine-4-sulfonamide (0.465 g, 2.8 mmol) and DBU (0.7 mL, 4.67 mmol). The generated brown solution was stirred for overnite. The reaction was worked up by diluting with EtOAc, washed by cold 1N HCl, brine, dried (MgSO4), removed the solvent and purified by Biotage 40+M column [EtOAc/hexane (with 0.1% HOAc): 2% to 60%] to afford the product as a yellow solid (0.99 g, 90%). 1H NMR (400 MHz, MeOD) δ ppm 1.34-1.51 (m, 3 H) 1.70-1.81 (m, 3 H) 1.84-1.98 (m, 4 H) 2.79-2.93 (m, 1 H) 3.36-3.43 (m, 4 H) 3.67-3.74 (m, 4 H) 7.52 (dd, J=8.56, 1.76 Hz, 1 H) 7.73 (d, J=8.31 Hz, 1 H) 7.86 (d, J=1.76 Hz, 1 H). Step 2: Preparation of Compound 1. A mixture of Compound 1A (0.48 g, 1.02 mmol), Pd(PPh3)4 (0.076 g, 0.07 mmol), LiCl (0.129 g, 3.1 mmol) and aqueous Na2CO3 (1N, 3 mL, 3 mmol) in Toluene/EtOH (1/1, 10 mL) was degassed. The mixture was heated at 80° C. under N2 for 3 h. The reaction mixture was cooled down, and removed the organic solvent in vacuo. The residue was acidified to pH 3 with cold 1N HCl, extracted with EtOAc/THF. The extraction was dried (Na2SO4), removed the solvents in vacuo to provide a brown tar. A mixture of Cs2CO3 (1.0 g, 3.06 mmol), methyl 2-(dimethoxyphosphoryl)acrylate (0.277 g, 1.43 mmol) and above product in DMF ( 5 mL) was stirred at 60° C. for 3 h and cooled down. The reaction mixture was acidified to pH 2, and extracted with EtOAc/ CH2Cl2. The extraction was washed with brine, dried (MgSO4), removed the solvents and purified by Biotage 25+M column[EtOAc/ hexane(with 0.1% HOAc): 2% to 55%) to afford a yellow solid. The solid was further purified by prep HPLC to afford compound 1 as a yellow solid (0.465 g, 81%). 1H NMR (400 MHz, MeOD) δ ppm 1.10-1.57 (m, 4 H) 1.77 (s, 2 H) 1.88-2.21 (m, 4 H) 2.80-2.93 (m, 1 H) 3.42-3.50 (m, 4 H) 3.71-3.78 (m, 4 H) 3.84 (s, 3 H) 4.12-4.28 (m, 1 H) 5.60-5.81 (m, 1 H) 7.59 (dd, 5 H) 7.89-7.97 (m, 2 H) 8.19 (s, 1 H), LC-MS (retention time: 3.61; MS m/z 564 M+H, Method 1).
    Figure US20070078122A1-20070405-C00728
  • 13-Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-carboxyl-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: Small amount of MeOH was added to a suspension of Compound 1 (0.46 g, 0.82) dispersed in THF (5 mL) and H2O (2 mL) till no solid in the mixture. LiOH.H2O (0.13 mmol 3.3 mmol)) was added. The mixture was stirred o/n, and removed the organic solvents in vacuo. The residue was acidified to pH 2, extracted with EtOAc/CH2Cl2. the extraction was washed with brine, dried (MgSO4), removed the solvents to afford the compound 2 as a yellow foam (0.441 g, 98%). Analycal sample was further purified by Prep HPLC. 1H NMR (400 MHz, MeOD) δ ppm 1.15-1.58 (m, 4 H) 1.78 (s, 2 H) 1.88-2.20 (m, 4 H) 2.82-2.93(m, 1 H) 3.41-3.50(m, 4 H) 3.70-3.78 (m, 4 H) 4.08-4.27 (m, 1 H) 5.61-5.80 (m, 1 H) 7.49-7.69 (m, 5 H) 7.90-7.96 (m, 2 H) 8.18 (s, 1 H); LC-MS (retention time: 3.54; MS m/z 550 M+H, Method 1).
    Figure US20070078122A1-20070405-C00729
  • 13-Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-[(cis-2,6-dimethylmorpholin-4-yl)carbonyl]piperidin-1-carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: A mixture of compound 2 (0.075 g, 0.16 mmol), triethyl amine (0.057 mL, 0.4 mmol), 2,6-dimethylmorpholine (0.043 g, 0.38 mmol) and TBTU (0.066 g, 0.20 mmol) in DMF (1.5 mL) was stirred for 2 h and purified by prep HPLC to afford compound 3 as a yellow solid (0.0427 g, 42%). LC-MS (retention time: 3.47; MS m/z 647 M+H, Method 1).
    Figure US20070078122A1-20070405-C00730
  • 13-Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-[[(1-(2,2,2-trifloruoethyl)piperazin-4-yl)]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: The trifluoroacetic acid salt of Compound 4 was obtained following the procedure described in preparation of compound 3 (44%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.12-1.59 (m, 4 H) 1.77 (d, J=8.06 Hz, 2 H) 1.86-2.17 (m, 4 H) 2.69 (s, 3 H) 2.77-2.89 (m, 1 H) 3.14 (q, J=9.32 Hz, 2 H) 3.44-3.57 (m, 5 H) 3.62 (s, 3 H) 3.76 (t, J=4.28 Hz, 4 H) 4.15 (s, 2 H) 4.32 (d, J=13.09 Hz, 1 H) 5.25 (s, 1 H) 6.87 (s, 1 H) 7.38-7.44 (m, 1 H) 7.44-7.61 (m, 4 H) 8.22 (s, 1 H); LC-MS (retention time: 3.45; MS m/z 700 M+H, Method 1).
    Figure US20070078122A1-20070405-C00731
  • 13-Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-[[]-(2-acetoxyacetyl)piperazin-4-yl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: 2-Chloro-2-oxoethyl acetate (1.5 mL, 14 mmol) was added to a solution of tert-butyl piperazine-1-carboxylate (2.0 g, 10.7 mmol), triethyl amine (2.2 mL, 16 mmoL) in dichloromethane (30 mL) at 0° C. The reaction mixture was stirred for 1.5 hr at r.t. removed the solvents in vacuo. The residue was taken up with dichloromethane/hexane and washed with cold 1 NHCl (2×), 1 N NaOH (2×), brine, dried (MgSO4), removed the solvents in vacuo to afford the product as a white solid (2.8 g, 91%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.46 (s, 9 H) 3.14-3.63 (m, J=50.11 Hz, 8 H). Step 2: A mixture of tert-butyl 4-(2-acetoxyacetyl)piperazine-1-carboxylate (0.073 g, 0.25 mmol) in trifluoroacetic acid/dichloromethane (1/1, 1.5 mL) was stirred for 0.5 h at r.t. The solvents were removed in vacuo to afford a brown residue. DMF (1.5 mL), Compound 2 (0.070 g, 0.13 mmol), Triethyl amine (0.089 mL 0.64 mmol), and TBTU (0.061 g, 0.19 mmol) were added to the residue. The reaction mixture was stirred for 1 h and purified by prep HPLC to afford compound 5 as a yellow solid (0.0552 g, 60%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.31-1.59 (m, 4 H) 1.68-1.83 (m, 2 H) 1.84-2.13 (m, 4 H) 2.16 (s, 3 H) 2.75-2.88 (m, 1 H) 3.22-3.66 (m, 12 H) 3.73-3.81 (m, 4 H) 4.28-4.41 (m, J=6.55 Hz, 1 H) 4.67 (s, 2 H) 5.06-5.24 (m, 1 H) 6.88 (s, 1 H) 7.40 (d, J=7.05 Hz, 1 H) 7.45-7.55 (m, 3 H) 7.56-7.60 (m, 1 H) 7.91 (d, J=8.56 Hz, 1 H) 8.04 (s, 1 H); LC-MS (method 2, retention time: 2.13; MS m/z 718 M+H, Method 2).
    Figure US20070078122A1-20070405-C00732
  • 13-Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-[[-(hydroxy-acetyl)piperazin-4-yl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: A mixture of Compound 5 (0.047 g, 0.07 mmol) LiOH.H2O (0.040 g, 1 mmol), THF (6 mL) MeOH (3 mL), and H2O (1 mL) was stirred for one day, acidified to pH 2 and extracted with Ethyl acetate/dicholoromethane (2×). The combined extracts were dried (MgSO4), removed the solvents and purified by prep HPLC to afford the compound 6 as a pale yellow foam (0.0347 g, 78%) 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.30-1.61 (m, 4 H) 1.70-1.82 (m, 2 H) 1.89-2.19 (m, 4 H) 2.77-2.87 (m, J=4.78 Hz, 1 H) 2.92-3.25 (m, 6 H) 3.35-3.62 (m, 6 H) 3.68-3.82 (m, 4 H) 4.16 (s, 2 H) 4.28-4.44 (m, 1 H) 5.07-5.23 (m, 1 H) 6.89 (s, 1 H) 7.40 (d, J=7.30 Hz, 1 H) 7.43-7.54 (m, 3 H) 7.56-7.61 (m, 1 H) 7.92 (d, J=8.31 Hz, 1 H) 8.10 (s, 1 H); LC-MS (retention time: 2.85; MS m/z 676 M+H, method 3).
    Figure US20070078122A1-20070405-C00733
  • 13-Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-[[4-(morpholin-4-yl)piperidin-1-yl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: Compound 7 was prepared from compound 2 by following the similar procedure of 3 in making compound 3 (47%). LC-MS (retention time: 2.09; MS m/z 702 M+H, Method 4).
    Figure US20070078122A1-20070405-C00734
  • 13-Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-[(1-acetylpiperazin-4-yl)carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: Compound 8 was prepared from compound 2 by following the similar procedure of Step 1 of Scheme 3 in making Compound 3 (20%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.29-1.56 (m, 4 H) 1.77 (s, 2 H) 1.88-2.13 (m, 4 H) 2.09 (s, 3 H) 2.77-2.88 (m, 1 H) 3.38-3.56 (m, 10 H) 3.60-3.69 (m, 2 H) 3.73-3.81 (m, 4 H) 4.27-4.40 (m, 1 H) 5.05-5.16 (m, 1 H) 6.89 (s, 1 H) 7.37-7.42 (m, 1 H) 7.45-7.61 (m, 4 H) 7.91 (d, J=8.56 Hz, 1 H) 7.99 (s, 1 H); LC-MS (retention time: 3.27, m/e 682 M+Na, Method 1).
    Figure US20070078122A1-20070405-C00735
  • Cyclohexyl-N-[(4-methylpiperazin-1-yl)sulfonyl]-6-(morpholin-4-carbonyl)-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: The trifluoroacetic acid salt of compound 11 was prepared from compound 11B and 11B by following the similar procedure of 10 in making compound 10 (18%). LC-MS (retention time: 3.00; MS m/z 662 M+H, Method 1).
    Figure US20070078122A1-20070405-C00736
  • 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[]-(hydroxy-acetyl)piperazin-4-yl)]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: Preparation of compound 12B. Compound 12B was prepared from compound 12A by following the similar procedure of Step 1 of scheme 3 in making Compound 3 (54%) 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.15-1.62 (m, 4 H) 1.71-1.80 (m, 2 H) 1.81-2.09 (m, 4 H) 2.16 (s, 3 H) 2.74-2.87 (m, 1 H) 3.03 (s, 6 H) 3.24-3.74 (m, 8 H) 3.90 (s, 3 H) 4.23-4.38 (m, 1 H) 4.67 (s, 2 H) 5.13-5.33 (m, 1 H) 6.79 (s, 1 H) 6.89 (d, J=2.77 Hz, 1 H) 7.05 (dd, J=8.69, 2.64 Hz, 1 H) 7.49 (d, J=8.81 Hz, 1 H) 7.54 (dd, J=8.44, 1.39 Hz, 1 H) 7.87 (d, J=8.56 Hz, 1 H) 8.18 (s, 1 H). Step 2: Preparation of compound 12. A mixture of compound 12B (0.061 g, 0.09 mmol) and aqueous NaOH (1N 0.5 mL, 0.5 mmol)n and a few drops of MeOH was stirred at r.t. for 3 h. removed the organic solvent and the residue was partitioned between aqueous NaH2PO4 and EtOAc/THF. The organic solvent was washed with brine and dried (MgSO4), removed the solvent and purified by prep HPLC to afford compound 12. (1H NMR (400 MHz, MeOD) δ ppm 1.13-1.53 (m, 4 H) 1.69-1.81 (m, 2 H) 1.86-2.21 (m, 4 H) 2.79-2.89 (m, 1 H) 2.98 (s, 6 H) 3.31-3.64 (m, 8 H) 3.89 (s, 3 H) 4.18 (s, 2 H) 4.29 (s, 1 H) 5.03-5.20 (m, 1 H) 6.96 (s, 1 H) 7.06 (d, J=2.52 Hz, 1 H) 7.12 (dd, J=8.56, 2.77 Hz, 1 H) 7.47-7.57 (m, 2 H) 7.87 (d, J=8.56 Hz, 1 H) 8.07 (s, 1 H).
    Figure US20070078122A1-20070405-C00737
  • Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-[[]-(2,2,2-trifluoroethyl)piperazin-4-yl]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: Preparation of compound 13A. A mixture of 2-formyl-4-methoxylphenylboronic acid (0.264 g, 1.18 mmol), 2-bromo-3-cyclohexyl-N-(4-morpholin-4-yl)sulfonyl)-1H-indole-6-carboxamide (0.53 g, 1.13 mmol), Pd(PPh3)4 (0.078 g, 0.07mmol), LiCl (0.129 g, 3.1 mmol) and aq. Na2CO3 (1N, 3 mL, 3 mmol) in Toluene/EtOH (1/1, 10 mL) was degassed, filled with N2 and heated at 80° C. for 3 h. The reaction mixture was cooled down, and added saturated NaH2PO4, extracted with EtOAc. the extraction was dried (Na2SO4), removed the solvent in vacuo to provide a brown tar residue. The residue was dissolved in minimum amount of CH2Cl2 and hexane was added till no solid coming out, filtered to provide a yellow solid. A mixture of above solid, Cs2CO3 (1.1 g, 3.38 mmol), and methyl 2-(dimethoxyphosphoryl)acrylate (0.77 g, 1.43 mmol) in DMF ( 5 mL) was stirred at 60° C. for 3 h. The reaction mixture was cooled down and acidified to pH 2, extracted with EtOAc/CH2Cl2. The extraction was washed with brine, dried (MgSO4), removed the solvent and purified by Biotage 40+M column[MeOH/dichloromethane: 0% to 20%) to afford compound 13A as a yellow solid. LC-MS (retention time: 3.53; MS m/z 594 M+H, Method 1). Step 2: Preparation of compound 13B. Compound 13B was prepared from Compound 13A by following the similar procedure of step 1 of Scheme 2 in making Compound 2 (100%) LC-MS (retention time: 3.50; MS m/z 580 M+H, Method 1). Step 3: Preparation of compound 13. Compound 13 was prepared from compound 13B by following the similar procedure of Step 1 of Scheme 3 in making compound 3 (100%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.13-1.61 (m, 4 H) 1.70-1.83 (m, 2 H) 1.85-2.22 (m, 4 H) 2.75-2.88 (m, 1 H) 2.91-3.25 (m, 4 H) 3.40-3.65 (m, 6 H) 3.67-4.05 (m, 8 H) 3.91 (s, 3 H) 4.32 (d, J=14.35 Hz, 1 H) 5.38 (d, J=13.60 Hz, 1 H) 6.86 (s, 1 H) 6.91 (d, J=2.52 Hz, 1 H) 7.08 (dd, J=8.69, 2.64 Hz, 1 H) 7.51 (d, J=8.56 Hz, 1 H) 7.57 (dd, J=8.44, 1.13 Hz, 1 H) 7.92 (d, J=8.56 Hz, 1 H) 8.30 (s, 1 H); LC-MS (retention time: 3.46; MS m/z 730 M+H, Method 1).
    Figure US20070078122A1-20070405-C00738
  • Cyclohexyl-N-[(morpholin-4-yl)sulfonyl]-6-[(morpholin-4-yl)carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. Step 1: compound 14 was prepared from compound 11B by following the similar procedure of Step 1 of Scheme 10 in making compound 10 (16%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.14-1.57 (m, 4 H) 1.76 (d, J=7.30 Hz, 2 H) 1.86-2.12 (m, 4 H) 2.74-2.87 (m, 1 H) 3.30-3.67 (m, 12 H) 3.73-3.81 (m, 4 H) 3.90 (s, 3 H) 4.23-4.42 (m, 1 H) 5.07-5.27 (m, 1 H) 6.80 (s, 1 H) 6.89 (d, J=2.52 Hz, 1 H) 7.06 (dd, J=8.69, 2.64 Hz, 1 H) 7.49 (d, J=8.56 Hz, 1 H) 7.55-7.67 (m, 1 H) 7.88 (d, J=8.31 Hz, 1 H) 8.17 (s, 1 H). LC-MS (retention time: 3.29; MS m/z 649 M+H, Method 1).
    Figure US20070078122A1-20070405-C00739
  • 13-Cyclohexyl-N-[(4-methoxyphenyl)sulfonyl]-6[(morpholin-4-yl)-carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamid. Step 1: Compound 19 was prepared from compound 19A and compound 19B by following the similar procedure of Step 1 of scheme 10 in making compound 10 (45%). 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.07-1.61 (m, 5 H) 1.67-2.07 (m, 5 H) 2.74-2.90 (m, 1 H) 3.34-3.71 (m, 8 H) 3.86 (s, 3 H) 4.22-4.52 (m, 1 H) 5.07-5.31 (m, 1 H) 6.87 (s, 1 H) 6.98 (s, 1 H) 7.00 (s, 1 H) 7.35-7.41 (m, 1 H) 7.43-7.52 (m, 3 H) 7.53-7.60 (m, 1 H) 7.85 (d, J=8.31 Hz, 1 H) 8.05-8.16 (m, 3 H) LC-MS (retention time: 3.44; MS m/z 640 M+H, Method 1).
  • A general procedure for the preparation of amides from carboxylic acids. A mixture of carboxylic acid (1 equiv), corresponding amine (R1R2NH, 1.2 equiv), triethylamine (2-3 equiv) and TBTU (1.3 equiv) in an. DMF was stirred at rt for 1-2 h until completion of the amide coupling. After aqueous workup isolated crude product was purified by prep. HPLC and analyzed according to the method listed.
    Figure US20070078122A1-20070405-C00740
  • 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[4-[(dimethylamino)carbonyl]piperidin-1-carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. LC/MS: Retention time: 1.937 min; m/e 646 (MH+, method 5).
    Figure US20070078122A1-20070405-C00741
  • 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[4-[(dimethylamino)carbonyl]piperidin-1-carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. LC/MS: Retention time: 1.947 min; m/e 676 (MH+, method 5); 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.14-1.68 (m, 6 H) 1.68-1.81 (m, 2 H) 1.84-2.15 (m, 4 H) 2.60-2.89 (m, 4 H) 2.94 (s, 3 H) 3.03 (s, 3 H) 3.05 (s, 6 H) 3.90 (s, 3 H) 4.27-4.59 (m, 5 H) 5.00-5.15 (m, 1 H) 6.81 (s, 1 H) 6.91 (d, J=2.27 Hz, 1 H) 7.05 (dd, J=8.69, 2.64 Hz, 1 H) 7.44-7.52 (m, 2 H) 7.87 (d, J=8.56 Hz, 1 H) 7.98 (s, 1 H).
    Figure US20070078122A1-20070405-C00742
  • 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[4-[(morpholin-4-yl)carbonyl]piperidin-1-carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. LC/MS: Retention time: 1.953 min; m/e 718 (MH+, method 5); 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.10-1.64 (m, 6 H) 1.75 (s, 2 H) 1.85-2.13 (m, 5 H) 2.51-2.88(m, 3H) 2.88-3.17 (m, 10H) 3.38-3.49 (m, 2H) 3.51-3.77 (m, 6H) 3.90 (s, 3 H) 4.34-4.46 (m, 1 H) 4.96-5.12 (m, 1 H) 6.76 (s, 1 H) 6.90 (d, J=2.77 Hz, 1 H) 7.05 (dd, J=8.69, 2.64 Hz, 1 H) 7.44 (dd, J=8.44, 1.38 Hz, 1 H) 7.48 (d, J=8.56 Hz, 1 H) 7.87 (d, J=8.56 Hz, 1 H) 7.93 (s, 1 H).
    Figure US20070078122A1-20070405-C00743
  • 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-6-(1-methyl-2-oxo-piperazin-4-carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. LS/MS: Retention time: 1.890 min; m/e 604 (MH+, method 5); 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.13-1.27 (m, 1 H) 1.30-1.47 (m, 2 H) 1.48-1.60 (m, 1 H) 1.76 (d, J=9.06 Hz, 2 H) 1.87-2.13 (m, 4 H) 2.77-2.91 (m, 1 H) 3.02 (s, 3 H) 3.04 (s, 6 H) 3.07-3.44 (m, 2 H) 3.60-3.74 (m, 1 H) 3.84-4.00 (m, 1 H) 4.29 (d, J=2.52 Hz, 2 H) 4.36-4.49 (m, 1 H) 5.20-5.36 (m, 1 H) 6.96 (s, 1 H) 7.41-7.61 (m, 5 H) 7.91 (d, J=8.56 Hz, 1 H) 8.19 (s, 1 H).
    Figure US20070078122A1-20070405-C00744
  • 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-6-(1-methyl-2-oxo-piperazin-4-carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. LS/MS: Retention time: 1.920 min; m/e 634 (MH+, method 5); 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.12-1.64 (m, 5 H) 1.68-2.12 (m, 5 H) 2.76-2.85 (m, 1 H) 2.99 (s, 3 H) 3.05 (s, 6 H) 3.29-3.38 (m, 2 H) 3.67-3.87 (m, 2 H) 3.90 (s, 3 H) 4.12-4.40 (m, 3 H) 5.12-5.25 (m, 1 H) 6.92 (s, 2 H) 7.07 (dd, J=8.56,2.52 Hz, 1 H) 7.45-7.52 (m, 2 H) 7.88 (d, J=8.56 Hz, 1 H) 8.08 (s, 1 H) 9.26 (s, 1 H).
    Figure US20070078122A1-20070405-C00745
  • 13-Cyclohexyl-N-[(4-methylpiperazin-1-yl)sulfonyl]-6-[4-[(dimethylamino)carbonyl]piperidin-1-carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. LS/MS: Retention time: 1.743 min; m/e 731 (MH+, method 5); 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.12-1.62 (m, 7 H) 1.75 (s, 3 H) 2.08 (s, 5 H) 2.83 (s, 3 H) 2.87-3.38 (m, 5 H) 2.90 (s, 3 H) 2.99 (s, 3 H) 3.42-3.75 (m, 6 H) 3.90 (s, 3 H) 4.15 (s, 2 H) 4.40 (s, 1 H) 5.00-5.12 (m, 1 H) 6.75 (s, 1 H) 6.89 (d, J=2.27 Hz, 1 H) 7.05 (dd, J=8.56, 2.52 Hz, 1 H) 7.40-7.52 (m, 2 H) 7.86 (d, J=8.31 Hz, 1 H) 7.94 (s, 1 H).
    Figure US20070078122A1-20070405-C00746
  • 13-Cyclohexyl-N-[(4-methylpiperazin-1-yl)sulfonyl]-6-(2,6-dimethylmorpholin-4-carbonyl)-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. LS/MS: Retention time: 1.817 min; m/e 690 (MH+, method 5); 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.95-1.55 (m, 11 H) 1.70-1.81 (m, 2 H) 1.85-2.10 (m, 3 H) 2.42-3.21 (m, 11 H) 3.37-3.78 (m, 5 H) 3.90 (s, 3 H) 4.09 (s, 2 H) 4.23-4.40 (m, 1 H) 5.00-5.17 (m, 1 H) 6.78 (s, 1 H) 6.89 (d, J=2.27 Hz, 1 H) 7.06 (dd, J=8.81, 2.52 Hz, 1 H) 7.46-7.54 (m, 2 H) 7.87 (d, J=8.56 Hz, 1 H) 8.07 (s, 1 H).
  • The following general conditions for HPLC pertain to the following experimental procedures until otherwise noted: LC retention times refer to a Phenomenex-Luna 3.0×50 mm S10 column w/gradient elution (A: 10% MeOH-90% H2O-0.1% TFA, B: 90% MeOH-10% H2O-0.1% TFA; 0% B to 100% B over 2 min), 5 uL injection, w/ flow rate of 4 mL/min.
    Figure US20070078122A1-20070405-C00747
  • N-(1H-benzimidazol-2-ylmethyl)-13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. To a stirred solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (134 mg, 0.24 mmol) in DMF (500 μL) were added 2-aminomethyl benzimidazole dihydrochloride hydrate (75 mg, 0.32 mmol), N,N-diisopropylethylamine (165 μL, 0.95 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (60 mg, 0.31 mmol), and 1-hydroxybenzotriazole (44 mg, 0.33 mmol). The suspension was allowed to stir at r.t. for 4 hr, at which point the solvent was removed under reduced pressure. CH2Cl2 (5 mL) was added, and the suspension filtered through Celite, and chromatographed on silica gel (gradient elution: 0%→10% MeOH in CH2Cl2) to afford the title compound as a pale yellow solid (24 mg, 14% yield). LC/MS (ESI) retention time: 1.57 min, m/z 683 (MH+); 1H NMR (400 MHz, CDCl3) δ 1.07-1.53 (m, 4 H) 1.63-1.78 (m, 3 H) 1.99 (s, 4 H) 2.25 (t, J=11.08 Hz, 1 H) 2.39 (s, 4 H) 2.59-2.87 (m, 3 H) 3.63 (s, 4 H) 4.14 (s, 1 H) 4.73-5.00 (m, 3 H) 6.78 (s, 1 H) 7.17 (ddd, J=9.63, 3.90, 3.59 Hz, 2 H) 7.34 (dd, J=7.05, 1.76 Hz, 1 H) 7.40-7.47 (m, 2 H) 7.50-7.58 (m, 4 H) 7.73 (d, J=8.31 Hz, 1 H) 8.16 (s, 1 H) 8.68 (s, 1 H).
    Figure US20070078122A1-20070405-C00748
  • 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-N-(1H-tetrazol-5-ylmethyl)-7H-indolo[2,1-a][2}benzazepine-10-carboxamide. To a stirred solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (135 mg, 0.24 mmol) in CH2Cl2 (1 mL) were added N,N-diisopropylethylamine (170 μL, 0.98 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (64 mg, 0.33 mmol), 1-hydroxybenzotriazole (47 mg, 0.35 mmol), and 5-(aminomethyl)tetrazole (33 mg, 0.33 mmol). The suspension was allowed to stir at r.t. for 23 hr, filtered through Celite, and chromatographed on silica gel (gradient elution: 0%→30% MeOH in CH2Cl2) to afford the title compound as a yellow solid (70 mg, 46% yield). LC/MS (ESI) retention time: 1.61 min, m/z 635 (MH+); 1H NMR (400 MHz, CD3OD) δ 1.08-1.23 (m, 1 H) 1.35-1.48 (m, 4 H) 1.66 -1.79 (m, 3 H) 1.86 -1.92 (m, 1 H) 1.96 -2.14 (m, 3 H) 2.44-2.60 (m, 5 H) 2.74 -2.89 (m, 2 H) 3.16 (dd, J=7.55 Hz, 1 H) 3.57 -3.73 (m, 5 H) 4.25 (s, 1 H) 4.94-5.08 (m, 1 H) 6.87 (s, 1 H) 7.43-7.51 (m, 3 H) 7.52-7.59 (m, 2 H) 7.83 (d, J=8.56 Hz, 1 H) 8.11 (s, 1 H).
    Figure US20070078122A1-20070405-C00749
  • 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-N-(2-pyridinylmethyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. To a stirred solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1 -piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (70 mg, 0.13 mmol) in CH2Cl2 (1 mL) were added N,N-diisopropylethylamine (85 μL, 0.49 mmol), 2-(aminomethyl)pyridine (17 mg, 0.16 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (34 mg, 0.18 mmol), and 1 -hydroxybenzotriazole (24 mg, 0.18 mmol). The suspension was allowed to stir at r.t. for 22 hr, filtered through Celite, and chromatographed on silica gel (gradient elution: 0%→15% MeOH in CH2Cl2) to afford the title compound as a yellow solid (43 mg, 51% yield). LC/MS (ESI) retention time: 1.57 min, m/z 643 (MH+); 1H NMR (400 MHz, CDCl3) δ 1.15-1.27 (m, 3 H) 1.29-1.45 (m, 3 H) 1.48-1.58 (m, 1 H) 1.61-1.70 (m, 1 H) 1.71-1.81 (m, 2 H) 1.86-1.97 (m, 1 H) 1.98-2.15 (m, 3 H) 2.27 (t, J=11.08 Hz, 1 H) 2.38 (s, 4 H) 2.60-2.77 (m, 2 H) 2.78-2.89 (m, 1 H) 3.61 (s, 4 H) 4.40 (s, 1 H) 4.79 (d, J=4.53 Hz, 2 H) 5.09 (s, 1 H) 6.81 (s, 1 H) 7.18-7.22 (m, 1 H) 7.36 (t, J=8.18 Hz, 2 H) 7.41-7.49 (m, 2 H) 7.50-7.59 (m, 2 H) 7.62-7.73 (m, 2 H) 7.89 (d, J=8.56 Hz, 1 H) 8.05 (s, 1 H) 8.56 (d, J=4.53 Hz, 1 H).
    Figure US20070078122A1-20070405-C00750
  • 13-cyclohexyl-N-(imidazo[1,2-a]pyridin-2-ylmethyl)-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. To a stirred solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (70 mg, 0.13 mmol) in CH2Cl2 (1 mL) were added N,N-diisopropylethylamine (85 μL, 0.49 mmol), 2-aminomethylimidazo[1,2-a]pyridine dihydrochloride (36 mg, 0.16 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (34 mg, 0. 18 mmol), and 1-hydroxybenzotriazole (24 mg, 0.18 mmol). The suspension was allowed to stir at r.t. for 17 hr, and the solvent was removed under reduced pressure. The resulting solid was suspended in DMF (1 mL) and stirred for an additional 4 hr before being concentrated under reduced pressure, dissolved in CH2Cl2, filtered through Celite, and chromatographed on silica gel (gradient elution: 0%→20% MeOH in CH2Cl2) to afford the title compound as a yellow solid (22 mg, 35% yield). LC/MS (ESI) retention time: 1.53 min, m/z 683 (MH+); 1H NMR (400 MHz, CDCl3) δ 1.13-1.21 (m, 1 H) 1.29-1.45 (m, 4 H) 1.57-1.67 (m, 1 H) 1.69-1.79 (m,2 H) 1.84-1.95 (m, 1 H) 1.96-2.12 (m, 3 H) 2.30-2.31 (m, 4 H) 2.57-2.75 (m, 2 H) 2.80-2.81 (m, 1 H) 3.60 (s, 4 H) 4.36 (s, 1 H) 4.80 (s, 2 H) 5.06 (s, 1 H) 6.74 (t, J=6.42 Hz, 1 H) 6.79 (s, 1 H) 7.07-7.18 (m, 1 H) 7.32-7.37 (m, 2 H) 7.39-7.46 (m, 2 H) 7.47-7.56 (m, 3 H) 7.60 (s, 1 H) 7.84 (d, J=8.56 Hz, 1 H) 7.99-8.10 (m, 2 H).
    Figure US20070078122A1-20070405-C00751
  • 13-cyclohexyl-N-[(5-methylpyrazinyl)methyl]-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. A solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (40 mg, 0.07 mmol), 2-(aminomethyl)-5-methylpyrazine (12 mg, 0.1 mmol), N,N-diisopropylethylamine (60 μL, 0.34 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (19 mg, 0.1 mmol), and 1-hydroxybenzotriazole (14 mg, 0.1 mmol) in CH2Cl2 (1.5 mL) was stirred at r.t. for 20 h, at which point it was introduced directly to silica gel and chromatographed (gradient elution: 0%→10% MeOH in CH2Cl2) to afford a yellow foam, which was triturated with Et2O and dried to give the title compound as a pale yellow solid (43 mg, 90% yield). LC/MS (ESI) retention time: 1.69 min, m/z 659 (MH+); 1H NMR (400 MHz, CDCl3) δ 1.28-1.44 (m, 3 H) 1.46-1.59 (m, 1 H) 1.61-1.70 (m, 1 H) 1.71-1.81 (m, 2 H) 1.85-1.96 (m, 1 H) 1.97-2.13 (m, 3 H) 2.29 (t, J=10.45 Hz, 1 H) 2.35-2.46 (m, 4 H) 2.55 (s, 3 H) 2.61-2.77 (m, 2 H) 2.77-2.89 (m, 2 H) 3.62 (s, 4 H) 4.38 (s, 1 H) 4.78 (d, J=5.04 Hz, 2 H) 5.00-5.18 (m, 1 H) 6.81 (s, 1 H) 7.32-7.40 (m, 2 H) 7.40-7.50 (m, 3 H) 7.51-7.59 (m, 1 H) 7.88 (d, J=8.56 Hz, 1 H) 8.01 (s, 1 H) 8.39 (s, 1 H) 8.56 (d, J=1.01 Hz, 1 H); 13C NMR (101 MHz, CDCl3) δ 21.18, 26.21, 27.03, 28.08, 33.26, 36.73, 41.91, 42.60, 49.52, 61.59, 67.07, 108.98, 116.90, 120.03, 121.21, 126.98, 127.94, 128.21, 129.27, 130.96, 131.23, 133.27, 134.01, 135.18, 135.25, 136.39, 142.94, 143.40, 149.41, 152.50, 168.10, 168.87.
    Figure US20070078122A1-20070405-C00752
  • 13-cyclohexyl-N-(2-furanylmethyl)-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. A solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (40 mg, 0.07 mmol), N,N-diisopropylethylamine (60 μL, 0.34 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (19 mg, 0.1 mmol), 1-hydroxybenzotriazole (14 mg, 0.1 mmol), and furfuryl amine (10 mg, 0.1 mmol) in CH2Cl2 (1.5 mL) was stirred at r.t. overnight, diluted with CH2Cl2 (3 mL), and chromatographed on silica gel (gradient elution: 0%→10% MeOH in CH2Cl2) to afford a yellow oil. Et2O (5 mL) was added to dissolve the oil, and concentration afforded the title compound as a pale yellow solid (42 mg, 95% yield). LC/MS (ESI) retention time: 1.74 min, m/z 633 (MH+); 1H NMR (400 MHz, CDCl3 ) δ 1.29-1.44 (m, 3 H) 1.46-1.57 (m, 1 H) 1.69-1.81 (m,3 H) 1.86-1.97 (m, 1 H) 1.98-2.11 (m, 3 H) 2.27-2.37 (m, 1 H) 2.38-2.49 (m, 4 H) 2.61-2.78 (m, 2 H) 2.78-2.89 (m, 1 H) 3.66 (s, 4 H) 4.38 (s, 1 H) 4.66 (d, J=5.29 Hz, 2 H) 5.06 (s, 1 H) 6.22-6.41 (m, 2 H) 6.64 (t, J=5.04 Hz, 1 H) 6.81 (s, 1 H) 7.33-7.50 (m, 5 H) 7.51-7.61 (m, 1 H) 7.85 (d, J=8.31 Hz, 1 H) 7.97 (s, 1 H); 13C NMR (101 MHz, CDCl3) δ 26.20, 27.02, 33.27, 36.73, 37.04, 41.92, 49.45, 61.67, 66.94, 107.54, 108.90, 110.48, 116.84, 120.05, 121.19, 127.05, 127.95, 128.21, 129.24, 130.08, 130.96, 131.24, 133.24, 134.00, 135.18, 136.39, 142.15, 151.57, 167.74, 168.88.
    Figure US20070078122A1-20070405-C00753
  • 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-N-[[(2R)-tetrahydro-2-furanyl]methyl]-7H-indolo[2,1-a][2}benzazepine-10-carboxamide. A solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (40 mg, 0.07 mmol), N,N-diisopropylethylamine (60 μL, 0.34 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (19 mg, 0.1 mmol), 1-hydroxybenzotriazole (14 mg, 0.1 mmol), and (R)-(−)-tetrahydrofurfurylamine (10 mg, 0.1 mmol) in CH2Cl2 (1.5 mL) was stirred at r.t. overnight, diluted with CH2Cl2 (5 mL), and chromatographed on silica gel (gradient elution: 0%→10% MeOH in CH2Cl2) to afford a yellow oil. Et2O (5 mL) was added to dissolve the oil, and concentration afforded the title compound as an off-white solid (32 mg, 72% yield). LC/MS (ESI) retention time: 1.75 min, m/z 637 (MH+); 1H NMR (400 MHz, CDCl) 8 1.31-1.44 (m, 3 H) 1.48-1.57 (m, 1 H) 1.58-1.69 (m, 2 H) 1.72-1.80 (m, 2 H) 1.87-1.96 (m, 3 H) 1.98-2.11 (m, 4 H)2.25-2.36 (m, 1 H) 2.42 (s, 3 H) 2.62-2.78 (m, 1 H) 2.78-2.89 (m, 1 H) 3.39 (ddd, J=12.53, 6.20 Hz, 1 H) 3.66 (s, 4 H) 3.74-3.85 (m, 2 H) 3.86-3.95 (m, 1 H) 4.40 (s, 1 H) 5.07 (s, 1 H) 6.60 (t, J=5.29 Hz, 1 H) 6.82 (s, 1 H) 7.34- 7.50 (m, 4 H) 7.52-7.59 (m, 1 H) 7.86 (d, J=8.56 Hz, 1 H) 7.97 (s, 1 H).
    Figure US20070078122A1-20070405-C00754
  • 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-N-[[(2S)-tetrahydro-2-furanyl]methyl-7H-indolo[2,1-a[2]benzazepine-10-carboxamide. A solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (40 mg, 0.07 mmol), N,N-diisopropylethylamine (60 μL, 0.34 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (19 mg, 0.1 mmol), 1-hydroxybenzotriazole (14 mg, 0.1 mmol), and (S)-(+)-tetrahydrofurfurylamine (10 mg, 0.1 mmol) in CH2Cl2 (1.5 mL) was stirred at r.t. overnight, diluted with CH2Cl2 (5 mL), and chromatographed on silica gel (gradient elution: 0%→10% MeOH in CH2Cl2) to afford a yellow oil. Et2O (5 mL) was added to dissolve the oil, and concentration afforded the title compound as an off-white solid (32 mg, 72% yield). LC/MS (ESI) retention time: 1.73 min, m/z 637 (MH+); 1H NMR (400 MHz, CDCl3) δ 1.27-1.43 (m, 3 H) 1.47-1.57 (m, 1 H) 1.58-1.70 (m, 2 H) 1.70-1.81 (m, 2 H) 1.86-1.97 (m, 3 H) 1.98-2.12 (m, 4 H) 2.25-2.35 (m, 1 H) 2.42 (s, 3 H) 2.63-2.77 (m, 1 H) 2.78-2.89 (m, 1 H) 3.29-3.46 (m, 1 H) 3.65 (s, 4 H) 3.74-3.85 (m, 2 H) 3.85-3.98 (m, 1 H) 4.09 (ddd, J=14.16, 7.11, 3.40 Hz, 1 H) 4.39 (s, 1 H) 5.08 (s, 1 H) 6.67-6.75 (m, 1 H) 6.82 (s, 1 H) 7.34-7.39 (m, 1 H) 7.40-7.50 (m, 3 H) 7.52-7.59 (m, 1 H) 7.86 (d, J=8.56 Hz, 1 H) 7.99 (s, 1 H).
    Figure US20070078122A1-20070405-C00755
  • 13-cyclohexyl-N-[2-(dimethylamino)-2-oxoethyl]-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. To a stirred solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (40 mg, 0.07 mmol) in CH2Cl2 (1.5 mL) were added N,N-diisopropylethylamine (60 μL, 0.34 mmol), 2-amino-N,N-dimethylacetamide monoacetate (16 mg, 0.1 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (19 mg, 0.1 mmol), and 1-hydroxybenzotriazole (14 mg, 0.1 mmol). The suspension was allowed to stir at r.t. for 2 days, then diluted with CH2Cl2, filtered through Celite, and chromatographed on silica gel (gradient elution: 0%→10% MeOH in CH2Cl2) to give the title compound as a yellow solid (22 mg, 48% yield). LC/MS (ESI) retention time: 1.66 min, m/z 638 (MH+); 1H NMR (400 MHz, CDCl3) δ 1.29-1.43 (m, 2 H) 1.47-1.59 (m, 1 H) 1.71-1.80 (m, 2 H) 1.87-1.96 (m, 1 H) 2.34-2.35 (m, 1 H) 2.40-2.51 (m, 3 H) 2.60-2.76 (m, 2 H) 2.77-2.89 (m, 1 H) 3.02 (s, 3 H) 3.04 (s, 3 H) 3.66 (s, 4 H) 4.25 (d, J=3.78 Hz, 2 H) 4.39 (s, 1 H) 5.07-5.08 (m, 1 H) 6.61 (s, 1 H) 6.81 (s, 1 H) 7.33-7.49 (m, 5 H) 7.51-7.59 (m, 1 H) 7.86 (d, J=8.56 Hz, 1 H) 8.02 (s, 1 H).
    Figure US20070078122A1-20070405-C00756
  • N-[2-(]H-benzimidazol-2-yl)ethyl]-13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. A solution of 13-cyclohexyl-6-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid (47 mg, 0.085 mmol), N,N-diisopropylethylamine (60 μL, 0.34 mmol), 2-(2-aminoethyl)benzimidazole dihydrochloride (23 mg, 0.1 mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (23 mg, 0.12 mmol), and 1-hydroxybenzotriazole (16 mg, 0.12 mmol) in CH2Cl2 (3.1 mL) was stirred at r.t. overnight, then introduced directly to silica gel. Elution (gradient: 0%→5% MeOH in CH2C12) gave the title compound as a yellow powder (20 mg, 34% yield). LC/MS (ESI) retention time: 1.57 min, m/z 697 (MH+); 1H NMR (400 MHz, CDCl3) δ 1.09-1.21 (m, 1 H) 1.22-1.37 (m, 3 H) 1.38-1.48 (m, 1 H) 1.58-1.68 (m, 1 H) 1.69-1.76 (m, 2 H) 1.87 (t, 1 H) 1.97 (t, 2 H) 2.27 (t, J=10.95 Hz, 1 H) 2.39 (s, 3 H) 2.61-2.72 (m, 1 H) 2.72-2.82 (m, 1 H) 3.26 (t, J=6.04 Hz, 2 H) 3.61-3.70 (m, 4 H) 3.98 (s, 2 H) 4.18 (s, 1 H) 4.86 (s, 1 H) 6.80 (s, 1 H) 7.13 (dd, J=6.04, 3.27 Hz, 2 H) 7.33-7.38 (m, 2 H) 7.40-7.46 (m, 2 H) 7.46-7.53 (m, 3 H) 7.73 (d, J=8.56 Hz, 1 H) 7.77-7.85 (m, 1 H) 8.04 (s, 1 H).
    Figure US20070078122A1-20070405-C00757
  • To 0.05 mmol of 1 in 1.0 mL of anhydrous N,N-Dimethylformamide (DMF) in a 3 dram vial equipped with a teflon lined screw cap was added 0.15 mmol (3 eq.) of 2-(1H-Benzotriazole-1-yl)-1,1,3,3,-Tetramethyluronium Tetrafluoroborate (TBTU) in 1.0 mL of anhydrous DMF followed by the addition of 0.1 mmol (2 eq.) of amine 2 in 1.0 mL of anhydrous DMF and 0.1 mmol (2 eq.) of triethylamine (neat). The reaction was shaken on an Innova 2000 orbital shaker at 240 rpm overnight, at room temperature. The reaction volume was then reduced to a total volume of 2.0 mL in a Savant Speedvac and the crude product was purified using a Shimadzu preparative HPLC employing acetonitrile/water and 10 mM trifluoroacetic acid buffer with a Waters Sunfire, C18, 19 mm×100 mm, 5 μm column at a focused gradient of 50-100% B (B=90% acetonitrile/HPLC water, 0.1% TFA) and a flow rate of 25 mL/min. Postpurification LC/MS data was obtained on a Shimadzu analytical LC/Micromass Platform LC (ESI+) at 220 nm using the following set of conditions: Phenomenex 10 μm C18, 4.6×30mm column, with a gradient of 0-100% B (B=90% HPLC grade methanol/0.1% trifluoroacetic acid/10% HPLC grade water), (A=90% HPLC grade water /0.1% trifluoroacetic acid/10% HPLC grade methanol), in 2 minutes with a 1 minute hold at a rate of 5 mL/minute.
    Figure US20070078122A1-20070405-C00758
  • 6-(((3S,5R)-4-Acetyl-3,5-dimethylpiperazin-1-yl)carbonyl)-13-cyclohexyl-N-((dimethylamino)sulfonyl)-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: δ (500 MHz, CDCl3) δ ppm 0.80 (m, 1H), 1.15 (m, 4 H), 1.39 (m, 4 H), 1.79 (m, 3 H), 1.99 (m, 3 H), 2.06 (s, 3 H), 2.82 (m, 4 H), 3.04 (s, 6 H), 3.17 (m, 1 H), 3.90 (s, 3 H), 4.14 (m, 2 H), 4.38 (m, 1 H) 5.19 (m, 1 H), 6.89 (m, 2 H), 7.07 (dd, J=8.78, 2.74 Hz, 1 H), 7.46-7.54 (m, 2 H), 7.87 (d, J=8.78 Hz, 1 H), 8.09 (s, 1 H), 9.28 (br s, 1 H). LC/MS: m/z 676.26, Rf 2.04 min., 97.3% purity.
    Figure US20070078122A1-20070405-C00759
  • 1-((2S,6R)-2,6-Dimethylpiperazin-1-yl)ethanone. To 1.0 g (4.67 mmol) of commercially available (3S,5R)-tert-butyl 3,5-dimethylpiperazine-1-carboxylate was added 5 mL of dry dichloroethane in a 100 mL round bottom flask equipped with a loose fitting septa. To this mixture was added 2.0 equivalents (9.33 mmol, 1.63 mL) of redistilled N,N-diisopropylethylamine and the flask was cooled to 0° C. To this solution was added 2.0 equivalents (9.33 mmol, 663.0 μL) of acetyl chloride portionwise. The ice bath was then removed and the solution was stirred at room temperature overnight. The crude product was taken up in a separatory funnel, washed with 5 mL of a saturated sodium bicarbonate solution, 5 mL of a brine solution and dried over magnesium sulfate. Evacuation of solvent gave a quantitative yield (1.2 g) of 1, (3S,5R)-tert-butyl 4-acetyl-3,5-dimethylpiperazine-1-carboxylate, as brown oily solid. LC/MS: m/z 257.25, Rf 1.35 min., 90.0% purity. To 75 mgs (0.29 mmmol) of 1 was added 2 mL of 1:1 solution of dichloroethane and trifluoroacetic acid in a 25 mL round bottom flask equipped with a loose fitting septa. The solution was stirred for about 1 hour at room temperature then evacuated to near dryness on a rotary evaporator to give a brown oil. The resulting oil was triturated with diethyl ether to give 65 mg (82% yield) of 2, 1-((2S,6R)-2,6-dimethylpiperazin-1-yl)ethanone, as a tan amorphous solid. 1H NMR (300 MHz, Tetrahydrofurn-d8): δ ppm 1.40 (d, J=7.32 Hz, 6 H), 2.07 (s, 3 H), 3.13 (dd, J=12.99, 5.31 Hz, 2 H), 3.28-3.38 (m, 2 H), 4.56 (br s, 1 H).
    Figure US20070078122A1-20070405-C00760
  • 6-((2-(Acetamidomethyl)morpholin-4-yl)carbonyl)-13-cyclohexyl-N-((dimethylamino)sulfonyl)-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (500 MHz, MeOD) δ ppm 1.21 (m, 1 H), 1.40-1.49 (m, 4 H), 1.76 (d, J=9.16 Hz, 2 H), 1.83 (m, 1 H), 1.90 (s, 3 H), 1.93-1.99 (m, 1 H), 2.00-2.10 (m, 3 H), 2.81 (m, 1 H), 2.84 (dd, J=10.65, 3.32Hz, 2 H), 3.00-3.06 (m, 6 H), 3.11-3.18(m, 1 H), 3.19-3.28 (m, 1 H), 3.41-3.51 (m,2H), 3.80-3.88(m, 1 H), 3.90 (s, 3 H), 4.31 (m, 1 H), 5.06-5.15 (m, 1 H), 6.93 (br s, 1 H), 7.08 (s, 1 H), 7.12 (dd, J=8.71, 2.63 Hz, 1 H), 7.51 (d, J=8.71 Hz, 1 H), 7.55 (dd, J=8.48, 1.60 Hz, 1 H), 7.88 (d, J=8.48 Hz, 1 H), 8.09 (s, 1 H). LC/MS: m/z 678.23, Rf 2.04 min., 95.0% purity.
    Figure US20070078122A1-20070405-C00761
  • N-(morpholin-2-ylmethyl)acetamide. To 136 mg (0.66 mmol) of commercially available (4-benzylmorpholin-2-yl)methanamine was added 4 mL of dry dichloroethane in a 10 mL sealed tube. To this solution was added 2.0 equivalents (1.32 mmol) of cold acetyl chloride drop-wise followed by 2.0 equivalents of redistilled N,N-diisopropylethylamine. The tube was sealed and the solution was stirred at 60° C. overnight. The crude product was returned to room temperature, evaporated to dryness, re-dissolved in N,N-dimethylformamide and purified using a Shimadzu preparative HPLC employing methanol/water and 10 mM trifluoroacetic acid buffer with a Phenomenex-Luna, C18, 30 mm×100 mm, 5 μm column with 0-100% B at a flow rate of 40 mL/min. Evacuation of solvent gave 230 mgs (96% yield) of 1, N-((4-benzylmorpholin-2-yl)methyl)acetamide, as the trifluoroacetic acid salt. LC/MS: m/z 249.21, Rf 0.41 min., 100% purity. To 0.63 mmol of 1 in a 25 mL round bottom flask was added approximately 5 mL of methanol and 100 mgs of 10% palladium on carbon. The round bottom flask was fitted with a septa, and a needle attached to balloon of hydrogen was inserted. The mixture was stirred at room temperature overnight. The crude product was then filtered through a pad of celite and the solvent evaporated to yield 170 mgs (99% yield) of 2, N-(morpholin-2-ylmethyl)acetamide, as a clear colorless viscous oil. 1H NMR: δ (300 MHz, DMF-d7) ppm 1.89 (s, 3 H), 2.97 (m, 2 H), 3.37 (m, 1 H), 3.45 (m, 1 H), 3.74 (m, 1 H), 3.90 (m, 2 H) 4.05 (m, 1 H), 4.63-4.76 (m, 1 H).
    Figure US20070078122A1-20070405-C00762
  • To 1.0 g of dimethyl ester 1 was added 1.0 equivalent of 1M n-Butyl ammonium hydroxide in methanol along with 75 mL of tetrahydrofuran. The mixture was stirred for 8 hours at room temperature. The crude product was concentrated en-vacuo, taken up in ethyl acetate and made slightly acidic (pH=5) by the addition of 1 M HCl. The organic layers were washed with brine, and the product dried over magnesium sulfate. The carboxylic acid 2 was evacuated to dryness to give a light yellow foam (yields 94-99%) which was used without firther purification. To 0.2 mmol of carboxylic acid 2 in 3 mL of N,N-dimethylformamide in a 2 dram vial was added 2 equivalents of amine and 2 equivalents of 2-(1H-Benzotriazole-1-yl)-1,1,3,3,-Tetramethyluronium Tetrafluoroborate (TBTU). The vial was capped and shaken over night at room temperature. The reaction volume was then reduced to a total volume of 2.0 mL in a Savant Speedvac and the crude product was purified using a Shimadzu preparative HPLC employing acetonitrile/water and 10 mM trifluoroacetic acid buffer with a Waters Sunfire, C18, 19 mm×100 mm, 5 μm column at a focused gradient of 50-100% B and a flow rate of 25 mL/min. Postpurification LC/MS data was obtained on a Shimadzu analytical LC/Micromass Platform LC (ESI+) at 220 nm using the following set of conditions: Phenomenex 10 μm C18, 4.6×30 mm column, with a gradient of 0-100% B (B=90% HPLC grade methanol/0.1% trifluoroacetic acid/10% HPLC grade water), (A=90% HPLC grade water/0.1% trifluoroacetic acid/10% HPLC grade methanol), in 2 minutes with a 1 minute hold at a rate of 5 mL/minute. To 0.15 mmol of methyl ester 3 was added 3 equivalents of Potassium trimethylsilanolate (TMSOK) and 3 mL of dry tetrahydrofuran. The mixture was stirred at room temperature overnight. After the overnight reaction, the crude product was evacuated to near dryness, taken up in ethyl acetate, and neutralized with 0.5 M HCl. After extraction the solvent was removed to give a near quantitative yield of carboxylic acid 4 (purity>90%) which was used without further purification. To 0.14 mmol of carboxylic acid 4 in 1 mL of dry tetrahydrofuran was added 3 equivalents of carbonyldiimidazole. The solution was heated for 2-3 hours at 70° C. in a 1 dram vial equipped with a screw cap. At this point, 1.4 equivalents of neat 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) was dripped into the mixture followed by the addition of N,N-Dimethylsulfamide (as a solid). The vial was returned to the heating bath and shaken overnight. The crude product 5 was then evacuated to dryness and purified using a Shimadzu preparative HPLC to give dimethylamino sulfonylindole 5 as a yellow amorphous solid (35-50% yield).
    Figure US20070078122A1-20070405-C00763
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-((3-fluoropiperidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (300 MHz, CHLOROFORM-D) δ ppm 1.21-1.44 (m, 6 H), 1.76 (m, 4 H), 1.94 (m, 1 H), 2.06 (s, 3 H), 2.83 (d, J=2.93 Hz, 2 H), 3.06 (m, 3 H), 3.30 (s, 6 H), 3.97 (s, 1 H), 4.48 (m, 1 H), 6.96 (s, 1 H), 7.38-7.44 (m, 1 H), 7.44-7.53 (m, 2 H) 7.54-7.61 (m, 1 H), 7.79 (d, J=8.42 Hz, 1 H), 7.91 (d, J=8.78 Hz, 1 H), 8.28 (s, 1 H). LC/MS: m/z 593.36, Rf 2.15 min., 100% purity.
    Figure US20070078122A1-20070405-C00764
  • 13-Cyclohexyl-6-((3-fluoropiperidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. LC/MS: m/z 487.28, Rf 2.13 min., 90% purity.
    Figure US20070078122A1-20070405-C00765
  • Methyl 13-cyclohexyl-6-((3-fluoropiperidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. LC/MS: m/z 501.28, Rf 2.24 min., 100% purity.
    Figure US20070078122A1-20070405-C00766
  • 6-((3-carbamoylpyrrolidin-1-yl)carbonyl)-1 3-cyclohexyl-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. LC/MS: m/z 498.25, Rf 2.05 min., 100% purity.
    Figure US20070078122A1-20070405-C00767
  • Methyl 6-((3-carbamoylpyrrolidin-1-yl)carbonyl)-13-cyclohexyl-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. LC/MS: m/z 512.29, Rf 2.15 min., 100% purity.
    Figure US20070078122A1-20070405-C00768
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-((3-fluoro-1,4′-bipiperidin-1′-yl)carbonyl)-7H-indolo[2,1-a][2}benzazepine-10-carboxamide. 1H NMR: (300 MHz, CHLOROFORM-D) δ ppm 1.21 (m, 2 H), 1.30-1.44 (m, 4 H), 1.52 (m, 1 H), 1.66 (m, 1 H), 1.77 (m, 5 H), 2.04 (m, 6 H), 2.82 (m, 5 H) 2.89 (m, 1 H), 2.94-3.08 (m, 2 H), 3.12 (m, 1 H), 3.48 (m, 3 H), 3.68 (m, 1 H), 4.42 (m, 1 H), 4.57 (m, 1 H), 4.88 (m, 1 H), 5.05 (m, 1 H), 5.17 (m, 1 H), 6.84 (s, 1 H), 7.37-7.43 (m, 1 H), 7.45-7.52 (m, 2 H), 7.54-7.60 (m, 1 H), 7.76 (d, J=8.78 Hz, 1 H), 7.92 (d, J=8.78 Hz, 1 H), 8.39 (s, 1 H). LC/MS: m/z 676.43, Rf 1.86 min., 91.2% purity.
    Figure US20070078122A1-20070405-C00769
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-((3-fluoro-1,4′-bipiperidin-1′-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. LC/MS: m/z 570.40, Rf 1.86 min., 86.1% purity.
    Figure US20070078122A1-20070405-C00770
  • Methyl 13-cyclohexyl-6-((3-fluoro-1,4′-bipiperidin-1′-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. LC/MS: m/z 584.39, Rf 1.88 min., 95.0% purity.
    Figure US20070078122A1-20070405-C00771
  • 13-Cyclohexyl-6-((3,3-difluoro-1,4′-bipiperidin-1′-yl)carbonyl)-N-((dimethylamino)sulfonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (300 MHz, CHLOROFORM-D) δ ppm 1.21 (m, 2 H), 1.32-1.45 (m, 4 H), 1.78 (m, 3 H), 1.94-2.10 (m, 9 H), 2.55-2.68 (m, 2 H), 2.69 (m, 6 H), 2.85 (m, 3 H), 2.89 (m, 2 H), 2.97-3.15 (m, 2 H), 3.48 (m, 1 H), 4.44 (m, 1 H), 5.19 (m, 1H), 6.86 (s, 1 H) 7.42 (m, 1 H), 7.46-7.53 (m, 2 H), 7.55-7.60 (m, 1 H), 7.78 (d, J=8.42 Hz, 1 H), 7.94 (d, J=8.42 Hz, 1 H), 8.40 (s, 1 H). LC/MS: m/z 694.46, Rf 1.88 min., 96.5% purity.
    Figure US20070078122A1-20070405-C00772
  • 13-Cyclohexyl-6-((3,3-difluoro-1,4′-bipiperidin-1′-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. LC/MS: m/z 588.43, Rf 1.88 min., 85.0% purity.
    Figure US20070078122A1-20070405-C00773
  • Methyl 13-cyclohexyl-6-((3,3-difluoro-1,4′-bipiperidin-1′-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. LC/MS: m/z 602.38, Rf 1.97 min., 100% purity.
    Figure US20070078122A1-20070405-C00774
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-(((3R)-3-fluoropyrrolidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (300 MHz, CHLOROFORM-D) δ ppm 1.27 (m, 1 H), 1.38 (m, 3H), 1.60 (m, 1 H), 1.77 (m, 3 H), 1.92 (m, 1 H), 2.08 (m, 4 H), 2.80-2.93 (m, 1 H), 3.49 (s, 1 H), 3.75 (m, 2 H) 3.86-4.00 (m, 2 H), 4.33 (m, 1 H), 5.18 (m, 4 H), 5.31 (m, 2 H), 7.11 (s, 1 H), 7.40-7.54 (m, 3 H), 7.56-7.63 (m, 1 H), 7.80 (d, J=8.78Hz, 1 H), 7.90 (d, J=8.78 Hz, 1 H), 8.36 (s, 1 H). LC/MS: m/z 579.26, Rf2.13 min., 100% purity.
    Figure US20070078122A1-20070405-C00775
  • 13-Cyclohexyl-6-(((3R)-3-fluoropyrrolidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. LC/MS: m/z 473.28, Rf 2.11 min., 90.0% purity.
    Figure US20070078122A1-20070405-C00776
  • Methyl-13-cyclohexyl-6-(((3R)-3-fluoropyrrolidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. LC/MS: m/z 487.25, Rf 2.22 min., 100% purity.
    Figure US20070078122A1-20070405-C00777
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-(((3S)-3-fluoropyrrolidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (300 MHz, CHLOROFORM-D) δ ppm 1.26 (m, 1 H), 1.37 (m, 3H), 1.60 (m, 1 H), 1.77 (m, 3 H), 1.92 (m, 1 H), 2.08 (m, 4 H), 2.80-2.93 (m, 1 H), 3.49 (s, 1 H), 3.74 (m, 2 H) 3.86-4.00 (m, 2 H), 4.34 (m, 1 H), 4.57(m, 4 H), 5.33 (m, 2 H), 7.11 (s, 1 H), 7.40-7.61 (m, 4 H), 7.79 (d, J=8.42 Hz, 1 H), 7.91 (d, J=8.42 Hz, 1 H), 8.35 (s, 1 H). LC/MS: m/z 579.17, Rf 2.11 min., 97.2% purity.
    Figure US20070078122A1-20070405-C00778
  • 13-Cyclohexyl-6-(((3S)-3-fluoropyrrolidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. LC/MS: m/z 473.26, Rf 2.12 min., 90.0% purity.
    Figure US20070078122A1-20070405-C00779
  • Methyl 13-cyclohexyl-6-(((3S)-3-fluoropyrrolidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. LC/MS: m/z 487.24, Rf 2.21 min., 100% purity.
    Figure US20070078122A1-20070405-C00780
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-((4-((3R)-3-fluoropyrrolidin-1-yl)piperidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (300 MHz, CHLOROFORM-D) δ ppm 1.21 (m, 1 H), 1.35 (m, 4 H), 1.79 (m, 3 H), 2.01 (m, 4 H), 2.28-2.35 (m, 2 H), 2.65-2.79 (m, 8 H), 3.04 (m, 5 H), 3.11 (m, 3 H), 3.47 (m, 1 H), 3.83 (m, 1H), 4.43 (m, 1 H), 5.24 (m, 1 H), 5.40 (m, 1 H), 6.90 (s, 1 H), 7.44 (m, 1 H), 7.50 (m, 2 H), 7.57 (m, 1 H), 7.79 (d, J=8.78 Hz, 1 H), 7.93 (d, J=8.78 Hz, 1 H), 8.36 (s, 1 H). LC/MS: m/z 662.45, Rf 1.86 min., 100% purity.
    Figure US20070078122A1-20070405-C00781
  • 13-Cyclohexyl-6-((4-((3R) -3-fluoropyrrolidin-1-yl)piperidin-1-yl) carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. LC/MS: m/z 556.38, Rf 1.86 min., 85.0% purity.
    Figure US20070078122A1-20070405-C00782
  • Methyl 13-cyclohexyl-6-((4-((3R)-3-fluoropyrrolidin-1-yl)piperidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. LC/MS: m/z 570.32, Rf 1.95 min., 100% purity.
    Figure US20070078122A1-20070405-C00783
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-((4-((3S)-3-fluoropyrrolidin-1-yl)piperidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (300 MHz, CHLOROFORM-D) δ ppm 1.20 (m, 1 H), 1.27-1.43 (m, 4 H), 1.75 (m, 3 H), 2.05 (m, 3 H), 2.32 (m, 3 H), 2.55 (m, 8 H), 2.80 (m, 5 H), 3.11 (m, 3 H), 3.47 (m, 1 H), 3.83 (m, 1H), 4.32-4.44 (m, 1 H), 5.20 (m, 1 H), 5.39 (m, 1 H), 6.89 (s, 1 H), 7.39-7.58 (m, 4 H), 7.79 (d, J=8.78 Hz, 1 H), 7.91 (d, J=8.78 Hz, 1 H) 8.36 (s, 1 H). LC/MS: m/z 662.39, Rf 1.86 min., 100% purity.
    Figure US20070078122A1-20070405-C00784
  • 13-cyclohexyl-6-((4-((3S)-3-fluoropyrrolidin-1-yl)piperidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. LC/MS: m/z 556.38, Rf 1.86 min., 85.0% purity.
    Figure US20070078122A1-20070405-C00785
  • Methyl 13-cyclohexyl-6-((4-((3S)-3-fluoropyrrolidin-1-yl)piperidin-1-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. LC/MS: m/z 570.32, Rf 1.94 min., 94.2% purity.
    Figure US20070078122A1-20070405-C00786
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-((4-fluoro-1,4′-bipiperidin-1′-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (300 MHz, CHLOROFORM-D) δ ppm 1.24 (m, 1 H), 1.37 (m, 3 H), 1.49 (m, 1 H), 1.67 (m, 1 H), 1.76 (m, 2 H), 1.95 (m, 1 H), 2.04 (m, 3 H), 2.13 (m, 4 H), 2.23 (m, 1 H), 2.31 (m, 1 H), 2.82 (m, 3 H), 2.89 (m, 2 H), 3.04-3.20 (m, 7 H), 3.34 (m, 2 H), 4.42 (m, 1 H), 4.59 (m, 1 H), 4.82 (m, 1 H), 5.00 (m, 1 H), 5.23 (m, 1 H), 6.84 (s, 1 H), 7.38-7.44 (m, 1 H), 7.50 (m, 2 H), 7.58 (m, 1 H), 7.79 (d, J=8.42 Hz, 1 H), 7.94 (d, J=8.42 Hz, 1 H), 8.43 (s, 1 H). LC/MS: m/z 676.46, Rf 1.87 min., 100% purity.
    Figure US20070078122A1-20070405-C00787
  • 13-Cyclohexyl-6-((4-fluoro-1,4′-bipiperidin-1′-yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. LC/MS: m/z 570.42, Rf 1.87 min., 85.0% purity.
    Figure US20070078122A1-20070405-C00788
  • Methyl 13-cyclohexyl-6-((4-fluoro-1,4′-bipiperidin-1′yl)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. LC/MS: m/z 584.32, Rf 1.94 min., 100% purity.
    Figure US20070078122A1-20070405-C00789
  • 6-((3-Carbamoylpiperidin-1-yl)carbonyl)-13-cyclohexyl-N-((dimethylamino)sulfonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (300 MHz, MeOD) δ ppm 1.19 (m, 3 H) 1.37-1.46 (m, 5 H), 1.65 (m, 2 H), 1.75 (m, 2 H), 1.86 (m, 2 H), 2.05 (m, 3 H), 2.83 (m, 2 H), 2.99 (m, 1 H), 3.28 (s, 6 H), 4.37 (m, 1 H), 5.11 (m, 1 H), 6.95 (s, 1 H), 7.47-7.53 (m, 3 H), 7.57-7.61 (m, 1 H), 7.69 (dd, J=8.42, 1.46 Hz, 1 H), 7.87 (d, J=8.42 Hz, 1 H), 8.18 (s, 1 H). LC/MS: m/z 618.36, Rf 2.05 min., 100% purity.
    Figure US20070078122A1-20070405-C00790
  • 6-((3-carbamoylpiperidin-1-yl)carbonyl)-13-cyclohexyl-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. LC/MS: m/z 512.31, Rf 2.05 min., 99.0% purity.
    Figure US20070078122A1-20070405-C00791
  • Methyl 6-((3-carbamoylpiperidin-1-yl)carbonyl)-13-cyclohexyl-7H-indolo[2, ]-a][2]benzazepine-10-carboxylate. LC/MS: m/z 526.26, Rf 2.17 min., 100% purity.
    Figure US20070078122A1-20070405-C00792
  • To 1.0 g of carboxylic acid 1 in a 100 mL round bottom flask equipped with a septa under nitrogen, was added 20 mL of dry dichloroethane (DCE). To this solution was then added 1.2 equivalents of Diphenylphosphorylazide (DPPA) in one portion followed by 3 equivalents of triethylamine. The solution was stirred overnight at room temperature. The reaction progress was followed by an analytical Shimadzu LC/MS. The crude mixture was passed through a 24 g SiliCycle/Isco silica gel cartridge with DCE to give acyl azide 2 as a light yellow foam after solvent evacuation (50-65% yield). The acyl azide was found to be stable at room temperature in a vacuum desiccator for up to one month. To 0.3 mmol of acyl azide 2 in 2 mL of dry toluene was added 1.2 equivalents of amine in a Biotage/Personal Chemistry microwave vial. The vial was capped and heated to 100° C. in a Biotage/Personal Chemistry Emrys Optomizer microwave for 25 minutes. The crude reaction mixture was then evacuated to near dryness, taken up in a 1:1 ethyl acetate/hexane mixture and purified by flash chromatography to yield urea 3 (50-55% yield). To 0.15 mmol of intermediate 3 was added 10 equivalents of potassium trimethylsilanolate (TMSOK) and 3 mL of dry tetrahydrofuran. The mixture was stirred at room temperature overnight. After the overnight treatment, the crude product was evacuated to near dryness, taken up in ethyl acetate, and neutralized with 0.5 M HCl. After extraction the solvent was removed to give a near quantitative yield of carboxylic acid 4 (purity >90%) which was used without further purification. To 0.14 mmol of carboxylic acid 4 in 1 mL of dry tetrahydrofuran was added 3 equivalents of carbonyldiimidazole. The solution was heated for 2-3 hours at 70° C. in a one dram vial equipped with a screw cap. At this point, 1.4 equivalents of neat 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) was dripped into the mixture followed by the addition of N,N-Dimethylsulfamide (as a solid). The vial was returned to the heating bath and shaken overnight. The crude reaction mixture was then evacuated to dryness and purified using a Shimadzu preparative HPLC to give dimethylamino sulfamide 5 as a yellow amorphous solid (35-50% yield).
    Figure US20070078122A1-20070405-C00793
  • Methyl 13-cyclohexyl-6-(((4-morpholin-4-ylpiperidin-1-yl)carbonyl)amino)-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylate. 1H NMR: (500 MHz, CHLOROFORM-D) δ ppm 1.38 (m, 2 H), 1.69 (m, 1 H), 1.75-1.81 (m, 3 H), 1.83 (m, 2 H), 2.05-2.12 (m, 1 H), 2.19-2.26 (m, 1 H), 2.72 (m, 1 H), 2.92-2.99 (m, 4 H), 3.15 (m, 2 H), 3.34-3.43 (m, 3 H), 3.52 (m, 1 H), 3.75-3.82 (m, 2 H), 3.90 (s, 3 H), 4.02 (d, J=2.44 Hz, 4 H), 4.32 (m, 1 H), 4.41-4.49 (m, 2 H), 4.60 (m, 1 H), 7.35-7.45 (m, 4 H), 7.72 (dd, J=8.55, 1.53 Hz, 1 H), 7.88 (d, J=8.55 Hz, 1 H), 8.01 (s, 1 H). LC/MS: m/z 585.36, Rf 1.98 min., 94.8% purity.
    Figure US20070078122A1-20070405-C00794
  • 13-Cyclohexyl-6-(((4-morpholin-4-ylpiperidin-1-yl)carbonyl)amino)-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. 1H NMR: (500 MHz, BENZENE-D6) δ ppm 1.07-1.15 (m, 1 H), 1.15-1.23 (m, 1 H), 1.24-1.32 (m, 1 H), 1.41 (m, 1 H), 1.57 (m, 2 H), 1.65 (m, 3 H), 1.86 (m, 1 H), 2.06-2.13 (m, 4 H), 2.24 (m, 2 H), 2.60 (m, 1 H), 2.69 (m, 2 H), 2.84 (m, 1 H), 3.09 (m, 1 H), 3.21 (m,1 H), 3.29-3.37 (m, 1 H), 3.41 (m, 2 H), 3.57 (m, 2 H), 3.69 (m, 1 H), 3.86 (m, 1 H), 4.03 (m,1 H), 4.22 (m,1 H), 4.35 (m, 1 H), 4.64 (m, 1H), 7.01 (d, J=7.02 Hz, 1 H), 7.09-7.13 (m, 1 H), 7.20 (m, 1 H), 7.44 (d, J=7.63 Hz, 1 H), 7.97 (d, J=8.55 Hz, 1 H), 8.24 (d, J=8.24 Hz, 1 H), 8.29 (s, 1 H). LC/MS: m/z 571.30, Rf 1.95 min., 98.0% purity.
    Figure US20070078122A1-20070405-C00795
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-((((2R, 6S)-2,6-dimethylmorpholin-4-yl)carbonyl)amino)-6,7-dihydro-5H-indolo[2,-a][2]benzazepine-10-carboxamide. 1H NMR: (500 MHz, CHLOROFORM-D) δ ppm 1.04 (d, J=6.41 Hz, 3 H), 1.10 (d, J=6.41 Hz, 3 H), 1.15 (m,l H), 1.27 (d,l H), 1.39-1.49 (m, 2 H), 1.63 (d, J=11.60 Hz, 1 H), 1.78 (m, 2 H), 1.89-1.99 (m, 1 H), 2.01-2.10 (m, 3 H), 2.32-2.40 )m, 1 H), 2.43-2.52 (m, 2 H), 2.83-2.92 (m, 1 H), 3.00 (s, 6 H), 3.46 (m, 1 H), 3.62-3.71 (m, 3 H) 3.92 (m,1 H), 4.39 (m, 1 H), 4.59 (m,l H), 7.38-7.46 (m, 4 H), 7.54-7.61 (m, 1 H), 7.89-7.92 (m, 2 H). LC/MS: m/z 622.25, Rf2.12 min., 100% purity.
    Figure US20070078122A1-20070405-C00796
  • Methyl 13-cyclohexyl-6-((((2R,6S)-2,6-dimethylmorpholin-4-yl)carbonyl)amino)-3-methoxy-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylate. 1H NMR: (500 MHz, CHLOROFORM-D) δ ppm 1.11 (d, J=6.10 Hz, 3 H), 1.15 (d, J=6.10 Hz, 3 H), 1.19-1.29 (m, 3 H), 1.36-1.44 (m, 1 H), 1.69 (m,l H), 1.78 (m, 2 H), 1.92-2.06 (m, 2 H), 2.19 (t, J=1.6 Hz, 1 H), 2.48-2.56 (m, 2 H), 2.96 (m, 2 H), 3.50 (d, J=12.82 Hz, 1 H), 3.54-3.63 (m, 2 H), 3.71 (d, J=12.21 Hz, 1 H), 3.81 (dd, J=15.11, 3.81 Hz, 1 H), 3.87 (s, 3 H), 3.91 (s, 3 H), 4.36 (d, J=8.24 Hz, 1 H), 4.43 (d, J=14.95 Hz, 1 H), 4.60-4.68 (m, 1 H), 6.91-6.98 (m, 2 H), 7.37 (d, J=8.24 Hz, 1 H), 7.76 (dd, J=8.55, 1.53 Hz, 1 H), 7.87 (d, J=8.24 Hz, 1 H), 8.01 (s, 1 H). LC/MS: m/z 560.33, Rf2.27 min., 100% purity.
    Figure US20070078122A1-20070405-C00797
  • To 64.8 mgs (0.11 mmol) of urea was added 4 mL of dry N,N-dimethylformamide and 1.2 equivalents (3.6 mgs) of 95% NaH under nitrogen in a 25 mL round bottom flask equipped with a septa. To this mixture was then added 2.0 equivalents (0.22 mmol, 13.6 μL) of methyl iodide. The mixture was stirred overnight at room temperature at which point another 2.0 equivalents of methyl iodide was added. The mixture was stirred for an additional 48 hours. The product was purified by flash chromatography (20-50% ethyl acetate in hexane) to give 50.5 mgs (80.0% yield) of the desired N-methyl urea (Intermediate A) as an amorphous yellow solid. 1H NMR: (500 MHz, CHLOROFORM-D) δ ppm 1.20 (m, 6 H), 1.24-1.31 (m, 1 H), 1.36-1.44 (m, 2 H), 1.62 (d, J=12.51 Hz, 0.2 H), 1.69 (d, J=12.51 Hz, 0.8 H), 1.78 (m, 2 H), 1.91-2.10 (m, 4 H), 2.63-2.71 (m, 4 H), 2.74 (dd, J=12.51, 5.49 Hz, 1 H), 2.82-3.04 (m, 3 H), 3.50-3.59 (m, 2 H), 3.66 (m, 2 H), 3.88 (s, 3 H), 3.92-3.97 (m, 3 H), 4.00 (m,l H), 4.43-4.50 (m, 1 H), 4.57 (m, 0.3 H), 4.63 (m, 0.7 H), 6.92-6.99 (m, 2 H), 7.32 (d, J=8.24 Hz, 0.8 H), 7.36 (d, J=8.24 Hz, 0.2 H), 7.75 (d, J=8.55 Hz, 1 H), 7.86 (m, 1 H), 8.03 (s, 0.7 H), 8.09 (s, 0.3 H). LC/MS: m/z 574.13, Rf 2.42 min., 100% purity.
    Figure US20070078122A1-20070405-C00798
  • 13-Cyclohexyl-6-((((2R,6S)-2,6-dimethylmorpholin-4-yl)carbonyl)(methyl)amino)-3-methoxy-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. 1H NMR: (500 MHz, CHLOROFORM-D) δ ppm 1.25 (m, 6 H), 1.27-1.47 (m, 1 H), 1.36-1.44 (m, 2 H), 1.60-1.78 (m, 3 H), 2.04 (m, 4 H), 2.58-2.94 (m, 8 H), 3.49-3.70 (m, 4 H), 3.88 (s, 3 H), 4.00 (m,l H), 4.50-4.68 (m, 2 H), 6.97 (m, 2 H), 7.34 (m,1 H), 7.88 (m, 2 H), 8.15 (s, 0.7 H), 8.23 (s, 0.3 H). LC/MS: m/z 560.31, Rf 2.27 min., 91.8% purity.
    Figure US20070078122A1-20070405-C00799
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-6-((((2R,6S)-2,6-dimethylmorpholin-4-yl)carbonyl)(methyl)amino)-3-methoxy-6,7-dihydro-5H-indolo[2,1]-a][2]benzazepine-10-carboxamide. 1H NMR: (500 MHz, CHLOROFORM-D) δ ppm 1.19 (m, 6 H), 1.25 (m, 1 H), 1.36-1.42 (m, 2 H), 1.58-1.71 (m, 1 H), 1.79 (m, 2 H), 1.91-2.05 (m, 4 H), 2.57-2.64 (m, 3 H), 2.67 (s, 3H), 2.74 (m, 1 H), 2.82-3.99 (m, 3 H), 3.02-3.14 (m, 6 H), 3.50 (m, 2 H), 3.66 (m, 2 H), 3.88 (s, 3 H), 3.97-4.12 (m,2 H), 4.47-4.62 (m, 2 H), 6.96 (m, 2 H), 7.31 (d, J=8.55 Hz, 0.7 H), 7.36 (d, J=8.55 Hz, 0.3 H), 7.44 (d, J=8.55 Hz, 0.7 H), 7.57 (d, J=8.55 Hz, 0.3 H), 7.89 (m, 1 H), 7.99 (s, 0.7 H), 8.04 (s, 0.3 H). LC/MS: m/z 666.33, Rf 2.20 min., 97.0% purity.
    Figure US20070078122A1-20070405-C00800
  • 13-Cyclohexyl-N-((dimethylamino)sulfonyl)-3-methoxy-6-((morpholin-4-ylcarbonyl)amino)-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxamide. 1H NMR: (500 MHz, CHLOROFORM-D) δ ppm 1.37 (m, 1 H), 1.36-1.44 (m, 2 H), 1.67 (d, J=12.51 Hz, 1 H), 1.79 (m, 2 H), 1.93 (d, J=12.82 Hz, 2 H), 1.96-2.05 (m, 3 H), 2.04 (m, 1 H), 2.97 (m, 1 H), 3.04 (s, 6 H), 3.19-3.28 (m, 2 H), 3.33-3.40 (m, 3 H), 3.62-3.71 (m, 4 H), 3.84 (m, 1 H), 3.88 (m, 3 H), 4.44 (d, J=7.32 Hz, 1 H), 4.51 (d, J=14.95 Hz, 1 H), 4.55-4.63 (m, 1 H), 6.88-6.98 (m, 2 H), 7.35-7.41 (m, 1 H), 7.54 (dd, J=8.39, 1.37 Hz, 0.8 H), 7.60 (dd, J=8.39, 1.37 Hz, 0.2 H), 7.88 (m, 1 H), 7.98 (s, 0.8 H), 8.11 (s, 0.2 H). LC/MS: m/z 624.37, Rf 2.08 min., 100% purity.
  • (6R)-13-Cyclohexyl-6-((morpholin-4-ylcarbonyl)amino)-6, 7-dihydro-5H-indolo[2,1a][2]benzazepine-10-carboxylic acid and (6S)-13-Cyclohexyl-6-((morpholin-4-ylcarbonyl)amino)-6,7-dihydro-5H-indolo[2, la][2]benzazepine-10-carboxylic acid. The chiral separation was accomplished using preparative chiral supercritical fluid chromatography (SFC) employing a Chiralpak AS-H, 30×250 mm, 5 μm column. The mixture of enantiomers was taken up in methanol (10 mg/2 mL), injected onto the column and eluted with 85% CO2 and 15% methanol with 0.1% trifluoroacetic acid buffer at a flow rate of 70 mL/minute. The temperature was maintained at 35° C. and the pressure at 150 bar throughout the experiment and the elution of the products was monitored by a UV detector at a wave length of 210 nm. Isomer A eluted 9.5-13.0 minutes. Isomer B eluted 27.5-32.0 minutes. The samples were concentrated en-vacuo to give enantiomerically pure ivory colored amorphous solids. Isomer A 1H NMR: (500 MHz, MeOD) δ ppm 1.20-1.30 (m, 2 H), 1.40-1.45 (m, 2 H), 1.59 (m, 1 H), 1.72-1.80 (m, 2 H), 1.91 (d, J=10.68 Hz, 1 H), 1.98-2.04 (m, 2 H), 2.05-2.11 (m, 1 H), 2.41-2.48 (m, 1 H), 2.86 (dd, J=13.28, 6.87 Hz, 1 H), 2.96 (m, 1 H), 3.34-3.42 (m, 3 H), 3.56-3.65 (m, 5 H), 4.37 (m, 1 H), 4.55 (d, J=14.65 Hz, 1 H), 7.37-7.46 (m, 4 H), 7.67 (dd, J=8.39, 1.37 Hz, 1 H), 7.84 (d, J=8.39 Hz, 1 H), 7.99 (s, 1 H). LC/MS: m/z 488.22, Rf2.14 min., 100% purity. Isomer B 1H NMR: (500 MHz, MeOD) δ ppm 1.20-1.29 (m, 2 H), 1.37-1.45 (m, 2 H), 1.60 (d, J=11.60 Hz, 1 H), 1.76 (m, 2 H), 1.91 (d, J=11.29 Hz, 1 H), 1.99-2.04 (m, 2 H), 2.07 (m, 1 H), 2.40-2.47 (m, 1 H), 2.86 (dd, J=13.12, 6.71 Hz, 1 H), 2.92-3.01 (m, 1 H), 3.34-3.42 (m, 3 H), 3.56-3.65 (m, 5 H), 4.34-4.40 (m, 1 H), 4.56 (d, J=14.95 Hz, 1 H), 7.36-7.46 (m, 4 H), 7.67 (dd, J=8.39, 1.37 Hz, 1 H), 7.84 (d, J=8.39 Hz, 1 H) 7.99 (s, 1 H). LC/MS: m/z 488.22, Rf 2.14 min., 100% purity.
  • (6R)-13-cyclohexyl-N-((dimethylamino)sulfonyl)-6-((morpholin-4-ylcarbonyl)amino)-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxamide and (6S)-13-cyclohexyl-N-((dimethylamino)sulfonyl)-6-((morpholin-4-ylcarbonyl)amino)-6,7-dihydro-5H-indolo[2,1-a][2}benzazepine-10-carboxamide. The chiral separation was accomplished using preparative chiral supercritical fluid chromatography (SFC) employing a Chiralpak OD-H, 30×250 mm, 5 μm column. The mixture of enantiomers was taken up in methanol (10 mg/2 mL), injected onto the column and eluted with 80% CO2 and 20% methanol with 0.1% trifluoroacetic acid buffer at a flow rate of 70 mL/minute. The temperature was maintained at 35° C. and the pressure at 150 bar throughout the experiment and the elution of the products was monitored by a UV detector at a wave length of 210 nm. Isomer A eluted at 10.7-12.5 minutes. Isomer B eluted at 15.8-19.5 minutes. The samples were concentrated en-vacuo to give enantiomerically pure yellow amorphous solids.
  • Isomer A 1H NMR: (500 MHz, MeOD) δ ppm 1.23-1.32 (m, 1 H), 1.45 (m, 2 H), 1.61 (m, 1 H), 1.78 (m, 2 H), 1.92-2.03 (m, 1 H), 2.03-2.12 (m, 3 H), 2.42-2.49 (m, 1 H), 2.88 (ddd, J=13.35, 7.02,6.79 Hz, 1 H), 2.96 (m, 1 H), 3.00 (s, 6 H), 3.36-3.44 (m, 3 H), 3.54-3.61 (m, 2 H), 3.61-3.69 (m, 3 H), 4.39 (m, 1 H), 4.61 (d, J=14.95 Hz, 1 H), 4.83-4.88 (m, 1 H), 7.39-7.48 (m, 4 H), 7.58 (dd, J=8.55, 1.53 Hz, 1 H), 7.90 (d, J=8.55, 1 H), 7.94 (s, 1 H). LC/MS: m/z 594.19, Rf2.06 min., 100% purity. Isomer B 1H NMR: (500 MHz, MeOD) δ ppm 1.24-1.33 (m, 1 H), 1.45 (m, 2 H), 1.61 (m, 1 H), 1.74-1.82 (m, 2 H), 1.92 (m, 1 H), 2.03-2.12 (m, 3 H), 2.42-2.49 (m, 1 H), 2.88 (ddd, J=13.58, 7.02, 6.87 Hz, 1 H), 3.00 (m, 7 H), 3.36-3.44 (m, 3 H), 3.54-3.61 (m, 2 H), 3.61-3.69 (m, 3 H), 4.39 (m, 1 H), 4.61 (d, J=14.95 Hz, 1 H), 4.83-4.88 (m, 1 H), 7.41-7.47 (m, 4 H), 7.57 (dd, J=8.55, 1.53 Hz, 1 H), 7.89 (d, J=8.55, 1 H), 7.94 (s, 1 H). LC/MS: m/z 594.21, Rf2.06 min., 100% purity.
    Figure US20070078122A1-20070405-C00801
  • 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-(azidocarbonyl)-13-cyclohexyl-6,7-dihydro-, methyl ester. To a mixture of the acid (5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-6,7-dihydro-, 10-methyl ester) (989.2 mg, 2.37 mmol) in PhMe (15 ml) at r.t. under N2 was added triethylamine (304 mg, 3.0 mmol), followed by diphenylphosphoryl azide (DPPA) (845 mg, 3.07 mmol). The mixture was stirred at r.t. for 3.5 hr. The volatiles were then evaporated and the residue purified by Biotage flash chromatography (gradient elution, 0 to 30% EtOAc/Hexane) to gave the acyl azide (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-(azidocarbonyl)-13-cyclohexyl-6,7-dihydro-, methyl ester) (532 mg); Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=443.16, HPLC Rt=2.197 min.
    Figure US20070078122A1-20070405-C00802
  • 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-(azidocarbonyl)-13-cyclohexyl-6,7-dihydro-3-methoxy-, methyl ester. This methoxyphenyl analog (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-(azidocarbonyl)-1 3-cyclohexyl-6,7-dihydro-3-methoxy-, methyl ester) was prepared in a similar manner; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=473.22, HPLC Rt=2.183 min.
    Figure US20070078122A1-20070405-C00803
  • 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6, 7-dihydro-6-[[(phenylmethoxy)carbonyl]amino]-, methyl ester. To a mixture of the acyl azide (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-(azidocarbonyl)-13-cyclohexyl-6,7-dihydro-, methyl ester) (57.4 mg, 0.13 mM) under N2 at r.t. in a microwave reaction tube was added a solution of benzyl alcohol (28 mg, 0.26 mmol) in PhMe (1 ml). The reaction mixture was then placed under microwave irradiation in an Emrys Optimizer (Personal Chemistry) at 100° C. and with the absorption level set to normal for 15 min. More benzyl alcohol (0.28 mg, 2.6 mmol) was then added to the reaction mixture, which was then placed under microwave irradiation under the same conditions for 45 min. The volatiles were then evaporated and the residue purified by Biotage flash chromatography (gradient elution, 0 to 20% EtOAc/Hexane) to gave the carbamate (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(phenylmethoxy)carbonyl]amino]-, methyl ester); Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=523.18, HPLC Rt=2.185 min.
    Figure US20070078122A1-20070405-C00804
  • 13-cyclohexyl-6,7-dihydro-6-[[phenylmethoxy)carbonyljamino]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(phenylmethoxy)carbonyl]amino]-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(phenylmethoxy)carbonyl]amino]-, methyl ester) using TMSOK in THF in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=509.21, HPLC Rt=2.082 min.
    Figure US20070078122A1-20070405-C00805
  • [13-cyclohexyl-10-[[[(dimethylamino)sulfonyljamino]carbonyl]-6,7-dihydro-5H-indolo[2,1-a][2]benzazepin-6-yl]-carbamic acid, phenylmethyl ester. Carbamic acid, [13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-6,7-dihydro-5H-indolo[2,1-a][2]benzazepin-6-yl]-, phenylmethyl ester) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(phenylmethoxy)carbonyl]amino]-) using 1,1′-carbonyldiimidazole (CDI) as a coupling reagent in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B 90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=615.20, HPLC Rt=2.048 min.
    Figure US20070078122A1-20070405-C00806
  • 13-cyclohexyl-6-[[(1,1-dimethylethoxy)carbonyl]amino]-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, methyl ester. To a mixture of the acyl azide (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-(azidocarbonyl)-13-cyclohexyl-6,7-dihydro-, methyl ester) (532 mg, 1.2 mmol) under N2 at r.t. in a microwave reaction tube was added tert-butyl alcohol (10 ml). The reaction mixture was then placed under microwave irradiation in an Emrys Optimizer (Personal Chemistry) at 100° C. and with the absorption level set to normal for 15 min. The mixture was then added with excess water. The white precipitates were filtered, washed with water twice and purified by Biotage flash chromatography (gradient elution, 0 to 40% EtOAc/Hexane) to gave the carbamate (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[(1,1-dimethylethoxy)carbonyl]amino]-6,7-dihydro-, methyl ester) (179.3 mg); Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=489.21, HPLC Rt=2.183 min.
    Figure US20070078122A1-20070405-C00807
  • 13-cyclohexyl-6-[[(1,1-dimethylethoxy)carbonyl]amino]-6,7-dihydro-3-methoxy-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, methyl ester. This methoxyphenyl analog (5H-indolo[2,1 -a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[(1,1-dimethylethoxy)carbonyl]amino]-6,7-dihydro-3-methoxy-, methyl ester) was prepared from the acyl azide (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-(azidocarbonyl)-13-cyclohexyl-6,7-dihydro-3-methoxy-, methyl ester) in a similar manner; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=519.30, HPLC Rt=2.165 min.
    Figure US20070078122A1-20070405-C00808
  • 6-amino-13-cyclohexyl-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, methyl ester. To (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[(1,1-dimethylethoxy)carbonyl]amino]-6,7-dihydro-, methyl ester) (179.3 mg) as obtained above at r.t. under N2 was added a solution of HCl in 1,4-dioxane (2 ml, 4M). The mixture was stirred at r.t. for 3 hr. 20 min. and then evaporated to dryness to give the hydrochloride salt of (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-amino-13-cyclohexyl-6,7-dihydro-, methyl ester); Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=389.24, HPLC Rt=1.790 min.
    Figure US20070078122A1-20070405-C00809
  • 6-amino-13-cyclohexyl-6,7-dihydro-3-methoxy-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, methyl ester. The hydrochloride salt of this methoxyphenyl analog (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-amino-13-cyclohexyl-6,7-dihydro-3-methoxy-, methyl ester) was prepared from 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[( 1,1-dimethylethoxy)carbonyl]amino]-6,7-dihydro-3-methoxy-, methyl ester in a similar manner; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=419.27, HPLC Rt=1.80 min.
    Figure US20070078122A1-20070405-C00810
  • 13-cyclohexyl-6,7-dihydro-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]aminoj-5H-indolo[2,1 -a][2]benzazepine-10-carboxylic acid, methyl ester. To the hydrochloride salt of (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-amino-13-cyclohexyl-6,7-dihydro-, methyl ester) (equivalent to 54.4 mg (0.1 1 mmol) of the Boc-amine (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[(1,1-dimethylethoxy)carbonyl]amino]-6,7-dihydro-, methyl ester)) at r.t. under N2 was added a solution of the acid chloride (32.7 mg, 0.22 mmol) in THF (1 ml), and then triethylamine (77 μl, 0.55 mmol). The mixture was stirred at r.t. for 1 hr, evaporated, and the residue obtained purified by Biotage flash chromatography (gradient elution, 0 to 100% EtOAc/Hexane) to gave the amide (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-, methyl ester) (45 mg); Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=501.23, HPLC Rt=2.073 min.
    Figure US20070078122A1-20070405-C00811
  • 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, methyl ester. This methoxyphenyl analog (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-, methyl ester) was prepared from 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-amino-13-cyclohexyl-6,7-dihydro-3-methoxy-, methyl ester in a similar manner; Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.5; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=531.29, HPLC Rt=2.028 min.
    Figure US20070078122A1-20070405-C00812
  • 13-cyclohexyl-6,7-dihydro-6-[[(tetrahydro-2H-pyran-4-yl)carbonylyamino]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-, methyl ester) using TMSOK in THF in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=487.19, HPLC Rt=1.978 min.
    Figure US20070078122A1-20070405-C00813
  • 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-5H-indolo[2,1-a][2]benzazepine-10-carboxamide. (5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-) using CDI as a coupling reagent in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO {tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=593.23, HPLC Rt=1.928 min.
    Figure US20070078122A1-20070405-C00814
  • 13-cyclohexyl-6,7-dihydro-6-[[[[1-(trifluoroacetyl)-4-piperidinyl]amino]carbonyl]amino]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[[[1-(trifluoroacetyl)-4-piperidinyl]amino]carbonyl]amino]-, methyl ester) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-amino-13-cyclohexyl-6,7-dihydro-, methyl ester) and the corresponding isocyanate under microwave conditions (PhMe, 100° C., normal absorption level); Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2O0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=611.32, HPLC Rt=2.100 min.
    Figure US20070078122A1-20070405-C00815
  • 13-cyclohexyl-6,7-dihydro-6-[[(3-methoxycyclohexyl)carbonyl]amino]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, methyl ester. (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(3-methoxycyclohexyl)carbonyl]amino]-, methyl ester) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-amino-13-cyclohexyl-6,7-dihydro-, methyl ester) and the corresponding acid chloride in a similar manner as described before; Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.6; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=529.31, HPLC Rt=2.100 min.
    Figure US20070078122A1-20070405-C00816
  • 13-cyclohexyl-6,7-dihydro-6-[[(3-methoxycyclohexyl)carbonyl]methylamino]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. To a mixture of the methyl ester (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(3-methoxycyclohexyl)carbonyl]amino]-, methyl ester) (47 mg, 88.9 μmol)) in DMF (1.5 ml) at r.t. under N2 was added NaH (107 mg, 2.68 mmol, 60% in oil), and the reaction mixture stirred for about 10 min. MeI (23 μl, 0.37 mmol) was then added to the mixture, which was stirred at r.t. for 18.5 hr. The reaction mixture was diluted with water (2 ml), and acidified with hydrochloric acid (1N). The precipitates were filtered, washed with water (3×1 ml), and dried under high vacuum to give the acid (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(3-methoxycyclohexyl)carbonyl]methylamino]-); Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.4; Analytical HPLC method: Solvent A=10% MeÕH90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50mm; LC/MS: (ES+) m/z (M+H)+=529.34, HPLC Rt=2.085 min.
    Figure US20070078122A1-20070405-C00817
  • 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[methyl[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[methyl[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-, methyl ester) in a similar manner; Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.3; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 mi/min, Column: Xterra MS C18 S7 3.0×50mm; LC/MS: (ES+) m/z (M+H)+=531.27, HPLC Rt=2.020 min.
    Figure US20070078122A1-20070405-C00818
  • 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[(3-methoxycyclohexyl)carbonyl]methylamino]-5H-indolo[2,1-a][2]benzazepine-10-carboxamide. (5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[(3-methoxycyclohexyl)carbonyl]methylamino]-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[[(3-methoxycyclohexyl)carbonyl]methylamino]-) using CDI as a coupling reagent in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=635.32, HPLC Rt=2.042 min.
    Figure US20070078122A1-20070405-C00819
  • 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[methyl[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-5H-indolo[2,1-a][2]benzazepine-10-carboxamide. (5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[methyl[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[methyl[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]-) using CDI as a coupling reagent in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2O0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=637.27, HPLC Rt=1.958 min.
    Figure US20070078122A1-20070405-C00820
  • 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, methyl ester. To a mixture of the acid (5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-, 10-methyl ester) (100 mg, 0.22 mmol) in CH2Cl2 (1 ml) at r.t. under N2 was added a solution of oxalyl chloride in CH2Cl2 (0.45 ml, 0.9 mmol, 2M ). 2 drops of DMF was then added using a syringe with a G21 needle. The mixture was stirred at r.t. for 1 hr, and then evaporated and dried under high vacuum. A solution of the tetrahydrofurfurylamine (0.14 ml, 1.36 mmol) in CH2Cl2 (1 ml) was then added to the residue. The reaction mixture was stirred for 1 hr, evaporated and purified by Biotage flash chromatography (gradient elution, 0 to 50% EtOAc/Hexane) to gave the amide (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]-, methyl ester); Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.45; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=531.26, HPLC Rt=2.070 min.
    Figure US20070078122A1-20070405-C00821
  • 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[(2-oxazolylmethyl)amino]carbonyl]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, methyl ester. (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[(2-oxazolylmethyl)amino]carbonyl]-, methyl ester) was prepared from 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-, 10-methyl ester and 2-aminomethyloxazole in a similar manner as described; Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.40; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=528.23, HPLC Rt=2.040 min.
    Figure US20070078122A1-20070405-C00822
  • 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[methyl[(tetrahydro-2-furanyl)methyl]amino]carbonyl]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[methyl[(tetrahydro-2-furanyl)methyl]amino]carbonyl]-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]-, methyl ester) by methylation using MeI and NaH in DMF in a similar manner as described before; Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.35; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=531.22, HPLC Rt=2.003 min.
    Figure US20070078122A1-20070405-C00823
  • 13-cyclohexyl-N˜10˜-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N˜6˜-methyl-N˜6˜-[(tetrahydro-2-furanyl)methyl]-5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide. (5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N˜10˜-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N˜6˜-methyl-N˜6˜-[(tetrahydro-2-furanyl)methyl]-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[methyl[(tetrahydro-2-furanyl)methyl]amino]carbonyl]-) using CDI as a coupling reagent in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2O0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=637.27, HPLC Rt=1.953 min.
    Figure US20070078122A1-20070405-C00824
  • 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[methyl(2-oxazolylmethyl)amino]carbonyl]-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[methyl(2-oxazolylmethyl)amino]carbonyl]-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[(2-oxazolylmethyl)amino]carbonyl]-, methyl ester) by methylation using MeI and NaH in DMF in a similar manner as described before; Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.30; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}10% H2O0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=531.31, HPLC Rt=1.970 min.
    Figure US20070078122A1-20070405-C00825
  • 13-cyclohexyl-N˜10˜-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N˜6˜-methyl-N˜6˜-(2-oxazolylmethyl)-5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide. 5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N˜10˜-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-N˜6˜-methyl-N˜6˜-(2-oxazolylmethyl)-) was prepared from (5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-3-methoxy-6-[[methyl(2-oxazolylmethyl)amino]carbonyl]-) using CDI as a coupling reagent in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeO{tilde over (H)}90% H2Õ0.1% TFA, Solvent B=90% MeO{tilde over (H)}20% H2Õ0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=634.22, HPLC Rt=1.937 min.
  • The Liquid chromatography and Mass spectrometry conditions which follow pertain to the following procedures until noted: LCMS data: Gradient time: 2 min; Flow rate: 4 mL/min;, Stop time: Gradient time: +1 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H2O with 0.1% TFA; Eluent B: 90% MeOH /10% H2O with 0.1% TFA; Column 6: Phenomenex-luna 10 μ C18 4.6×50 mm S10.
    Figure US20070078122A1-20070405-C00826
  • ESI-MS m/z 388(M-17, positive ion mode); 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 1.29-1.62 (m, 3 H) 1.70-2.09 (m, 7 H) 2.95-3.17 (m, 1 H) 3.90 (d, J=2.20 Hz, 3 H) 6.38 (d, J=23.05 Hz, 1 H) 7.03 (d, 1 H) 7.18 (s, 1 H) 7.21 (s, 1 H) 7.66-7.73 (m, 2 H) 8.12 (d, J=15.00 Hz, 1 H).
    Figure US20070078122A1-20070405-C00827
  • ESI-MS m/z 388(M-17, positive ion mode), m/z 405(M): 1H NMR (500 MHz, Acetone) δ ppm 1.80-2.13 (m, 3 H) 2.23-2.53 (m, 7 H) 3.62-3.79 (m, 1 H) 4.38 (s, 3 H) 6.64 (d, J=2.14 Hz, 2 H) 6.66 (d, J=9.46 Hz, 1 H) 7.31 (d, J=9.16 Hz, 1 H) 7.47 (d, J=7.93 Hz, 1 H) 7.87 (d, J=7.93 Hz, 1 H) 8.17 (d, J=8.24 Hz, 1 H) 8.28 (d, J=8.54 Hz, 1 H) 8.67 (s, 1 H).
    Figure US20070078122A1-20070405-C00828
  • ESI-MS m/z 474(MH+); 1H NMR (300 MHz, 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 1.14-1.47 (m, 3 H) 1.88 (d, J=75.75 Hz, 7 H) 2.73-2.82 (m, 1 H) 6.10 (d, J=10.61 Hz, 2 H) 6.89 (s, 1 H) 6.95-6.98 (m, 1 H) 7.60-7.77 (m, 2 H) 7.77-7.86 (m, 1 H) 8.25 (s, 1 H).
    Figure US20070078122A1-20070405-C00829
  • ESI-MS m/z 538(MH+); 1H NMR (300 MHz, DMSO-D6) δ ppm 1.02-1.51 (m, 4 H) 1.61-2.14 (m, 6 H) 2.40-2.59 (m, 6 H) 2.69-2.89 (m, 1 H) 3.89 (s, 3 H) 4.07-4.26 (m, 1 H) 5.45-5.67 (m, 1 H) 7.53-7.74 (m, 5 H) 7.88 (s, 1 H) 7.94 (d, J=8.42 Hz, 1 H) 8.18 (s, 1 H).
    Figure US20070078122A1-20070405-C00830
  • ESI- MS m/z 557(MH+); 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 0.75-2.49 (m, 21 H) 2.71-2.97 (m, 2 H) 3.24-3.47 (m, 1 H) 3.88-3.99 (m, 3 H) 4.39 (s, 1 H) 5.02 (d, J=13.17 Hz, 1 H) 6.08 (d, J=13.54 Hz, 2 H) 6.60 (s, 1 H) 6.80 (s, 1 H) 6.94 (s, 1 H) 7.71 (d, J=8.05 Hz, 1 H) 7.83 (d, 1 H) 8.08 (s, 1 H).
    Figure US20070078122A1-20070405-C00831
  • ESI-MS m/z 543(MH+); 1 H NMR (300 MHz, CHLOROFORM-D) δ ppm 0.62-2.17 (m, 19 H) 2.21-2.46 (m, 2 H) 2.68-2.93 (m, 1 H) 3.25-3.46 (m, 1 H) 4.39 (d, 1 H) 5.20 (d, 1 H) 6.08 (d, J=14.64 Hz, 2 H) 6.61 (s, 1 H) 6.81 (s, 1 H) 6.96 (s, 1 H) 7.75-7.89 (m, 2 H) 8.42 (s, 1 H).
    Figure US20070078122A1-20070405-C00832
  • ESI-MS m/z 649(MH+); 1H NMR (300 MHz, DMSO-D6) δ ppm 2.72-2.83 (m, 2 H) 2.85-2.92 (m, J=4.39 Hz, 6 H) 4.34 (d, 1 H) 5.09 (d, J=1.83 Hz, 1 H) 6.20 (d, J=21.59 Hz, 2 H) 6.76 (s, 1 H) 7.03 (s, 1 H) 7.15 (s, 1 H) 7.65 (d, J=8.78 Hz, 1 H) 7.89 (d, J=8.78 Hz, 1 H) 8.51 (s, 1 H).
    Figure US20070078122A1-20070405-C00833
  • 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 1.07-2.17 (m, 10 H) 2.68-2.91 (m, 1 H) 3.83 (s, 3 H) 3.95 (s, 3 H) 4.17-4.41 (m, 1 H) 5.60-5.79 (m, 1 H) 5.99-6.23 (m, 1 H) 7.00 (d, 1 H) 7.07 (d, 1 H) 7.74 (dd, 1 H) 7.85 (d, J=8.55 Hz, 1 H) 7.88 (s, 1 H) 8.28 (s, 1 H).
    Figure US20070078122A1-20070405-C00834
  • ESI-MS m/z 460(MH+); 1H NMR (500 MHz, Acetone) δ ppm 1.35-2.26 (m, 10 H) 2.86-3.01 (m, 1 H) 3.91 (s, 3 H) 4.33 (s, 1 H) 5.73 (s, 1 H) 6.07-6.38 (m, 2 H) 7.13-7.17 (m, 1 H) 7.18-7.22 (m, 1 H) 7.67-7.72 (m, 1 H) 7.89 (s, 1 H) 7.93 (d, J=8.55 Hz, 1 H) 8.29 (s, 1 H).
    Figure US20070078122A1-20070405-C00835
  • ESI-MS m/z 557(MH+); 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 0.78-2.16 (m, 16 H) 2.40 (s, 2 H) 2.72-2.87 (m, 2 H) 2.90-3.08 (m, 1 H) 3.24-3.52 (m, 1 H) 3.86-3.89 (m, 1 H) 3.92 (s, 3 H) 4.35-4.59 (m, 1 H) 4.92-5.18 (m, 1 H) 5.97-6.18 (m, 2 H) 6.75 (s, 1 H) 6.94 (d, 1 H) 7.01 (d, 1 H) 7.71 (dd, 1 H) 7.83 (q, 1 H) 8.11 (s, 1 H).
    Figure US20070078122A1-20070405-C00836
  • ESI-MS m/z 543(MH+); 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 0.73-2.16 (m, 16 H) 2.26-2.53 (m, 2 H) 2.56-2.93 (m, 2 H) 3.26-3.67 (m, 2 H) 4.35-4.62 (m, 1 H) 5.09-5.41 (m, 1 H) 5.92-6.18 (m, 2 H) 6.74-6.80 (m, 1 H) 6.95 (d, 1 H) 7.03 (d, 1 H) 7.79 (d, 1 H) 7.86 (d, 1 H) 8.41-8.45 (m, 1 H).
    Figure US20070078122A1-20070405-C00837
  • LCMS: m/z 690(MH+), ret time 1.88 min.
    Figure US20070078122A1-20070405-C00838
  • 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 1.10-1.57 (m, 3 H) 1.89 (s, 7 H) 2.72-2.83 (m, 1 H) 2.92-3.05 (m, 6 H) 3.64-3.69 (m, 3 H) 3.87-3.91 (m, 3 H) 4.02-4.16 (m, 5 H) 5.12-5.53 (m, 1 H) 6.95-6.99 (m, 1 H) 7.05 (d, 1 H) 7.27-7.36 (m, 2 H) 7.44-7.52 (m, 2 H) 7.67 (d, 1 H) 7.83 (d, 1 H) 8.11-8.14 (m, 1 H).
    Figure US20070078122A1-20070405-C00839
  • Step 1. A solution of tert-butyl piperazine-1-carboxylate (372.5 mg, 2.0 mmol) and N,N-diisopropylethylamine (517 mg, 4 mmol) in DMSO (2 mL) was rapidly added to a stirred solution of Fmoc-Gly OH (594.6 mg, 2 mmol) and TBTU (707 mg, 2.2 mmol) in DMSO (2 mL) at 10° C. The cooling bath was removed and stirred continued for 30 min at 22° C. The mixture was poured into water and the precipitated solid extracted into ethyl acetate. The organic solution was washed (water(2×), dilute HCl, brine), dried (sodium sulfate) and concentrated to leave the product as a yellow froth. A portion (140 mg) was purified on a silicic acid thick layer plate. The plate was eluted with methylene chloride:ethyl acetate (4:1). The band containing the product was extracted. The extract was concentrated and the residue crystallized form methanol to leave the titled compound. LC/MS m/z 466(MH+); 1H NMR (300 MHz, CHLOROFORM-D) δ ppm 1.44 (s, 9 H) 3.31-3.38 (m, J=5.49 Hz, 2 H) 3.38-3.48 (m, 4 H) 3.55-3.65 (m, J=5.49 Hz, 2 H) 4.02 (d, J=4.03 Hz, 2 H) 4.20 (t, J=7.14 Hz, 1 H) 4.35 (d, J=7.32 Hz, 2 H) 5.79 (s, 1 H) 7.28 (t, J=7.50 Hz, 2 H) 7.37 (t, J=7.14 Hz, 2 H) 7.58 (d, J=6.95 Hz, 2 H) 7.73 (d, J=7.32 Hz, 2 H). Step 2. A solution of tert-butyl 4-(2-(((9H-fluren-9-yl)methoxy)carbonyl)acetyl)piperazine-1-carboxylate in TFA and methylene chloride (1:1) was stirred for 1 hr at 22° C. The solution was concentrated and the residue diluted with hexanes. Removal of the hexanes left the titled compound as a hygroscopic colorless foam. LCMS: m/z 366(MH+), ret time 2.06 min. 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-6-[[4-(2-aminoacetyl)-1-piperazinyl]carbonyl-7H-indolo[2,1-a][2]benzazepine-10-carboxamide trifluoroacetate. Diisopropylethylamine (55 mL, 0.315 mmol) was added to a stirred solution at 22° C. of 6-carboxy-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-5H-indolo[2,1-a][2]benzaepine-10-carboxamide (50 mg, 0.0788 mmol), (9H-fluoren-9-yl)methyl 2-oxo-2-(piperazin-1-yl)ethylcarbamate trifluoroacetate (83 mg, 0.173 mmol), and TBTU (56 mg, 0.173 mmol) in DMSO (0.3 mL). The solution was stirred for 30 min and then diluted with water to precipitate the Fmoc protected product. This product was dried in a desicator charged with phosphorous pentoxide. Piperidine (0.4 mL) was added to a solution of the dried solid in DMF (1 mL). After 30 min the solution was injected on a Shimadzu preparative liquid chromatograph fitted with a reverse phase column. The column was eluted with methanol, water containing 0.1% TFA. The methanol was removed on a rotary evaporator. The solution was lyophilized to leave the product as a TFA salt (12.8 mg, 16.5% yield). ESI-MS m/z 663(MH+); 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 1.05-1.49 (m, 3 H) 1.59-2.09 (m, 10 H) 2.71-3.04 (m, 6 H) 3.27-3.63 (m, 8 H) 3.80-3.83 (m, 3 H) 3.92-4.17 (m, 3 H) 4.96-5.12 (m, 1 H) 6.80 (d, 1 H) 6.88 (d, 1 H) 6.97 (d, 1 H) 7.41 (d, 1 H) 7.52 (d, 1 H) 7.75 (d, 1 H) 7.97-8.16 (m, 2 H) 8.18-8.21 (m, 1 H).
  • The Liquid chromatography and Mass spectrometry conditions which follow pertain to the following procedures until noted: LCMS data: Gradient time: 2 min; Flow rate: 4 mL/min; Stop time: Gradient time +2 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H2O with 0.1% TFA; Eluent B: 90% MeOH/10% H2O with 0.1% TFA; Column 1: Phenomenex 10 μ C18 4.6×50 mm.
    Figure US20070078122A1-20070405-C00840
  • LCMS: m/z 635 (MH+), ret time 2.89 min.
    Figure US20070078122A1-20070405-C00841
  • LCMS: m/z 649 (MH+), ret time 2.88 min.
    Figure US20070078122A1-20070405-C00842
  • LCMS: m/z 621 (MH+), ret time 2.86 min.
    Figure US20070078122A1-20070405-C00843
  • LCMS: m/z 650 (MH+), ret time 2.59 min.
    Figure US20070078122A1-20070405-C00844
  • LCMS: m/z 664 (MH+), ret time 2.51 min.
    Figure US20070078122A1-20070405-C00845
  • LCMS: m/z 662 (MH+), ret time 2.03 min.
    Figure US20070078122A1-20070405-C00846
  • LCMS: m/z 665 (MH+), ret time 2.03 min.
    Figure US20070078122A1-20070405-C00847
  • LCMS: m/z 679 (MH+), ret time 2.06 min.
    Figure US20070078122A1-20070405-C00848
  • LCMS: m/z 674 (MH+), ret time 2.06 min.
    Figure US20070078122A1-20070405-C00849
  • ESI-MS m/z 637 (MH+); 1H NMR (500 MHz, MeOD) δ ppm 1.38-1.82 (m, 4 H) 1.95-2.42 (m, 6 H) 3.04-3.52 (m, 5 H) 3.24-3.27 (m, 6 H) 3.60-3.85 (m, 3 H) 4.15 (s, 3 H) 4.21-4.71 (m, 2 H) 4.54-4.71 (m, 1 H) 5.30-5.46 (m, 1 H) 7.20 (s, 1 H) 7.33 (s, 1 H) 7.38 (dd, J=8.55, 2.44 Hz, 1 H) 7.80 (dd, J=19.84, 8.55 Hz, 2 H) 8.14 (d, J=8.55 Hz, 1 H) 8.35 (s, 1 H).
    Figure US20070078122A1-20070405-C00850
  • LCMS: m/z 663 (MH+), ret time 2.72 min.
    Figure US20070078122A1-20070405-C00851
  • LCMS: m/z 524 (MH+), ret time 2.23 min.
    Figure US20070078122A1-20070405-C00852
  • LCMS: m/z 561 (MH+), ret time 2.64 min.
    Figure US20070078122A1-20070405-C00853
  • LCMS: m/z 662 (MH+), ret time 1.75 min.
    Figure US20070078122A1-20070405-C00854
  • LCMS: m/z 590 (MH+), ret time 2.50 min.
    Figure US20070078122A1-20070405-C00855
  • LCMS: m/z 590 (MH+), ret time 2.66 min.
    Figure US20070078122A1-20070405-C00856
  • LCMS: m/z 654 (MH+), ret time 2.53 min.
    Figure US20070078122A1-20070405-C00857
  • LCMS: m/z 618 (MH+), ret time 2.52 min.
    Figure US20070078122A1-20070405-C00858
  • LCMS: m/z 688 (MH+), ret time 2.68 min.
    Figure US20070078122A1-20070405-C00859
  • LCMS: m/z 589 (MH+), ret time 2.56 min.
    Figure US20070078122A1-20070405-C00860
  • LCMS: m/z 674 (MH+), ret time 2.64 min.
    Figure US20070078122A1-20070405-C00861
  • LCMS: m/z 652 (MH+), ret time 2.72 min.
    Figure US20070078122A1-20070405-C00862
  • LCMS: m/z 646 (MH+), ret time 2.59 min.
    Figure US20070078122A1-20070405-C00863
  • LCMS: m/z 621 (MH+), ret time 2.62 min.
    Figure US20070078122A1-20070405-C00864
  • LCMS: m/z 595 (MH+), ret time 2.52 min.
    Figure US20070078122A1-20070405-C00865
  • LCMS: m/z 605 (MH+), ret time 2.65 min.
    Figure US20070078122A1-20070405-C00866
  • LCMS: m/z 623 (MH+), ret time 2.64 min.
    Figure US20070078122A1-20070405-C00867
  • LCMS: m/z 730 (MH+), ret time 2.68 min.
    Figure US20070078122A1-20070405-C00868
  • LCMS: m/z 648 (MH+), ret time 2.46 min.
    Figure US20070078122A1-20070405-C00869
  • LCMS: m/z 589 (MH+), ret time 2.55 min.
    Figure US20070078122A1-20070405-C00870
  • LCMS: m/z 584 (MH+), ret time 2.47 min.
    Figure US20070078122A1-20070405-C00871
  • LCMS: m/z 589 (MH+), ret time 1.91 min.
    Figure US20070078122A1-20070405-C00872
  • ESI-MS m/z 690 (MH+); 1H NMR (500 MHz, MeOD) δ ppm 1.19-1.56 (m, 6 H) 1.59-1.72 (m, 1 H) 1.75-2.20 (m, 8 H) 2.84-3.00 (m, 3 H) 3.03 (s, 6 H) 3.07-3.31 (m, 5 H) 3.36-3.49 (m, 1 H) 3.67-3.85 (m, 2 H) 3.94 (s, 3 H) 4.04-4.20 (m, 2 H) 4.42-4.51 (m, 1 H) 5.13-5.24 (m, 1 H) 6.99 (s, 1 H) 7.05-7.11 (m, 1 H) 7.16-7.22 (m, 1 H) 7.57-7.63 (m, 2 H) 7.97 (d, J=8.55 Hz, 1 H) 8.15 (s, 1 H).
    Figure US20070078122A1-20070405-C00873
  • ESI-MS m/z 695 (MH+); 1H NMR (500 MHz, MeOD) δ ppm 1.27-1.58 (m, 6 H) 1.61-1.73 (m, 1 H) 1.78-2.23 (m, 8 H) 2.83-2.92 (m, 2 H) 2.93-3.01 (m, 2 H) 3.04 (s, 6 H) 3.14-3.30 (m, 6 H) 3.36-3.48 (m, 1 H) 3.72-3.84 (m, 1 H) 4.08-4.19 (m, 1 H) 4.49 (s, 1 H) 5.22 (s, 1 H) 7.02 (s, 1 H) 7.54-7.61 (m, 2 H) 7.62-7.66 (m, 2 H) 8.02 (d, J=8.85 Hz, 1 H) 8.18 (s, 1 H).
    Figure US20070078122A1-20070405-C00874
  • LCMS: m/z 632 (MH+), ret time 2.17 min.
    Figure US20070078122A1-20070405-C00875
  • LCMS: m/z 766 (MH+), ret time 2.03 min.
    Figure US20070078122A1-20070405-C00876
  • LCMS: m/z 782 (MH+), ret time 1.99 min.
    Figure US20070078122A1-20070405-C00877
  • LCMS: m/z 713 (MH+), ret time 2.07 min.
    Figure US20070078122A1-20070405-C00878
  • LCMS: m/z 760 (MH+), ret time 2.21 mm
    Figure US20070078122A1-20070405-C00879
  • LCMS: m/z 789 (MH+), ret time 2.23 min.
    Figure US20070078122A1-20070405-C00880
  • LCMS: m/z 670 (MH+), ret time 1.86 min.
    Figure US20070078122A1-20070405-C00881
  • LCMS: m/z 699 (MH+), ret time 1.91 min.
    Figure US20070078122A1-20070405-C00882
  • LCMS: m/z 663 (MH+), ret time 2.07 min.
    Figure US20070078122A1-20070405-C00883
  • LCMS: m/z 538 (MH+), ret time 2.41 min.
    Figure US20070078122A1-20070405-C00884
  • The Liquid chromatography and Mass spectrometry conditions which follow pertain to the following procedures until noted: LCMS: m/z 575 (MH+), ret time 2.73 min LCMS data: Gradient time: 2 min; Flow rate: 4 mL/min; Stop time: Gradient time +1 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H2O with 0.1% TFA; Eluent B: 90% MeOH/10% H2O with 0.1% TFA; Column 3: Phenomenex-luna 10 4.6×50 mm S10.
    Figure US20070078122A1-20070405-C00885
  • The acid (150 mg, 0.23 mmol), DMAP (55 mg, 0.46 mmol) and piperazin-3-one (25 mg 0.25) were dissolved in THF (3 mL). HATU (130 mg, 0.34 mmol) was added and the mixture was stirred at rt for 18 h. Solvent was removed in vacuo and the residue was dissolved in MeOH, a solid was removed by filtration and the solution was concentrated and purified using prep HPLC to afford the title compound as a yellow solid.
    Figure US20070078122A1-20070405-C00886
  • 13-cyclohexyl-6-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-N-[2-(4-morpholinyl)ethyl]-7H-indolo[2,-a][2]benzazepine-10-carboxamide. The title compound was prepared as described above for 13-Cyclohexyl-6-(2,6-dimethyl-4-morpholinylcarbonyl)-5H-indolo[2,1-a][2]benzazepine-N-(2-hydroxyethyl)-10-carboxamide using aminoethylmorpholino as the amine counterpart. After prep HPLC the title compound was obtained as a yellow solid. 1HNMR (500 MHz, DMSO) δ 9.74 (bs, 1H), 8.70 (m, 1H), 8.17 (s, 1H), 7.91 (d, J=8.5 Hz, 1H), 7.57 (m, 4H), 6.96 (s, 1H), 5.08 (br s, 1H), 4.37 (br s, 1H), 4.03 (m, 2H), 3.78-3.58 (m, 8H), 3.19 (m, 2H), 2.77 (m, 1H), 2.54 (m, 6H), 2.10-1.0 (m, 16 H). LCMS: m/e 611 (M+H)+, ret time 2.00 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00887
  • 13-cyclohexyl-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 6-(2-acetyl-1-methylhydrazide). A mixute of 13-cyclohexyl-6-(carboxy)-5H-indolo[2,1-a][2]benzazepine-10-carboxylate (200 mg, 0.48 mmol), DMAP (117 mg, 0.96 mmol) and N′-methylacetohydrazide (84 mg, 0.96 mmol) in THF (10 mL) was treated with HATU (366 mg, 0.96 mmol) and stirred at rt for 1 h. Solvent was removed in vacuo and AcOEt (25 mL) and H2O (25 mL) were added. The organic layer was separated and dried over Na2SO4. The residue was dissolved in 5 mL of MeOH and 5 mL of THF. NaOH (1N, 1.44 mL) was added and the mixture was heated at 70° C. for 18 h, then NaOH (1N, 2 mL) was added and the temperature was raised to 80° C. After 1 h, the reaction was cooled to rt and quenched with HCl (1N). Volatiles were removed in vacuo, the solid was dissolved in DMF/MeOH and purified using prep HPLC to afford the title compound as a yellow solid (83 mg). 1HNMR (500 MHz, DMSO) δ 8.20 (s, 1H), 7.94 (d, J==8.5 Hz, 1H), 7.65-7.52 (m, 5H), 7.21 (br s, 1H), 5.15 (br s, 1H), 4.37 (br s, 1H), 3.05 (s, 6H), 2.75 (m, 1H), 2.10-1.15 (m, 10H). LCMS: m/e 472 (M+H)+, ret time 2.23 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00888
  • 13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid, 2-acetyl-1-methylhydrazide. 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-, 6-(2-acetyl-1-methylhydrazide) (95 mg, 0.2 mmol) was dissolved in THF (2mL), CDI (39 mg, 0.24 mmol) was added and the mixture was heated at 50° C. for 2 h, then cooled at rt. A solution of DBU (42 uL, 0.28 mmol) in THF (0.5 mL) was added dropwise, followed by dimethylsulfonyl amide (30 mg, 0.24 mmol). The mixture was heated at 50° C. for 18 h. Volatiles were removed in vacuo and the residue was purified using prep HPLC to afford the title compound as a yellow solid (20 mg). 1HNMR (500 MHz, DMSO) δ 8.43 (br s, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.70-7.60 (m, 5H), 7.18 (br s, 1H), 5.23 (br s, 1H), 4.25 (br s, 1H), 3.05 (s, 3H), 2.97 (s, 6H), 2.75 (m, 1H), 2.10-1.15 (m, 10H). LCMS: m/e 578 (M+H)+, ret time 2.18 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00889
  • 13-cyclohexyl-N-[[[2-(dimethylamino)ethyl]methylamino]sulfonyl]-6-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide. The title compound was prepared as described above for 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-N-[(methylamino)sulfonyl]-, using N,N-dimethylethane-1,2-diamine sulfonylurea. 1HNMR (500 MHz, DMSO) δ 9.43 (br s, 1H), 8.51 (br s, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.70-7.60 (m, 5H), 6.95 (br s, 1H), 5.13 (br s, 1H), 4.39 (br s, 1H), 3.38-2.80 (m, 10H), 2.75 (m, 1H), 2.70-1.00 (m, 16H). LCMS: m/e 662 (M+H)+, ret time 2.09 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00890
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-N-[2-(4-morpholinyl)ethyl]-. The title compound was prepared as described above for 13-Cyclohexyl-6-(2,6-dimethyl-4-morpholinylcarbonyl)-5H-indolo[2,1-a][2]benzazepine-N-(2-hydroxyethyl)-10-carboxamide using aminoethylmorpholino as the amine counterpart. After prep HPLC the title compound was obtained as a yellow solid. 1HNMR (500 MHz, DMSO) δ 9.74 (bs, 1H), 8.70 (m, 1H), 8.17 (s, 1H), 7.91 (d, J=8.5 Hz, 1H), 7.57 (m, 4H), 6.96 (s, 1H), 5.08 (br s, 1H), 4.37 (br s, 1H), 4.03 (m, 2H), 3.78-3.58 (m, 8H), 3.19 (m, 2H), 2.77 (m, 1H), 2.54 (m, 6H), 2. 10-1.0 (m, 16 H). LCMS: m/e 611 (M+H)+, ret time 2.00 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00891
  • 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-, 6-(2-acetyl-1-methylhydrazide). A mixute of 13-cyclohexyl-6-(carboxy)-5H-indolo[2,1-a][2]benzazepine-10-carboxylate (200 mg, 0.48 mmol), DMAP (117 mg, 0.96 mmol) and N′-methylacetohydrazide (84 mg, 0.96 mmol) in THF (10 mL) was treated with HATU (366 mg, 0.96 mmol) and stirred at rt for 1 h. Solvent was removed in vacuo and AcOEt (25 mL) and H2O (25 mL) were added. The organic layer was separated and dried over Na2SO4. The residue was dissolved in 5 mL of MeOH and 5 mL of THF. NaOH (1N, 1.44 mL) was added and the mixture was heated at 70° C. for 18 h, then NaOH (1N, 2 mL) was added and the temperature was raised to 80° C. After 1 h, the reaction was cooled to rt and quenched with HCl (1N). Volatiles were removed in vacuo, the solid was dissolved in DMF/MeOH and purified using prep HPLC to afford the title compound as a yellow solid (83 mg). 1HNMR (500 MHz, DMSO) δ 8.20 (s, 1H), 7.94 (d, J=8.5 Hz, 1H), 7.65-7.52 (m, 5H), 7.21 (br s, 1H), 5.15 (br s, 1H), 4.37 (br s, 1H), 3.05 (s, 6H), 2.75 (m, 1H), 2.10-1.15 (m, 10H). LCMS: m/e 472 (M+H)+, ret time 2.23 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00892
    Figure US20070078122A1-20070405-C00893
  • 7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid, 13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-, 2-acetyl-1-methylhydrazide. 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxylic acid, 13-cyclohexyl-, 6-(2-acetyl-1-methylhydrazide) (95 mg, 0.2 mmol) was dissolved in THF (2mL), CDI (39 mg, 0.24 mmol) was added and the mixture was heated at 50° C. for 2 h, then cooled at rt. A solution of DBU (42 uL, 0.28 mmol) in THF (0.5 mL) was added dropwise, followed by dimethylsulfonyl amide (30 mg, 0.24 mmol). The mixture was heated at 50° C. for 18 h. Volatiles were removed in vacuo and the residue was purified using prep HPLC to afford the title compound as a yellow solid (20 mg). 1HNMR (500 MHz, DMSO) δ 8.43 (br s, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.70-7.60 (m, 5H), 7.18 (br s, 1H), 5.23 (br s, 1H), 4.25 (br s, 1H), 3.05 (s, 3H), 2.97 (s, 6H), 2.75 (m, 1H), 2.10-1.15 (m, 10H). LCMS: m/e 578 (M+H)+, ret time 2.18 min, column 3, 2 minute gradient.
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[[[2-(dimethylamino)ethyl]methylamino]sulfonyl]-6-[[(2R, 6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-. The title compound was prepared as described above for 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-N-[(methylamino)sulfonyl]-, using N,N-dimethylethane-1,2-diamine sulfonylurea. 1HNMR (500 MHz, DMSO) δ 9.43 (br s, 1H), 8.51 (br s, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.70-7.60 (m, 5H), 6.95 (br s, 1H), 5.13 (br s, 1H), 4.39 (br s, 1H), 3.38-2.80 (m, 10H), 2.75 (m, 1H), 2.70-1.00 (m, 16H). LCMS: mile 662 (M+H)+, ret time 2.09 min, column 3, 2 minute gradient.
    Figure US20070078122A1-20070405-C00894
  • To a flask containing a solution of compound A (1.2 g, xx mmol) in MeOH (20 mL) was added a catalytic amount of Pd (10% in C) and a balloom filled with H2 was placed on top. The mixture was stirred at rt for 24 h. The catalyst was removed by filtration and the solution was concentrated to afford a pale yellow solid containing compound B (˜70% pure) which was used in the next step without further purification. This solid (200 mg, 0.39 mmol) was dissolved in THF (4 mL) and treated with DMAP (143 mg, 1.17 mmol), hydrazine (34 mg, 0.39 mmol) and HATU (222 mg, 0.58 mmol). The mixture was stirred at rt for 18 h. Solvent was removed in vacuo and H2O was added. The solid was collected by filtration and purified using reverse phase prep HPLC to afford the title compound C as a pale yellow solid (28 mg). 1HNMR (500 MHz, DMSO) δ 8.45 (br s, 1H), 8.09 (m, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.70-7.40 (m, 5H), 4.7 (m, 1H), 3.05 (d, J=12.0 Hz, 3H), 3.05 (s, 6H), 2.97 (m, 1H), 2.1(s, 3H), 2.10-1.15 (m, 10H). LCMS: m/e 580 (M+H)+, ret time 2.25 min, column 3, 2 minute gradient.
  • The general methods described below pertain to the experimental procedures below until further noted: LCMS data: Stop time: Gradient time +1 minute; Starting conc: 0% B unless otherwise noted; Eluent A: 5% CH3CN/95% H2O with 10 mM NH4OAc (for columns A, D and E); 10% MeOH/90% H2O with 0.1% TFA (for columns B and C); Eluent B: 95% CH3CN/5% H2O with 10 mM NH4OAc (for columns A, D and E); 90% MeOH/10% H2O with 0.1% TFA (for columns B and C); Column A: Phenomenex 10 μ 4.6×50 mm C18; Column B: Phenomenex C18 10 μ 3.0×50 mm; Column C: Phenomenex 4.6×50 mm C18 10; Column D: Phenomenex Lina C18 513.0×50 mm; Column E:Phenomenex 5μ 4.6×50 mm C18.
  • Preparative HPLC data: Gradient: Linear over 20 min. unless otherwise noted; Starting conc: 15% B unless otherwise noted; Ending conc: 100% B; Eluent A: 5% CH3CN/95% H2O with 10 mM NH4OAc; Eluent B: 95% CH3CN/5% H2O with 10 mM NH4OAc; Column: Sunfire Prep C18 OBD 5130×100 mm.
    Figure US20070078122A1-20070405-C00895
  • 7H-Indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6,N6-bis[2-(dimethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy-. To a stirred solution of glycine, N-(carboxymethyl)-N-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]- (43 mg, 0.066 mmol), dimethylamine (2M in THF, 0.13 mL, 0.26 mmol) and triethylamine (0.037 mL) in DMF (1 mL) was added HATU (75 mg, 0.20 mmol). The reaction mixture was stirred at rt for 2 h, and additional dimethylamine (2M in THF, 0.10 mL, 0.20 mmol) and HATU (70 mg, 0.18 mmol) were added. The reaction was stirred at rt overnight, diluted with H2O (˜10 mL), acidified with IN HCl(aq.) (˜0.25 mL) and the precipitate was collected by filtration and flushed with H2O to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6,N6-bis[2-(dimethylamino)-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy- (31 mg, 0.044 mmol, 67%) as a yellow solid. 1HNMR (300 MHz, CD3OD) δ 8.22 (d, J=1.5 Hz, 1H), 7.93 (d, J=8.8 Hz, 1H), 7.62 (dd, J=1.5, 8.8 Hz, 1H), 7.56 (d, J=8.8 Hz, 1H), 7.16 (dd, J=2.6, 8.8 Hz, 1H), 7.03 (br s, 1H), 7.02 (d, J=2.6 Hz, 1H), 5.27-5.09 (m, 1H), 4.49-4.28 (m, 3H), 4.15-4.02 (m, 1H), 3.93 (s, 3H), 3.90-3.77 (m, 1H), 3.07 (s, 3H), 3.04 (s, 6H), 2.98-2.83 (m, 1H), 2.54 (s, 3H), 2.37 (s, 3H), 2.20-1.19 (m, 10H). LCMS: m/e 705 (M−H)−, ret time 2.67 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00896
  • D-alanine, N-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-N-methyl-. To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (150 mg, 0.28 mmol), (R)-methyl 2-(methylamino)propanoate hydrochloride (64 mg, 0.42 mmol) and triethylamine (0.16 mL) in DMF (2 mL) was added HATU (137 mg, 0.36 mmol). The reaction mixture was stirred at rt for 2.5 h, diluted with H2O (˜10 mL), acidified with 1M HCl (aq.). (˜0.5 mL) and the precipitate was collected by filtration and flushed with H2O. To a solution of the yellow solids in THF/MeOH (1:1, 3 mL) was added 1M NaOH (aq.) (0.6 mL, 0.6 mmol). The reaction solution was heated in a sealed tube with microwave irradiation at 70° C. for 20 min. The reaction was cooled, neutralized with 1M HCl (aq.) (0.6 mL, 0.6 mmol) and concentrated to remove organic solvents. The residue was slurried with H2O and the solids were collected by filtration and washed with H2O to yield D-alanine, N-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-N-methyl- (154 mg, 0.25 mmol, 89%) as a yellow solid. 1HNMR (300 MHz, CD3OD) δ 8.12 (s, 1H), 7.93 (d, J=8.4 Hz, 1H), 7.63-7.54 (m, 2H), 7.16 (dd, J=2.7, 8.6 Hz, 1H), 7.14-6.99 (m, 2H), 5.25-5.02 (m, 1H), 4.62-4.33 (m, 2H), 3.93 (s, 3H), 3.03 (s, 6H), 3.01-2.82 (m, 4H), 2.21-1.20 (m, 10H). LCMS: m/e 621 (M−H)−, ret time 2.07 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00897
  • 7H-Indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[(1R)-2-(dimethylamino)-1-methyl-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-. To a stirred solution of D-alanine, N-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-N-methyl- (50 mg, 0.08 mmol), dimethylamine (2M in THF, 0.080 mL, 0.16 mmol) and triethylamine (0.05 mL) in DMF (1.5 mL) was added HATU (46 mg, 0.12 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜10mL), acidified with 1M HCl (aq.) (˜0.50 mL), stirred 30 min. and the precipitate was collected by filtration and flushed with H2O. The solids were dissolved into MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[(1R)-2-(dimethylamino)-1-methyl-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl- (28 mg, 0.043 mmol, 54%) as a yellow solid. 1HNMR (300 MHz, CDCl3) δ 10.10-9.41 (m, 1H), 8.07 (s, 1H), 7.86 (d, J=8.8 Hz, 1H), 7.71-7.55 (m, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.03 (dd, J=2.6, 8.4 Hz, 1H), 6.89 (d, J=2.6 Hz, 1H), 6.78-6.61 (m, 1H), 5.37-5.02 (m, 1H), 4.96-4.79 (m, 1H), 4.46-4.27 (m, 1H), 3.88 (s, 3H), 3.19-2.71 (m, 7H), 3.02 (s, 6H), 2.49-1.09 (m, 16H). LCMS: m/e 648 (M−H)−, ret time 2.82 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00898
    Figure US20070078122A1-20070405-C00899
  • 7H-Indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-[(1R)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-. To a stirred solution of D-alanine, N-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-N-methyl- (50 mg, 0.08 mmol), morpholine (14 mg, 0.16 mmol) and triethylamine (0.05 mL) in DMF (1.5 mL) was added HATU (46 mg, 0.12 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜10 mL), acidified with 1M HCl (aq.) (˜0.50 mL), stirred 30 min. and the precipitate was collected by filtration and flushed with H2O. The solids were dissolved into MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-[(1R)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]- (26 mg, 0.038 mmol, 47%) as a yellow solid. 1HNMR (300 MHz, CDCl3) δ 8.07 (br s, 1H), 7.87 (d, J=8.8 Hz, 1H), 7.70-7.57 (m, 1H), 7.50 (d, J=8.8 Hz, 1H), 7.03 (dd, J=2.6, 8.8 Hz, 1H), 6.88 (d, J=2.6 Hz, 1H), 6.74-6.62 (m, 1H), 5.32-5.12 (m, 1H), 4.97-4.82 (m, 1H), 4.47-4.29 (m, 1H), 3.88 (s, 3H), 3.90-2.72 (m, 9H), 3.02 (s, 6H), 2.52-1.10 (m, 16H). LCMS: m/e 690 (M−H)−, ret time 2.82 min, column A, 4 minute gradient.
  • Carbamic acid, [1-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-3-azetidinyl]-, 1,1-dimethylethyl ester. To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (300 mg, 0.56 mmol), tert-butyl azetidin-3-ylcarbamate (192 mg, 1.2 mmol) and triethylamine (0.33 mL) in DMF (3 mL) was added HATU (320 mg, 0.84 mmol). The reaction mixture was stirred at rt for 3 h, additional tert-butyl azetidin-3-ylcarbamate (100 mg, 0.58 mmol) and HATU (120 mg, 0.32 mmol) were added and the reaction mixture was stirred at rt for 2 h and then diluted with H2O and stirred. The resulting precipitate was collected by filtration, flushed with H2O, dissolved into MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield carbamic acid, [1-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-3-azetidinyl]-, 1,1-dimethylethyl ester (282 mg, 0.041 mmol, 73%) as a yellow solid. 1HNMR (300 MHz, CDCl3) δ 8.23 (br s, 1H), 7.84 (d, J=8.8 Hz, 1H), 7.54 (d, J=8.4 Hz, 1H), 7.47 (d, J=8.4 Hz, 1H), 7.04 (dd, J=2.6, 8.8 Hz, 1H), 6.97 (br s, 1H), 6.86 (d, J=2.6 Hz, 1H), 5.66-5.42 (m, 1H), 4.56-3.83 (m, 6H), 3.89 (s, 3H), 3.01 (s, 6H), 2.87-2.72 (m, 1H), 2.12-1.08 (mm, 11H), 1.40 (s, 9H). LCMS: m/e 690 (M−H)−, ret time 3.26 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00900
  • 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-3-methoxy-. To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (100 mg, 0.19 mmol), 2-(piperazin-1-yl)ethanol (44 mg, 0.34 mmol) and triethylamine (0.12 mL) in DMF (1.0 mL) was added HATU (99 mg, 0.26 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O and concentrated. The residue was dissolved into MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-3-methoxy- (108 mg, 0.17 mmol, 88%) as a yellow solid. 1HNMR (300 MHz, CD3OD) δ 8.14 (s, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.64 (d, J=8.8 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.15 (dd, J=2.6, 8.4 Hz, 1H), 7.09 (d, J=2.6 Hz, 1H), 6.96 (s, 1H), 5.21-5.03 (m, 1H), 4.51-4.29 (m, 1H), 3.93 (s, 3H), 3.66-3.59 (m, 2H), 3.59-3.36 (m 2H), 3.00 (s, 6H), 2.94-2.80 (m, 1H), 2.54-1.08 (m, 18H). LCMS: m/e 648 (M−H)−, ret time 2.52 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00901
  • 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(hydroxymethyl)-1-piperidinyl]carbonyl]-3-methoxy-. To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (100 mg, 0.19 mmol), piperidin-4-ylmethanol (39 mg, 0.34 mmol) and triethylamine (0.12 mL) in DMF (1.0 mL) was added HATU (99 mg, 0.26 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O and concentrated. The residue was dissolved into MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(hydroxymethyl)-1-piperidinyl]carbonyl]-3-methoxy- (103 mg, 0.16 mmol, 86%) as a yellow solid. 1HNMR (300 MHz, CD3OD) δ 8.09 (s, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.59 (dd, J=1.2, 8.4 Hz, 1H), 7.52 (d, J=8.8 Hz, 1H), 7.09 (dd, J=2.6, 8.8 Hz, 1H), 7.05 (d, J=2.6 Hz, 1H), 6.90 (s, 1H), 5.17-4.97 (m, 1H), 4.46-4.24 (m, 1H), 3.90 (s, 3H), 3.37-3.26 (m, 2H), 2.98 (s, 6H), 2.95-2.74 (m, 3H), 2.19-1.01 (m, 17H). LCMS: m/e 633 (M−H)−, ret time 2.74 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00902
  • 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[(3-amino-1-azetidinyl)carbonyl]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-. To a solution of carbamic acid, [1-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-3-azetidinyl]-, 1,1-dimethylethyl ester (60 mg, 0.087 mmol) in CH2Cl2 (1.5 mL) was added trifluoroacetic acid (1.5 mL). The reaction mixture was stiffed at rt for 2 h, concentrated and the residue was dissolved into MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[(3-amino-1-azetidinyl)carbonyl]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy- (31 mg, 0.05 mmol, 60%) as a fluffy yellow solid. 1HNMR (300 MHz, d6-DMSO) δ 8.16 (s, 1H), 7.74 (d, J=8.4 Hz, 1H), 7.64 (d, J=8.4 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H), 7.28-7.17 (m, 3H) 5.57-5.26 (m, 1H), 4.72-4.46 (m, 1H), 3.98-3.08 (m, 5H), 3.87 (s, 3H), 2.75 (s, 6H), 2.83-2.68 (m, 1H), 2.12-0.96 (m, 12H). LCMS: m/e 592 (M+H)+, ret time 3.14 min, column B, 4 minute gradient.
    Figure US20070078122A1-20070405-C00903
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-3-methoxy-. 10% Palladium on carbon (60 mg, 0.06 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-3-methoxy- (67 mg, 0.10 mMol) in MeOH (3 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen overnight and again vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated. The residue was dissolved into MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-3-methoxy- (24 mg, 0.037 mmol, 36%) as a yellow solid. Mixture of atrope diastereomers. 1HNMR (300 MHz, CDCl3) δ 8.22-7.98 (m, 1H), 7.90-7.79 (m, 1H), 7.58-7.48 (m, 1H), 7.35-7.26 (m, 1H), 7.07-6.74 (m, 2H), 4.80-3.34 (m, 12H), 3.11-2.43 (m, 14H), 2.11-1.12 (m, 11H). LCMS: m/e 650 (M−H)−, ret time 2.54 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00904
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-(hydroxymethyl)-1-piperidinyl]carbonyl]-3-methoxy-. 10% Palladium on carbon (60 mg, 0.06 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(hydroxymethyl)-1-piperidinyl]carbonyl]-3-methoxy- (71 mg, 0.11 mmol) in MeOH (3 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen overnight and again vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated. The residue was dissolved into MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-(hydroxymethyl)-1-piperidinyl]carbonyl]-3-methoxy- (49 mg, 0.077 mmol, 69%) as a yellow solid. Mixture of atrope diastereomers. 1HNMR (300 MHz, CDCl3) δ 10.12-8.98 (m, 1H), 8.10-7.90 (m, 1H), 7.88-7.76 (m, 1H), 7.55-7.42 (m, 1H), 7.36-7.25 (m, 1H), 6.97-6.75 (m, 2H), 4.69-2.40 (m, 22H), 2.11-0.90 (m, 15H). LCMS: m/e 635 (M−H)−, ret time 2.75 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00905
  • 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[3-(hydroxymethyl)-1-azetidinyl]carbonyl]-3-methoxy. To a solution of tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (70 mg, 0.37 mmol) in CH2Cl2 (1 mL) was added trifluoroacetic acid (1 mL). The reaction mixture was stirred at rt for 2 h, concentrated, and the residue was combined with 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (72 mg, 0.13 mmol), triethylamine (0.10 mL), DMF (2.5 mL) and HATU (72 mg, 0.19 mmol). The reaction mixture was stirred at rt for 2 h and then additional azetidin-3-ylmethanol (prepared by stirring tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (70 mg, 0.37 mmol) with trifluoroacetic acid (1 mL) for 10 min, and then concentrating to dryness) in DMF (0.5 mL) and HATU (70 mg, 0.18 mmol) were added. The reaction mixture was stirred 0.5 h, diluted with MeOH (0.5 mL) and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[3-(hydroxymethyl)-1-azetidinyl]carbonyl]-3-methoxy- (67 mg, 0.11 mmol, 85%) as a yellow solid. 1HNMR (300 MHz, CDCl3) δ 8.08 (br s, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.63 (br d, J=8.4 Hz, 1H), 7.47 (d, J=8.8 Hz, 1H), 7.11(s, 1H), 7.04 (dd, J=8.8 Hz, 1H), 6.90 (d, J=2.6 Hz, 1H), 5.50-5.33 (m, 1H), 4.49-3.52 (m, 7H), 3.89 (s, 3H), 3.01 (s, 6H), 2.93-2.70 (m, 1H), 2.17-1.06 (m, 11H). LCMS: m/e 605 (M−H)−, ret time 2.63 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00906
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[3-(hydroxymethyl)-1-azetidinyl]carbonyl]-3-methoxy-. 10% Palladium on carbon (70 mg, 0.07 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[3-(hydroxymethyl)-1-azetidinyl]carbonyl]-3-methoxy- (52 mg, 0.086 mmol) in MeOH/CH2Cl2 (6:1, 3.5 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated. The residue was passed through a plug of silica gel (flushing with 10% MeOH/EtOAc) and concentrated to dryness to yield 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[3-(hydroxymethyl)-1-azetidinyl]carbonyl]-3-methoxy- (47 mg, 0.077 mmol, 90%) as a yellow solid. Mixture of atrope diastereomers. 1HNMR (300 MHz, CDCl3) δ 10.36-9.70 (m, 1H), 8.01-7.91 (m, 1H), 7.86-7.75 (m, 1H), 7.59-7.43 (m, 1H), 7.33-7.26 (m, 1H), 6.94-6.82 (m, 2H), 4.61-3.58 (m, 9H), 3.46-2.53 (m, 10H), 2.11-0.76 (m, 14H). LCMS: m/e 607 (M−H)−, ret time 2.56 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00907
  • 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[3-(dimethylamino)-1-azetidinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-3-methoxy-. To a solution of carbamic acid, [1-[[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepin-6-yl]carbonyl]-3-azetidinyl]-, 1,1-dimethylethyl ester (136 mg, 0.20 mmol) in ClCH2CH2Cl (3 mL) was added trifluoroacetic acid (3 mL). The reaction mixture was stirred at rt for 2 h, concentrated and 60% of the residue was dissolved into MeOH. To this stirring solution at rt was added NaCNBH3 (90 mg 1.5 mmol) and then formaldehyde (37 wt % in H2O, 0.15 mL, 5.4 mmol). The reaction mixture was stirred for 2 h, diluted with MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[3-(dimethylamino)-1-azetidinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-3-methoxy- (52 mg, 0.084 mmol, 72% over two steps) as a yellow solid. 1HNMR (300 MHz, CDCl3) δ 8.07 (d, J=1.4 Hz, 1H), 7.85 (d, J=8.8 Hz, 1H), 7.50 (dd, J=1.4, 8.8 Hz, 1H), 7.49 (d, J=8.8 Hz, 1H), 7.05 (dd, J=2.6, 8.6 Hz, 1H), 7.04 (s, 1H), 6.88 (d, J=2.6 Hz, 1H), 5.59-5.36 (m, 1H), 4.27-3.85 (m, 5H), 3.89 (s, 3H), 3.46 (s, 3H), 3.03 (s, 6H), 2.86-2.72 (m, 1H), 2.11 (s, 3H), 2.14-1.11 (m, 10H). LCMS: m/e 618 (M−H)−, ret time 2.81 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00908
  • 7H-Indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-(2-pyridinylmethyl)-. To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (80 mg, 0.15 mmol), N-methyl-1-(pyridin-2-yl)methanamine hydrochloride (33 mg, 0.27 mmol) and triethylamine (0.085 mL, 0.60 mmol) in DMF (1 mL) was added HATU (80 mg, 0.21 mmol). The reaction mixture was stirred at rt for 30 min., diluted with MeOH (˜1 mL) and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N10-[(dimethylamino)sulfonyl]-3-methoxy-N6-methyl-N6-(2-pyridinylmethyl)- (74 mg, 0.12 mmol, 77%) as a yellow solid. 1HNMR (300 MHz, CDCl3) δ 8.49 (br s, 1H), 8.09 (s, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.51 (d, J=8.4 Hz, 1H), 7.75-6.79 (m, 6H), 5.33-5.03 (m, 1H), 4.73-4.50 (m, 2H), 4.45-4.18 (m, 1H), 3.86 (s, 3H), 3.05 (s, 6H), 2.92 (s, 3H), 2.87-2.71 (m, 1H), 2.12-1.06 (m, 10H). LCMS: m/e 640 (M−H)−, ret time 2.90 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00909
  • 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]carbonyl]-3-methoxy-. To a stirred solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (80 mg, 0.15 mmol), 2-(2-(piperazin-1-yl)ethoxy)ethanol (50 mg, 0.29 mmol) and triethylamine (0.10 mL) in DMF (1 mL) was added HATU (80 mg, 0.21 mmol). The reaction mixture was stirred at rt for 1 h diluted with MeOH (˜1 mL) and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]carbonyl]-3-methoxy- (90 mg, 0.13 mmol, 87%) as a yellow solid. 1HNMR (300 MHz, CD3OD) δ 8.11 (d, J=1.5 Hz, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.60 (dd, J=1.5, 8.4 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H), 7.11 (dd, J=2.6, 8.8 Hz, 1H), 7.05 (d, J=2.6 Hz, 1H), 6.91 (s, 1H), 5.17-4.99 (m, 1H), 4.44-4.23 (m, 1H), 3.89 (s, 3H), 3.73-3.25 (m, 10H), 2.97 (s, 6H), 2.90-2.77 (m, 1H), 2.58-2.50 (m, 2H), 2.46-1.12 (m, 14H). LCMS: m/e 692 (M−H)−, ret time 2.45 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00910
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[3-(dimethylamino)-1-azetidinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-. 10% Palladium on carbon (50 mg, 0.05 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[3-(dimethylamino)-1-azetidinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-3-methoxy- (32 mg, 0.052 mmol) in MeOH/CH2Cl2 (1:1, 3 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen overnight, filtered through a pad of celite and concentrated to yield 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[3-(dimethylamino)-1-azetidinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy- (30 mg, 0.048 mmol, 93%) as a tan solid. Mixture of atrope diastereomers and amide rotamers. 1HNMR (300 MHz, CD3OD) δ 8.15-7.94 (m, 1H), 7.89-7.80 (m, 1H), 7.60-7.48 (m, 1H), 7.39-7.30 (m, 1H), 7.09-6.84 (m, 2H), 4.74-2.50 (m, 24H), 2.16-1.08 (m, 12H). LCMS: m/e 622 (M+H)+, ret time 3.15 min, column B, 4 minute gradient.
    Figure US20070078122A1-20070405-C00911
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]carbonyl]-3-methoxy-. 10% Palladium on carbon (40 mg, 0.04 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]carbonyl]-3-methoxy- (48 mg, 0.069 mmol) in MeOH/CH2Cl2 (2:1, 3 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen overnight and again vacuum flushed with nitrogen (3×) and then with hydrogen (4×) and stirred under a balloon of hydrogen for 3 d. The reaction was treated with additional 10% palladium on carbon (40 mg, 0.04 mmol), vacuum flushed with nitrogen (3×) and then with hydrogen (4×) and stirred under a balloon of hydrogen overnight. The reaction was filtered through a pad of celite and concentrated. The residue was dissolved into MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]carbonyl]-3-methoxy- (23 mg, 0.033 mmol, 48%) as a yellow solid. Mixture of atrope diastereomers. 1HNMR (300 MHz, CD3OD) δ 8.17-7.97 (m, 1H), 7.90-7.82 (m, 1H), 7.67-7.53 (m, 1H), 7.41-7.33 (m, 1H), 7.11-6.86 (m, 2H), 4.61-4.41 (m, 1H), 4.14-3.26 (m, 16H), 3.05-2.88 (m, 7H), 2.84-2.59 (m, 8H), 2.20-1.18 (m 10H). LCMS: m/e 694 (M−H)−, ret time 2.54 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00912
  • 7H-Indolo[2,1a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[3-[(dimethylamino)carbonyl]-1-azetidinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-3-methoxy-. To a stirred solution of 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (75 mg, 0.37 mmol), dimethylamine (2M in THF, 0.37 mL, 0.74 mmol) and triethylamine (0.20 mL) in DMF (2.0 mL) was added HATU (213 mg, 0.66 mmol). The reaction mixture was stirred at rt for 0.5 h, diluted with H2O (10 mL) and extracted with CH2Cl2 (3×5 mL). The combine organics were concentrated, dissolved into ClCH2CH2Cl (6 mL) and treated with trifluoroacetic acid (4 mL). The reaction mixture was stirred at rt for 2 h and concentrated to dryness. The residue was dissolved into MeOH, loaded onto an SCX cartridge, flushed with MeOH, eluted with 2M NH3 in MeOH and concentrated to dryness. To a stirred solution of the residue (45 mg), 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (60 mg, 0.11 mmol), and triethylamine (0.15 mL) in DMF (1.5 mL) was added HATU (60 mg, 0.16 mmol). The reaction mixture was stirred at rt for 2 h, treated with additional HATU (60 mg, 0.16 mmol) and stirred 3 H. The reaction mixture was diluted with MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[3-[(dimethylamino)carbonyl]-1-azetidinyl]carbonyl]-N-[(dimethylamino)sulfonyl]-3-methoxy- (19 mg, 0.029 mmol, 27%) as a yellow solid. 1HNMR (300 MHz, CD3OD) δ 8.15 (s 1H), 7.88 (d, J=8.4 Hz, 1H), 7.61 (d, J=8.4 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.27 (s, 1H), 7.16 (dd, J=2.6, 8.4 Hz, 1H), 7.12 (d, J=2.6 Hz, 1H), 5.60-5.32 (m, 1H), 4.68-4.06 (m, 5H), 3.93 (s, 3H), 3.84-3.68 (m, 1H), 3.01 (s, 6H), 2.95 (s, 3H), 2.93 (s, 3H), 2.94-2.82 (m, 1H), 2.21-1.12 (m, 10H). LCMS: m/e 646 (M−H)−, ret time 2.70 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00913
  • 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-6-[[3-(4-morpholinylcarbonyl)-1-azetidinyl]carbonyl]-. To a stirred solution of 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (75 mg, 0.37 mmol), morpholine (0.065 mL, 0.74 mmol) and triethylamine (0.20 mL) in DMF (2.0 mL) was added HATU (213 mg, 0.66 mmol). The reaction mixture was stirred at rt for 0.5 h, diluted with H2O (10 mL) and extracted with CH2Cl2 (3×5 mL). The combine organics were concentrated, dissolved into ClCH2CH2Cl (6 mL) and treated with trifluoroacetic acid (4 mL). The reaction mixture was stirred at rt for 2 h and concentrated to dryness. The residue was dissolved into MeOH, loaded onto an SCX cartridge, flushed with MeOH, eluted with 2M NH3 in MeOH and concentrated to dryness. To a stirred solution of the residue (38 mg), 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (60 mg, 0.11 mmol), and triethylamine (0.15 mL) in DMF (1.5 mL) was added HATU (60 mg, 0.16 mmol). The reaction mixture was stirred at rt for 2 h, treated with additional HATU (60 mg, 0.16 mmol) and stirred 3 h. The reaction mixture was diluted with MeOH and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-6-[[3-(4-morpholinylcarbonyl)-1-azetidinyl]carbonyl]- (19 mg, 0.028 mmol, 25%) as a yellow solid. 1HNMR (300 MHz, CD3OD) δ 8.16 (s 1H), 7.88 (d, J=8.4 Hz, 1H), 7.63 (d, J=8.4 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.27 (s, 1H), 7.17 (dd, J=2.6, 8.4 Hz, 1H), 7.13 (d, J=2.6 Hz, 1H), 5.60-5.32 (m, 1H), 4.67-4.05 (m, 5H), 3.94 (s, 3H), 3.83-3.52 (m, 7H), 3.41-3.21 (m, 2H), 3.07 (s, 6H), 2.95-2.82 (m, 1H), 2.20-1.16 (m, 10H). LCMS: m/e 688 (M−H)−, ret time 2.67 min, column A, 4 minute gradient.
    Figure US20070078122A1-20070405-C00914
  • 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(2-hydroxy-2-methyl-l-oxopropyl)-1-piperazinyl]carbonyl]-3-methoxy-. To a solution of tert-butyl piperazine-1-carboxylate (372 mg, 2.0 mmol), 2-hydroxy-2-methylpropanoic acid (229 mg, 2.2 mmol) and triethylamine (1.1 mL) in DMF (7 mL) was added HATU (988 mg, 2.6 mmol). The reaction mixture was stirred at rt for 2 h, then diluted with H2O, neutralized with 1N aqueous HCl (8 mL), concentrated, and the residue was partitioned between EtOAc and H2O. The organic phase was separated, washed with brine and concentrated to a white solid (1.1 g). The solid was dissolved into ClCH2CH2Cl (10 mL) and treated with trifluoroacetic acid (5 mL). The reaction mixture was stirred at rt for 2 h, and concentrated to yield crude 2-hydroxy-2-methyl-1-(piperazin-1-yl)propan-1-one (1.1 g) as yellow semi-solid.
  • To a solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (90 mg, 0.17 mmol), 2-hydroxy-2-methyl-1-(piperazin-1-yl)propan-1-one (150 mg, 0.87 mmol) and triethylamine (0.20 mL, 1.4 mmol) in DMF (2 mL) was added HATU (120 mg, 0.31 mmol). The reaction mixture was stirred at rt for 2 h, then diluted with MeOH and purified by prep HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(2-hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]carbonyl]-3-methoxy- (78 mg, 0.11 mmol, 67%) as a yellow solid. 1HNMR (300 MHz, MeOD) δ 8.16 (s, 1H), 7.89 (d, J=8.4 Hz, 1H), 7.65 (dd, J=1.5, 8.4 Hz, 1H), 7.56 (d, J=8.4 Hz, 1H), 7.15 (dd, J=2.6, 8.4 Hz, 1H), 7.10 (d, J=2.6 Hz, 1H), 6.98 (s, 1H), 5.24-5.03 (m, 1H), 4.50-4.31 (m, 1H), 3.93 (s, 3H), 3.87-3.26 (m, 8H), 2.98 (s, 6H), 2.95-2.80 (m, 1H), 2.24-1.16 (m, 10H), 1.40 (s, 6H). LCMS: m/e 692 (M+H)+, ret time 2.14 min, column B, 2 minute gradient.
    Figure US20070078122A1-20070405-C00915
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-(2-hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]carbonyl]-3-methoxy-. 10% Palladium on carbon (40 mg, 0.04 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(2-hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]carbonyl]-3-methoxy- (39 mg, 0.056 mmol) in MeOH/CH2Cl2 (1:1, 2 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen overnight and again vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen for 1 d, filtered through a pad of celite and concentrated to give a light yellow solid (31 mg). Part of the residue (20 mg) was dissolved MeOH/CH2Cl2 (1:1, 2 mL) treated with 10% palladium on carbon (40 mg, 0.04 mmol), vacuum flushed with nitrogen (3×) and then with hydrogen (4×) and stirred under a balloon of hydrogen overnight. The reaction was filtered through a pad of celite, concentrated and purified by preparative HPLC (MeOH/H2O/0.1% TFA) to yield 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-(2-hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]carbonyl]-3-methoxy- (5.6 mg, 0.008 mmol, 22%) as a yellow solid. Mixture of atrope diastereomers. 1HNMR (300 MHz, MeOD) δ 8.16 (s, 0.3H), 7.99 (s, 0.7H), 7.90 (d, J=8.4 Hz, 0.3H), 7.87 (d, J=8.4 Hz, 0.7H), 7.65-7.52 (m, 1H), 7.39 (d, J=8.4 Hz, 0.7H), 7.39 (d, J=8.4 Hz, 0.3H), 7.15-6.88 (m, 2H), 4.67-3.46 (m, 10H), 3.91 (s, 2.1H), 3.88 (s, 0.9H), 3.03 (s, 6H), 2.99-2.65 (m, 4H), 2.20-1.21 (m, 10H), 1.49 (s, 1.8H), 1.48 (s, 4.2H). LCMS: m/e 694(M+H)+, ret time 2.14 min, column B, 2 minute gradient.
    Figure US20070078122A1-20070405-C00916
  • 7H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[(1-hydroxycyclopropyl)carbonyl]-1-piperazinyl]carbonyl]-3-methoxy-. To a solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (150 mg, 0.28 mmol), tert-butyl piperazine-1-carboxylate (68 mg, 0.36 mmol) and triethylamine (0.16 mL) in DMF (3 mL) was added HATU (138 mg, 0.36 mmol). The reaction mixture was stirred at rt for 1.5 h, diluted with H2O (5 mL) and neutralized with 1N aqueous HCl (1.1 mL). The resulting precipitate was collected by filtration, washed with H2O and dried under nitrogen. The solid was dissolved into ClCH2CH2Cl (2 mL) and treated with trifluoroacetic acid (2 mL). The reaction mixture was stirred at rt for 2 h, and concentrated under vacuum to a crude yellow oil. Part of this material (˜0.18 mmol) was added to a solution of 1-hydroxycyclopropanecarboxylic acid (24 mg, 0.23 mmol), HATU (89 mg, 0.23 mmol) and triethylamine (0.13 mL) in DMF (2 mL). The reaction mixture was stirred at rt for 2 h, and additional 1-hydroxycyclopropanecarboxylic acid (30 mg, 0.29 mmol), HATU (100 mg, 0.26 mmol) and triethylamine (0.10 mL) were added. The reaction was stirred at rt overnight and half of the mixture was diluted with MeOH/DMSO and purified by prep HPLC (MeOH/H2O/0.1% TFA) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[(1-hydroxycyclopropyl)carbonyl]-1-piperazinyl]carbonyl]-3-methoxy- (51 mg, 0.074 mmol, 81%) as a yellow solid. 1HNMR (300 MHz, MeOD) δ 8.13 (d, J=1.5, 1H), 7.93 (d, J=8.4 Hz, 1H), 7.60 (dd, J=1.5, 8.4 Hz, 1H), 7.57 (d, J=8.4 Hz, 1H), 7.16 (dd, J=2.6, 8.4 Hz, 1H), 7.13 (d, J=2.6 Hz, 1H), 7.02 (s, 1H), 5.26-5.06 (m, 1H), 4.49-4.28 (m, 1H), 3.93 (s, 3H), 3.87-3.42 (m, 8H), 3.02 (s, 6H), 2.95-2.82 (m, 1H), 2.24-1.14 (m, 10H), 1.08-1.00 (m, 2H), 0.92-0.84 (m, 2H). LCMS: m/e 690 (M+H)+, ret time 2.13 min, column B, 2 minute gradient.
    Figure US20070078122A1-20070405-C00917
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-[(1-hydroxycyclopropyl)carbonyl]-1-piperazinyl]carbonyl]-3-methoxy-. 10% Palladium on carbon (60 mg, 0.06 mmol) was added to a solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-[(1-hydroxycyclopropyl)carbonyl]-1-piperazinyl]carbonyl]-3-methoxy- (58 mg, 0.084 mmol) in MeOH/CH2Cl2 (2:1, 3 mL) and the reaction mixture was vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen overnight and again vacuum flushed with nitrogen (3×) and then with hydrogen (4×). The reaction was stirred under a balloon of hydrogen for 1 d, treated with trifluoroacetic acid (2 drops), vacuum flushed with nitrogen (3×) and then with hydrogen (4×) and stirred 3 h. The reaction mixture was filtered through a pad of celite and concentrated. The residue was dissolved MeOH (2 mL) treated with 10% palladium on carbon (70 mg, 0.07 mmol), vacuum flushed with nitrogen (3×) and then with hydrogen (4×) and stirred under a balloon of hydrogen for 2 d. The reaction was filtered through a pad of celite, concentrated and purified by preparative HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 5H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[4-[(1-hydroxycyclopropyl)carbonyl]-1-piperazinyl]carbonyl]-3-methoxy- (8.3 mg, 0.012 mmol, 14%) as a white solid. Mixture of atrope diastereomers. 1HNMR (300 MHz, MeOD) δ 8.11-7.96 (m, 1H), 7.89-7.81 (m, 1H), 7.67-7.54 (m, 1H), 7.42-7.33 (m, 1H), 7.13-6.87 (m, 2H), 4.63-4.43 (m, 1H), 4.43-3.39 (m, 12 H)), 3.02-2.97 (m, 6H), 2.96-2.66 (m, 4H), 2.21-1.10 (m, 14H). LCMS: m/e 692 (M+H)+, ret time 2.17 min, column B, 2 minute gradient.
    Figure US20070078122A1-20070405-C00918
  • 7H-Indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-1-methyl-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy-. To a solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (90 mg, 0.17 mmol), (S)-2-amino-3-hydroxy-N,N,2-trimethylpropanamide (61 mg, 0.42 mmol) and triethylamine (0.12 mL) in DMF (2 mL) was added HATU (160 mg, 0.42 mmol). The reaction mixture was stirred at rt for 16 h, then diluted with MeOH/DMSO and purified by prep HPLC (MeOH/H2O/0.1% TFA) to yield an orange solid, which was further purified by prep HPLC (CH3CN/H2O with 10 mM NH4OAc) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[(1S)-2-(dimethylamino)-1-(hydroxymethyl)-1-methyl-2-oxoethyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy- (14 mg, 0.021 mmol, 12%) as a bright yellow solid. 1HNMR (300 MHz, MeOD) δ 8.15 (s, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.66-7.53 (m, 3H), 7.22-7.12 (m, 2H), 5.67-5.47 (m, 1H), 4.27-4.09 (m, 1H), 4.07-3.77 (m, 2H), 3.95 (s, 3H), 3.10-2.68 (m, 6H), 3.02 (s, 6H), 2.97-2.83 (m, 1H), 2.21-1.13 (m, 13H). LCMS: m/e 666 (M+H)+, ret time 1.94 min, column B, 2 minute gradient.
  • The following general procedures pertain to the following examples until further noted.
    Figure US20070078122A1-20070405-C00919
  • To 1.0 g of carboxylic acid 1 in a 100 mL round bottom flask equipped with a septa under nitrogen, was added 20 mL of dry dichloroethane (DCE). To this solution was then added 1.2 equivalents of Diphenylphosphorylazide (DPPA) in one portion followed by 3 equivalents of triethylamine. The solution was stirred overnight at room temperature. The reaction progress was followed by an analytical Shimadzu LC/MS. The crude mixture was passed through a 24 g SiliCycle/Isco silica gel cartridge with DCE to give acyl azide 2 as a light yellow foam after solvent evacuation (50-65% yield). The acyl azide was found to be stable at room temperature in a vacuum desiccator for up to one month. To 0.2 mmol of acyl azide 2 in 1.5 mL of dry toluene was added 1.2 equivalents of amine in a Biotage/Personal Chemistry microwave vial. The vial was capped and heated to 100° C. in a Biotage/Personal Chemistry Emrys Optomizer microwave for 25 minutes. The crude reaction mixture was then evacuated to near dryness, taken up in 2 mL acetonitrile and purified using a Shimadzu preparative HPLC employing acetonitrile/water and 10 mM trifluoroacetic acid buffer with a Waters Sunfire, C18, 19 mm×100 mm, 5 μm column at a focused gradient of 50-100% B and a flow rate of 25 mL/min., to give dimethylamino sulfamide ureas 3 as yellow amorphous solids (35-50% yield). Postpurification LC/MS data was obtained on a Shimadzu analytical LC/Micromass Platform LC (ESI+) at 220 nm using the following set of conditions: Phenomenex 10 μm C18, 4.6×30 mm column, with a gradient of 0-100% B (B=90% HPLC grade methanol/0.1% trifluoroacetic acid/10% HPLC grade water), (A=90% HPLC grade water/0.1% trifluoroacetic acid/10% HPLC grade methanol), in 2 minutes with a 1 minute hold at a rate of 5 mL/minute.
    Figure US20070078122A1-20070405-C00920
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[[[2-[(acetylamino)methyl]-4-morpholinyl]carbonyl]amino]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.23-1.31 (m, 1 H), 1.40-1.46 (m, 2 H), 1.70 (m, 1 H), 1.75-1.83 (m, 2H), 1.85-1.94 (m, 3H), 1.98-2.03 (m, 2 H), 2.21-2.34 (m, 1 H), 2.71-2.81 (m, 1 H), 2.87-2.97 (m, 3 H), 3.01-3.06 (m, 6 H), 3.07-3.16 (m, 1 H), 3.20-3.29 (m, 1 H), 3.30-3.38 (m, 1 H), 3.41-3.49 (m, 1 H), 3.52 (m, 1 H), 3.56-3.64 (m, 1 H), 3.76 (m, 2 H), 3.88 (s, 3 H), 4.00 (m, 1 H), 4.46 (m, 1 H), 4.55 (m, 1 H), 4.63 (m, 1 H), 6.93-6.97 (m, 2 H), 7.38 (m, 1 H), 7.49 (m, 1 H), 7.85-7.90 (m, 1 H), 7.96 (s, 1 H). LC/MS: m/z 695.44 (MH+), Rf 2.15 min., 98.9% purity.
    Figure US20070078122A1-20070405-C00921
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[[(2R,6S)-2,6-dimethyl-4 morpholinyl]carbonyl]amino]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.11-1.19 (m, 5 H), 1.27 (m, 1 H), 1.36-1.45 (m, 2 H), 1.68 (m, 1 H), 1.79 (m, 2 H), 1.92-2.04 (m, 4 H), 2.23 (t, J=12.05 Hz, 1 H), 2.50-2.58 (m, 2 H), 2.97 (m, 2 H), 3.04-3.08 (m, 6 H), 3.47 (d, J=12.51 Hz, 1 H), 3.55-3.60 (m, 1 H), 3.61-3.70 (m, 2 H), 3.79 (dd, J=15.26, 2.44 Hz, 1 H), 3.88 (m, 3 H), 4.43 (m, 1 H), 4.48 (d, J=15.26 Hz, 1 H), 4.61 (m, 1 H), 6.92-7.00 (m, 2 H), 7.34-7.41 (m, 1 H), 7.50-7.58 (m, 1 H), 7.89 (m,1 H), 7.98 (s, 1 H). LC/MS: m/z 652.38 (MH+), Rf 2.11 min., 98.0% purity.
    Figure US20070078122A1-20070405-C00922
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[[[(3R, 5S)-4-acetyl-3,5-dimethyl-1-piperazinyl]carbonyl]amino]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-, rel-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.26 (m, 4 H), 1.37 (m, 5 H), 1.44 (m, 2 H), 1.70 (m, 1 H) 1.77-1.82 (m, 2 H), 1.94 (m, 1 H), 1.99 (m, 3 H), 2.14-2.22 (m, 3 H), 2.26 (m, 1 H), 2.90-2.95 (m, 1 H), 2.98-3.07 (m, 7 H), 3.17 (m, 2 H), 3.83 (d, J=15.56 Hz, 1 H), 3.88 (s, 3 H), 4.48 (d, J=14.95 Hz, 1 H), 4.61 (m, 2 H), 4.70 (m, 1 H), 6.94 (s, 1 H), 6.97 (m, 1 H), 7.38 (m, 1 H), 7.46-7.55 (m, 1 H), 7.89 (m, 1 H), 7.95 (m, 1 H). LC/MS: m/z 693.47 (MH+), Rf 2.07 min., 94.8% purity.
    Figure US20070078122A1-20070405-C00923
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]carbonyl]amino]-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.21-1.30 (m, 1 H), 1.36-1.44 (m, 1 H), 1.65 (d, J=11.90 Hz, 1 H), 1.78 (d, J=9.46 Hz, 2 H), 1.96 (d, J=11.90 Hz, 1 H), 1.98-2.07 (m, 3 H), 2.25 (t, J=12.21 Hz, 1 H), 2.87-2.95 (m, 5 H), 2.96-3.01 (m, 6 H), 3.02-3.06 (m, 1 H), 3.43-3.52 (m, 2 H), 3.60-3.69 (m, 2 H), 3.72-3.81 (m, 5 H), 3.84-3.90 (m, 3 H), 4.37 (d, J=14.95 Hz, 1 H), 4.56-4.65 (m, 1 H), 4.71-4.80 (m, 2 H), 6.92-6.99 (m, 2 H), 7.39 (d, J=8.55 Hz, 1 H), 7.86-7.94 (m, 2 H), 8.50 (s, 1 H). LC/MS: m/z 695.85 (MH+), Rf 2.14 min., 100.0% purity.
    Figure US20070078122A1-20070405-C00924
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]amino]-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.28 (m, 1 H), 1.34-1.48 (m, 2 H), 1.70 (m, 1 H), 1.78 (m, 2 H), 1.94 (m, 1 H), 1.98-2.04 (m, 4 H), 2.19 (t, J=11.75 Hz, 1 H), 2.68 (t, J=11.75 Hz, 1 H), 2.89-2.98 (m, 3 H), 3.00 (s, 6 H), 3.03-3.07 (m, 1 H), 3.14 (m, 1 H), 3.26 (m, 2 H), 3.44 (m, 1 H), 3.48 (m, 2 H), 3.58 (m, 1 H), 3.62 (m, 1 H), 3.73-3.82 (m, 1 H), 3.88 (s, 3 H), 3.92-4.07 (m, 3 H), 4.32 (m, 1 H), 4.47-4.55 (m, 2 H), 4.55-4.62 (m, 1 H), 6.91-6.97 (m, 2 H), 7.36 (d, J=8.24 Hz, 1 H), 7.50-7.55 (m, 1 H), 7.89 (d, J=8.24 Hz, 1 H), 8.04 (s, 1 H). LC/MS: m/z 707.50 (MH+), Rf 1.89 min., 99.0% purity.
    Figure US20070078122A1-20070405-C00925
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[[2-[(dimethylamino)methyl]-4-morpholinyl]carbonyl]amino]-N-[(dimethylamino) sulfonyl]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.27 (m, 1 H), 1.35-1.41 (m, 1 H), 1.69 (m, 1 H), 1.77 (m, 2 H), 1.92 (m, 1 H), 1.96-2.04 (m, 2 H), 2.23-2.31 (m, 1 H), 2.78-2.88 (m, 4 H), 2.88-2.97 (m, 4 H), 2.98-3.06 (m, 6 H), 3.09 (d, J=1.53 Hz, 2 H), 3.22 (m, 1 H), 3.34 (m, 1 H), 3.44 (m, 1 H), 3.44-3.49 (m, 2 H), 3.49-3.58 (m, 1 H), 3.62 (m, 1 H), 3.78 (m, 1 H), 3.79-3.85 (m, 1 H), 3.85-3.90 (m, 3 H), 3.90-3.99 (m, 1 H), 4.44-4.52 (m, 1 H), 4.54 (m, 1 H), 6.90-6.99 (m, 2 H), 7.32-7.39 (m, 1 H), 7.54 (m, 1 H), 7.89 (d, J=8.55 Hz, 1 H), 7.98 (s, 1 H). LC/MS: m/z 681.49 (MH+), Rf 1.89 min., 93.1% purity.
    Figure US20070078122A1-20070405-C00926
  • 5H-Indolo[2,1a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[2-(1-pyrrolidinylmethyl)-4-morpholinyl]carbonyl]amino]-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.26 (m, 1 H), 1.35-1.48 (m, 2 H), 1.67 (m, 1 H), 1.78 (m, 2 H), 1.90 (m, 1 H), 1.98-2.07 (m, 6 H), 2.25-2.34 (m, 1 H), 2.77-2.83 (m, 1 H), 2.87-2.95 (m, 2 H), 2.96-3.05 (m, 6 H), 3.06-3.12 (m, 1 H), 3.17 (m, 1 H), 3.31-3.35 (m, 1 H), 3.47-3.50 (m, 1 H), 3.53 (m, 1 H), 3.64-3.70 (m, 2 H), 3.77-3.86 (m, 2 H), 3.87-3.88 (m, 3 H), 3.91-3.93 (m, 2 H), 3.95-4.04 (m, 1 H), 4.19 (d, J=13.73 Hz, 1 H), 4.36 (m, 1 H), 4.41-4.48 (m, 1 H), 4.50 (m, 1 H), 6.91-6.99 (m, 2 H), 7.32-7.38 (m, 1 H), 7.55-7.76 (m, 1 H), 7.86-7.93 (m, 1 H), 8.02-8.53 (m, 1 H). LC/MS: m/z 707.5 (MH+), Rf 1.90 min., 94.1% purity.
    Figure US20070078122A1-20070405-C00927
  • 1,4-Piperazinedicarboxamide, N-[13-cyclohexyl-10-[[[(dimethylamino) sulfonyl]amino]carbonyl]-6,7-dihydro-3-methoxy-5H-indolo[2,1-a][2]benzazepin-6-yl]-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.23-1.31 (m, 1 H), 1.34-1.44 (m, 2 H), 1.66 (m, 1 H), 1.78 (m, 2 H), 1.94 (m, 1 H), 1.99 (m, 2 H), 2.15 (m, 1 H), 2.90-2.99 (m, 2 H), 3.00-3.06 (m, 6 H), 3.23-3.31 (m, 2 H), 3.46-3.56 (m, 6 H), 3.77-3.86 (m, 1 H), 3.88 (s, 3 H), 4.39 (d, J=7.63 Hz, 1 H), 4.51 (d, J=14.95 Hz, 1 H), 4.61 (m, 1 H), 6.90-6.98 (m, 2 H), 7.38 (d, J=8.55 Hz, 1 H), 7.44 (d, J=8.55 Hz, 1 H), 7.89 (d, J=8.55 Hz, 1 H), 7.96 (s, 1 H). LC/MS: m/z 666.42 (MH+), Rf 2.02 min., 92.7% purity.
    Figure US20070078122A1-20070405-C00928
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[4-[2-[(1-methylethyl)amino]-2-oxoethyl]-1-piperazinyl]carbonyl]amino]-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.10-1.14 (m, 6 H), 1.26 (m, 1 H), 1.35-1.39 (m, 1 H), 1.42 (m, 1 H), 1.70 (m, 1 H), 1.78 (d, J=11.60 Hz, 2 H), 1.93-2.00 (m, 4 H), 2.26 (t, J=12.05 Hz, 1 H), 2.88-2.98 (m, 3 H), 2.99-3.05 (m, 6 H), 3.42 (m, 4 H), 3.68 (dd, J=15.26, 3.05 Hz, 1 H), 3.85-3.89 (m, 4 H), 3.90-3.94 (m, 1 H), 3.95-4.04 (m, 3 H), 4.45 (m, 1 H), 4.66 (d, J=14.95 Hz, 1 H), 4.78 (m, 1 H), 6.81 (d, J=7.63 Hz, 1 H), 6.91-6.99 (m, 2 H), 7.33-7.40 (m, 2 H), 7.87 (d, J=8.24 Hz, 1 H). LC/MS: m/z 722.56 (MH+), Rf 1.91 min., 96.4% purity.
    Figure US20070078122A1-20070405-C00929
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[[[3-(acetylethylamino)-1-pyrrolidinyl]carbonyl]amino]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.09-1.18 (m, 3 H), 1.20-1.29 (m, 2 H), 1.35-1.44 (m, 2 H), 1.68 (m, 1 H), 1.78 (m, 2 H), 1.91 (m, 2 H), 1.98 (m, 1 H), 2.01 (m, 1 H), 2.08 (m, 3 H), 2.14 (m, 1 H), 2.16-2.23 (m, 1 H), 2.29-2.33 (m, 1 H), 2.89-2.97 (m, 2 H), 2.99-3.07 (m, 7 H), 3.24-3.33 (m, 2 H), 3.35 (m, 1 H), 3.41 (m, 1 H), 3.74 (dd, J=14.95, 3.05 Hz, 1 H), 3.85-3.90 (s, 3 H), 4.26 (m, 1 H), 4.50 (d, J=15.26 Hz, 1 H), 4.57 (m, 1 H), 6.93 (m, 1 H), 6.96 (m, 1 H), 7.37 (m, 1 H), 7.56-7.66 (m, 1 H), 7.89 (m, 1 H), 7.95-8.02 (m, 1 H). LC/MS: m/z 693.46 (MH+), Rf 2.11 min., 100.0% purity.
    Figure US20070078122A1-20070405-C00930
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[(1,1-dioxido-4-thiomorpholinyl)carbonyl]amino]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.27 (m, 1 H), 1.36-1.48 (m, 2 H), 1.65-1.68 (m, 1 H), 1.78-1.80 (m, 2 H), 1.92-2.00 (m, 3 H), 2.21 (m, 1 H), 2.99-3.00 (m, 3 H), 3.04 (s, 6 H), 3.08-3.13 (m, 3 H), 3.71 (m, 2 H), 3.79-3.86 (m, 1 H), 3.88 (s, 3 H) 3.95 (m, 2H), 4.50 (d, J=15.26 Hz, 1 H), 4.58 (m, 1 H), 4.63 (m, 1 H), 6.92-7.00 (m, 2 H), 7.33-7.42 (m, 2 H), 7.85-7.91 (m, 1 H), 7.94 (s, 1 H). LC/MS: m/z 672.35 (MH+), Rf 2.02 min., 96.8% purity.
    Figure US20070078122A1-20070405-C00931
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[(1S,4S)-2-oxa-5-azabicyclo [2.2.1]hept-5-ylcarbonyl]amino]-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.27 (m, 1 H), 1.36-1.46 (m, 2 H), 1.68 (m, 1 H), 1.78 (m, 2 H), 1.90-1.96 (m, 3 H), 1.97-2.07 (m, 3 H), 2.08-2.26 (m, 1 H), 2.92-3.00 (m, 2 H), 3.02-3.07 (m, 6 H), 3.08-3.17 (m, 1 H), 3.31 (m, 1 H), 3.78-3.82 (m, 1 H), 3.88 (s, 3 H), 3.92-4.02 (m, 1 H), 4.23 (m, 1 H), 4.46-4.63 (m, 3 H), 4.74 (m, 1 H), 6.92-7.00 (m, 2 H), 7.35-7.42 (m, 1 H), 7.52-7.62 (m, 1 H), 7.86-7.96 (m, 2 H). LC/MS: m/z 636.40 (MH+), Rf 2.06 min., 97.9% purity.
    Figure US20070078122A1-20070405-C00932
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[[2-(4-morpholinyl)ethyl]amino]carbonyl]amino]-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.22-1.29 (m, 1 H), 1.34-1.45 (m, 2 H), 1.64 (m, 1 H), 1.77 (m, 2 H), 1.91 (m, 1 H), 1.95-2.03 (m, 2 H), 2.23 (t, J=12.05 Hz, 1 H), 2.88-2.97 (m, 4 H), 2.99-3.06 (m, 6 H), 3.20 (m, 1 H), 3.34 (m, 1 H), 3.48 (m, 2 H), 3.59 (m, 1 H), 3.65 (m, 1 H), 3.75 (dd, J=15.11, 3.36 Hz, 1 H), 3.83 (m, 1 H), 3.87 (m, 3 H), 3.89 (m, 1 H), 3.92 (m, 1 H), 3.96-4.03 (m, 2 H), 4.43 (m, 2 H), 6.92 (m, 2 H), 7.35 (m, 1 H), 7.47 (m,1 H), 7.84-7.88 (m, 2 H). LC/MS: m/z 667.45 (MH+), Rf 1.88 min., 98.0% purity.
    Figure US20070078122A1-20070405-C00933
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]amino]-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.24-1.31 (m, 1 H), 1.35-1.43 (m, 2 H), 1.68 (m, 1 H,) 1.78 (m, 2 H), 1.92 (m, 2 H), 1.97-2.14 (m, 10 H), 2.19-2.24 (m, 1 H), 2.70 (m, 1 H), 2.86-2.97 (m, 4 ), 2.98-3.02(m, 6H), 3.16(m, 1 H), 3.71-3.81 (m,3 H) 3.87-3.91 (m, 4H), 4.02 (m, 1 H), 4.51 (d, J=14.95 Hz, 1 H), 4.59 (m, 1 H), 4.69 (m, 1 H), 6.92-6.96 (m, 2 H), 7.35 (d, J=8.24 Hz, 1 H), 7.62 (m, 1 H), 7.89 (d, J=8.54 Hz, 1 H), 8.10 (s, 1 H). LC/MS: m/z 691.48 (MH+), Rf 1.89 min., 98.0% purity.
    Figure US20070078122A1-20070405-C00934
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]amino]-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.23-1.32 (m, 1 H), 1.38-1.47 (m, 2 H), 1.67 (m, 1 H), 1.79 (m, 2 H), 1.93 (m, 1 H), 1.96-2.06 (m, 2 H), 2.24-2.32 (m, 1 H), 2.77-2.84 (m, 1 H), 2.85 (s, 3 H), 2.93-2.96 (m, 2 H), 3.00 (s, 3 H), 3.05 (m, 3 H), 3.18-3.28 (m, 5 H), 3.64-3.67 (m, 2 H), 3.74-3.78 (m, 1 H), 3.89 (s, 3 H), 4.50 (d, J=15.26 Hz, 1 H), 4.58 (m, 2 H), 6.93 (d, J=2.44 Hz, 1 H), 6.98 (dd, J=8.55, 2.44 Hz, 1 H), 7.38 (d, J=8.24 Hz, 1 H), 7.49 (dd, J=8.54, 1.53 Hz, 1 H), 7.86-7.93 (m, 2 H). LC/MS: m/z 701.39 (MH+), Rf 2.05 min., 100.0% purity.
    Figure US20070078122A1-20070405-C00935
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[[(4-acetyl-1-piperazinyl)carbonyl]amino]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.22-1.32 (m, 1 H), 1.36-1.47 (m, 2 H), 1.66 (m, 1 H), 1.79 (m, 2 H), 1.93 (m, 1 H), 1.97-2.06 (m, 3 H), 2.10-2.16 (s, 3 H), 2.14-2.24 (m, 1 H), 2.83-2.98 (m, 2 H), 300-3.09 (m, 6 H), 3.22 (m, 1 H), 3.31-3.41 (m, 2 H), 3.51-3.61 (m, 4 H), 3.64-3.71 (m, 1 H), 3.73-3.82 (m, 1 H), 3.88 (s, 3 H), 4.50 (m, 1 H), 4.55-4.64 (m, 1 H), 6.93 (m, 1 H), 6.95-6.99 (m, 1 H), 7.38 (d, J=8.24 Hz, 1 H), 7.47 (dd, J=8.55, 1.53 Hz, 1 H), 7.86-7.92 (m, 1 H), 7.94 (s, 1 H). LC/MS: m/z 665.45 (MH+), Rf 2.05 min., 97.4% purity.
    Figure US20070078122A1-20070405-C00936
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[[[2-(dimethylamino)-2-oxoethyl]methylamino]carbonyl]amino]-N-[(dimethylamino) sulfonyl]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm: 1.22-1.33 (m, 1 H), 1.34-1.46 (m, 2 H), 1.65 (m, 1 H), 1.78 (m, 2 H), 1.93 (m, 1 H), 1.98-2.08 (m, 3 H), 2.26 (m, 1 H), 2.82-3.04 (m, 16 H), 3.55 (m, 1 H), 3.75 (m, 1 H), 3.88 (m, 3 H), 4.39 (m, 1 H), 4.58-4.63 (m, 1 H), 4.69-4.75 (m, 2 H), 6.91-6.96 (m, 2 H), 7.35-7.40 (m, 1 H), 7.87-7.89 (m, 2 H), 8.64-8.66 (m, 1 H). LC/MS: m/z 653.42 (MH+), Rf 2.10 min., 100.0% purity.
  • (6R)-5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[[[2-(dimethylamino)-2-oxoethyl]methylamino]carbonyl]amino]-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy- and (6S)-5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[[[2-(dimethylamino)-2-oxoethyl]methylamino]carbonyl]amino]-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-. The chiral separation the R & S enantiomers was accomplished using preparative chiral supercritical fluid chromatography (SFC) employing a ChiralCel OD-H, 30×250 mm, 5 μm column. The mixture of enantiomers was taken up in isopropanol (4 mg/1 mL), injected onto the column and eluted with 80% CO2 and 20% methanol with 0.1% trifluoroacetic acid buffer at a flow rate of 70 mL/minute. The temperature was maintained at 35° C. and the pressure at 150 bar throughout the experiment and the elution of the products was monitored by a UV detector at a wave length of 210 nm. Isomer A eluted at 13.92 minutes. Isomer B eluted at 17.93 minutes. The samples were concentrated en-vacuo to give enantiomerically pure yellow amorphous solids. Isomer A: 1H NMR (500 MHz, CHLOROFORM-D): δ ppm 1.20-1.29 (m, 1 H), 1.33-1.43 (m, 2 H), 1.65 (d, J=11.12 Hz, 1 H), 1.77 (m, 2 H), 1.92 (d, J=11.12 Hz, 1 H), 1.98-2.08 (m, 3 H), 2.26 (t, J=12.21 Hz, 1 H), 2.82 (br s, 3 H), 2.85-2.89 (m, 1 H), 2.93 (s, 3 H), 3.00 (s, 6 H) 3.03 (s, 3 H), 3.04 (s, 3H), 3.54 (d, J=14.95 Hz, 1 H), 3.75 (dd, J=14.95, 2.75 Hz, 1 H), 3.88 (s, 3 H), 4.39 (d, J=14.95 Hz, 1 H), 4.59 (m, 1 H), 4.71 (m, 2 H), 6.93 (s, 1 H), 6.95 (d, J=8.55 Hz, 1 H), 7.39 (d, J=8.55 Hz, 1 H), 7.89 (m, 2 H), 8.64 (s, 1 H). LC/MS: m/z 653.41 (MH+), Rf 2.08 min., 99.0% purity. Isomer B: 1H NMR (500 MHz, CHLOROFORM-D): δ ppm 1.18-1.29 (m, 1 H), 1.37-1.44 (m, 2 H), 1.65 (d, J=12.51 Hz, 1 H), 1.78 (m, 2 H), 1.93 (d, J=12.51 Hz, 1 H), 1.98-2.07 (m, 3 H), 2.26 (t, J=12.21 Hz, 1 H), 2.83 (br s, 3 H), 2.85-2.89 (m, 1 H), 2.92 (s, 3 H), 3.00 (s, 6 H) 3.03 (s, 3 H), 3.04 (s, 3H), 3.57 (d, J=15.26 Hz, 1 H), 3.75 (dd, J=14.95, 2.75 Hz, 1 H), 3.88 (s, 3 H), 4.40 (d, J=15.26 Hz, 1 H), 4.59 (m, 1 H), 4.73 (m, 2 H), 6.93 (s, 1 H), 6.96 (d, J=8.24 Hz, 1 H), 7.39 (d, J=8.24 Hz, 1 H), 7.89 (m, 2 H), 8.62 (s, 1 H). LC/MS: m/z 653.46 (MH+), Rf 2.09 min., 95.3% purity.
    Figure US20070078122A1-20070405-C00937
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[(ethylmethylamino)carbonyl]amino]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.09-1.18 (m, 3 H), 1.36 (m, 1 H), 1.51 (m, 2 H), 1.68 (m, 1 H), 1.84 (m, 2 H), 1.99 (m, 1 H), 2.08-2.20 (m, 3 H), 2.57 (t, J=12.20 Hz, 1 H), 2.88 (s, 3 H), 2.94-3.02 (m, 2 H), 3.04-3.10 (m, 6 H), 3.32-3.41 (m, 1 H), 3.72 (m, 1 H), 3.97 (m, 3 H), 4.55 (m, 1 H), 4.68 (m, 1 H), 4.76 (m, 1 H), 7.05-7.12 (m, 1 H), 7.18 (s, 1 H), 7.48-7.51 (m, 1H), 7.74-7.79 (m, 1 H), 7.96-8.02 (m, 1H), 8.17 (s, 1 H). LC/MS: m/z 596.35 (MH+), Rf 2.08 min., 99.4% purity.
    Figure US20070078122A1-20070405-C00938
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[[[2-(dimethylamino)ethyl]methylamino]carbonyl]amino]-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.27 (m, 1 H), 1.44 (m, 2 H), 1.60 (m, 1 H), 1.76 (m, 2 H), 1.90 (m, 1 H), 2.49 (m, 1 H), 2.84-2.91 (m, 3 H), 2.93-3.01 (m, 8 H), 3.02-3.05 (m, 1 H), 3.10 (m, 4H), 3.30 (m, 1 H), 3.47 (m, 1 H) 3.60 (m, 1 H), 3.68 (m, 1 H,) 3.88 (s, 3 H), 3.96 (m, 1 H), 4.02 (m, 2 H), 4.10 (m, 1 H), 4.54 (m, 1 H), 4.61 (d, J=14.95 Hz, 1 H), 4.67 (m, 1H), 7.02-7.07 (m, 2 H), 7.41-7.45 (m, 1 H), 7.70 (d, J=8.55 Hz, 1 H), 7.89 (d, J=8.55 Hz, 1 H), 8.30 (s, 1 H). LC/MS: m/z 639.58 (MH+), Rf 1.87 min., 100.0% purity.
    Figure US20070078122A1-20070405-C00939
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[(aminocarbonyl)amino]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.27 (m, 1 H), 1.44 (m, 2 H), 1.60 (m, 1 H), 1.76 (m, 2 H), 1.92 (m, 3 H), 2.22 (m, 1 H), 2.63-2.73 (m, 1 H), 2.98 (m, 6 H), 3.23-3.30 (m, 1 H), 3.71 (m, 1 H), 3.89 (s, 3 H), 4.43 (m, 1 H), 4.54 (m, 1 H), 4.59-4.69 (m, 1 H), 6.96-7.10 (m, 2 H), 7.41 (m, 1 H), 7.68-7.74 (m, 1 H), 7.93 (m, 1 H), 8.17-8.34 (m, 1 H). LC/MS: m/z 554.21 (MH+), Rf 2.02 min., 100.0% purity.
    Figure US20070078122A1-20070405-C00940
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[[2-[(2-methoxyethyl)amino]-2-oxoethyl]methylamino]carbonyl]amino]-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.26 (m, 1 H), 1.45 (m, 2 H), 1.61 (m, 1 H), 1.76 (m, 2 H), 1.92 (m, 1 H), 2.08 (m, 3 H), 2.44-2.52 (m, 1 H), 2.86 (m, 4 H), 2.96 (m, 6 H), 3.22 (s, 2 H), 3.30 (m, 2 H), 3.37 (m, 4 H), 3.65 (m, 1 H), 3.84 (m, 1 H), 3.89 (s, 3 H), 4.09 (m, 1 H), 4.44 (m, 1 H), 4.51 (m, 1 H), 7.02 (d, J=7.93 Hz, 1 H), 7.06-7.10 (m, 1 H), 7.42-7.45 (m, 1 H), 7.72 (d, J=8.24 Hz, 1 H), 7.91 (m, 1 H), 8.34 (s, 1 H). LC/MS: m/z 683.40 (MH+), Rf 2.08 min., 98.4% purity.
    Figure US20070078122A1-20070405-C00941
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino) sulfonyl]-6,7-dihydro-3-methoxy-6-[[[[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino]carbonyl]amino]-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.26 (m, 1 H) 1.43 (m, 2 H), 1.59 (m, 1 H), 1.71-1.80 (m, 2 H), 1.90 (m, 1 H), 1.99 (m, 2 H), 2.24 (m, 1 H), 2.64 (m, 1 H), 2.90-3.01 (m, 9 H), 3.44 (m, 1 H), 3.50 (m, 1 H), 3.61 (m, 1 H), 3.67 (m, 1 H), 3.84-3.92 (m, 3 H), 3.95-4.02 (m, 4 H), 4.40 (m, 1 H), 4.50 (m, 1 H), 4.59 (m, 1H), 6.98-7.03 (m, 1 H), 7.08 (s, 1 H), 7.21-7.24 (m, 1 H), 7.41 (m, 1 H), 7.63-7.71 (m, 1 H), 7.86-7.93 (m, 1 H), 8.04-8.28 (m, 1 H), 8.71-8.79 (m, 1 H). LC/MS: m/z 662.44 (MH+), Rf 1.85 min., 95.0% purity.
    Figure US20070078122A1-20070405-C00942
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[methyl[2-[(1-methylethyl)amino]-2-oxoethyl]amino]carbonyl]amino]-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 0.99 (d, J=6.41 Hz, 3 H), 1.07-1.16 (m, 3 H), 1.21-1.30 (m, 1 H), 1.44 (m, 2 H), 1.60 (m, 1 H), 1.76 (m, 2 H), 1.93 (m, 2 H), 2.45 (m, 1 H), 2.85-2.90 (m, 1 H), 2.92-3.00 (m, 10 H), 3.30 (m, 1 H), 3.48 (m, 1 H), 3.65 (d, J=14.95 Hz, 1 H), 3.81 (m, 1 H), 3.89 (s, 3 H), 3.96-4.02 (m, 2 H), 4.44 (m, 1 H), 4.51 (d, J=14.95 Hz, 1 H), 7.02 (d, J=8.24 Hz, 1 H), 7.07-7.10 (m, 1 H), 7.43 (m, 1 H), 7.72 (m, 1 H), 7.91 (m, 1 H), 8.35 (s, 1 H). LC/MS: m/z 667.44 (MH+), Rf 2.09 min., 99.5% purity.
    Figure US20070078122A1-20070405-C00943
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[methyl[(tetrahydro-2H-pyran-4-yl)methyl]amino]carbonyl]amino]-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.04-1.13 (m, 1 H), 1.16-1.26 (m, 2 H), 1.42 (m, 2 H), 1.50 (m, 2 H), 1.57 (m, 1 H), 1.73 (m, 2 H), 1.81 (m, 1 H), 1.87 (m, 2 H), 2.41-2.49 (m, 1 H), 2.79 (m, 2 H), 2.87-2.99 (m, 9 H), 3.05 (m, 1 H), 3.15-3.26 (m, 3 H), 3.48 (m, 1 H), 3.63 (m, 1 H), 3.77 (m, 1 H), 3.80-3.87 (m, 4 H), 4.44 (m, 1 H), 4.57 (m, 1 H), 4.64 (m, 1 H), 6.93-7.00 (m, 1 H), 7.06 (s, 1 H), 7.38 (m, 1 H), 7.65 (m, 1 H), 7.88 (m, 1 H), 8.05-8.30 (m, 1 H). LC/MS: m/z 666.42 (MH+), Rf 2.10 min., 100.0% purity.
    Figure US20070078122A1-20070405-C00944
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[methyl[(tetrahydro-2H-pyran-2-yl)methyl]amino]carbonyl]amino]-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 0.99-1.12 (m, 1 H), 1.26 (m, 2 H), 1.40 (m, 1 H), 1.44 (m, 3 H), 1.58 (m, 2 H), 1.66 (m, 1 H), 1.76 (m, 2 H), 1.92 (m, 1 H), 2.68 (m, 1 H), 2.87 (m, 2 H), 2.92-3.02 (m, 9 H), 3.11 (m, 1 H), 3.20-3.30 (m, 3 H), 3.51 (m, 1 H), 3.65 (m, 1 H), 3.74 (m, 1 H), 3.86-3.92 (m, 4 H), 4.27 (m, 1 H), 4.50 (m, 1 H), 4.61-4.77 (m, 1 H), 6.98-7.10 (m, 2 H), 7.42 (m, 1 H), 7.68-7.75 (m, 1 H), 7.90-7.95 (m, 1 H), 8.06-8.25 (m, 1 H). LC/MS: m/z 666.47 (MH+), Rf 2.26 min., 100.0% purity.
    Figure US20070078122A1-20070405-C00945
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 6-[[[(2-amino-2-oxoethyl) methylamino]carbonyl]amino]-13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.29 (m, 1 H), 1.46 (m, 2 H), 1.65 (m, 1 H), 1.77 (m, 2 H), 1.92 (m, 1 H), 2.01 (m, 2 H), 2.13 (m, 1 H), 2.67 (t, J=12.51 Hz, 1 H), 2.84 (s, 3 H), 2.87-2.96 (m, 3 H), 2.98-3.01 (s, 6 H), 3.55-3.64 (m, 2 H), 3.88-3.95 (s, 3 H), 4.42 (m, 1 H), 4.57-4.65 (m, 1 H), 7.12 (m, 1 H) 7.31 (m, 1 H), 7.39 (m, 1 H), 7.76-7.83 (m, 1 H), 7.94 (m, 1 H), 8.20 (s, 1 H). LC/MS: m/z 625.35 (MH+), Rf 2.06 min., 97.8% purity.
    Figure US20070078122A1-20070405-C00946
  • 1,3-Pyrrolidinedicarboxamide, N˜1˜-[13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-6,7-dihydro-3-methoxy-5H-indolo[2,1-a][2]benzazepin-6-yl]-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.27 (m, 1 H), 1.43 (m, 2 H), 1.60 (m, 1 H), 1.76 (m, 2 H) 1.89 (m, 1 H), 2.01 (m, 2 H), 2.12 (m, 1 H), 2.51 (m, 1 H), 2.90-2.95 (m, 2 H), 2.98 (s, 6 H), 3.02-3.12 (m, 2 H), 3.29-3.45 (m, 4 H), 3.53 (m, 1 H), 3.65 (m, 1 H), 3.89 (s, 3 H), 4.48-4.67 (m, 2 H), 7.01 (m, 1 H), 7.10 (m, 1 H), 7.41 (m, 1 H), 7.69 (m, 1 H), 7.91 (m, 1 H), 8.04-8.08 (m, 1 H). LC/MS: m/z 651.38 (MH+), Rf 2.01 min., 95.0% purity.
    Figure US20070078122A1-20070405-C00947
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-6-[[[[2-(cyclopropylamino)-2-oxoethyl]methylamino]carbonyl]amino]-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 0.34-0.48 (m, 2 H), 0.55-0.71 (m, 2 H), 1.28 (m, 1 H), 1.45 (m, 2 H), 1.61 (m, 1 H), 1.76 (m, 2 H), 1.92 (m, 1 H), 2.01 (m, 1 H), 2.13 (m, 1 H), 2.48 (m, 1 H), 2.67-2.80 (m, 2 H), 2.81-2.90 (m, 3 H), 2.92-3.01 (m, 9 H), 3.57-3.68 (m, 1 H), 3.75-3.97 (m, 4 H), 4.38-4.48 (m, 1 H), 4.50-4.60 (m, 1 H), 7.01-7.05 (m, 1 H), 7.06-7.14 (m, 1 H), 7.38-7.47 (m, 1 H), 7.71-7.81 (m, 1 H), 7.91-7.94 (m, 1 H), 8.20-8.37 (m, 1 H). LC/MS: m/z 665.38 (MH+), Rf 2.08 min., 95.0% purity.
    Figure US20070078122A1-20070405-C00948
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[(3-methoxy-1-azetidinyl)carbonyl]amino]-. 1H NMR (500 MHz, Acetone-D6) δ ppm 1.26 (m, 1 H), 1.44 (m, 2 H), 1.62 (m, 1 H), 1.76 (m, 2 H), 1.91 (m, 1 H), 2.01 (m, 1 H), 2.41 (t, J=12.21 Hz, 1 H), 2.64-2.72 (m, 1 H), 2.85-2.93 (m, 1 H), 2.96 (m, 1 H), 2.97-3.01 (m, 6 H), 3.20-3.25 (m, 3 H), 3.67 (m, 2 H), 3.71-3.78 (m, 1 H), 3.89 (s, 3 H), 3.93 (m, 1 H), 4.05-4.18 (m, 1 H), 4.19-4.24 (m, 1 H), 4.42 (m, 1 H), 4.57 (d, J=14.95 Hz, 1 H), 4.61-4.67 (m, 1H), 6.99-7.10 (m, 2 H), 7.39-7.44 (m, 1 H), 7.66-7.71 (m, 1 H), 7.90-7.95 (m, 1 H), 8.16-8.35 (m, 1 H). LC/MS: m/z 624.37 (MH+), Rf 2.07 min., 100.0% purity.
    Figure US20070078122A1-20070405-C00949
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[methyl[2-(4-methyl-1-piperazinyl)-2-oxoethyl]amino]carbonyl]amino]-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.29 (m, 1 H), 1.44-1.54 (m, 2 H), 1.63 (m, 1 H), 1.80 (m, 2 H), 1.95 (m, 1 H), 2.00 (m, 1 H), 2.49 (t, J=12.81 Hz, 1 H), 2.85-2.94 (m, 2 H), 2.95-3.04 (m, 12 H), 3.59 (m, 1 H), 3.69 (m, 2 H), 3.79 (m, 1 H), 3.87-3.95 (m, 4 H), 3.95-4.03 (m, 2 H), 4.45-4.53 (m, 2 H), 4.67-4.71 (m, 1 H), 7.06 (m, 1 H), 7.14 (m, 1 H), 7.41-7.49 (m, 1 H), 7.72-7.81 (m, 1 H), 7.96 (dd, J=8.55, 1.53 Hz, 1 H), 8.37-8.46 (m, 1 H). LC/MS: m/z 708.50 (MH+), Rf 1.87 min., 96.9% purity.
    Figure US20070078122A1-20070405-C00950
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-6-[[(3-hydroxy-1-azetidinyl)carbonyl]amino]-3-methoxy-. 1H NMR (500 MHz, Acetone-D6) δ ppm 1.30 (m, 1 H), 1.47 (m, 2 H), 1.64 (m, 1 H), 1.80 (m, 2 H), 1.95 (m, 1 H), 2.04 (m, 1 H), 2.43 (t, J=11.90 Hz, 1 H), 2.71 (m, 1 H), 2.92 (m, 2 H), 2.99 (m, 1 H), 3.02 (m, 6 H), 3.64 (m, 2 H), 3.70 (m, 1 H), 3.93 (s, 3 H), 4.00 (m, 1 H), 4.13 (m, 1 H), 4.44 (m, 1 H), 4.57-4.68 (m, 2 H), 7.02-7.13 (m, 2 H), 7.42-7.46 (m, 1 H), 7.72-7.74 (m, 1 H), 7.94-7.97 (m, 1 H), 8.16-8.38 (m, 1 H). LC/MS: m/z 610.33 (MH+), Rf 2.01 min., 95.0% purity.
    Figure US20070078122A1-20070405-C00951
  • 5H-Indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6,7-dihydro-3-methoxy-6-[[[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]carbonyl]amino]-, rel-. 1H NMR (500 MHz, Acetone-D6) δ ppm: 1.28 (m, 4 H), 1.45-1.54 (m, 5 H), 1.66 (m, 1 H), 1.78-1.88 (m, 2 H), 1.95 (m, 2 H), 2.43 (t, J=11.90 Hz, 1 H), 2.96-3.01 (m, 2 H), 3.03-3.05 (m, 9 H), 3.19 (m, 1 H), 3.37 (m, 1 H), 3.55 (m, 1 H), 3.68-3.77 (m, 1 H), 3.93 (m, 3 H), 3.96-4.02 (m, 4 H), 4.49 (m, 2 H), 4.69 (m, 1 H), 7.15 (m, 1 H), 7.25-7.29 (m, 1 H), 7.47-7.50 (m, 1 H), 7.76 (m, 1 H), 7.93-7.99 (m, 1 H), 8.10 (m, 1H). LC/MS: m/z 665.54 (MH+), Rf 1.85 min., 95.0% purity.
  • General LC/MS conditions as shown below were utilized for the procedures below until further noted: LCMS data: Gradient time: 2 min; Flow rate: 4 mL/min; Stop time: Gradient time +2 minute; Starting conc: 0% B; Eluent A: 10% MeOH/90% H2O with 0.1% TFA; Eluent B: 90% MeOH/10% H2O with 0.1% TFA; Column 1: Phenomenex 10 μ C18 4.6×50 mm.
    Figure US20070078122A1-20070405-C00952
  • ESI-MS m/e 667 (MH+), 1H NMR (500 MHz, MeOD) δ 1.12-2.23 (m, 11 H) 2.82-2.96 (m, 2 H) 3.01-3.07 (m, 6 H) 3.28-3.46 (m, 5 H) 3.71-3.87 (m, 1 H) 3.93 (s, 3 H) 4.27-4.46 (m, 1 H) 4.43-4.68 (m, 1 H) 5.17 (m, 1 H) 7.03 (s, 1 H) 7.08-7.22 (m, 2 H) 7.58 (dd, J=14.80, 8.39 Hz, 2 H) 7.92 (d, J=8.54 Hz, 1 H) 8.11 (s, 1 H).
    Figure US20070078122A1-20070405-C00953
  • ESI-MS m/e 545 (MH+), 1H NMR (500 MHz, MeOD) δ 1.14-2.23 (m, 11 H) 2.67-3.03(m, 4H) 3.35-3.59 (m, 3 H) 3.69-3.92 (m, 2 H) 3.92-3.99 (m, 6 H) 4.32-4.45 (m, 1 H) 5.12-5.26 (m, 1 H) 7.03-7.26 (m, 3 H) 7.48-7.60 (m, 1 H) 7.66-7.76 (m, 1 H) 7.86-7.95 (m, 1 H) 8.19-8.31 (m, 1 H).
    Figure US20070078122A1-20070405-C00954
  • ESI-MS m/e 531 (MH+), 1 H NMR (500 MHz, MeOD) δ 1.17-2.23 (m, 11 H) 2.68-3.00 (m, 4 H) 3.36-3.60 (m, 3 H) 3.65-3.93 (m, 2 H) 3.95-4.00 (m, 3 H) 4.35-4.46 (m, 1 H) 5.13-5.24(m, 1 H) 7.05-7.27 (m, 3 H) 7.50-7.59 (m, 1 H) 7.70-7.78 (m, 1 H) 7.87-7.95 (m, 1 H) 8.21-8.32 (m, 1 H).
    Figure US20070078122A1-20070405-C00955
  • ESI-MS m/e 542 (MH+), 1H NMR (500 MHz, MeOD) δ ppm 0.84-1.55 (m, 10 H) 1.80 (d, J=10.99 Hz, 2 H) 1.94-2.21 (m, 4 H) 2.70-3.00 (m, 4 H) 3.23-3.39 (m, 2 H) 3.96 (s, 3 H) 3.98 (s, 3 H) 4.29-4.51 (m, 2 H) 5.21 (d, J=14.95 Hz, 1 H) 7.16-7.27 (m, 3 H) 7.58 (t, J=8.09 Hz, 1 H) 7.75 (dd, J=8.39, 1.37 Hz, 1 H) 7.95 (d, J=8.55 Hz, 1 H) 8.28 (s, 1 H).
    Figure US20070078122A1-20070405-C00956
  • ESI-MS m/e 528 (MH+), 1H NMR (500 MHz, MeOD) δ 0.70-1.56 (m, 10 H) 1.72-1.85 (m, 2 H) 1.92-2.23 (m, 4 H) 2.62-3.03 (m, 4 H) 3.17-3.40 (m, 2 H) 3.96-4.00 (m, 3 H) 4.26-4.54 (m, 2 H) 5.21 (d, J=14.65 Hz, 1 H) 7.09-7.30 (m, 3 H) 7.52-7.64 (m, 1 H) 7.71-7.83 (m, 1 H) 7.90-8.00 (m, 1 H) 8.28 (s, 1 H).
    Figure US20070078122A1-20070405-C00957
  • ESI-MS m/e 519 (MH+), 1H NMR (500 MHz, MeOD) δ 1.17-2.24 (m, 11 H) 2.72-3.25 (m, 5 H) 3.35-3.96 (m, 4 H) 4.43 (s, 1 H) 5.18 (s, 1 H) 6.97 (s, 1 H) 7.25-7.41 (m, 2 H) 7.59-7.79 (m, 2 H) 7.86-7.96 (m, 1 H) 8.25 (s, 1 H).
    Figure US20070078122A1-20070405-C00958
  • ESI-MS m/e 533 (MH+), 1H NMR (500 MHz, MeOD) δ ppm 1.16-2.25 (m, 11 H) 2.76-2.93 (m, 2 H) 2.92-3.26 (m, 3 H) 3.34-3.65 (m, 4 H) 3.91-3.99 (m, 3 H) 4.42 (s, 1 H) 5.18 (s, 1 H) 6.97 (s, 1 H) 7.27-7.42 (m, 2 H) 7.60-7.69 (m, 1 H) 7.69-7.78 (m, 1 H) 7.85-7.99 (m, 1 H) 8.19-8.28 (m, 1 H).
    Figure US20070078122A1-20070405-C00959
  • ESI-MS m/e 593 (MH+).
    Figure US20070078122A1-20070405-C00960
  • ESI-MS m/e 673 (MH+), 1H NMR (500 MHz, MeOD) δ 1.18-1.34 (m, 1 H) 1.38-1.58 (m, 3 H) 1.75-1.86 (m, 2 H) 1.98-2.21 (m, 4 H) 2.83-2.95 (m, 2 H) 3.04 (d, J=1.53 Hz, 6 H) 3.95 (s, 3 H) 4.11-4.28 (m, 2 H) 4.36-4.64 (m, 2 H) 4.97-5.10 (m, 1 H) 5.42-5.58 (m, 1 H) 7.15-7.22 (m, 2 H) 7.31 (s, 1 H) 7.55-7.63 (m, 2 H) 7.92 (d, J=8.24 Hz, 1 H) 8.14 (s, 1 H).
    Figure US20070078122A1-20070405-C00961
  • ESI-MS m/e 688 (MH+), 1H NMR (500 MHz, MeOD) δ 0.34-0.51 (m, 2 H) 0.69-1.04 (m, 6 H) 1.21-1.59 (m, 7 H) 1.75-2.20 (m, 6 H) 2.85-3.14 (m, 5 H) 3.02 (s, 6 H) 3.38-3.72 (m, 3 H) 3.94 (d, J=1.22 Hz, 3 H) 4.07-4.55 (m, 2 H) 5.16-5.28 (m, 1 H) 7.04 (s, 1 H) 7.12 (s, 1 H) 7.18-7.23 (m, 1 H) 7.56-7.66 (m, 2 H) 7.99 (d, J=8.54 Hz, 1 H) 8.18 (s, 1 H).
    Figure US20070078122A1-20070405-C00962
  • ESI-MS m/e 785 (MH+), 1H NMR (500 MHz, MeOD) δ 1.22-1.61 (m, 22 H) 1.75-1.85 (m, 2 H) 1.93-2.19 (m, 4 H) 2.81-2.97 (m, 2 H) 3.04 (d, J=1.22 Hz, 6 H) 3.95 (d, J=1.22 Hz, 3 H) 4.07-4.30 (m, 2 H) 4.38-4.63 (m, 2 H) 4.94-5.08 (m, 1 H) 5.43-5.56 (m, 1 H) 7.15-7.22 (m, 2 H) 7.31 (s, 1 H) 7.59 (t, J=9.00 Hz, 3 H) 7.92 (d, J=8.54 Hz, 1 H) 8.14 (s, 1 H).
    Figure US20070078122A1-20070405-C00963
  • ESI-MS m/e 639 (MH+), 1 H NMR (500 MHz, MeOD) δ 1.22-1.32 (m, 1 H) 1.40-1.58 (m, 3 H) 1.76-1.86 (m, 2 H) 1.94-2.19 (m, 4 H) 2.84-2.99 (m, 2 H) 3.03 (s, 6 H) 3.08-3.24 (m, 1 H) 3.40-3.55 (m, 2 H) 3.57-3.71 (m, 2 H) 3.85-3.91 (m, 1 H) 3.94 (s, 3 H) 4.19-4.53 (m, 3 H) 5.12-5.25 (m, 1 H) 6.95-7.04 (m, 1 H) 7.12 (s, 1 H) 7.18 (dd, J=8.55, 2.75 Hz, 1 H) 7.53-7.65 (m, 2 H) 7.94 (d, J=8.55 Hz, 1 H) 8.16 (s, 1 H).
    Figure US20070078122A1-20070405-C00964
  • ESI-MS m/e 639 (MH+), 1H NMR (500 MHz, MeOD) δ 1.17-1.34 (m, 1 H) 1.38-1.56(m,3H) 1.75-1.86 (m, 2 H) 1.93-2.21 (m, 4 H) 2.87-3.01 (m, 2 H) 3.04 (s, 6 H) 3.10-3.24 (m, 1 H) 3.38-3.77 (m, 3 H) 3.82-3.95 (m, 1 H) 3.97 (s, 3 H) 4.00-4.23 (m, 1 H) 4.24-4.55 (m, 3 H) 5.20 (d, J=14.34 Hz, 1 H) 7.21 (dd, J=17.24, 8.09 Hz, 3 H) 7.56 (t, J=8.09 Hz, 1 H) 7.62 (d, J=8.24 Hz, 1 H) 7.96 (d, J=8.85 Hz, 1 H) 8.17 (d, J=8.85 Hz, 1 H).
    Figure US20070078122A1-20070405-C00965
  • 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[(2S-2-(methoxymethyl)-4-morpholinyl)carbonyl]-5H-indolo[2,1-a][2]benzazepine-10-carboxamide. TBTU (32 mg, 0.10 mmol) was added to a stirred solution at 22° C. of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (40.5 mg, 0.075 mmol), (2S)-2-(methoxymethyl)morpholine hydrochloride (17 mg, 0.01 mmol), and TEA (37.9 mg, 0.375 mmol) in DMSO (0.30 mL). After stirring for 1 hr the solution was diluted with water and acidified with dilute HCl to precipitate the titled compound as a gel. The mixture was extracted with ethyl acetate. The extract was washed (water (2×), brine), dried (sodium sulfate), and concentrated to leave a foam. A solution of the foam in methylene chloride was applied to a silicic acid thick layer plate. The plate was developed with methylene chloride −3% acetic acid. The band containing the product was removed and extracted with methylene chloride −10% methanol. Removal of the solvents left the product (22.2 mg, 45 % yield) as a yellow solid. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 0.85-2.04(m, 10 H) 3.06 (s, 6 H) 3.11-3.82 (m, 8 H) 3.90 (s, 3 H) 4.35 (s, 1 H) 5.11 (s, 1 H) 6.75-6.84 (m, 1 H) 6.91 (d, J=2.44 Hz, 1 H) 7.06 (dd, J=8.55, 2.75 Hz, 1 H) 7.49 (d, J=8.55 Hz, 1 H) 7.55 (d, J=8.24 Hz, 1 H) 7.88 (d, J=8.54 Hz, 1 H) 8.16 (s, 1 H) 9.45 (s, 1 H).
    Figure US20070078122A1-20070405-C00966
  • 13-Cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[(2R-2-(methoxymethyl)-4-morpholinyl)carbonyl]-5H-indolo[2,1-a][2]benzazepine-10-carboxamide. TBTU (89 mg, 0.276 mmol) was added to a stirred solution at 22° C. of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (123.5 mg, 0.230 mmol), (2R)-2-(methoxymethyl)morpholine hydrochloride (54 mg, 0.322 mmol), and TEA (93 mg, 0.92 mmol) in DMSO (1.2 mL). After stirring for 2 hr the solution was diluted with water and acidified with dilute HCl to precipitate the titled compound as a gel. The mixture was extracted with chloroform. The extract was washed (water (2×), brine), dried (magnesium sulfate), and concentrated to leave a froth. A solution of the froth in methylene chloride was applied to a silicic acid thick layer plate. The plate was developed with methylene chloride −2% acetic acid. The band containing the product was removed and extracted with methylene chloride −10% methanol. Removal of the solvents left the product as a yellow solid. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 0.85-2.05 (m, 10 H) 3.06 (s, 6 H) 3.14-3.33 (m, 5 H) 3.80-3.88 (m, 1 H) 3.90 (s, 3 H) 4.35 (s, 1 H) 5.13 (s, 1 H) 6.76-6.83 (m, 1 H) 6.90 (d, J=2.14 Hz, 1 H) 7.06 (dd, J=8.70, 2.59 Hz, 1 H) 7.48 (d, 1 H) 7.54 (d, J=8.24 Hz, 1 H) 7.88 (d, J=8.55 Hz, 1 H) 8.14 (s, 1 H) 9.54 (s, 1 H).
  • The following general HPLC method applies to the procedures that follow until otherwise noted:
  • Shimadzu LC-MS discovery software; % A=10% methanol, 90% water, 0.1% TFA; % B=90% methanol, 10% water, 0.1% TFA;Initial % B=50; Final % B=100; Gradient=5 min; Runtime=6 min; Flow rate=5 ml/min; UV@ 220 nm; Column=Phenomenex Luna C18, 10u, 3.0 mm×50 mm; Product Retention time=4.2 min. MS m/z 487(MH+).
    Figure US20070078122A1-20070405-C00967
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[(5-methoxy-2,5-dioxopentyl)amino]carbonyl]-, methyl ester. 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-(chlorocarbonyl)-13-cyclohexyl-, methyl ester (499 mg, 1.15 mMol) was dissolved in 10 ml of anhydrous dichloromethane and methyl 5-aminolevulinate hydrochloride (244 mg, 1.34 mMol) was added to the reaction mixture followed by 0.5 ml of pyridine (6.2 mMol). The reaction was stirred under nitrogen at room temperature for 40 hours. Volatiles were removed in vacuuo and the residue was partitioned between ethyl acetate and 0.1 N hydrochloric acid. The organic phase was washed with brine, dried over magnesium sulfate to yield 603 mg of crude product. The product was combined with 433 mg of a previous reaction run under the same conditions. The mixture was purified by silica column chromatography eluting with a gradient of 20% ethyl acetate in dichloromethane to 20% ethyl acetate in dichloromethane to yield 0.56 g (45%) of product. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 8.28 (s, 1 H) 7.87 (d, J=8.55 Hz, 1 H) 7.74 (dd, J=8.55, 1.22 Hz, 1 H) 7.59 (d, J=7.93 Hz, 1 H) 7.43-7.56 (m, 3 H) 7.38 (s, 1 H) 6.71 (t, J=4.12 Hz, 1 H) 5.65 (d, J=10.99 Hz, 1 H) 4.31 (d, J=27.16 Hz, 2 H) 4.14-4.23 (m, 1 H) 3.94 (s, 3 H) 3.67 (s, 3 H) 2.80-2.91 (m, 1 H) 2.01-2.16 (m, 3 H) 1.70-2.00 (m, 3 H) 1.29-1.70 (m, 6 H) 1.14-1.31 (m, 2 H).
    Figure US20070078122A1-20070405-C00968
  • Methyl 13-cyclohexyl-6-(((2-(4-(methyloxy)phenyl)-2-oxoethyl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 6-(chlorocarbonyl)-13-cyclohexyl-, methyl ester (500 mg, 1.15 mMol) was dissolved in 10 ml of anhydrous dichloromethane and 2-amino-4-methoxyacetophenone hydrochloride (280 mg, 1.39 mMol) was added to the reaction mixture followed by 0.3 ml of diisopropylethyl amine(1.72 mMol). The reaction was stirred under nitrogen for 23.5 hrs. Volatiles were removed in vacuuo and the residue was partitioned between ethyl acetate and 1.0 N hydrochloric acid. The organic phase was washed with brine, dried over magnesium sulfate to yield 648 mg of crude product. The crude product was adsorbed onto 1.65 g of silica gel and chromatographed on 20 g of silica gel using a gradient of dichloromethane to 5% ethyl acetate in dichloromethane. Trailing product was removed from the column using 10% ethyl acetate in dichloromethane. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 1.17-1.50 (m, 5 H) 1.52-1.84 (m, 6 H) 1.85-1.98 (m, 1 H) 2.00-2.15 (m, 3 H) 2.78-2.92 (m, 1 H) 3.88 (s, 3 H) 3.94 (s, 3 H) 4.19 (d, J=11.60 Hz, 1 H) 4.79 (d, J=25.64 Hz, 2 H) 5.71 (d, J=9.16 Hz, 1 H) 6.97 (d, J=8.85 Hz, 2 H) 7.13 (s, 1 H) 7.43-7.56 (m, 4 H) 7.60 (d, J=7.32 Hz, 1 H) 7.71-7.79 (m, 1 H) 7.87 (d, J=8.55 Hz, 1 H) 7.96 (d, J=8.85 Hz, 2 H) 8.32 (s, 1 H); MS m/z 563(MH+).
    Figure US20070078122A1-20070405-C00969
  • Methyl 13-cyclohexyl-3-(methyloxy)-6-(((5-(methyloxy)-2,5-dioxopentyl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. 13-cyclohexyl-3-(methyloxy)-10-((methyloxy)carbonyl)-7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid (1.00 g, 2.24 mMol) was dissolved in 20 ml of DMF along with 1-hydroxy-7-azabenzotriazole (483 mg, 3.5 mMol). The reaction was placed under nitrogen and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (663 mg, 3.5 mMol) was added and the reaction stirred for 1 hr at room temperature. 5-aminolevleunic acid hydrochloride (608 mg, 3.35 mMol) was added to the reaction followed by diisopropylethyl amine (0.44 mL, 2.5 mMol). The reaction was stirred overnight under nitrogen at room temperature. Volatiles were removed in vacuuo and the residue was partitioned between ethyl acetate and 0.1 N hydrochloric acid. The aqueous phase was extracted with ethyl acetate and the organic phases combined, washed with brine and dried over magnesium sulfate. Volatiles were removed in vacuuo to yield 1.47 g of crude product which was combined with 698 mg of a previous experiment. The crude product was purified by silica gel chromatography eluting with a gradient of 10% ethyl acetate/dichloromethane to 25% ethyl acetate/dichloromethane to yield 1.64 g (84%) of product as a yellow solid. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 1.12-1.30 (m, 1 H) 1.32-1.50 (m, 2 H) 1.77 (d, J=9.16 Hz, 2 H) 1.89-1.99 (m, 1 H) 1.99-2.18 (m, 3 H) 2.67 (t, J=6.10 Hz, 2 H) 2.72-2.87 (m, 3 H) 3.67 (s, 3 H) 3.91 (s, 3 H) 3.94 (s, 3 H) 4.15 (d, J=19.23 Hz, 1 H) 4.31 (d, J=34.79 Hz, 2 H) 5.62 (d, J=12.82 Hz, 1 H) 6.70 (t, J=4.12 Hz, 1 H) 6.96 (d, J=2.44 Hz, 1 H) 7.08 (dd, J=8.55, 2.75 Hz, 1 H) 7.33 (s, 1 H) 7.51 (d, J=8.55 Hz, 1 H) 7.73 (d, J=8.24 Hz, 1 H) 7.84 (d, J=8.24 Hz, 1 H) 8.26 (s, 1 H); MS m/z 573(MH+); MS m/z 571(M−H)−.
    Figure US20070078122A1-20070405-C00970
  • Methyl 13-cyclohexyl-3-(methyloxy)-6-(((2-oxoethyl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. 13-cyclohexyl-3-(methyloxy)-10-((methyloxy)carbonyl)-7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid (1.50 g, 3.37 mMol) was dissolved in 32 ml of DMF along with 1-hydroxy-7-azabenzotriazole (697 mg, 5.1 mMol). The reaction was placed under nitrogen and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (967 mg,5.04 mMol) was added and the reaction stirred for 1.5 hr at room temperature. Aminoacetaldehyde dimethylacetal (0.44 mL, 4.1 mMol) was added to the reaction and the reaction stirred at room temperature under nitrogen for 16 hrs. Volatiles were removed in vacuuo and the residue was partitioned between ethyl acetate and 0.1 N hydrochloric acid. The aqueous phase was extracted with ethyl acetate and the organic phases combined, washed with 0.1N hydrochloric acid then brine and dried over magnesium sulfate. Volatiles were removed in vacuuo to yield 1.98 g of crude product which was used in the next reaction without purification. The crude acetal (1.4 g, 2.7 mMol) was dissolved in 30 mL of acetone and 2M hydrochloric acid (1.6 mL, 3.2 mMol) and briefly heated to reflux then allow to stir for 2.5 hrs before being briefly heated to reflux again and allowed to stir an additional 1.5 hrs. 1N hydrochloric acid (200 mL) was added to the reaction and a precipitate filtered off and rinsed with water and dried in vacuuo, to yield 1.14 g (87%) of crude product. The product was purified by silica gel chromatography eluting with a gradient of 15% ethyl acetate in hexanes to 25% ethyl acetate in hexanes to yield 0.81 g (62%) of product as a yellow solid. 1H NMR (500 MHz, CHLOROFORM-D) δ ppm 1.25 (t, J=7.17 Hz, 1 H) 1.31-1.48 (m, 2 H) 1.48-1.63 (m, 3 H) 1.77 (d, J=9.46 Hz, 2 H) 1.86-1.98 (m, 1 H) 1.98-2.16 (m, 3 H) 2.77-2.89 (m, 1 H) 3.91 (s, 3 H) 3.94 (s, 3 H) 4.18 (d, J=14.04 Hz, 1 H) 4.32 (d, J=34.79 Hz, 2 H) 5.62 (d, J=11.29 Hz, 1 H) 6.65 (s, 1 H) 6.97 (d, J=2.75 Hz, 1 H) 7.09 (dd, J=8.55, 2.75 Hz, 1 H) 7.35 (s, 1 H) 7.52 (d, J=8.85 Hz, 1 H) 7.73 (d, J=8.55 Hz, 1 H) 7.84 (d, J=8.54 Hz, 1 H) 8.26 (s, 1 H) 9.71 (s, 1 H).
    Figure US20070078122A1-20070405-C00971
  • 5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6,7-dihydro-6-[(methylcarbonyl)amino]-, methyl ester. Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=523.30, HPLC Rt=1.853 min.
    Figure US20070078122A1-20070405-C00972
  • Methyl 13-cyclohexyl-3-(methyloxy)-6-((((2S)-tetrahydro-2-furanylmethyl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. Prepared from 13-cyclohexyl-3-(methyloxy)-10-((methyloxy)carbonyl)-7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid in a similar manner as described before. Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.65; Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=529.27, HPLC Rt=2.115 min.
    Figure US20070078122A1-20070405-C00973
  • 13-Cyclohexyl-3-(methyloxy)-6-((methyl((2S)-tetrahydro-2-furanylmethyl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. Prepared from methyl 13-cyclohexyl-3-(methyloxy)-6-((((2S)-tetrahydro-2-furanylmethyl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate by methylation using MeI and NaH in DMF in a similar manner as described before; Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.45; Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=529.21, HPLC Rt=2.035 min.
    Figure US20070078122A1-20070405-C00974
  • 13-Cyclohexyl-N10-((dimethylamino)sulfonyl)-N6-methyl-3-(methyloxy)-N6-((2S)-tetrahydro-2-furanylmethyl)-7H-indolo[2,1-a][2}benzazepine-6,10-dicarboxamide. Prepared from 13-Cyclohexyl-3-(methyloxy)-6-((methyl((2S)-tetrahydro-2-furanylmethyl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid using CDI as a coupling reagent in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=635.28, HPLC Rt=1.978 min.
    Figure US20070078122A1-20070405-C00975
  • Methyl 13-cyclohexyl-3-(methyloxy)-6-((tetrahydro-2H-pyran-4-ylamino)carbonyl)-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylate. Prepared in a similar manner as described before. Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.50; Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=531.40, HPLC Rt=2.072 min.
    Figure US20070078122A1-20070405-C00976
  • 13-Cyclohexyl-3-(methyloxy)-6-((methyl(tetrahydro-2H-pyran-4-yl)amino)carbonyl)-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. Prepared from Methyl 13-cyclohexyl-3-(methyloxy)-6-((tetrahydro-2H-pyran-4-ylamino)carbonyl)-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylate by methylation using MeI and NaH in DMF in a similar manner as described before; Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.30; Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=531.21, HPLC Rt=1.998 min.
    Figure US20070078122A1-20070405-C00977
  • 13-Cyclohexyl-N10-((dimethylamino)sulfonyl)-N6-methyl-3-(methyloxy)-N6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide. Prepared from 13-Cyclohexyl-3-(methyloxy)-6-((methyl(tetrahydro-2H-pyran-4-yl)amino)carbonyl)-6,7-dihydro-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid using CDI as a coupling reagent in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=637.20, HPLC Rt=1.937 min.
    Figure US20070078122A1-20070405-C00978
  • Methyl 13-Cyclohexyl-3-(methyloxy)-6-((tetrahydro-2H-pyran-4-ylamino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate. Prepared in a similar manner as described before. Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.70; Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=529.15, HPLC Rt=2.092 min.
    Figure US20070078122A1-20070405-C00979
  • 13-Cyclohexyl-3-(methyloxy)-6-((methyl(tetrahydro-2H-pyran-4-yl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid. Prepared from methyl 13-Cyclohexyl-3-(methyloxy)-6-((tetrahydro-2H-pyran-4-ylamino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylate by methylation using MeI and NaH in DMF in a similar manner as described before; Analytical thin layer chromatography (5% MeOH/CH2Cl2) Rf=0.50; Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=529.32, HPLC Rt=1.995 min.
    Figure US20070078122A1-20070405-C00980
  • 13-Cyclohexyl-N10-((dimethylamino)sulfonyl)-N6-methyl-3-(methyloxy)-N6-(tetrahydro-2H-pyran-4-yl)-7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide. Prepared from 13-cyclohexyl-3-(methyloxy)-6-((methyl(tetrahydro-2H-pyran-4-yl)amino)carbonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid using CDI as a coupling reagent in a similar manner as described before; Analytical HPLC method: Solvent A=10% MeOH-90% H2O-0.1% TFA, Solvent B=90% MeOH-10% H2O-0.1% TFA, Start % B=0, Final % B=100, Gradient time=2 min, Flow Rate=5 ml/min, Column: Xterra MS C18 S7 3.0×50 mm; LC/MS: (ES+) m/z (M+H)+=635.46, HPLC Rt=1.937 min.
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (830 mg, 2.0 mmol), 1-(piperazin-1-yl)ethanone (310 mg, 2.4 mmol) and triethylamine (0.85 mL) in DMF (8 mL) was added HATU (910 mg, 2.4 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜15 mL) and the solids were collected by filtration washed with H2O and dried under vacuum overnight to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(acetyl)-1-piperazinyl]carbonyl]-, methyl ester (1.19 g, 2.3 mmol, quant.) as a yellow solid. LCMS: m/e 526 (M+H)+, ret time 2.96 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00981
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(acetyl)-1-piperazinyl]carbonyl]-, methyl ester (1.14 g, 2.2 mmol) was dissolved into MeOH//THF (1:1, 10 mL) and treated with 1M aqueous NaOH (3 mL). The reaction mixture was stirred and heated at 85° C. with microwave irradiation for 30 min in a sealed tube. The clear solution was neutralized with 1M aqueous HCl (3 mL) and concentrated to remove organic solvents. The resultant solids were collected by filtration, washed with H2O and dried under vacuum to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(acetyl)-1-piperazinyl]carbonyl] (1.09 g, 0.21 mmol, 97%) as a yellow solid which was used without further purification. LCMS: m/e 512 (M+H)+, ret time 2.80 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00982
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(acetyl)-1-piperazinyl]carbonyl] (400 mg, 0.78 mmol), N,N-dimethylsulfamide (390 mg, 3.13 mmol) and DMAP (380 mg, 3.13 mmol) in dimethylacetamide (6 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (450 mg, 2.34 mmol). The reaction solution was stirred at 50° C. for 3 h, concentrated, purified by preparative HPLC (CH3CN/H2O with NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(acetyl)-1-piperazinyl]carbonyl] (135 mg, 0.22 mol, 28%) as a yellow powder. 1HNMR (500 MHz, DMSO-d6) δ 11.62 (s, 1H), 8.44 (s, 1H), 7.93 (d, J=8.5 Hz, 1H), 7.65 (d, J=8.5 Hz, 1H), 7.62-7.55 (m, 4H), 7.04 (s, 1H), 5.19 (br s, 1H), 4.34 (br s, 1H), 3.59-3.30 (m, 8H), 2.91 (s, 6H), 2.85-2.75 (m, 1H), 2.10-1.36 (m, 10H), 1.99 (s, 3H). LCMS: m/e 616 (M−H)−, ret time 1.57 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00983
  • To a stirred solution of methyl 7H-indolo[2,1-a][2]benzazepine-10-carboxylate, 13-cyclohexyl, 6-carboxylic acid (830 mg, 2.0 mmol), 1-(methylsulfonyl)piperazine (394 mg, 2.4 mmol) and triethylamine (0.85 mL) in DMF (10 mL) was added HATU (910 mg, 2.4 mmol). The reaction mixture was stirred at rt for 2 h, diluted with H2O (˜15 mL) and the solids were collected by filtration, washed with H2O and dried under vacuum overnight to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-, methyl ester (1.08 g, 1.9 mmol, 96%) as a yellow solid. LCMS: m/e 562 (M+H)+, ret time 2.85 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00984
  • 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl]-, methyl ester (1.04 g, 1.9 mmol) was dissolved into MeOH//THF (1:1, 10 mL) and treated with 1M aqueous NaOH (2.5 mL). The reaction mixture was stirred and heated at 80° C. with microwave irradiation for 15 min in a sealed tube. The clear solution was neutralized with 1M aqueous HCl (3 mL) and concentrated to remove organic solvents. The resultant solids were collected by filtration, washed with H2O and dried under vacuum to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl] (0.93 g, 0.17 mmol, 92%) as a yellow solid which was used without further purification. LCMS: m/e 548 (M+H)+, ret time 2.88 min, column B, 3 minute gradient.
    Figure US20070078122A1-20070405-C00985
  • To a stirred solution of 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-6-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl] (430 mg, 0.79 mmol), N,N-dimethylsulfamide (390 mg, 3.13 mmol) and DMAP (380 mg, 3.13 mmol) in dimethylacetamide (6 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (450 mg, 2.34 mmol). The reaction solution was stirred at 50° C. for 3 h, concentrated, purified by preparative HPLC (CH3CN/H2O with NH4OAc buffer) to yield 7H-indolo[2,1-a][2]benzazepine-10-carboxamide, 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-[[4-(methylsulfonyl)-1-piperazinyl]carbonyl] (135 mg, 0.22 mol, 28%) as a yellow powder. 1HNMR (500 MHz, DMSO-d6) δ 11.65 (s, 1H), 8.41 (br s, 1H), 7.94 (d, J=8.5 Hz, 1H), 7.65 (dd, J=1.5, 8.5 Hz, 1H), 7.63-7.55 (m, 4H), 7.04 (s, 1H), 5.19 (br s, 1H), 4.34 (br s, 1H), 3.66-3.31 (m, 8H), 2.92 (s, 6H), 2.84 (s, 3H), 2.82-2.75 (m, 1H), 2.11-1.06 (m, 10H). LCMS: m/e 652(M−H)1, ret time 1.63 min, column A, 2 minute gradient.
    Figure US20070078122A1-20070405-C00986
  • HATU (36 mg, 0.093 mmol) and triethylamine (19 mg, 0.19 mmol) were added to a solution of 13-cyclohexyl-N-[(dimethylamino)sulfonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide-6-carboxylic acid (50 mg, 0.093 mmol) in DMF (1 mL). The mixture was stirred at rt for 1 h, and then 1-methylaminocyclopropane-1 carboxylic acid hydrochloride (14 mg, 0.093 mmol) and TEA (19 mg, 0.19 mmol) in H2O (0.3 ml) were added and the mixture was stirred at rt for 1 h. To this mixture HATU (150 mg, 0.40 mmol) and triethylamine (19 mg, 0.19 mmol) were added, followed by 2.0 M dimethylamine in methanol solution (0.20 ml, 0.40 mmol). The reaction was stirred at rt overnight, diluted with methanol and purified by prep HPLC (MeCN/H2O 10 mM NH4OAc system) to yield 7H-indolo[2,1-a][2]benzazepine-6,10-dicarboxamide, 13-cyclohexyl-N6-[1′-(dimethylcarbamoyl)cyclopropyl]-N10-[(dimethylamino)sulfonyl]-3-methoxy- as yellow solid (23 mg, 0.035 mmol, 38%). 1H NMR (300 MHz, MeOD) δ ppm 1.10-2.20 (m, 14 H), 2.80-3.10 (m, 16 H), 3.93 (s, 3 H), 4.32 (br s, 1 H), 5.13 (br s, 1 H), 7.00-7.10 (m, 2 H), 7.15 (dd, J=8.8, 2.6 Hz, 1 H), 7.55 (d, J=8.8 Hz, 1 H), 7.63 (d, J=8.4 Hz, 1 H), 7.90 (d, J=8.4 Hz, 1 H), 8.10 (s, 1H). LCMS: M-1/e 660, ret time 1.51 min, column D, 2 minute gradient.

Claims (15)

1. A compound of formula I
Figure US20070078122A1-20070405-C00987
wherein:
R1 is CO2R6 or CONR7R8;
R2 is CONR9R10, CO2benzyl, NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO((R16)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((N(R6)2)alkyl), NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), NHCON(R6)((COR15)alkyl), NHCON(R6)((tetrahydropyranyl)alkyl),
Figure US20070078122A1-20070405-C00988
R3 is hydrogen or alkyl;
R4 is hydrogen, halo, alkyl, alkoxy, or benzyloxy;
R5 is C5-7cycloalkyl;
R6 is hydrogen, alkyl, or cycloalkyl;
R7 is hydrogen, alkyl, cycloalkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
R8 is hydrogen, alkyl, or cycloalkyl;
or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
R9 is cycloalkyl, dihydroxyalkyl, (alkoxy)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-4 substituents selected from the group consisting of halo, hydroxy, OPO(OR6)2, alkoxy, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (hydroxy)alkoxyalkyl, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)(R6)amino, (alkoxyCO)(R6)amino, (alkoxyalkylCO)(R6)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, ((hydroxy)cycloalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (alkylCO)(R6)aminoalkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
Figure US20070078122A1-20070405-C00989
provided that if NR9R10 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl it cannot be substituted with 0-2 substituents selected from alkyl, hydroxy, amino, alkylamino, dialkylamino, pyrrolidinyl, piperdinyl or pyridinyl; or NR9R10 taken together is
Figure US20070078122A1-20070405-C00990
or NR9R10 taken together is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR6, NCO2R6, or O;
R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, ((R6)(R6)N)alkylamino, (((R6)(R6)N)alkyl)2amino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy;
R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, hydroxy, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, ((R6CO)(R6)amino)alkyl, (R15)alkyl, (R6CO)(R6)amino, R15, alkylCO, CF3CO, CO2R6, CON(R6)2, or SO2R6;
or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O;
R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents; and
the dashed line is either a single bond or a double bond, provided that if the dashed line is a single bond, the carbon bearing the asterisk is either of the R configuration, the S configuration, or a mixture of R and S configurations;
or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 where R2 is NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO((R16)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((N(R6)2)alkyl), NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), NHCON(R6)((COR15)alkyl), NHCON(R6)((tetrahydropyranyl)alkyl),
Figure US20070078122A1-20070405-C00991
3. A compound of claim 1 where R2 is CONR9R10.
4. A compound of claim 1 where NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 1-4 substituents selected from the group consisting of halo, OPO(OR6)2, alkoxy, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (hydroxy)alkoxyalkyl, (alkoxy)alkyl, (alkylCO)(R6)amino, (alkoxyCO)(R6)amino, (alkoxyalkylCO)(R6)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, ((hydroxy)cycloalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (alkylCO)(R6)aminoalkyl, (PhCONH)alkyl, (R12)alkyl, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
Figure US20070078122A1-20070405-C00992
5. A compound of claim 1 where NR9R10 taken together is
Figure US20070078122A1-20070405-C00993
6. A compound of claim 1 where NR9R10 taken together is a [2.2.1 ] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR6, NCO2R6, or O.
7. A compound of claim 1 where the dashed line is a single bond and the carbon bearing the asterisk is of the R configuration.
8. A compound of claim 1 where the dashed line is a single bond and the carbon bearing the asterisk is of the S configuration.
9. A compound of formula I
Figure US20070078122A1-20070405-C00994
wherein:
R1 is CONR7R8;
R2 is CO2R6, CO2benzyl, CONR9R10, NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO((R16)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((N(R6)2)alkyl), NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), NHCON(R6)((COR15)alkyl), NHCON(R6)((tetrahydropyranyl)alkyl),
Figure US20070078122A1-20070405-C00995
R3 is hydrogen or alkyl;
R4 is hydrogen, halo, alkyl, alkoxy, or benzyloxy;
R5 is C5-7cycloalkyl;
R6 is hydrogen, alkyl, or cycloalkyl;
R7 is (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
R8 is hydrogen, alkyl, or cycloalkyl;
or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
R9 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-4 substituents selected from the group consisting of halo, hydroxy, OPO(OR6)2, alkoxy, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (hydroxy)alkoxyalkyl, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)(R6)amino, (alkoxyCO)(R6)amino, (alkoxyalkylCO)(R6)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, ((hydroxy)cycloalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (alkylCO)(R6)aminoalkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
Figure US20070078122A1-20070405-C00996
or NR9R10 taken together is
Figure US20070078122A1-20070405-C00997
or NR9R10 taken together is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR , NCO2R6, or O;
R11 is haloalkyl, alkoxy, ((R6)(R6)N)alkylamino, (((R6)(R6)N)alkyl)2 amino, N,O-dimethylhydroxylamino;
R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy;
R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or tetrahydrofuranyl, and is substituted with 0-2 alkyl substituents;
R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, hydroxy, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, ((R6CO)(R6)amino)alkyl, (R15)alkyl, (R6CO)(R6)amino, R15, alkylCO, CF3CO, CO2R6, CON(R6)2, or SO2R6;
or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O;
R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents;
R16 is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, or pyridinyl, and is substituted with 0-2 alkyl substituents; and the dashed line is either a single bond or a double bond, provided that if the dashed line is a single bond, the carbon bearing the asterisk is either of the R configuration, the S configuration, or a mixture of R and S;
or a pharmaceutically acceptable salt thereof.
10. A compound of formula II
Figure US20070078122A1-20070405-C00998
wherein:
R1 is CO2R6 or CONR7R8;
R4 is hydrogen, halo, alkyl, alkoxy, or benzyloxy;
R5 is C5-7cycloalkyl;
R6 is hydrogen, alkyl, or cycloalkyl;
R7 is hydrogen, alkyl, cycloalkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
R8 is hydrogen, alkyl, or cycloalkyl;
or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, ((R6)(R6)N)alkylamino, (((R6)(R6)N)alkyl)2amino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy; and
R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
or a pharmaceutically acceptable salt thereof.
11. A compound of formula III
Figure US20070078122A1-20070405-C00999
wherein:
R1 is CO2R6 or CONR7R8;
R2 is CO2R6, CO2benzyl, CONR9R10, NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO((R16)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((N(R6)2)alkyl), NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), NHCON(R6)((COR15)alkyl), NHCON(R6)((tetrahydropyranyl)alkyl),
Figure US20070078122A1-20070405-C01000
R3 is hydrogen or alkyl;
R5 is C5-7cycloalkyl;
R6 is hydrogen, alkyl, or cycloalkyl;
R7 is hydrogen, alkyl, cycloalkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
R8 is hydrogen, alkyl, or cycloalkyl;
or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
R9 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R112)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-4 substituents selected from the group consisting of halo, hydroxy, OPO(OR6)2, alkoxy, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (hydroxy)alkoxyalkyl, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)(R6)amino, (alkoxyCO)(R6)amino, (alkoxyalkylCO)(R6)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, ((hydroxy)cycloalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (alkylCO)(R6)aminoalkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
Figure US20070078122A1-20070405-C01001
or NR9R10 taken together is
Figure US20070078122A1-20070405-C01002
Figure US20070078122A1-20070405-C01003
or NR9R10 taken together is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR6, NCO2R6, or O;
R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, ((R6)(R6)N)alkylamino, (((R6)(R6)N)alkyl)2amino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy;
R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, hydroxy, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, ((R6CO)(R6)amino)alkyl, (R15)alkyl, (R6CO)(R6)amino, R15, alkylCO, CF3CO, CO2R6, CON(R6)2, or SO2R6;
or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O;
R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents;
R16 is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, or pyridinyl, and is substituted with 0-2 alkyl substituents; and
the dashed line is either a single bond or a double bond, provided that if the dashed line is a single bond, the carbon bearing the asterisk is either of the R configuration, the S configuration, or a mixture of R and S;
or a pharmaceutically acceptable salt thereof.
12. A compound of formula IV
Figure US20070078122A1-20070405-C01004
wherein:
R1 is CO2R6 or CONR7R8;
R2 is CO2R6, CO2benzyl, CONR9R10, NHCO2(alkyl), NHCO2benzyl, NHCO(alkyl), NHCO(cycloalkyl), NHCOR14, NHCO((R15)alkyl), NHCO((R16)alkyl), NHCO(tetrahydropyranyl), NHCO(methoxycycloalkyl), NHCON(R6)2, NHCON(R6)((N(R6)2)alkyl), NHCON(R6)((CO2R6)alkyl), NHCON(R6)((CON(R6)2)alkyl), NHCON(R6)((COR15)alkyl), NHCON(R6)((tetrahydropyranyl)alkyl),
Figure US20070078122A1-20070405-C01005
R3 is hydrogen or alkyl;
R5 is C5-7cycloalkyl;
R6 is hydrogen, alkyl, or cycloalkyl;
R7 is hydrogen, alkyl, cycloalkyl, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)(R6))alkyl, (alkyl)CONH, tetrazolyl, tetrahydropyranyl, sulfolanyl, SO2R11, SO2R12, or (R13)alkyl;
R8 is hydrogen, alkyl, or cycloalkyl;
or NR7R8 taken together is pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, and haloalkyl;
R9 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
R10 is hydrogen, alkyl, cycloalkyl, hydroxyalkyl, dihydroxyalkyl, (alkoxy)alkyl, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (R12)alkyl, (CHO)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (COR15)alkyl, (R16)alkyl, ((alkoxyalkyl)amido)alkyl, (alkylamido)alkyl, (tetrahydrofuranyl)alkyl, (dioxolanyl)alkyl, (alkylCO)(R6)amino, ((alkylCO)(R6)amino)alkyl, tetrahydropyranyl, or sulfolanyl;
or NR9R10 taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-4 substituents selected from the group consisting of halo, hydroxy, OPO(OR6)2, alkoxy, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (hydroxy)alkoxyalkyl, (alkoxy)alkyl, amino, alkylamino, dialkylamino, (alkylCO)(R6)amino, (alkoxyCO)(R6)amino, (alkoxyalkylCO)(R6)amino, (alkylCO)alkylamino, (cycloalkyl)(PhSO2)amino, CO2R6, CON(R6)2, CONH(alkenyl), (R12)CO, (alkyl)CO, (cycloalkyl)CO, (hydroxyalkyl)CO, ((hydroxy)cycloalkyl)CO, (aminoalkyl)CO, (acetoxyalkyl)CO, PhCO, (furanyl)CO, (benzodioxanyl)CO, (alkyl)CO2, SO2R11, SO2R12, (CO2R6)alkyl, (CON(R6)2)alkyl, (COR12)alkyl, (alkylCO)(R6)aminoalkyl, (PhCONH)alkyl, (R12)alkyl, R12, phenyl, methoxyphenyl, pyrrolyl, furanyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrazolyl,
Figure US20070078122A1-20070405-C01006
or NR9R10 take together is
Figure US20070078122A1-20070405-C01007
Figure US20070078122A1-20070405-C01008
or NR9R10 taken together is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 NR6, NCO2R6, or O;
R11 is alkyl, haloalkyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, ((R6)(R6)N)alkylamino, (((R6)(R6)N)alkyl)2amino, N,O-dimethylhydroxylamino, or phenyl, wherein the phenyl is substituted with 0-2 substituents selected from the group consisting of halo, alkyl, haloalkyl, and alkoxy;
R12 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 substituents selected from halo, alkyl, haloalkyl, and alkoxy;
R13 is pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, imidazopyridinyl, or benzimidazole, and is substituted with 0-2 alkyl substituents;
R14 is azetidine, pyrrolidinyl, piperidinyl, piperazinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, or S,S-dioxothiomorpholinyl, and is substituted with 0-3 substituents selected from halo, alkyl, hydroxy, alkoxy, aminoalkyl, (alkylamino)alkyl, (dialkylamino)alkyl, (CO2R6)alkyl, (CON(R6)2)alkyl, ((R6CO)(R6)amino)alkyl, (R15)alkyl, (R6CO)(R6)amino, R15, alkylCO, CF3CO, CO2R6, CON(R6)2, or SO2R6;
or R14 is a [2.2.1] or [2.2.2] bridged bicyclic amine wherein the bicycle contains 0-1 O;
R15 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homomorpholinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl, and is substituted with 0-2 halo, alkyl, or alkoxy substituents;
R16 is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, or pyridinyl, and is substituted with 0-2 alkyl substituents; and
the dashed line is either a single bond or a double bond, provided that if the dashed line is a single bond, the carbon bearing the asterisk is either of the R configuration, the S configuration, or a mixture of R and S;
or a pharmaceutically acceptable salt thereof.
13. A compound of claim 1 or 9 selected from the group consisting of
Figure US20070078122A1-20070405-C01009
Figure US20070078122A1-20070405-C01010
Figure US20070078122A1-20070405-C01011
Figure US20070078122A1-20070405-C01012
Figure US20070078122A1-20070405-C01013
Figure US20070078122A1-20070405-C01014
Figure US20070078122A1-20070405-C01015
Figure US20070078122A1-20070405-C01016
Figure US20070078122A1-20070405-C01017
Figure US20070078122A1-20070405-C01018
Figure US20070078122A1-20070405-C01019
Figure US20070078122A1-20070405-C01020
Figure US20070078122A1-20070405-C01021
Figure US20070078122A1-20070405-C01022
Figure US20070078122A1-20070405-C01023
Figure US20070078122A1-20070405-C01024
Figure US20070078122A1-20070405-C01025
Figure US20070078122A1-20070405-C01026
Figure US20070078122A1-20070405-C01027
Figure US20070078122A1-20070405-C01028
Figure US20070078122A1-20070405-C01029
Figure US20070078122A1-20070405-C01030
Figure US20070078122A1-20070405-C01031
Figure US20070078122A1-20070405-C01032
Figure US20070078122A1-20070405-C01033
Figure US20070078122A1-20070405-C01034
Figure US20070078122A1-20070405-C01035
Figure US20070078122A1-20070405-C01036
Figure US20070078122A1-20070405-C01037
Figure US20070078122A1-20070405-C01038
Figure US20070078122A1-20070405-C01039
Figure US20070078122A1-20070405-C01040
Figure US20070078122A1-20070405-C01041
Figure US20070078122A1-20070405-C01042
Figure US20070078122A1-20070405-C01043
Figure US20070078122A1-20070405-C01044
Figure US20070078122A1-20070405-C01045
Figure US20070078122A1-20070405-C01046
Figure US20070078122A1-20070405-C01047
Figure US20070078122A1-20070405-C01048
Figure US20070078122A1-20070405-C01049
Figure US20070078122A1-20070405-C01050
Figure US20070078122A1-20070405-C01051
Figure US20070078122A1-20070405-C01052
Figure US20070078122A1-20070405-C01053
Figure US20070078122A1-20070405-C01054
Figure US20070078122A1-20070405-C01055
Figure US20070078122A1-20070405-C01056
Figure US20070078122A1-20070405-C01057
Figure US20070078122A1-20070405-C01058
Figure US20070078122A1-20070405-C01059
Figure US20070078122A1-20070405-C01060
Figure US20070078122A1-20070405-C01061
Figure US20070078122A1-20070405-C01062
Figure US20070078122A1-20070405-C01063
Figure US20070078122A1-20070405-C01064
Figure US20070078122A1-20070405-C01065
Figure US20070078122A1-20070405-C01066
Figure US20070078122A1-20070405-C01067
Figure US20070078122A1-20070405-C01068
Figure US20070078122A1-20070405-C01069
Figure US20070078122A1-20070405-C01070
Figure US20070078122A1-20070405-C01071
Figure US20070078122A1-20070405-C01072
Figure US20070078122A1-20070405-C01073
Figure US20070078122A1-20070405-C01074
Figure US20070078122A1-20070405-C01075
Figure US20070078122A1-20070405-C01076
Figure US20070078122A1-20070405-C01077
Figure US20070078122A1-20070405-C01078
Figure US20070078122A1-20070405-C01079
Figure US20070078122A1-20070405-C01080
Figure US20070078122A1-20070405-C01081
Figure US20070078122A1-20070405-C01082
Figure US20070078122A1-20070405-C01083
Figure US20070078122A1-20070405-C01084
Figure US20070078122A1-20070405-C01085
Figure US20070078122A1-20070405-C01086
Figure US20070078122A1-20070405-C01087
Figure US20070078122A1-20070405-C01088
Figure US20070078122A1-20070405-C01089
Figure US20070078122A1-20070405-C01090
Figure US20070078122A1-20070405-C01091
Figure US20070078122A1-20070405-C01092
Figure US20070078122A1-20070405-C01093
Figure US20070078122A1-20070405-C01094
Figure US20070078122A1-20070405-C01095
Figure US20070078122A1-20070405-C01096
Figure US20070078122A1-20070405-C01097
Figure US20070078122A1-20070405-C01098
Figure US20070078122A1-20070405-C01099
Figure US20070078122A1-20070405-C01100
Figure US20070078122A1-20070405-C01101
Figure US20070078122A1-20070405-C01102
Figure US20070078122A1-20070405-C01103
Figure US20070078122A1-20070405-C01104
Figure US20070078122A1-20070405-C01105
Figure US20070078122A1-20070405-C01106
Figure US20070078122A1-20070405-C01107
14. A composition comprising a compound of claim 1, 9, 10, 11, or 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
15. A method of treating hepatitis C infection comprising administering a therapeutically effective amount of a compound of claim 1, 9, 10, 11, or 12 to a patient.
US11/516,435 2005-09-13 2006-09-06 Indolobenzazepine HCV NS5B inhibitors Active 2026-12-28 US7473688B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/516,435 US7473688B2 (en) 2005-09-13 2006-09-06 Indolobenzazepine HCV NS5B inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71669305P 2005-09-13 2005-09-13
US77150106P 2006-02-08 2006-02-08
US11/516,435 US7473688B2 (en) 2005-09-13 2006-09-06 Indolobenzazepine HCV NS5B inhibitors

Publications (2)

Publication Number Publication Date
US20070078122A1 true US20070078122A1 (en) 2007-04-05
US7473688B2 US7473688B2 (en) 2009-01-06

Family

ID=37637507

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/516,435 Active 2026-12-28 US7473688B2 (en) 2005-09-13 2006-09-06 Indolobenzazepine HCV NS5B inhibitors

Country Status (5)

Country Link
US (1) US7473688B2 (en)
AR (1) AR055165A1 (en)
PE (1) PE20070839A1 (en)
TW (1) TW200745120A (en)
WO (1) WO2007033175A1 (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173440A1 (en) * 2005-09-30 2007-07-26 Houck David R Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
US20070185083A1 (en) * 2006-02-08 2007-08-09 Bristol-Myers Squibb Company HCV NS5B Inhibitors
US20070184024A1 (en) * 2005-09-12 2007-08-09 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20070270405A1 (en) * 2006-05-17 2007-11-22 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20070270406A1 (en) * 2006-05-22 2007-11-22 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20070275947A1 (en) * 2006-05-25 2007-11-29 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20070275930A1 (en) * 2006-05-25 2007-11-29 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20070287694A1 (en) * 2006-06-08 2007-12-13 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20080146537A1 (en) * 2006-05-17 2008-06-19 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US20080171015A1 (en) * 2007-01-11 2008-07-17 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080188458A1 (en) * 2007-02-02 2008-08-07 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080206191A1 (en) * 2007-02-22 2008-08-28 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080221090A1 (en) * 2007-03-05 2008-09-11 Bristol-Myers Squibb Company HCV NS5B Inhibitors
US20080227769A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080226591A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080226592A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080226593A1 (en) * 2007-03-15 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080226590A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080255038A1 (en) * 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
US20090042860A1 (en) * 2007-08-09 2009-02-12 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20090074715A1 (en) * 2007-08-09 2009-03-19 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
WO2009099596A2 (en) 2008-02-04 2009-08-13 Idenix Pharamaceuticals, Inc. Macrocyclic serine protease inhibitors
US20090312300A1 (en) * 2008-06-06 2009-12-17 Keqiang Li Novel macrocyclic peptides
US20100144608A1 (en) * 2008-09-11 2010-06-10 Yiyin Ku Macrocyclic hepatitis C serine protease inhibitors
US20100195379A1 (en) * 2009-02-02 2010-08-05 Qualcomm Incorporated System and Method of Pulse Generation
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
CN101977914A (en) * 2008-03-27 2011-02-16 百时美施贵宝公司 Compounds for the treatment of hepatitis c
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012135581A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7795247B2 (en) 2004-10-26 2010-09-14 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetracyclic indole derivatives as antiviral agents
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
CA2693533A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2375065T3 (en) * 2007-11-20 2012-02-24 Bristol-Myers Squibb Company INDILOBENZAZEPIN INHIBITORS CONDENSED WITH HCV NS5B CYCLOPROPYL.
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CN101903351B (en) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 Viral polymerase inhibitors
MX2010010245A (en) * 2008-03-27 2010-10-05 Bristol Myers Squibb Co Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors.
JP2011515484A (en) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Pyrrolidine-fused indolobenzazepine HCVNS5B inhibitor
JP2011517673A (en) 2008-03-27 2011-06-16 ブリストル−マイヤーズ スクイブ カンパニー Aromatic heterocycle fused indolobenzdiazepine HCVNS5B inhibitor
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2385838A1 (en) 2009-01-07 2011-11-16 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
JP2012517468A (en) * 2009-02-11 2012-08-02 ブリストル−マイヤーズ スクイブ カンパニー Compounds for the treatment of hepatitis C
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400963A (en) * 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
DE602005013922D1 (en) 2004-02-24 2009-05-28 Japan Tobacco Inc CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITOR
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
JP2008517987A (en) 2004-10-26 2008-05-29 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184024A1 (en) * 2005-09-12 2007-08-09 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US7485633B2 (en) 2005-09-12 2009-02-03 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7754685B2 (en) 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
US20070173440A1 (en) * 2005-09-30 2007-07-26 Houck David R Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
US20070185083A1 (en) * 2006-02-08 2007-08-09 Bristol-Myers Squibb Company HCV NS5B Inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US20080146537A1 (en) * 2006-05-17 2008-06-19 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US20070270405A1 (en) * 2006-05-17 2007-11-22 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US20070270406A1 (en) * 2006-05-22 2007-11-22 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20070275930A1 (en) * 2006-05-25 2007-11-29 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20070275947A1 (en) * 2006-05-25 2007-11-29 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456167B2 (en) 2006-05-25 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US20070287694A1 (en) * 2006-06-08 2007-12-13 Bristol-Myers Squibb Company Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
US20080171015A1 (en) * 2007-01-11 2008-07-17 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20080188458A1 (en) * 2007-02-02 2008-08-07 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20080206191A1 (en) * 2007-02-22 2008-08-28 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US7998951B2 (en) 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US20080221090A1 (en) * 2007-03-05 2008-09-11 Bristol-Myers Squibb Company HCV NS5B Inhibitors
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20080226592A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US20080226590A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080227769A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20080226591A1 (en) * 2007-03-14 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20080226593A1 (en) * 2007-03-15 2008-09-18 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
US20080255038A1 (en) * 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
US20090074715A1 (en) * 2007-08-09 2009-03-19 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US20090042860A1 (en) * 2007-08-09 2009-02-12 Bristol-Myers Squibb Company Compounds for the Treatment of Hepatitis C
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2009099596A2 (en) 2008-02-04 2009-08-13 Idenix Pharamaceuticals, Inc. Macrocyclic serine protease inhibitors
US20100016578A1 (en) * 2008-02-04 2010-01-21 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8093379B2 (en) 2008-02-04 2012-01-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8003659B2 (en) 2008-02-04 2011-08-23 Indenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CN101977914A (en) * 2008-03-27 2011-02-16 百时美施贵宝公司 Compounds for the treatment of hepatitis c
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20090312300A1 (en) * 2008-06-06 2009-12-17 Keqiang Li Novel macrocyclic peptides
US20100144608A1 (en) * 2008-09-11 2010-06-10 Yiyin Ku Macrocyclic hepatitis C serine protease inhibitors
US8420596B2 (en) 2008-09-11 2013-04-16 Abbott Laboratories Macrocyclic hepatitis C serine protease inhibitors
US9309279B2 (en) 2008-09-11 2016-04-12 Abbvie Inc. Macrocyclic hepatitis C serine protease inhibitors
US8642538B2 (en) 2008-09-11 2014-02-04 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20100195379A1 (en) * 2009-02-02 2010-08-05 Qualcomm Incorporated System and Method of Pulse Generation
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US9173887B2 (en) 2010-12-22 2015-11-03 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9567355B2 (en) 2010-12-22 2017-02-14 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US9453007B2 (en) 2010-12-22 2016-09-27 Abbvie Inc. Hepatitis C inhibitors and uses thereof
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012135581A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US10201541B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9744170B2 (en) 2014-01-03 2017-08-29 Abbvie Inc. Solid antiviral dosage forms
US10105365B2 (en) 2014-01-03 2018-10-23 Abbvie Inc. Solid antiviral dosage forms
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof

Also Published As

Publication number Publication date
WO2007033175A1 (en) 2007-03-22
TW200745120A (en) 2007-12-16
AR055165A1 (en) 2007-08-08
PE20070839A1 (en) 2007-09-10
US7473688B2 (en) 2009-01-06

Similar Documents

Publication Publication Date Title
US7473688B2 (en) Indolobenzazepine HCV NS5B inhibitors
US7485633B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7547690B2 (en) Compounds for the treatment of Hepatitis C
US7456165B2 (en) HCV NS5B inhibitors
US7521443B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7348425B2 (en) Inhibitors of HCV replication
US7538102B2 (en) Compounds for the treatment of Hepatitis C
US20060046983A1 (en) Inhibitors of HCV replication
US7541353B2 (en) Compounds for the treatment of hepatitis C
US7538103B2 (en) Compounds for the treatment of hepatitis C
US7652004B2 (en) Compounds for the treatment of hepatitis C
US8129367B2 (en) Compounds for the treatment of Hepatitis C
US8124601B2 (en) Compounds for the treatment of Hepatitis C
US8133884B2 (en) Compounds for the treatment of hepatitis C
EP2280978B1 (en) Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8143243B2 (en) Compounds for the treatment of hepatitis C

Legal Events

Date Code Title Description
AS Assignment

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BERGSTROM, CARL P.;BENDER, JOHN A.;GENTLES, ROBERT G.;AND OTHERS;REEL/FRAME:018404/0981;SIGNING DATES FROM 20061004 TO 20061018

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12